<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>Novartis Accelerates Cancer Immunotherapy Efforts with Aduro Biotech Alliance</title>
	<pubDate>2015-03-30T17:33:05+02:00</pubDate>
	<wp:post_id>5914</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis announced today the launch of a new immuno-oncology 
research group with Glenn Dranoff, MD from the Dana Farber Cancer Institute 
joining the company to lead the new research group.<wbr> Alongside it has 
announced an immunotherapies alliance Aduro.<wbr> The latter is focused on 
discovery and development of next generation cancer immunotherapyies 
targeting  the STING signaling pathway.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement with Aduro, Novartis will make an upfront 
payment of $200 million to Aduro and will make an initial equity investment in 
the company for $25 million, with a commitment for another $25 million equity 
investment at a future date.<wbr> </div><div style="margin-bottom: 10px;">Aduro will lead commercialization activities and book sales in the US, with 
Novartis leading commercialization and recognizing sales in the rest of the 
world.<wbr> The companies will share in profits in the US, Japan and major European 
countries.<wbr> Novartis will pay Aduro a royalty for sales in the rest of the world.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Value of a STING Approach</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="hugin">
<P class="hugin">STING is a signaling pathway that when activated is known to 
initiate broad innate and adaptive immune responses in tumors.<wbr> Aduro's novel 
small molecule cyclic dinucleotides (CDN's) have proven to generate an immune 
response in preclinical models that specifically attacks tumor cells.<wbr> </P></DIV> </div><div style="margin-bottom: 10px;"><DIV class="hugin">Addition of STING agonists further enhances the diverse 
Novartis cancer immunotherapy portfolio that includes novel CAR T-cell therapy 
and checkpoint inhibitors.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="hugin">Currently Novartis's CART program, CTL019, is in phase 2 
clinical trials and checkpoint inhibitors targeting PD1, LAG3, and TIM3 are 
expected to enter the clinic in mid-2015.<wbr></DIV> </div><div><DIV class="hugin">Source: <A href="http://www.novartis.com">www.<wbr>novartis.<wbr>com</A></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10346">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-30T17:33:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-30T17:33:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva to Acquire Auspex for $3.5bln</title>
	<pubDate>2015-03-30T16:36:26+02:00</pubDate>
	<wp:post_id>5915</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Teva&rsquo;s strategy is to be a top player in CNS, and build an infrastructure and an expertise in Huntington to provide services and solutions that are holistic and beyond just the product.<wbr> Auspex's deuterium platform is being developed for the treatment of chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome.<wbr> According to Teva's management SD-809 for HD is expected to win regulatory approval and be launched commercially in 2016.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>RATIONALE for TEVA</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>Excellent strategic fit strengthening Teva&rsquo;s leadership in central nervous system disorders
</LI>
<LI>Opportunity to establish leadership in movement disorders　
</LI>
<LI>Numerous programs under development supporting multiple horizons for growth
</LI>
<LI>Innovative and proven deuteration technology provides platform value
</LI>
<LI>Enhances Teva&rsquo;s long-term growth profile, profitability, and business mix
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Deal Terms</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><P align="left">Tender offer for all outstanding shares of Auspex for $101.<wbr>00 per share in cash</P> </div><div style="margin-bottom: 10px;"><P align="left">　</P> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Auspex Ongoing Programs</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><P align="left">- Pivotal data from ARM-TD, the first of two pivotal trials for SD-809 in t<SPAN style="text-decoration: underline;">ardive dyskinesia</SPAN>, is anticipated mid-2015 with readout from AIM-TD, the second pivotal trial in TD expected in 2016.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Management outlined that " .<wbr>.<wbr>.<wbr> tetrabenazine is approved for tardive dyskinesia in Europe.<wbr> And secondly, when you look at non-regulatory studies, it being a large number of publications around 12.<wbr> 10 out of 12 of these studies showed significantly positive result.<wbr> So, with tardive dyskinesia again of course one has to get the data, so, I don&rsquo;t want to preempt the data, but, I think there is a reasonable confident based on its approval in Europe plus the knowledge and the discussion with physician to treat patients as well as the published data that there is an overwhelming chance of success with this particular &ndash; and these results, the top-line results, which are anticipated very soon".<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">- Top-line Ph1b data for SD-809 in <SPAN style="text-decoration: underline;">Tourette's Syndrome</SPAN> is expected mid-2015 and Ph1 healthy volunteer data for SD-560 versus pirfenidone, is also due mid-2015.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">It was reported " .<wbr>.<wbr>.<wbr> tetrabenazine is approved for Tourette syndrome in Canada and also when you go through and you review the literature and again about 12 publications on tetrabenazine in tardive dyskinesia, again nine or 10 of them having illustrating and providing positive result, so Tourette syndrome again, I think, we believe that the likelihood of success is high, but obviously, it&rsquo;s again, we await unless it is early in development"</P> </div><div style="margin-bottom: 10px;"><P align="left">Auspex recently acquired <a href="http://investor.auspexpharma.com/releasedetail.cfm?releaseid=890806" class="defaultlink">Imphar</a>, giving it WW rights for SD-1077, deuterated levodopa, for <SPAN style="text-decoration: underline;">Parkinson's disease.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><UL><LI>SD-1077 (deuterium containing levodopa) has been shown in preclinical models to improve the half-life of dopamine in the brain resulting in a prolonged treatment effect.<wbr> Auspex is advancing SD-1077 through preclinical studies in preparation for initiation of clinical development by the end of 2015.<wbr> Data from the clinical studies are expected in 2016.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Teva's Huntington's Programs</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Huntexil</STRONG> </div><div style="margin-bottom: 10px;">Teva Claims Ph2/<wbr>3 clinical results in 2015 and a US Submission in 2016 </div><div style="margin-bottom: 10px;">Ranks 3 in the Teva&rsquo;s TOP4 important clinical milestones for 2015 (source: JPM 01/<wbr>2015) </div><div style="margin-bottom: 10px;"><STRONG>Laquinimod</STRONG> </div><div style="margin-bottom: 10px;">likely to be a disease modifying drug (DMD) </div><div style="margin-bottom: 10px;">Ph2 ongoing (<A href="http://clinicaltrials.gov/ct2/show/NCT02215616?term=teva+AND+HUNTINGTON+AND+LAQUINIMOD&amp;rank=1">NCT02215616</A>) - Completion Dec 2016 /<wbr> Jan 2017 </div><div style="margin-bottom: 10px;">The slide kit from March 30 presentation is attached for additional information </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Q&amp;A Session</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Value creation of the deal ".<wbr>.<wbr>.<wbr> able to generate during the next five years at least <SPAN style="text-decoration: underline;">$2 billion of net revenue, and that&rsquo;s been in a way, that is based on the three products</SPAN> in development only, we see an opportunity that goes far beyond that to other pipeline products, to the technology that might generate for us as a potential solution but as we go along and basically that&rsquo;s &ndash; that&rsquo;s a really conservative number, so next five years, we believe $2 billion of net revenues, that&rsquo;s clearly very high gross margin and that strategy which is also this phase, <SPAN style="text-decoration: underline;">we are concentrated to the U.<wbr>S.<wbr> only, so once we are able to go beyond the U.<wbr>S.<wbr> it will of course enhance the top-line and the profit</SPAN> </div><div>When asked about pricing, management answered ".<wbr>.<wbr>.<wbr> So while the pricing from a &ndash; an HDE standpoint is in that neighborhood of $80,000 to $85,000, our assumption is that, TD and TS will warrant a price premium approach in that area.<wbr> So again it was very clear in an unaided way just how significant and serious these conditions were and gives us enormous optimism that our strength in neurology and our patient services and model we have today will really help us achieve a success and ultimately serve these patients in a meaningful way.<wbr>"<BR><BR>Process to end up with Auspex deal " .<wbr>.<wbr>.<wbr> basically we&rsquo;ve met based 200 potential opportunities during the fourth quarter of 2014 and we then lead to 25 targets and targets basically which are very consistent with fully aligned with the framework that I shared with you also today.<wbr> <BR>Auspex meets basically all the requisitions in a very, very slow fashion.<wbr> And that&rsquo;s why, I totally expect to be for us a flexible, which also I believe conveys a strong message, an important one, but it doesn&rsquo;t come with the expense of additional move that we might entertain going forward.<wbr><BR>It was a competitive process, we are not expose of course to details that might be interesting, but going to the company, it was exposed to those details.<wbr> So it was competitive but it&rsquo;s not something I can address and maybe I&rsquo;ll ask Michael or maybe I will ask Pratik to address that".<wbr> </div><!-- Comment details --><a name="neurology7952attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7952_1_Teva%255fTo%255fAcquire%255fAuspex%255fInvestor%255fPresentation%255fMarch%255f30%255f2015%5b1%5d.pdf">Teva_To_Acquire_Auspex_Investor_Presentation_March_30_2015[1].pdf</a>&nbsp;&nbsp;(410,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7952">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-30T16:36:26+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-30T16:36:26+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</title>
	<pubDate>2015-03-27T14:16:48+01:00</pubDate>
	<wp:post_id>5916</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</span>&nbsp;<br><span style="font-size: 12px;">Eisai has announced today the FDA approval of its in-house developed Lenvima (lenvatinib mesylate) as a treatment for locally recurrent ore metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.<wbr> Lenvima was granted priority review status by the FDA and the approval comes in only six months from the submission of the NDA, in August 2014.<wbr> US is the first market where Lenvima has granted authorization.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10269">...</a><br></div><div>During the CHMP meeting held on 23-26 March, the European Medicine Agency recommended Lenvima (lenvatinib) for approval and granted marketing authorization for the treatment of adults with progressive, locally, advanced or metastatic differentiated thyroid carcinoma, whose disease has progressed despite receiving radioactive iodine.<wbr> Lenvima was reviewed under EMA's accelerated assessment program being a drug that would significantly improve the treatment for this serious condition.<wbr>  The European approval arrives just over a month the US approval.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10345">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10266">View thread  Oncology10266: Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-27T14:16:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-27T14:16:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Researcher from UCI Gets $5M to Develop Stem Cells for Huntington's Disease</title>
	<pubDate>2015-03-27T13:20:55+01:00</pubDate>
	<wp:post_id>5917</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new grant is for two and a half years to identify and testing stem cell-based treatments for Huntington’s.<wbr> Pre-investigational meetings with the US FDA on possible new drugs, and clinical trials with neural stem cells, could follow.<wbr> </div><div style="margin-bottom: 10px;">Thompson’s team has studied the disease for 7 years on prior California Institute for Regenerative Medicine funding, and produced stem cell lines from the skin of people with the Huntington’s genetic mutation in order to study the disease.<wbr> </div><div>Source: <A href="http://www.ocbj.com/news/2015/mar/26/uci-stem-cell-researcher-gets-5m/">http:/<wbr>/<wbr>www.<wbr>ocbj.<wbr>com/<wbr>news/<wbr>2015/<wbr>mar/<wbr>26/<wbr>uci-stem-cell-researcher-gets-5m/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7950">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-27T13:20:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-27T13:20:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>WHIO Encourages Wider Data Sharing In Europe To Control Drug Costs</title>
	<pubDate>2015-03-27T12:35:48+01:00</pubDate>
	<wp:post_id>5918</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a paper released yesterday by the WHO, it urges European 
government to better share expertise about the cost-effectiveness of new 
medicines to counter the budget constraints posed by the arrival of a wave of 
costly new drugs.<wbr> </div><div style="margin-bottom: 10px;">It notes that only a few countries across Europe have a robust system in 
place to evaluate the cost-effectiveness of new medicines </div><div style="margin-bottom: 10px;">It suggests that drug supply and pricing is often fixed through deals between 
governments and drugmakers that are "generally rather opague" making it 
difficult to achieve transparency needed to help reduce prices.<wbr> </div><div style="margin-bottom: 10px;">With the assessment of economic intervention outside of the remit of the 
licensing bodies such as the EMA the WHO has felt the need to intervene.<wbr> </div><div style="margin-bottom: 10px;">Zsuzsanna Jakab, WHO regional director for Europe is quoted as saying " The 
ultimate goal is to protect patient's interests and ensure that they are not 
provided with expensive new medicines that offer little or no improvement to 
health outcomes.<wbr>" </div><div style="margin-bottom: 10px;">He went onto note that "The drug industry is currently enjoying a 
research-let revival with more new therapies reaching the market especially for 
chronic diseases such as cancer, type-2 diabetes and hepatitis C.<wbr>" </div><div>"Costs for some drugs", he suggests "are rising at an unsustainable rate with 
cancer drug prices doubling in 10 Yrs.<wbr>to a typical range of $6000-10,000 a month 
often with little relationship between reimbursed costs and associated health 
benefits.<wbr> The result is very uneven access to drugs across Europe as government 
employ a range of methods to rein in bills.<wbr>"<BR>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11133">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-27T12:35:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-27T12:35:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Germany's Cost Watchdog Determines That Valeant's Provenge Has Added Benefit After All</title>
	<pubDate>2015-03-26T16:50:02+01:00</pubDate>
	<wp:post_id>5919</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Germany's IQWG has reversed a decision that it took in January 2015 claiming that Provenge offered no added benefit for men with metastatic prostate cancer Based on new data it now claims that it does have an indication of added benefit.<wbr> </div><div style="margin-bottom: 10px;">However, qualifying this statement the IQWG stated that this added benefit is not quantifiable.<wbr> The G-BA will now use this dossier in its assessment of Provenge to make a final decision on the extent of this benefit and the price of the vaccine.<wbr> </div><div style="margin-bottom: 10px;">The additional data supplied by Valeant apparently showed advantages in terms of mortality and a more consistent picture in comparison with the primary analysis of the data in the dossier.<wbr> </div><div>Source: FierceVaccines </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10344">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-26T16:50:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-26T16:50:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>VBL Therapeutics: Promising Results For Thyroid Cancer And Glioblastoma</title>
	<pubDate>2015-03-26T15:52:28+01:00</pubDate>
	<wp:post_id>5920</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: VBL Therapeutics, a late-stage clinical biotechnology company focused on first-in-class cancer treatments, reported on the 2014 financial results and in particular on the unique mechanism of VB-111, a gene-based biologic for solid tumor indications with ongoing trials in glioblastoma (rGBM), thyroid and ovarian cancer.<wbr> VB-111 is based on the Vascular Targeting System (VTS), which enables systemic administration of gene therapy to act as a 'biological knife' to destroy vasculature.<wbr> If proven successful, this gene-based approach would provide an alternative to the numerous marketed kinase inhibitors.<wbr> </div><div style="margin-bottom: 10px;">In particular VBL Therapeutics announced: </div><div style="margin-bottom: 10px;"><UL><LI>Top line results from VB-111 phase 2a trial in patients with recurrent iodine-resistant differentiated thyroid cancer.<wbr> VB-111 provided disease stabilization and demonstrated a good safety profile.<wbr>
</LI>
<LI>Positive interim top-line results from ongoing Phase 2 trial in patients with rGBM and, in particular, significant improvement in OS in patients treated with VB-111 as a standalone drug and who, upon further progression, was treated in combination with bevacizumab, compared to patients treated with bevacizumab alone upon further progression.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The FDA has also determined that VBL-111 may proceed with its pivotal Phase 3 trials in patients with rGBM and removed the partial clinical hold on the trial that was ongoing due to special protocol assessment.<wbr> </div><div>Source: VBL Therapeutics </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=8003">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-26T15:52:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-26T15:52:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Probi Strengthens Presence in the North American Market</title>
	<pubDate>2015-03-26T12:17:55+01:00</pubDate>
	<wp:post_id>5921</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi has signed a distribution and supply agreement with Jamieson, the leading producer of vitamins, minerals and supplements (VMS) and the N°2 in the probiotics Canadian market.<wbr> The launch of Probi Digestis® occured in March 2015.<wbr> Jamieson plans an extensive national marketing campaign starting in May.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Probi has already received its first order valued at MSEK 2.<wbr>5.<wbr> </div><div style="margin-bottom: 10px;">Jamieson’s new range of gastrointestinal products, Digestive CareTM, will feature Probi Digestis® within the line’s leading product, Daily Relief.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://jamiesonvitamins.com/fr/supplement">http:/<wbr>/<wbr>jamiesonvitamins.<wbr>com/<wbr>fr/<wbr>supplement</A> </div><div style="margin-bottom: 10px;">Established in 1922, Jamieson is Canada’s largest manufacturer and distributor of advanced natural-health products and a world-leading innovator in the development of proprietary formulas.<wbr> </div><div style="margin-bottom: 10px;">With corporate offices in Toronto, Jamieson exports products to more than 50 countries.<wbr> </div><div>Source: Probi </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2306">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-26T12:17:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-26T12:17:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ Has Adopted A Policy For Sharing Clinical Trial Data Information</title>
	<pubDate>2015-03-25T18:10:59+01:00</pubDate>
	<wp:post_id>5922</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As part of the data transparency effort, AstraZeneca has become the latest pharmaceutical company to adopt a policy toward sharing information requested by researchers.<wbr> A board has specifically formed comprising of external scientists who will review data requests and AZ will consider to share information on data summaries, study protocols, case reports and statistical analyses for trials dating back to 2009.<wbr> However, how independent the board is questioned as only 2 out of 4 members declare no previous relationship with AZ.<wbr> </div><div style="margin-bottom: 10px;">The move comes as the pharmaceutical industry grapples over the extent to which data should be disclosed in the wake of scandals over safety or effectiveness data that was not publicly shared.<wbr> Consumer groups and academics complain such information is kept out of reach at the expense of patients.<wbr> Drug makers argue that disclosure may compromise trade secrets or patient privacy.<wbr> </div><div style="margin-bottom: 10px;">The move by AstraZeneca was largely praised by academics who have been pressuring the industry to release data, although they also questioned the independence of the review board.<wbr> Of the four members, two of the scientists have acknowledged that they did consulting work for AstraZeneca over the past few years.<wbr> </div><div>Source: AstraZeneca Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11131">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-25T18:10:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-25T18:10:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: ESMO Intelligence - Novartis's Activities At ESMO</title>
	<pubDate>2015-03-25T17:08:09+01:00</pubDate>
	<wp:post_id>5923</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">ESMO Intelligence - Novartis's Activities At ESMO</span>&nbsp;<br><span style="font-size: 12px;">Comment: </span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7821">...</a><br></div><div>The new sandostatin LAR preparation has become commercially available today in UK.<wbr> Novartis had previously proven bioequivalence between octreotide LAR and the new vehicle (new Sandostatin LAR preparation).<wbr> UK prescribing details can be find on the <a href="http://www.medicines.org.uk/emc/medicine/1321" class="defaultlink">EMC website</a>.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=8002">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7821">View thread  Endocrinology7821: ESMO Intelligence - Novartis's Activities At ESMO</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-25T17:08:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-25T17:08:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Analysts Call with GI Experts Provide Insight on Actavis and Salix Drugs for IBS-D</title>
	<pubDate>2015-03-25T14:00:53+01:00</pubDate>
	<wp:post_id>5924</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Recently interviewed by analysts, GI experts (a clinical Professor of Medicine in the Division of Gastroenterology at the U.<wbr> of California at San Diego, and a director of the Gastrointestinal Motility Program and Laboratoy at Cedars-Sinai Medical Center) gave their opinion on Actavis' eluxadoline and Salix' Xifaxan (which could be approved this year), and their views on the IBS-d market opportunity.<wbr> Given the multifactorial nature of IBS-D, and the different mechanism of action for the drugs, both experts consider Xifaxan and eluxadoline to be complementary rather than competitive products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Xifaxan is a locally acting antibiotic that targets small intestinal bacterial overgrowth – SIBO (a recognized cause of IBS-D), whereas eluxadoline is a locally acting mixed mu receptor agonist that provides pain relief and slows motility in the small intestine, offering relief of the diarrhea and abdominal pain symptoms of IBS-D.<wbr> </LI>
<LI>In addition, Xifaxan use is intermittent, whereas eluxadoline is a chronic therapy.<wbr> </LI>
<LI>The response rates for improvement of stool consistency and pain relief are comparable for both products and the physician decision on which to prescribe depends on whether a patient has SIBO</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Unmet need for IBS-D treatment is high</STRONG>, and significant commercial prospects exist for both Xifaxan and eluxadoline.<wbr> Despite the high prevalence of IBS-D there are no currently approved treatment options.<wbr> In fact, expert2 believes that the addressable market for IBS-D has barely been penetrated, leaving an opportunity to grow the market once treatments are approved.<wbr> Moreover, given the multifactorial nature of IBS and the different mechanisms of action for Xifaxan (antibiotic targeting bacterial overgrowth) and eluxadoline (opioid agonist that targets gut transit), there is an<U> important, potentially complementary</U>, role for both products </div><div style="margin-bottom: 10px;">Expert1 noted that treatment which often starts with an anti-diarrheal agent (he prefers loperamide) and an anti-spasmodic to address abdominal pain has limited success.<wbr> </div><div style="margin-bottom: 10px;">Expert1 prescribes Xifaxan for some patients with IBS-D, noting that the drug is quite effective for patients with small intestinal bacterial overgrowth.<wbr> He also noted that in patients that respond to Xifaxan, the improvement is often durable.<wbr> He is not concerned about antibiotic resistance given that there is limited systemic absorption of Xifaxan and no evidence so far of resistance developing in patients treated with Xifaxan.<wbr>  </div><div style="margin-bottom: 10px;">Expert1 does not have direct experience with eluxadoline, but views the clinical trial design and results as good.<wbr> He noted that eluxadoline appears to be very effective at controlling diarrhea, but has a lesser effect on abdominal pain.<wbr> He speculated that eluxadoline could potentially be more universally effective for IBS-D relative to Xifaxan given its known mechanism of action and that Xifaxan efficacy may be dependent on the bacterial makeup of a patient’s gut.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety concerns and REMS program may be biggest hurdles to eluxadoline adoption</STRONG>.<wbr> Expert2 was most concerned with the incidences of pancreatitis reported in the Phase II and III eluxadoline trials.<wbr> Given this he expects eluxadoline, if approved, will likely have a REMS program.<wbr> Note that data suggest that the incidences of pancreatitis in the eluxadoline studies were relatively low at just 9 of 2,500 patients (though he believes this is still too high), all of which occurred in patients with identifiable risk factors such as alcohol abuse and prior cholecystectomy.<wbr> </div><div><EM>Sources: "Tidbits from Expert call on IBS" /<wbr> Deutsche Bank Jan 30 2015 - "Call with Leading Thought Leader Increases our Confidence in IBS-D Market Opportunity" /<wbr> Sterne Agee Jan 29 2015.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2302">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-25T14:00:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-25T14:00:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cosmo Reports Market Performance with Uceris® and Lialda® in 2014</title>
	<pubDate>2015-03-25T08:53:08+01:00</pubDate>
	<wp:post_id>5925</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results for 2014, management highlighted that Uceris sales increased &gt;120%, and Lialda market share reached 33% in the US.<wbr> When it comes to pipeline, it was outlined the NDA filing set for Q1:16 for rifamycin (Traveller's diarrhea); subsequent indications (uncomplicated diverticulitis and IBS) are managed by Dr Falk.<wbr> Cosmo has got two tools to support endoscopics, namely Methylene Blue MMX® (Ph3 data available in Q3:15), and Endoscopic Mucosal Resection (medical device classified as a class II medical device in US and as either a class IIa or IIb medical device in EU; EU approval planned Q4:15).<wbr> A selection of key slides is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="gastroenterology2299attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(40,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(60,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2299_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(53,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2299">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-25T08:53:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-25T08:53:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Flexion Reports Positive Progress With FX006 For Patients Suffering From Osteoarthritis Knee Pain</title>
	<pubDate>2015-03-24T18:15:51+01:00</pubDate>
	<wp:post_id>5926</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Flexion has reported that 2014 was a transformational year for the 
company with two public stock offerings that place the company in a strong 
position to execute on its business plan.<wbr> To that end, FX006 has 
advanced into two pivotal clinical trials that are expected to 
form the basis for a regulatory submission for this new 
long-acting osteoarthritis product that in trials to date has 
demonstrated 60% pain reduction over 3 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy vs.<wbr> Botox</STRONG> </div><div style="margin-bottom: 10px;">How this level of efficacy compares with that observed with Allergan's 
botulinum toxin has yet to be determined with Allergan's phII 160 patient 
osteoarthritis knee pain study due to complete in January 2016 in terms of  
the primary endpoint which is -change from Baseline in 
the 7-Day Average Daily Pain Score </div><div style="margin-bottom: 10px;">Clinical Trial Identifier NCT02230956 </div><div style="margin-bottom: 10px;"><STRONG>Anticipated Events For Flexion in 2015</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Results of pivotal Phase 2b trial with FX-006 in the fourth 
  quarter</LI>
<LI>Complete final, pivotal Phase 3 clinical trial enrollment for 
FX006</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>2014 Achievements</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Completed  of two rounds of financing which have raised a totatl of 
  $173m</LI>
<LI> Completed and reported positive data from the FX006 Phase 2a 
  synovial fluid pharmacokinetic clinical trial</LI>
<LI>Initiated and completed enrollment in a confirmatory, pivotal Phase 2b 
  multi-center, randomized, double-blind, placebo-controlled study in 310 
  patients with OA of the knee.<wbr> Results will address the safety, tolerability 
  and efficacy of FX006</LI>
<LI>Initiated a Phase 3 clinical trial of FX006 that will be the final step 
  before submitting an NDA to the U.<wbr>S.<wbr>FDA</LI>
<LI>Entered an exclusive worldwide licensing agreement with the SwRI® to use 
  proprietary microsphere technology to produce Flexion's sustained-release drug 
  candidates, including FX006</LI>
<LI>Received from the U.<wbr>S.<wbr> Patent and Trademark Office a composition of matter 
  patent (No.<wbr> 8828440), entitled "Corticosteroids for the Treatment of Joint 
  Pain," which provides coverage for FX006 into 2031</LI>
</UL> </div><div style="margin-bottom: 10px;">Additionally the company has strengthened Flexion's board of directors by 
adding Ann Merrifield, former President of Genzyme Biosurgery, Sandesh (Sandy) 
Mahatme, LLM, Senior Vice President, Chief Financial Officer at Sarepta 
Therapeutics, Inc.<wbr> and Scott Canute, former President of Global Manufacturing 
and Corporate Operations at Genzyme Corporation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Flexion Story</STRONG> </div><div style="margin-bottom: 10px;">FX-006 is a sustained-release, intra-articular steroid 
for patients with moderate-to-severe 
osteoarthritis or 
OA.<wbr> It combines the commonly administrated 
steroid, triamcinolone 
acetonide or TCA that has been approved by the FDA with a sustained-release polymer 
called PLGA, which is then manufactured as microspheres.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Following injection into the knee, the microspheres slowly dissolve in the fluid of the joint into their component sugar parts, releasing TCA in parallel.<wbr> This results in delivering therapeutic 
concentrations of 
drug in the joint for months while minimizing drug exposure in the blood.<wbr> In clinical trials to-date, it has enabled long-lasting local pain relief while avoiding systemic side effects, which remain a liability of many currently available therapies.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">To-date, three clinical trials have been completed to test FX006 against immediate-release TCA 
injection.<wbr> And most recently, we completed enrollment of our pivotal Phase IIb clinical trial against placebo.<wbr> In aggregate, over 440 patients have been treated with FX006.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Flexion's clinical development program began by conducting two pharmacokinetic clinical 
trials that compare the persistence of FX006 to immediate-release TCA 
in the joint by measuring synovial fluid concentrations following a single intra-articular 
administration.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Data from these studies demonstrate that with FX006 administration, 
likely therapeutic 
concentrations of 
TCA are achieved for at least three months, whereas with immediate-release TCA, 
drug concentrations 
become unmeasurable 
within a matter of weeks.<wbr> The 
trials also demonstrated that plasma concentrations 
of TCA are dramatically less with FX006 than with immediate-release 
TCA, which could advantage FX006 in terms of fewer systemic side effects.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The persistence of meaningful concentrations 
of TCA in synovial fluid after FX006 injection provides a pharmacokinetic basis for the efficacy observed in Flexion's completed Phase IIb dose-ranging trial.<wbr> That <STRONG>clinical trial show that FX006 conferred amongst the largest pain relief signals seen in OA clinical trials with almost 60% pain reduction at three months,</STRONG> which 
was the final time point assessed in the study.<wbr> The ongoing pivotal trials have been designed to assess efficacy through six months to determine if and how much analgesia FX006 can deliver past the already observed three-month time point.<wbr> </P> </div><div>Source: <A href="http://www.flexion.com">www.<wbr>flexion.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7949">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-24T18:15:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-24T18:15:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Probi AB Announces Collaborative Research Agreement for Future Probiotic Development</title>
	<pubDate>2015-03-24T13:05:45+01:00</pubDate>
	<wp:post_id>5927</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi AB has signed a four-year collaborative research agreement with Professor Michiel Kleerebezem at the Host Microbe Interactomics Group (Wageningen University) to clarify mechanisms of action for anti-inflammatory activity of probiotic bacteria in order to enable a continued development of novel effective probiotic products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- combines expertise in cell biology, immunology, microbiology and functional genomics to increase the understanding of molecular interactions occurring in the cross-talk between microbes and their hosts.<wbr> </div><div style="margin-bottom: 10px;">- research ranges from work on the molecular mechanisms of diseases caused by pathogenic bacteria to the interactions between beneficial bacteria and their hosts.<wbr> </div><div><EM>Source: ProbiAB</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2297">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-24T13:05:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-24T13:05:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Avidocin™ Proteins Prevent C.Difficile in Mice Without Harming Protective Gut Bacteria</title>
	<pubDate>2015-03-24T12:52:55+01:00</pubDate>
	<wp:post_id>5928</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A study published today in <EM>mBio</EM> demonstrated that AvidBiotics' Avidocin™ proteins administered to mice prevented infection by <EM>C.<wbr>difficile</EM> bacteria without disrupting the healthy gut bacteria.<wbr> By leaving healthy gut bacteria intact, the therapies preserve natural resistance to colonization by disease-causing microbes and simultaneously reduce the need for broad spectrum antibiotics.<wbr> FIM trials are expected in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The study was led by researchers from AvidBiotics, the developers of the Avidocin technology, in collaboration with scientists at the Sanger Institute and the Cleveland VA Medical Center.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Genetically modified versions of R-type bacteriocins – proteins naturally produced by bacteria to kill competing strains.<wbr> </LI>
<LI>Tailored to target particular species or strains of bacteria, often with the targeting protein encoded within the DNA of the target bacterium itself.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The technology leverages the abundance of new microbial genomic information being generated to rapidly construct novel antibacterials and can be rapidly re-engineered to kill emerging dangerous bacterial strains.<wbr> </div><div style="margin-bottom: 10px;">Avidocin technology also enables a new approach to microbiome research through selective elimination of a single species or strain of bacteria.<wbr> Avidocins could be the first technology of its kind to enable this selective elimination, allowing researchers to better understand the role an individual strain plays in human health and disease.<wbr> The application of Avidocin proteins to manipulate the gut bacterial population could expand into therapeutic applications for broader disease areas, such as allergy, autoimmunity, diabetes, and obesity.<wbr> </div><div><EM>Source: AvidBiotics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2296">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-24T12:52:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-24T12:52:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GI Company Synergy Pharm. Seen as a Potential Takeout Candidate</title>
	<pubDate>2015-03-23T13:03:48+01:00</pubDate>
	<wp:post_id>5929</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside its financial results released last week, management outlined that plecanatide is now patent protected until 2031 by a method-of-use patent issued in March, that according to analysts meaningfully enhances the product's attractiveness to a potential partner.<wbr> Synergy is focused on the development of novel therapies to treat GI diseases and disorders.<wbr> The company&rsquo;s proprietary platform technology is based on the naturally occurring human GI peptide &ndash; uroguanylin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Milestones for Plecanatide</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Chronic idiopathic constipation (CIC)</SPAN> </div><div style="margin-bottom: 10px;"><P align="left">Top line data from the first Ph3 are expected in 2Q:15, with data from the second Ph3 anticipated in 3Q:15.<wbr> Both of these trials are testing the 3.<wbr>0 mg and 6.<wbr>0 mg doses of plecanatide.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">- the 3.<wbr>0 mg dose previously generated statistically significant efficacy data and diarrhea rates in the 9-10% range in the Phase IIb trials in both CIC and IBS-C.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">- the 6.<wbr>0 mg dose was not tested in either trial but is expected to work given the positive efficacy signal noted for the 9.<wbr>0 mg dose tested in the IBS-C trial and provides another dosing option for physicians (like the two doses available for Linzess).<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
Analysts anticipates NDA submission in 2015 and data disclosure from two Ph3 trials in IBS-C in 2015/<wbr>2016

</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">IBS-C</SPAN> </div><div style="margin-bottom: 10px;"><P align="left">The second Ph3 trial of plecanatide in IBS-C is expected to start in 1H:15.<wbr> Data from the first Ph3 trial of plecanatide</P> </div><div style="margin-bottom: 10px;"><P align="left">in IBS-C are expected by end of 2015 with the second trial reading out in 2H:16.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
Analyst anticipates NDA filing in IBS-C in 2H:16.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="text-decoration: underline;">Ulcerative Colitis (UC)</SPAN></P> </div><div><P align="left">Ph1b data of SP-333 expected this year</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2295">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-23T13:03:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-23T13:03:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Aesthetics Announces Positive Results From Comparative Post-Marketing Trial</title>
	<pubDate>2015-03-19T18:11:47+01:00</pubDate>
	<wp:post_id>5930</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz has reported the results of the first large (n=250), 
multicentre, parallel-group study to compare the efficacy of Xeomin to Botox in 
the treatment of glabellar frown lines.<wbr> The data is consistent with smaller 
previously published comparisons and demonstrates that results with Xeomin are 
similar to Botox both in terms of efficacy and safety.<wbr> </div><div style="margin-bottom: 10px;">The co-lead investigators were Dr Fredric Brandth MD and board certified 
dermatologics in Manhattan and Miami and Dr Michael Kane a board certified 
plastic surgeon in private practices in Manhattan.<wbr> Clinical Trial Identifier 
NCT02096081 </div><div style="margin-bottom: 10px;">Complete analysis of the data from the trial remains in progress and will 
presented at an upcoming meeting.<wbr> However, the results demonstrated that the 
trial met its primary effiacy endpoint, defined as a 1-point improvement from 
baseline on the Facial Wrinke Scale (FWS) at maximum frown.<wbr> at 1 month after a 
single treatment .<wbr> Similar efficacy profiles were demonstrated between the two 
treatment groups at all timepoints (1,2,3,and 4 months post treatment.<wbr> </div><div><A href="http://www.merzusa.com">www.<wbr>merzusa.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7946">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-19T18:11:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-19T18:11:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive PK Results from Phase1a and 1b Studies of SYN-004 for C.Difficile Infection</title>
	<pubDate>2015-03-19T17:45:05+01:00</pubDate>
	<wp:post_id>5931</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The PK data confirmed that SYN-004 acts as Synthetic Biologics intended.<wbr> SYN-004 goes directly to the gut where intravenous (IV) antibiotics are excreted, with the intention of protecting the microbiome from a cascading set of events that often lead to potentially deadly <I>C.<wbr> difficile</I> infections.<wbr> The company  intends to continue the clinical development of SYN-004 in a Phase 2a clinical trial to evaluate the ability of SYN-004 to degrade residual IV antibiotic in the GI tract, therefore potentially protecting the gut microbiome and preventing <I>C.<wbr> difficile</I> infection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>The Phase 1a</U>, single-ascending dose PK study provided data to support Synthetic Biologics' hypothesis that SYN-004 taken orally was not systemically available in the dose range tested.<wbr> The PK data from this study measured blood levels of a single dose of SYN-004 in participants over a 10-fold dose range.<wbr> Minimal levels of SYN-004 were observed in the bloodstream across the dose range investigated in the participants.<wbr> </div><div style="margin-bottom: 10px;"><U>The Phase 1b</U>, multiple-ascending dose PK study provided data to further support that SYN-004 is not systemically available, as no meaningful levels of SYN-004 were observed in the bloodstream after participants received multiple doses of SYN-004 four times a day over a seven-day period.<wbr> The PK data confirm Synthetic Biologics' expectations based on previous data from the first generation enzyme (P1A).<wbr> </div><div><U>Safety</U> In addition, no clinically significant safety events were observed, and both the single and multiple doses of SYN-004 were well tolerated by the participants of the Phase 1 studies.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2294">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-19T17:45:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-19T17:45:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biosimilar of Remicade Submitted for CD in Europe</title>
	<pubDate>2015-03-19T17:38:12+01:00</pubDate>
	<wp:post_id>5932</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Samsung filed the MAA application based on the outcomes from a large head-to-head preclinical data package focused on both SB2 and Remicade (the original drug), which was compared in a phI study that also included healthy participants.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In addition, the company also presented data from a head-to-head phIII equivalence trial, which examined patients who suffer from moderate-to-severe rheumatoid arthritis (RA), one of the conditions for which the drug is indicated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Ifapproved by the EMA, SB2 is going to be commercialized by Biogen Idec and is expected to become available to treat the same conditions as Remicade.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2293">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-19T17:38:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-19T17:38:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Samsung Initiates Coverage Of Medy-Tox Providing Some New Insights</title>
	<pubDate>2015-03-19T13:45:27+01:00</pubDate>
	<wp:post_id>5933</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Samsung's Report on MedyTox assumes that Innotox will contribute 10% to Allergan's botulinum toxin sales and will capture 7.<wbr>2% share of the global market by 2023 generating sales of $510m.<wbr> Allergan is expected to commence phIII trials in Q415 although indications were given by Allergan last year that it would need to conduct confirmatory phII trials first, potentially because phII material came from a different plant and that production out of Osong will be based on a plant-based cell culture media.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Neuromodulator Sales Outlook</STRONG> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7945_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The report notes that current Neuronox sales go to nations not requiring additional clinical trials beyond those undertaken in Korea, with top destinations being Japan, Thailand, Brazil and Iran.<wbr> Japan apparently accounts for 30% of export sales as it requires no additional overseae trial for botulinum toxin to be imported for cosmetic purposes.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7945_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7945_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">The Samsung analyst is suggesting that Innotox has several advantages over Neuronox apart from being available in liquid form.<wbr> </div><div style="margin-bottom: 10px;"><OL><LI>It is manufactured using a plant (not animal) culture media, which leads to better reproducibility,
</LI>
<LI>There is as a consequence less risk of viral contamination; and,
</LI>
<LI>It is easier to strip the protein form.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;">The analyst believes Innotox will go on widespread global sale no later than 2019, although as stated above a confirmatory phII study does not seem to have been factored into their forecast.<wbr> Of course, if for cosmetic purposes, a similar development programme is pursued to that being undertaken by Alphaeon (Daewoong) then a 2019 approval could be more realistic.<wbr> However, we have yet to see whether its programme is deemed adequate for approval.<wbr> Prior to Alphaeon initiating its aesthetic development programme, Daewoong had similarly gained approval in Korea based on a phIII GL study.<wbr> The difference in the case of Medytox, is we are at looking at production in a different plant using we suspect, although not confirmed, a different cell culture system than that used for the phIII trial.<wbr> </div><div>Source: Samsung Securities Report 13th March 2015.<wbr> </div><!-- Comment details --><a name="neurology7945attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7945_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7945_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(70,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7945_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7945">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-19T13:45:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-19T13:45:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: OXiGENE's Combretastatin A-4 Phosphate (ZYBRESTAT®) to Enter POC Trial for GI-NET</title>
	<pubDate>2015-03-18T16:05:33+01:00</pubDate>
	<wp:post_id>5934</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">OXiGENE's Combretastatin A-4 Phosphate (ZYBRESTAT®) to Enter POC Trial for GI-NET</span>&nbsp;<br><span style="font-size: 12px;">Comment: The protocol of the Ph2 will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic GI-NETs with elevated biochemical markers who have relapsed during or after receiving prior standard of care therapies, including octreotide, chemotherapy or targeted therapy.<wbr> PE will assess change from one or more baseline biomarker values for each patient to each study visit and study end.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7662">...</a><br></div><div>OxiGene has announced in the 2014 financial results that they are planning to progress the Phase II study for ZYBRESTAT (fosbretabulin) in GI-NET.<wbr> More specifically the CEO stated the intention of completing the enrollment in the ongoing Phase II study <a href="https://clinicaltrials.gov/ct2/show/NCT02132468?term=fosbretabulin&rank=8&submit_fld_opt=" class="defaultlink">(NCT02132468)</a>, due to deliver data for primary outocme measures in December 2016.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=8001">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7662">View thread  Endocrinology7662: OXiGENE's Combretastatin A-4 Phosphate (ZYBRESTAT®) to Enter POC Trial for GI-NET</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-18T16:05:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-18T16:05:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Glide Announces Results For The SDI Technology Planned To Deliver Octreotide Novel Formulation</title>
	<pubDate>2015-03-18T15:47:34+01:00</pubDate>
	<wp:post_id>5935</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Glide Technologies has reported results for two different studies using its innovative Solid Dose Injection system (SDI) to deliver a solid dose of drug formulation through the patient skin.<wbr> The first study confirmed the ability of the SDI system to deliver the drug through a well-established model of human skin.<wbr> The second study proved the utility and ease-of-use of the system's design and operation in naive human volunteers.<wbr> Glide is undergoing the development of an octreotide solid formulation delivery through the SDI system, and planning to design a bioequivalent study in Q4 2015, after the optimization of the device design, currently ongoing.<wbr> Following the final development stages, manufactuiring scale-up will be taken on by Albany Molecular Research (AMRI).<wbr> </div><div style="margin-bottom: 10px;">In the skin delivery study, prototypes of the SDI design were used to deliver 100 placebo solid doses in established in vivo model of human skin.<wbr> The placebo was design to replicate the characteristics of the octreotide formulation that Glide is planning to evaluate.<wbr> The results of the delivery trial demonstrate that SDI achieves 100% penetration rate into the skin and deliver consistently the solid dose.<wbr> The 22 volunteers also scored the overall comfort and ease-of-use of the device, resulting highly in each of the usability tests undertaken.<wbr> </div><div style="margin-bottom: 10px;">Even if the SDI technology would deliver octreotide formulation via immediate release, it is indeed an interesting device to keep in mind in an industry where the trend is shifting to more patient-focused and targeted products.<wbr> </div><div>Source: Glide and FierceBiotech </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7998">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-18T15:47:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-18T15:47:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NCCN Updates Guideline To Reflect Approval Of New CRPC Therapies</title>
	<pubDate>2015-03-18T15:31:57+01:00</pubDate>
	<wp:post_id>5936</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NCCN 20th Annual Conference was held and presented end of last week.<wbr> For men diagnosed with metastatic CRPC, options recommended in the guidelines for first-line therapy are enzalutamide, abiraterone plus prednisone, and docetaxel plus prednisone.<wbr> Dr, Andrew Armstrong (Vice Chair of the Panel NCCN Prostate Cancer) was interviewed by Medscape, tasquinimod, ipilimumab, and H2H cabazitaxel versus docetaxel were noted as the emerging trials to change clinical practice.<wbr> </div><div style="margin-bottom: 10px;">Update on the NCCN guidelines reflects </div><div style="margin-bottom: 10px;"><UL><LI>recent approval of Provenge (supported by the IMPACT trial),
</LI>
<LI>Xtandi in chemo na&iuml;ve setting (supported by data from PREVAIL),
</LI>
<LI>evidences generated from CHAARTED trial supporting docetaxel use in mCRPC,
</LI>
<LI>Zytiga + prednisone: supporting evidence from COU-AA-302
</LI>
</UL> </div><div style="margin-bottom: 10px;">The key changes in NCCN 2015 version include: </div><div style="margin-bottom: 10px;">Symptomatic disease is replaced by "visceral metastases" and therapy options are now stratified by if the patients have "visceral metastases" or not.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>First line therapy, no visceral metastases: therapy options added include enzalutamide, abiraterone + predniosone, docetaxel + prednisone, and radium 223 (for symptomatic bone mets)
</LI>
<LI>First line therapy, with visceral metastases: therapy option added includes enzalutamide.<wbr>
</LI>
<LI>Second line therapy options are now stratified according to if patients have visceral mets or not as well as prior therapies with enzalutamide/<wbr>abiraterone or docetaxel
</LI>
</UL> </div><div style="margin-bottom: 10px;">Details of the NCCN guideline can be found <STRONG><SPAN style="text-decoration: underline;"><a href="http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf" class="defaultlink">here</a></SPAN></STRONG> </div><div>Source: Medscape, NCCN </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10342">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-18T15:31:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-18T15:31:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Galeterone Ph3 Trial In mCRPC Remains On Track For 1H 2015</title>
	<pubDate>2015-03-17T18:29:37+01:00</pubDate>
	<wp:post_id>5937</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Galeterone Ph3 Trial In mCRPC Remains On Track For 1H 2015</span>&nbsp;<br><span style="font-size: 12px;">Comment: During TOKAI's 2014 financial report webcast, TOKAI reiternated the progress to begin Phase 3 ARMOR3-SV trial reamins on track in the 1H 2015 with the completion for companion AR-V7 clinical trial assay.<wbr> In terms of financial, TOKAI ended 2014 with over $105 m cash that will suffice for funding into 2017 - allowing TOKAI to take galeterone as a wholly owned WW assest through topline data due by late 2016.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10335">...</a><br></div><div>Comment: TOKAI and Qiagen today announced an expansion of the agreement for the development and commercialization of an AR-V7 companion diagnostic for use with galeterone.<wbr> Qiagen is a global leader in <STRONG>liquid biopsy-based</STRONG> solutions for precision medicine and has the expertise to commercialize the companion diagnostic.<wbr> Under the expanded agreement, Tokai will receive the exclusive right from Qiagen to its newly acquired circulating tumour cell (CTC) enrichment technology for use with galeterone.<wbr> This technology was used in a study to detect AR-V7 expression that was reported by r<SPAN style="font-family: Arial,sans-serif;">esearchers from Johns Hopkins University at ASCO GU 2015 and their analysis revealed that men who were AR-V7 positive did markedly better on chemotherapy than with hormone treatment, while AR-V7-negative patients experienced similar efficacy from either treatment.<wbr> </SPAN> The development of the companion test (with the incorporated of the newly acquired CTC technology) is expected to complete in 1H 2015 to be incorporated as part of the SOP for the Ph3 ARMOR3-SV.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10341">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10335">View thread  Oncology10335: Galeterone Ph3 Trial In mCRPC Remains On Track For 1H 2015</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-17T18:29:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-17T18:29:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Auspex on Track to Submit NDA for Chorea Associated with Huntington's Disease</title>
	<pubDate>2015-03-17T17:57:02+01:00</pubDate>
	<wp:post_id>5938</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results management reported it plans to submit a NDA under Section 505(b)(2) for Austedo (for HD) by mid-2015.<wbr> The company plans to pursue a Section 505(b)(2) regulatory pathway for Austedo (for tardive dyskinesia) and file an NDA in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>HD Program Update</STRONG> </div><div style="margin-bottom: 10px;">Auspex successfully completed its FIRST-HD Phase 3 clinical trial of Austedo as a potential treatment for people with chorea associated with Huntington's disease and the four-week switch portion of its ARC-HD clinical trial.<wbr> </div><div style="margin-bottom: 10px;">The company has also completed a thorough QT study of SD-809 in healthy volunteers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>TD Program Update</STRONG> </div><div style="margin-bottom: 10px;">Auspex completed target enrollment for its ARM-TD trial of Austedo in tardive dyskinesia in February 2015 and expects to report top-line results in mid-2015.<wbr> </div><div style="margin-bottom: 10px;">Auspex is also conducting an additional pivotal trial of Austedo in people with tardive dyskinesia, AIM-TD (<U>A</U>ddressing <U>I</U>nvoluntary <U>M</U>ovements in <U>T</U>ardive <U>D</U>yskinesia), with topline results from its ARM-TD trial in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Financial Results</STRONG> </div><div style="margin-bottom: 10px;">For the three months ended December 31, 2014, Auspex reported a net loss of $20.<wbr>0 million, an increase of $12.<wbr>4 million from the $7.<wbr>6 million net loss reported for the comparable period in 2013.<wbr> </div><div style="margin-bottom: 10px;">For the twelve months ended December 31, 2014, the company reported a net loss of $59.<wbr>5 million, an increase of $43.<wbr>9 million from the $15.<wbr>6 million net loss reported for 2013.<wbr> </div><div>Research and development expenses for the three months ended December 31, 2014 were $16.<wbr>4 million, compared to $3.<wbr>5 million for the same period in 2013.<wbr> For the twelve months ended December 31, 2014, research and development expenses were $37.<wbr>7 million, compared to $10.<wbr>0 million for 2013.<wbr> The increases in our research and development expenses are primarily attributable to the advancement of our Austedo clinical programs during 2014, including the completion of two Phase 3 Huntington's disease clinical trials and the initiation of two pivotal clinical trials for tardive dyskinesia </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7943">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-17T17:57:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-17T17:57:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Trial for Vibrating Capsule for Chronic Constipation Underway</title>
	<pubDate>2015-03-17T16:31:17+01:00</pubDate>
	<wp:post_id>5939</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The randomized, double-blind trial aims to determine the efficacy of Vibrant Ltd's tiny, motorized capsule in alleviating constipation.<wbr> PE will assess FBM.<wbr> The seven-year-old startup’s owned by a number of private investors, as well as the founders is actively looking to partner out.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2292_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The device is programmed to begin vibrating 6 to 8 hours after being swallowed, which is the average amount of time it takes to travel to the large intestine.<wbr> </div><div style="margin-bottom: 10px;">The stimulation provided by the device has been demonstrated to produce intestinal contractions and help move stool through the GI tract.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reference: <A href="https://clinicaltrials.gov/ct2/show/NCT02030756?spons=Vibrant+Ltd&amp;rank=2">NCT02030756</A> </div><div style="margin-bottom: 10px;">Design: Participants will be randomly assigned to receive two capsules per week for 8 weeks or placebo, and will record in a diary the frequency and completeness of bowel movements, abdominal pain, straining, and when they took the capsules, the release said.<wbr> Including a 2 week preparation period and a 2 week follow-up period, each patient will participate in the trial for a total of 12 weeks.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 144 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients aged 18 years and older.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with chronic idiopathic constipation according to Rome III criteria and who have not experienced relief of their symptoms from available therapies (osmotic and stimulant laxatives which was used for at least one month at recommended dose).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with more than 1 bowel movement/<wbr>2 weeks and &lt; 3 bowel movement/<wbr>week.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Colonoscopy performed in the past 10 years prior to study participation, unless the patients are &lt;50 years old and without alarming signs and symptoms</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient signed ICF</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">For women with childbearing potential, adequate contraception</LI>
</UL> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Location /<wbr> country (# of sites): Israel (7); USA (7)</P> </div><!-- Comment details --><a name="gastroenterology2292attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2292_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(28,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2292">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-17T16:31:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-17T16:31:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Timeline to Re-initiate Omeros Huntington's Program Still Unclear</title>
	<pubDate>2015-03-17T14:47:13+01:00</pubDate>
	<wp:post_id>5940</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results for Q4 and FY14, management reported its continued evaluation of data from a single nonclinical rat study in the OMS824 program.<wbr> The company is finalizing the package of nonclinical materials requested by the <ORG>FDA</ORG>, and looks forward to re-activating enrollment in its Ph2 in the "near future" (analysts anticipate in H2:15).<wbr> OMIDRIA, Omeros' most advanced drug, is expected to reach the US market next month (analysts currently project $32.<wbr>6MM in product sales in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7942_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">- broad launch planned for early April in the US </div><div style="margin-bottom: 10px;">- currently under review for marketing approval by the <ORG>European Medicines Agency</ORG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7942_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology7942attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7942_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7942_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(29,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7942">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-17T14:47:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-17T14:47:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sirtex's SIRFLOX Study Fails To Meet Primary Endpoint</title>
	<pubDate>2015-03-17T12:33:19+01:00</pubDate>
	<wp:post_id>5941</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: More than $1bn has been knocked off Sirtex shares as the company's metastatic colorectal cancer (mCRC) SIRFLOX study failed to meet its primary endpoint of demonstrating a statistically significant improvement in overall PFS.<wbr> The study did, however, show a statistically significant improvement in PFS in the liver, an important secondary endpoint.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Negative Primary Endpoint<BR></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">The preliminary analysis undertaken has shown that adding SIR-Spheres Y-90 resin microspheres to a current first-line systemic chemotherapy regimen for the treatment of non-resectable metastatic colorectal cancer does not result in a statistically significant improvement in overall PFS, a measure of progression of existing tumours and/<wbr>or the development of new tumours in any organ or body site.<wbr><BR></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Positive Secondary Endpoint<BR></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">The positive results with the secondary study endpoint is important as liver tumours are commonly the only, or dominant site of disease in patients with mCRC and are the major site of disease influencing survival.<wbr> Up to 90% of mCRC patients die of liver failure due to the local effects of the liver tumours to which Sir-Spheres are specifically targeted.<wbr><BR></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">400 Patient Liver Cancer Study Underway<BR></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Final results and more detailed analysis will be presented at ASCO later this year.<wbr> Meanwhile the group will await with interest the results of the <STRONG>SARAH</STRONG> study which recently completed enrolment and is evaluating in a randomised controlled study the therapeutic value fo Sir-Spheres vs.<wbr> sorafenib in advanced HCC.<wbr> <STRONG>Results are expected late 2016.<wbr></STRONG><BR></SPAN> </div><div>Source: <A href="http://www.sirtex.com">www.<wbr>sirtex.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10339">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-17T12:33:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-17T12:33:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Chiasma Raises $33.8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</title>
	<pubDate>2015-03-17T11:18:18+01:00</pubDate>
	<wp:post_id>5942</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Chiasma has today announced the appointment of David Stack (CEO and chairman of Pacira Pharmaceuticals) as Chairman of the Board, and John Scarlett (CEO and president of Geron Corporation) as a member of the board.<wbr> Roni Mamluk, CEO, on commenting the news stressed the "benefit from the deep experience and knowledge Dave and John will bring to Chiasma as we move oral octreotide toward a NDA submission by the middle of this year.<wbr>.<wbr>.<wbr>".<wbr> Once again Chiasma is confirming their intention on submitting an NDA to the FDA this year, with possible US approval in 2016.<wbr></span>&nbsp;<br></div><div>Further to new board members, Chiasma has now appointed Mark Leuchtenberger as CEO, a proven leader with successful track record in new products commercialization.<wbr> Leuchtenberger has 25 years experience in the pharmaceutical industry and from 1996 to 2002 was at Biogen, responsible for North America and the international commercial operations, including late-stage development, launch and marketing of Avonex, now a $3 billion product.<wbr> Roni Mamluk, previous CEO, will remain in the company as chief development officer.<wbr> Chiasma is also expanding its US operations in the Boston area.<wbr> The company is clearly pushing on a new strategy to ensure the best in-house capabilities and expertise to launch the first formulation of oral octreotide.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7994">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7902">View thread  Endocrinology7902: Chiasma Raises $33.<wbr>8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-17T11:18:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-17T11:18:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Highlights of Versartis Presentation at ENDO</title>
	<pubDate>2015-03-16T18:14:23+01:00</pubDate>
	<wp:post_id>5943</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Highlights of Versartis Presentation at ENDO</span>&nbsp;<br><span style="font-size: 12px;">Comment:  Versartis was selected to present data from its ongoing Extension Study of pre-pubertal children with moderate growth hormone deficiency (GHD) in a poster presentation at ENDO 2015 in San Diego, CA.<wbr> While previously disclosed this is the first time the results are being presented in a scientific meeting.<wbr> Highlights of the poster presentation are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7986">...</a><br></div><div style="margin-bottom: 10px;">A bit of primary intelligence on Versartis at ENDO indicates that the company US plan is better established, but the EU plan is more uncertain (likely to lead to partnership).<wbr> Three different prototypes for the devices have been assessed, with final decision undergoing.<wbr> Please see below additional information.<wbr> </div><div><UL><LI> </LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7990">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7986">View thread  Endocrinology7986: Highlights of Versartis Presentation at ENDO</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-16T18:14:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-16T18:14:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NICE issues Final Appraisal Determination Recommending Takeda's Entyvio for UC</title>
	<pubDate>2015-03-16T18:04:40+01:00</pubDate>
	<wp:post_id>5944</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NICE has issued a final appraisal determination (FAD) recommending Entyvio (vedolizumab), within its marketing authorisation, as an option for the treatment of moderately to severely active ulcerative colitis (UC) in adults, only if the company provides the medication with a discount agreed in a patient access scheme (PAS).<wbr> NICE further noted in the FAD that Entyvio was to be given until it stops working or surgery is needed.<wbr> Patients should be reassessed to see whether treatment should continue at 12 months after it was started.<wbr> Treatment should only continue if there is clear evidence of ongoing clinical benefits.<wbr> For people in complete remission at 12 months, it was suggested that it was worth considering stopping treatment with Entyvio and resuming it in case of a relapse.<wbr> Patients who continue treatment with Entyvio will have to be reassessed at least every 12 months to see whether continued treatment is justified.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">When considering the cost-effectiveness analysis, NICE's Appraisal Committee noted that it would assess whether Entyvio was cost effective in two patient sub-groups separately.<wbr> These sub-groups comprise people who had not had TNF-alpha inhibitor treatment before and those in whom TNF-alpha inhibitors have failed, as opposed to the whole population.<wbr> </div><div style="margin-bottom: 10px;">In the case of patients for whom treatment with a TNF-alpha inhibitor has failed, the committee noted that it preferred using the base case estimate by Woehl et al.<wbr> or Swinburn et al.<wbr> rather than the company's one.<wbr> Incremental cost-effectiveness ratios (ICERs) were consequently noted to be around the upper limit that is considered to be a cost-effective use of the National Health Service's resources, at GBP31,900 (USD47,014.<wbr>5) and GBP27,500 per quality-adjusted life year (QALY) gained, respectively.<wbr> </div><div style="margin-bottom: 10px;">For patients who had not had treatment with a TNF-alpha inhibitor before, the manufacturer estimated that the pairwise ICERs with adalimumab and conventional therapy were GBP7,000 and GBP5,000 per QALY gained, respectively.<wbr> In addition, the committee noted that the application of utility values by Swinburn et al.<wbr> rather than Woehl et al.<wbr>, as well as assuming a one-year stopping rule, Entyvio's ICER would be under GBP20,000 per QALY gained making it the dominant option versus its comparators.<wbr> The company and the Department of Health have agreed on a PAS, according to which Entyvio would be made available with a simple discount to the list price, which is applicable at the point of purchase or invoicing.<wbr> </div><div style="margin-bottom: 10px;">Next Steps: The FAD is available for appeal until 27 March, with the final guidance expected in April.<wbr> </div><div>Source: IHS GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2291">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-16T18:04:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-16T18:04:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: A Positive Synergy With Ipilimumab and PROSTVAC May Present A Future Oppoutunity Of First Immuno-Oncology Doublet Entry In mCRPC</title>
	<pubDate>2015-03-16T17:21:02+01:00</pubDate>
	<wp:post_id>5945</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">A Positive Synergy With Ipilimumab and PROSTVAC May Present A Future Oppoutunity Of First Immuno-Oncology Doublet Entry In mCRPC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Bavarian Nordic will present updated overall survival data from combination of PROSTVAC + Ipilimumab at the ASCO GU 2015 in Orlando on Thursday 26th Feb (Board 8general poster session A 11:30am -1 pm).<wbr> The Ph1 Proof of Concept trial is led by NCI and ~20% of men with advanced prostate cancer treated with combination remain alive at 80 months after initating treatment.<wbr> The observed median OS was 31.<wbr>3 months for all doses cohotrts and 37.<wbr>2 months for ipi 10 mg/<wbr>kg cohort.<wbr> At the time of initiation, docetaxel was the only approved agent and the predicted OS was 18.<wbr>5 months.<wbr> A total of 30 pateints enrolled in the Ph1 tial was therefore randomised to receive either combination or Prostvac + Placebo.<wbr> The presentation will focus on the comparison of data from three independent trial (2 x Ph2 PRSTVAC montherapy trial and Ph1 PROTVAC+Ipi combination trial) and the authors conclude that the positive data warrnats pivitol trial to evaluate this potential synergy in mechamism action of two immuno-modulating agents.<wbr> Given chemo naive mCRPC space is getting very crowded, especially both abiraterone and enzalutamide have demonstrated <STRONG><SPAN style="text-decoration: underline;">significant survival benefit</SPAN></STRONG> , the critical challenge for Bavarian Nordic and BMS is to overcome the present competitive hurdle.<wbr> The strategic intention and progress of futrue pivitol trial needs to be closely followed.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10287">...</a><br></div><div>Comment: The study was presented as poster and interestingly the authors concluded that the study provides a strong rationale to combine PROSTVAC with anti-PD-1 or anti-PDL1, largely due to superior side effects profile compared to CTLA4 inhibition.<wbr> Pictures of the posters are kindly provided by Dr.<wbr> Patrick Cabri (Global Medical Affairs Director Decapeptyl/<wbr>Duphereline, Uro-Oncology Franchise) </div><!-- Comment details --><br><a name="oncology10338attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10338_1_Prostvac%2b%20Ipi%20study%20design.JPG">Prostvac+ Ipi study design.JPG</a>&nbsp;&nbsp;(17,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10338_2_Prostvac%2b%20Ipi%20Ph1%20waterfall%20plot.JPG">Prostvac+ Ipi Ph1 waterfall plot.JPG</a>&nbsp;&nbsp;(22,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10338_3_Prostvac%2b%20Ipi%20Ph1%20OS%20data.JPG">Prostvac+ Ipi Ph1 OS data.JPG</a>&nbsp;&nbsp;(21,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10338_4_Prostvac%2b%20Ipi%20Ph1%20OS%20data%20II.JPG">Prostvac+ Ipi Ph1 OS data II.JPG</a>&nbsp;&nbsp;(18,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10338_5_Final%20Conclusion.JPG">Final Conclusion.JPG</a>&nbsp;&nbsp;(53,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10338">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10287">View thread  Oncology10287: A Positive Synergy With Ipilimumab and PROSTVAC May Present A Future Oppoutunity Of First Immuno-Oncology Doublet Entry In mCRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-16T17:21:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-16T17:21:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Jevtana's Been Delisted From NHS' Cancer Drugs Fund</title>
	<pubDate>2015-03-16T16:59:09+01:00</pubDate>
	<wp:post_id>5946</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NHS England has published a list of 'delisted drug" from current cancer drug fund last week - Cabazitaxel is being delisted for mCRPC patients who had previously treated with a docetaxel-containing regimen.<wbr> Also docetaxel (for the use in combination with ADT as primary treatment for hormone sensitive metastatic prostate cancer) is also currently on the "waiting list" for the final decision.<wbr> Despite of the decision,  NHS England remains in dialogue with Sanofi to explore immediate ways of maintaining access to patients for cabazitaxel until the outcome of any NICE review </div><div style="margin-bottom: 10px;">Cabazitaxel is available on the CDF since 2012.<wbr> There have been 707 request submitted to the CDF for cabazitaxel in the last 18 months.<wbr> This decision will mean cabazitaxel will no longer be available for new patients in England on the NHS.<wbr> </div><div style="margin-bottom: 10px;">Professor Amit Bahl, Consultant Clinical Oncologist at Bristol Haematology and Oncology Centre commented, "The decision to de-list cabazitaxel is highly detrimental to patients as it is an important treatment for some men with prostate cancer who may have no other treatment options available to them.<wbr> It is incomprehensible that as clinicians we will no longer be able to treat patients with important therapies proven to extend survival.<wbr> Having treated several patients with cabazitaxel I am very aware of the real life difference it makes to their survival and quality of life and would like future patients to have the opportunity to avail this treatment.<wbr>" </div><div style="margin-bottom: 10px;">Other Prostate Cancer Agents That Remain On The CDF Include: </div><div style="margin-bottom: 10px;">Abiraterone (Zytiga): chemo na&iuml;ve, asymptomatic (pain score 0/<wbr>1) or mildly symptomatic (pain score 2-3) metastatic CRPC patients (without visceral disease) </div><div style="margin-bottom: 10px;">Enzalutamide (Xtandi):  chemo na&iuml;ve, asymptomatic (pain score 0/<wbr>1) or mildly symptomatic (pain score 2-3) metastatic CRPC patients </div><div style="margin-bottom: 10px;">Radium-223 (Xofigo): Post-docetaxel CRPC patients with more than 2 bone metastases (without visceral mets) </div><div>Source: globaldata, NHS (<a href="http://www.england.nhs.uk/wp-content/uploads/2015/03/ncdf-list-mar-15.pdf" class="defaultlink" title="http://www.england.nhs.uk/wp-content/uploads/2015/03/ncdf-list-mar-15.pdf">england.nhs.uk/<wbr>wp&hellip;</a>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10337">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-16T16:59:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-16T16:59:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: UK Cancer Drug Fund Poised To De-list Novartis's Afinitor (Everolimus)</title>
	<pubDate>2015-03-16T14:31:00+01:00</pubDate>
	<wp:post_id>5947</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: UK Cancer Drug Fund Poised To De-list Novartis's Afinitor (Everolimus)</span>&nbsp;<br><span style="font-size: 12px;">Today was announced that NHS England has performed a U-turn on the decision of delisting Everolimus from the CDF, as it was announced in January.<wbr> Novartis has worked with the CDF to reach an agreement for keeping everolimus on the CDF list for advanced breast cancer and kidney cancer as the drug meets the clinical threshold set by the NHS in these indications.<wbr>  Novartis could not find an agreement for well-differentiated pNETs and has accepted delisting everolimus in this indication.<wbr> Novartis will supply Afinitor to pNET patients on 'named patients basis', upon request from oncologists through their local clinical commissioning group (CCG).<wbr> The NHS is due to publish a new list for the revised drugs which will be included in the CDF.<wbr></span>&nbsp;<br></div><div>The NHS has published a <a href="http://www.england.nhs.uk/wp-content/uploads/2015/03/ncdf-list-mar-15.pdf" class="defaultlink">new list</a>for the revised drugs which will be included in the CDF - Everolimus is on the CDF list only for advanced breast cancer and metastatic renal cell carcinoma, but has been delisted for well-differentiated pNET.<wbr> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8138c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Afinitor is no longer be available from Cancer Drugs Funds to treat pNET, effectively July 21.<wbr> (Source: Biocentury) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7989">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7911">View thread  Endocrinology7911: UK Cancer Drug Fund Poised To De-list Novartis's Afinitor (Everolimus)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-16T14:31:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-16T14:31:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alimentary Health's Alflorex Got Strong Endorsement from Irish Pharmacists</title>
	<pubDate>2015-03-16T11:11:39+01:00</pubDate>
	<wp:post_id>5948</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After just 1 year on the market, Alflorex (a range of probiotics for adults and children) has won 'Best Irish Pharmacy Product 2015' at the OTC Pharmacy Awards.<wbr> The company has published key scientific papers detailing the clinical work of AH’s <EM>Bifidobacterium infantis</EM> 35624 in IBS.<wbr> The company partners with companies at all stages of a programme – from joint research in the early discovery phases to in-licensing of fully developed products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.alimentaryhealth.ie/products/Alflorex">http:/<wbr>/<wbr>www.<wbr>alimentaryhealth.<wbr>ie/<wbr>products/<wbr>Alflorex</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2287_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><A href="http://www.alimentaryhealth.ie/publications">http:/<wbr>/<wbr>www.<wbr>alimentaryhealth.<wbr>ie/<wbr>publications</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2287">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-16T11:11:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-16T11:11:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norgine Adds Next Generation Endoscopic Device to Existing Bowel Prep Portfolio</title>
	<pubDate>2015-03-16T10:43:11+01:00</pubDate>
	<wp:post_id>5949</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: From Q2:15, Norgine will distribute and commercialise in the UK Arc Medical Design's ENDOCUFF VISION, a Class 1 sterile medical device used in colonoscopy.<wbr> The deal covers major EU markets.<wbr> Results from a recent study published in December 2014 shows that the adenoma detection rates (ADR) significantly increased with the use of the Endocuff compared to standard colonoscopy (35.<wbr>4%[95% confidence interval{CI} 29–41%] vs.<wbr> 20.<wbr>7%[95%CI 15–26%], p,0.<wbr>0001).<wbr> Significantly more sessile polyps were detected by Endocuff-assisted colonoscopy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Trial Reference <A href="https://clinicaltrials.gov/ct2/show/NCT02034929?term=NCT02034929&amp;rank=1">NCT02034929</A> </div><div style="margin-bottom: 10px;">Paper Reference: Higher Adenoma Detection Rates with Endocuff-Assisted Colonoscopy – A Randomized Controlled Multicenter Trial - Martin Floer et al.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Endocuff is a device mounted on the tip of the colonoscope to help flatten the colonic folds during withdrawal </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2286_1_copiedImage%5b0%5d.png"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2311c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Norgine has acquired a 70% stake in Arc Medical Design Ltd.<wbr> while retaining Arc Medical Design existing management, who will retain a 30% ownership stake.<wbr> This transaction advances the growth of Norgine's colon cancer prevention and detection franchise and strengthens the global launch of Arc Medical Design&rsquo;s products.<wbr> </div><div>Source: <A href="http://www.norgine.com/media/press-release/norgine-completes-acquisition-of-a-majority-stake-in-arc-medical-design">http:/<wbr>/<wbr>www.<wbr>norgine.<wbr>com/<wbr>media/<wbr>press-release/<wbr>norgine-completes-acquisition-of-a-majority-stake-in-arc-medical-design</A> </div></div><a name="gastroenterology2286attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2286_1_copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(268,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2286">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-16T10:43:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-16T10:43:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galeterone Ph3 Trial In mCRPC Remains On Track For 1H 2015</title>
	<pubDate>2015-03-13T15:42:28+01:00</pubDate>
	<wp:post_id>5950</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During TOKAI's 2014 financial report webcast, TOKAI reiternated the progress to begin Phase 3 ARMOR3-SV trial reamins on track in the 1H 2015 with the completion for companion AR-V7 clinical trial assay.<wbr> In terms of financial, TOKAI ended 2014 with over $105 m cash that will suffice for funding into 2017 - allowing TOKAI to take galeterone as a wholly owned WW assest through topline data due by late 2016.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recent Business Highlights;</SPAN> ARMOR3-SV poster presentation at ASCO GU and annoucement of Companion test development partnership with John Hopkins University </div><div style="margin-bottom: 10px;"><OL dir="ltr"><LI>Tokai presented the protocol and rationale for the ARMOR3-SV Phase 3 trial and supported a CME event discussing AR-V7 in prostate cancer.<wbr> Announced Selection of AR-V7 Assay and Companion Diagnostic Development Partner: In January 2015, Tokai announced that it had obtained an exclusive, worldwide license from the Johns Hopkins University related to patent applications and know-how covering an assay that has been used to determine the AR-V7 status of prostate cancer patients for use with galeterone and announced a collaboration with Qiagen to develop a non-invasive AR-V7 companion diagnostic for use with galeterone.<wbr> Qiagen initiated development of the AR-V7 assay as a companion diagnostic in October 2014 and the Company expects the AR-V7 assay to be available for use for its planned ARMOR3-SV trial in the first half of 2015.<wbr>
</LI>
<LI>Reported Interim Results from Ongoing ARMOR2 Trial: At the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in November 2014, Tokai presented updated interim results from the ongoing Phase 2 ARMOR2 trial evaluating galeterone as a treatment for patients with castration-resistant prostate cancer (CRPC).<wbr> Data demonstrating PSA50 reductions, time to PSA progression and duration of therapy suggests efficacy in patients with C-terminal loss, a segment of the population linked to poor responsiveness to hormonal agents commonly used to treat CRPC.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Financial Results</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>Cash and cash equivalents as of December 31, 2014 was $105.<wbr>3 million compared to $31.<wbr>8 million at December 31, 2013.<wbr>
</LI>
<LI>Research and development expenses were $3.<wbr>8 million in the fourth quarter of 2014 compared to $4.<wbr>3 million in the fourth quarter of 2013 and $14.<wbr>6 million for the full year 2014 compared to $12.<wbr>2 million for the full year 2013.<wbr>
</LI>
<LI>General and administrative expenses were $2.<wbr>5 million in the fourth quarter of 2014 compared to $1.<wbr>2 million in the fourth quarter of 2013 and $8.<wbr>9 million for the full year 2014 compared to $3.<wbr>5 million for the full year 2013.<wbr>
</LI>
<LI>Net Loss was $6.<wbr>2 million for the fourth quarter of 2014 compared to $5.<wbr>5 million for the fourth quarter of 2013 and $23.<wbr>3 million for the full year 2014 compared to $15.<wbr>8 million for the full year 2013.<wbr>
</LI>
</UL> </div><div>Source: TOKAI Press Release </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10341c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: TOKAI and Qiagen today announced an expansion of the agreement for the development and commercialization of an AR-V7 companion diagnostic for use with galeterone.<wbr> Qiagen is a global leader in <STRONG>liquid biopsy-based</STRONG> solutions for precision medicine and has the expertise to commercialize the companion diagnostic.<wbr> Under the expanded agreement, Tokai will receive the exclusive right from Qiagen to its newly acquired circulating tumour cell (CTC) enrichment technology for use with galeterone.<wbr> This technology was used in a study to detect AR-V7 expression that was reported by r<SPAN style="font-family: Arial,sans-serif;">esearchers from Johns Hopkins University at ASCO GU 2015 and their analysis revealed that men who were AR-V7 positive did markedly better on chemotherapy than with hormone treatment, while AR-V7-negative patients experienced similar efficacy from either treatment.<wbr> </SPAN> The development of the companion test (with the incorporated of the newly acquired CTC technology) is expected to complete in 1H 2015 to be incorporated as part of the SOP for the Ph3 ARMOR3-SV.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10335">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-13T15:42:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-13T15:42:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progress Of Bavituximab In HCC</title>
	<pubDate>2015-03-13T15:16:56+01:00</pubDate>
	<wp:post_id>5951</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Peregrine Pharmaceuticals, Inc.<wbr> a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced financial results for the third quarter of fiscal year (FY) 2015 ended January 31, 2015.<wbr> The company provided an update on its advancing clinical pipeline including data from a Phase II IST that evaluated bavituximab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC), and also recalled the translation data presented at the Society of Immunotherapy of Cancer Annual Meeting and preclinical data showed in 2014 San Antonio Breast Cancer Symposium (SABCS) that bavituximab can block immunosuppression within the tumor macro-environment and induce an anti-tumor immune response via fighting tumour T-lymphocytes and decresing tumour inflammatory myeloid derived suppressor cells.<wbr> Currently Peregrine is preparing for US launch for NSCLC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>HCC: Data from the Phase II IST evaluating bavituximab in combination with sorafenib</STRONG> (conducted by Dr.<wbr> Adam Yopp, Assistant Professor of Surgery at the University of Texas Southwestern Medical Center) </div><div style="margin-bottom: 10px;">Data demonstrated that the combination of bavituximab in sorafenib is also in an improved Time to Progression of 6.<wbr>7 months and the disease specific survival of 8.<wbr>7 months.<wbr> Importantly, the combination of bavituximab and sorafenib was well tolerated in patients with advanced HCC with no indications of auto-immune adverse events which have been seen with other check-point immunotherapies.<wbr> This trial is also the subject of an oral presentation by Dr.<wbr> Yopp at the Society of Surgical Oncology at the Annual Cancer Symposium towards the end of March 2015.<wbr>.<wbr> During the presentation, Peregine emphaised on the immune activation events were also observed in HCC patients, thus painting a consistent translational picture from preclinical to clinical as to the breadth of bavituximab&rsquo;s ability as a combination therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Preclinical Data And Biomarker Discovery </STRONG> </div><div style="margin-bottom: 10px;">Peregine annouced three posters have been accepted for presentation at the upcoming AACR Annual Meeting in April as a result of the investment in developing new assays incorporating into trials to assess immune changes within the tumor macro-environment and characterize changes in numbers and types of immune cells.<wbr> One of these posters will discuss data generated using a proprietary XVIVO system using patient tumors which was developed by the lab of Dr.<wbr> Scott Antonia, who is the Thoracic Oncology Department Chair, in the immunology program leader at the H.<wbr> Lee Moffitt Cancer Center in Florida.<wbr> </div><div style="margin-bottom: 10px;">Data presented at the 2014 San Antonio Breast Cancer Symposium was recalled during the webcast to emphsis MOA of bavituximab as an immuno-modulating agent that works within tumour microenvironment, and independent of PD-1 checkpoint blockade pathway.<wbr> Bavituximab demonstrated statistically significant tumor growth inhibition as well as statistically significant increases in the percentages of CD4 and CD8 tumor infiltrating lymphocytes and decreases in tumor associated myeloid-derived suppressor cells, all of which are key indicators of immune activation in breast tumor models when compared to a control antibody.<wbr> </div><div>Source: Peregine Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10334">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-13T15:16:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-13T15:16:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>23andMe to Move Beyond Genetic Testing to Making Drugs</title>
	<pubDate>2015-03-13T09:47:08+01:00</pubDate>
	<wp:post_id>5952</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company is planning to use customer data to make pharma drugs for different disorders.<wbr> Richard Scheller, who retired from Genentech in December last year, will be leading the drug-discovery unit.<wbr> Presently, 23andMe has built one of the world's largest databases of individual genetic information, and has forged alliances with Genentech, for Parkinson&rsquo;s disease, and Pfizer, for irritable bowel syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Big Pharmas Attracted by the Concept</STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2015" class="defaultlink">GastroEnterology2015: Pfizer Supports Translational Research for IBD</a> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11082" class="defaultlink">PharmaWorld11082: Roche Starts Collaboration With 23andMe on Parkinson's Disease</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11120">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-13T09:47:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-13T09:47:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights of Versartis Presentation at ENDO</title>
	<pubDate>2015-03-12T20:27:27+01:00</pubDate>
	<wp:post_id>5953</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  Versartis was selected to present data from its ongoing Extension Study of pre-pubertal children with moderate growth hormone deficiency (GHD) in a poster presentation at ENDO 2015 in San Diego, CA.<wbr> While previously disclosed this is the first time the results are being presented in a scientific meeting.<wbr> Highlights of the poster presentation are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Highlights from the Poster Presentation</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>VRS-317 is safe and well tolerated after 12 months of treatment
<UL><LI>Lower rate of related adverse events in second 6 months<BR> 
</LI>
</UL>

</LI>
<LI>All regimens provide similar IGF-I responses comparable to those of daily rhGH and with minimal excursions of IGF-I SDS exceeding 2
<UL><LI>Dose response confirmed by IGF-I SDS moving up nearly 1.<wbr>0 standard deviation (SD); this was achieved by increasing the dose from 2.<wbr>5 to 3.<wbr>5mg/<wbr>kg semi-monthly<BR> 
</LI>
</UL>

</LI>
<LI>Adjusting VRS-317 dose from 2.<wbr>5 mg/<wbr>kg semi-monthly to 3.<wbr>5 mg/<wbr>kg semi-monthly resulted in:
<UL><LI>Expected increase in IGF-I response (mentioned above) without overexposure
</LI>
<LI>Patients who switched from 1.<wbr>15 mg/<wbr>kg weekly to 3.<wbr>5 mg/<wbr>kg semi-monthly (n=5) experienced a height velocity increase from 7.<wbr>5 to 9.<wbr>3 cm/<wbr>yr<BR> 
</LI>
</UL>

</LI>
<LI>Less waning of the growth response was observed over the first 12 months of VRS-317 treatment than typically observed with daily rhGH therapy.<wbr>
</LI>
</UL> </div><div>Poster is attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20150331&edate=20150101&rs=/link%20Endocrinology7986%401" class="defaultlink">@1</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7990c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">A bit of primary intelligence on Versartis at ENDO indicates that the company US plan is better established, but the EU plan is more uncertain (likely to lead to partnership).<wbr> Three different prototypes for the devices have been assessed, with final decision undergoing.<wbr> Please see below additional information.<wbr> </div><div><UL><LI> </LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div></div><a name="endocrinology7986attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7986_1_VSR%255fClinical%255fPoster%255f11x17%255fc1%255fv5%2d030215%255fFINAL%255f2%255f.pdf">VSR_Clinical_Poster_11x17_c1_v5-030215_FINAL_2_.pdf</a>&nbsp;&nbsp;(2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7986">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-12T20:27:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-12T20:27:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Hanmi's Once a Week GH</title>
	<pubDate>2015-03-12T20:12:34+01:00</pubDate>
	<wp:post_id>5954</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the 97th ENDO Hanmi confirmed the safety and duration of more than a week in Ph1 clinical trials on Korean healthy adult males when LAPSLrhGH was injected with a single dose.<wbr> Also, the company confirmed the safety, longer duration, and suitable doses for the future development of LAPSrhGH through ongoing Ph2 clinical studies on adult patients suffering from growth hormone deficiency in 22 medical institutions, not only in Korea, but also in 8 Eastern European countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Drug Development Milestone</STRONG> </div><div style="margin-bottom: 10px;">According to the company Feb 5th presentation, a Ph3 is expected to start at the beginning of 2018.<wbr> </div><div>Source: Hanmi </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7985">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-12T20:12:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-12T20:12:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progress of VT-464: Early Pipeline Entry In mCRPC</title>
	<pubDate>2015-03-12T19:26:09+01:00</pubDate>
	<wp:post_id>5955</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Professor Johann de Bono presented tolerability pharmacokinetic and pharmacodynamic results from Innocrin&rsquo;s Phase 1/<wbr>2 clinical study of oral twice-daily VT-464 (Innocrinpharm) in men with castrate resistant prostate cancer (CRPC) who were either treatment-na&iuml;ve or had previously failed abiraterone or enzalutamide therapy at ASCO GU.<wbr> Results from this study support VT-464&rsquo;s CYP17 lyase selectivity as well as efficacy as demonstrated by PSA reductions of 50% and 90% in 2 of 7 prior Xtandi patients.<wbr> </div><div style="margin-bottom: 10px;">William Moore Ph.<wbr>D.<wbr> President and CEO of Innocrin said &ldquo;The potent reduction of patients&rsquo; circulating androgens due to VT-464 in the absence of any signs of mineralocorticoid excess syndrome cortisol depletion adrenal insufficiency or hypokalemia support its unprecedented CYP17 lyase selectivity.<wbr> Moreover the observation of PSA responses in men who have failed Xtandi&reg; combined with VT-464&rsquo;s unique AR antagonist mechanism and 7-hour plasma half-life warrants its further evaluation as a once-daily oral therapy without glucocorticoid supplementation in patients who have failed enzalutamide or abiraterone/<wbr>prednisone.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">Innocrin discovers and develops novel best-in-class oral inhibitors of CYP17 lyase a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC).<wbr> VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin.<wbr> CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis polycystic ovary syndrome and congenital adrenal hyperplasia.<wbr> Innocrin&rsquo;s investors include Novartis Venture Fund Lilly Ventures Hatteras Venture Partners Intersouth Partners Lurie Holdings and Astellas Venture Management.<wbr> </div><div>Source: <A href="http://www.innocrinpharma.com/">www.<wbr>innocrinpharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10333">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-12T19:26:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-12T19:26:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Brief Highlight from ENETS 2015: Novartis Negative Reports for Advanced pNET</title>
	<pubDate>2015-03-12T19:04:20+01:00</pubDate>
	<wp:post_id>5956</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The pressure was on for Novartis at ENETS today, as it presented two posters with results for the phase II randomized study of everolimus alone or in combination with pasireotide LAR in advanced, progressive pNET(COOPERATE-2) and the phase II randomized study of BEZ235 or everolimus in patients with advanced pNET.<wbr> Previous intelligence already recorded COOPERATE-2 not having met its primary endpoint (UKINETs, December 14).<wbr> Data presented today reported no difference was observed in median PFS or preliminary OS for the pasireotide+everolimus arm in the study.<wbr> Of note, median PFS in the everolimus monotherapy arm was 16.<wbr>6 months, longer than the value obtained in RADIANT-3 study, reported as 10.<wbr>8 months.<wbr> We also were aware that trials with BEZ235 had been suspended, but data presented today, while showing clinical activity, proved that the drug tolerability did not justify further continuation of the trial.<wbr> Formulation issues were listed as the main cause for failure.<wbr> </div><div>Further data and more in deep considerations, pictures and Q&amp;A of the session will be posted on Traction at the end of the conference, in the final report.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7984">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-12T19:04:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-12T19:04:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: UK Cancer Drug Fund Poised To De-list Novartis's Afinitor (Everolimus)</title>
	<pubDate>2015-03-12T18:30:38+01:00</pubDate>
	<wp:post_id>5957</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">UK Cancer Drug Fund Poised To De-list Novartis's Afinitor (Everolimus)</span>&nbsp;<br><span style="font-size: 12px;">Comment: Mentioned as a possibility at the UKINETs meeting before Christmas 
in relation to the drug's use to treat pNET, Novartis is reportedly becoming 
more vocal in its complaint about the de-listing process in which so far six 
breast cancer drugs are poised to be banned.<wbr> Afinitor appears to be one of 
the six having breast cancer amongst kidney and pNET as its approved 
indications.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7911">...</a><br></div><div>Today was announced that NHS England has performed a U-turn on the decision of delisting Everolimus from the CDF, as it was announced in January.<wbr> Novartis has worked with the CDF to reach an agreement for keeping everolimus on the CDF list for advanced breast cancer and kidney cancer as the drug meets the clinical threshold set by the NHS in these indications.<wbr>  Novartis could not find an agreement for well-differentiated pNETs and has accepted delisting everolimus in this indication.<wbr> Novartis will supply Afinitor to pNET patients on 'named patients basis', upon request from oncologists through their local clinical commissioning group (CCG).<wbr> The NHS is due to publish a new list for the revised drugs which will be included in the CDF.<wbr> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7989c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The NHS has published a <a href="http://www.england.nhs.uk/wp-content/uploads/2015/03/ncdf-list-mar-15.pdf" class="defaultlink">new list</a>for the revised drugs which will be included in the CDF - Everolimus is on the CDF list only for advanced breast cancer and metastatic renal cell carcinoma, but has been delisted for well-differentiated pNET.<wbr> </div><span style="font-weight: bold; font-style: italic;"></span><a name="Endocrinology8138c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Afinitor is no longer be available from Cancer Drugs Funds to treat pNET, effectively July 21.<wbr> (Source: Biocentury) </div></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7983">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7911">View thread  Endocrinology7911: UK Cancer Drug Fund Poised To De-list Novartis's Afinitor (Everolimus)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-12T18:30:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-12T18:30:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Low-Cost Rotavirus Vaccine to Reach the Indian Market</title>
	<pubDate>2015-03-11T19:30:25+01:00</pubDate>
	<wp:post_id>5958</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Low-Cost Rotavirus Vaccine to Reach the Indian Market</span>&nbsp;<br><span style="font-size: 12px;">Comment: Bharat Biotech has announced positive results from a Ph3 clinical trial of a ROTAVAC®, a rotavirus vaccine developed and manufactured in India.<wbr> The company has announced a price of US$ 1.<wbr>00/<wbr>dose for the vaccine, and will soon file for registration in India.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=1885">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Prime Minister Narendra Modi on 9 March 2015 launched Rotavac, the</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> third such vaccine, besides GSK's Rotarix and Merck&rsquo;s RotaTeq against rotavirus.<wbr> Rotavac will cost a mere 1$ (vs 75$ for RotaTeq and over 106$ for Rotarix).<wbr></SPAN> </div><div><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/24px Muli, Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">In India, diarrhoea caused by rotavirus kills nearly 80 thousand children under the age of 5 years and lead to 10 lakh hospitalizations every year.<wbr> India accounts for 22% of the global deaths that occurs due to diarrhoea-causing rotavirus.<wbr></SPAN></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2284">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1885">View thread  GastroEnterology1885: Low-Cost Rotavirus Vaccine to Reach the Indian Market</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-11T19:30:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-11T19:30:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Valeant to Explore Takeover of Salix</title>
	<pubDate>2015-03-11T19:27:05+01:00</pubDate>
	<wp:post_id>5959</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Valeant to Explore Takeover of Salix</span>&nbsp;<br><span style="font-size: 12px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Valeant has bought Salix.<wbr> The transaction represents approximately $14.<wbr>5 Billion and will </STRONG>create a new Specialty Platform for Growth.<wbr> It is <SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 12px/20px HelveticaNeue-Light, 'Helvetica Neue Light', 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">expected to close in the second quarter of 2015.<wbr></SPAN></STRONG></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2260">...</a><br></div><div>According to the Wall St Journal ENDO Pharmaceuticals has just submitted a competing bid for Salix of between $170 per share and $175 per share.<wbr>  Salix reached an agreement in February to be purchased by Valeant Pharmaceuticals for $158 per share.<wbr> Endo reportedly sent a private offer letter to Salix's board today.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2283">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2216">View thread  GastroEnterology2216: Valeant to Explore Takeover of Salix</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-11T19:27:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-11T19:27:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's Investor Day - Key Specialty & Consumer Health Takeaways</title>
	<pubDate>2015-03-11T18:27:40+01:00</pubDate>
	<wp:post_id>5960</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer highlighted its aim to increase sales of its main H/<wbr>C division 
by 6% per year on average through 2017 to more than €25bn hoping to capitalise 
on its new drugs like Xarelta, Xofigo &amp; Eylea.<wbr> Xofigo for the treatment 
of CRPC bone metastases generated 2014 sales of €157m and is projected to 
meet a €300m target in 2015.<wbr> Bayer is hoping to increase its core 
H/<wbr>C operating profit margin to 29-31% up from 27.<wbr>5% last year.<wbr> 
Consumer Health is expected to grow by 4% per annum over 
the 2015-17 period to &gt; €10bn.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The New Bayer</STRONG> </div><div style="margin-bottom: 10px;">Management propose to transform the group into more of a pure life 
science business exiting Material Sciences and completing implementation of 
the new structure by January 2016.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_1_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_2_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_3_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Pharmaceutical Performance &amp; R&amp;D Highlights</STRONG> </div><div style="margin-bottom: 10px;">Xofigo (Radium 223) for the treatment of CRPC bone metastases is clearly 
performing well, despite its production setback and is seen as an important 
growth product for the company.<wbr> Bayer acknowledges the presence of Orion's 
ODM-201 in its portfolio which is is now developing for MOCRPC.<wbr> Nothing was 
stated with regard to recruitment in this study although there is a specific 
mention of the trial concluding in 2018.<wbr> Reference is also made to regorafanib 
in the context of its HCC phIII trial programme which is scheduled to complete 
in April 2016.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_13_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_4_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_5_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_6_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_7_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_8_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_9_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>OTC Brands &amp; Performance</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_10_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_11_ScreenCapture13.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_12_ScreenCapture14.jpg"> </div><!-- Comment details --><a name="oncology10332attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_1_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(132,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_2_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(154,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(157,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_4_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(134,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_5_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(127,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_6_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(201,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_7_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(162,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_8_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(162,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_9_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(168,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_10_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(168,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_11_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(168,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_12_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(193,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10332_13_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(101,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10332">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-11T18:27:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-11T18:27:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>VEGF Targeted Therapy Development Progress For Bladder Cancer</title>
	<pubDate>2015-03-11T13:59:07+01:00</pubDate>
	<wp:post_id>5961</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Trials evaluating established chemotherapeutics as single agents or in combination with other agents have often yielded discouraging results in bladder cancer.<wbr> Previous attempts to add targeted therapy with drugs that act on various pathways, including sorafenib (Nexavar) and sunitinib (<EM>Sutent</EM>, Pfizer), have shown limited to no activity During ASCO GU earlier, two VEGF targeted agents have shown early evidence in the Ph2 study in combination with chemotherapy for the treatment in bladder cancer.<wbr> In a small single group Ph2 study - pazopanib (Votrient, Novartis) + paclitaxel and ramucirumab (Cyramza, Eli Lilly) + docetaxel.<wbr> </div><div style="margin-bottom: 10px;">Metastatic urothelial carcinoma is an incurable disease typically treated with a platinum-based chemotherapy combination such as methotrexate, vinblastine, doxorubicin, and cisplatin or cisplatin plus gemcitabine.<wbr>Responses of 45% to 55% are typically observed, and median overall survival is 13 months.<wbr> The critical challenge is despite these high response rates, cures are infrequent and relapse is inevitable.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Pazopanib+Paclitaxel Ph2 Study: Presented at Genitourinary Cancers Symposium (GUCS) 2015: Abstract 294.<wbr> February 27, 2015</STRONG>.<wbr></SPAN> </div><div style="margin-bottom: 10px;">This is a small single-group phase 2 trial, pazopanib + paclitaxel showed 50% overall response rate in patients with relapsed or refractory urothelial carcinoma although tempered by a significant rate of myelosuppression.<wbr> the overall response rate was 50%, and 11% of the patients achieved a complete response.<wbr> However, these results were tempered by a significant rate of myelosuppression, which necessitated a reduction in the dose of pazopanib in 75% of patients and the addition of growth factors in 44% of patients.<wbr> On the basis of these results, Dr Srinivas noted that this combination is worthy of further Ph3 study to evaluate pazopanib combined with paclitaxel in patients with advanced urothelial cancer previously treated with systemic therapy for metastatic disease.<wbr> The lack of sponsorship's interest (GSK at the time) limited further evaluation of this combination strategy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Table.<wbr> Outcomes for 28 Evaluable Patients</STRONG> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="inline_data_table"><TBODY><TR><TD><STRONG>Response</STRONG></TD>
<TD><STRONG>n</STRONG></TD>
<TD><STRONG>%</STRONG></TD>
</TR>
<TR valign="top"><TD>Complete</TD>
<TD>3</TD>
<TD>11</TD>
</TR>
<TR valign="top"><TD>Partial</TD>
<TD>12</TD>
<TD>43</TD>
</TR>
<TR valign="top"><TD>Unconfirmed</TD>
<TD>1</TD>
<TD>4</TD>
</TR>
<TR valign="top"><TD>Confirmed</TD>
<TD>11</TD>
<TD>39</TD>
</TR>
<TR valign="top"><TD>Stable disease</TD>
<TD>11</TD>
<TD>39</TD>
</TR>
<TR valign="top"><TD>Progressive disease</TD>
<TD>2</TD>
<TD>7</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="text-decoration: underline;">Ph2 Ramucirumab + Docetaxel (Genitourinary Cancers Symposium (GUCS) 2015.<wbr> Abstract 295.<wbr> Presented February 27, 2015.<wbr>)</SPAN></STRONG> </div><div style="margin-bottom: 10px;">In the study, 150 patients with advanced urothelial carcinoma and ECOG performance status 0-1 who had relapsed 1 year or less after treatment with a platinum-based regimen.<wbr> They were randomly assigned to receive docetaxel 75 mg/<wbr>m<SUP></SUP> intravenously alone (n = 44) or in combination with ramucirumab 10 mg/<wbr>kg IV on day 1 of repeating 21-day cycles (n = 46), or in combination with icrucumab 12 mg/<wbr>kg on days 1 and 8 of a 21-day cycle (n = 49).<wbr> Treatment continued until disease progression or unacceptable toxicity.<wbr> </div><div style="margin-bottom: 10px;">The interim analysis of a phase 2 randomized trial showed that the combination regimen significantly increased progression-free survival (22 weeks) as compared with docetaxel alone (10.<wbr>4 weeks).<wbr> At the planned interim analysis, the ramucirumab plus docetaxel combination conferred a statistically significant progression-free survival improvement of greater than 11.<wbr>5 weeks and reduced the risk of disease progression by 61%.<wbr>(the progression-free survival for the docetaxel alone group was 10.<wbr>4 weeks, compared with 22 weeks for the docetaxel plus ramucirumab group (hazard ratio [HR], 0.<wbr>388; <EM>P </EM>&lt; .<wbr>001).<wbr>) For overall survival, Dr Petrylak cautioned that the data are not yet mature, but they did appear better for the combination of ramucirumab and docetaxel compared with docetaxel alone (48.<wbr>9 week vs 33.<wbr>4 weeks; HR, 0.<wbr>775; <EM>P </EM>= .<wbr>387).<wbr> Overall survival for docetaxel plus icrucumab was 27.<wbr>7 weeks (HR, 1.<wbr>080; <EM>P </EM>= .<wbr>754).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Table.<wbr> Overall Response</STRONG> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="inline_data_table"><TBODY><TR valign="TOP"><TD>&nbsp;</TD>
<TD><STRONG>Docetaxel Alone</STRONG></TD>
<TD><STRONG>Doc + Ram</STRONG></TD>
<TD><STRONG>Doc + Icr</STRONG></TD>
</TR>
<TR valign="TOP"><TD>Complete response rate</TD>
<TD>0</TD>
<TD>1</TD>
<TD>1</TD>
</TR>
<TR valign="TOP"><TD>Partial response rate</TD>
<TD>2</TD>
<TD>8</TD>
<TD>4</TD>
</TR>
<TR valign="TOP"><TD>Stable disease</TD>
<TD>17</TD>
<TD>22</TD>
<TD>10</TD>
</TR>
<TR valign="TOP"><TD>Progressive disease</TD>
<TD>17</TD>
<TD>7</TD>
<TD>26</TD>
</TR>
<TR valign="TOP"><TD>Not evaluable</TD>
<TD>8</TD>
<TD>8</TD>
<TD>8</TD>
</TR>
<TR valign="TOP"><TD>Disease control rate: cr + pr + sd, n (%)</TD>
<TD>19 (43)</TD>
<TD>31(67)</TD>
<TD>15(31)</TD>
</TR>
<TR valign="TOP"><TD><EM>P-</EM>value</TD>
<TD>&nbsp;</TD>
<TD>0.<wbr>03</TD>
<TD>0.<wbr>28</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Dr.<wbr> Jonathan E.<wbr> Rosenberg, MD, from Memorial Sloan Kettering Cancer Center, in New York City, noted that the study had both strengths and weaknesses.<wbr> " <STRONG><EM>It had a randomized design, and all endpoints trend in the same direction, and 11 months' median overall survival is robust in this patient population</EM></STRONG>.<wbr><EM><STRONG>There was a provocative trend towards overall survival, and while it's not the primary endpoint of the study, it is certainly trending in the right direction.<wbr></STRONG></EM>" </div><div>Source: MedScape </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10330">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-11T13:59:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-11T13:59:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Potentially The Next Big Commercial Opportunity In the Aesthetic Market</title>
	<pubDate>2015-03-10T18:22:23+01:00</pubDate>
	<wp:post_id>5962</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Potentially The Next Big Commercial Opportunity In the Aesthetic Market</span>&nbsp;<br><span style="font-size: 12px;">Comment:- Kythera Biopharmaceuticals has announced its NDA submission to the 
US FDA for the approval of ATX-101, an new injectable aesthetic product for the 
reduction of submental fat commonly known as " double chin".<wbr> Highlights of a 
recent presentation given by Kythera highlight the potential synergies with 
toxin therapy.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7575">...</a><br></div><div>KYTHERA Biopharmaceuticals has announced that the US FDA Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to support approval of ATX-101 (deoxycholic acid) injection for improvement in appearance of moderate to severe convexity or fullness associated with submental fat in adults, often referred to as double chin.<wbr>If approved, ATX-101 would be first-in-class submental contouring injectable drug.<wbr> If approved by FDA, KYTHERA anticipates launching ATX-101 in second half of 2015.<wbr> It will be interesting to observe whether Kythera becomes an acquisition target based on ATX-101's approval given the high ongoing level of interest in facial aesthetic M&amp;A.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7941">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7575">View thread  Neurology7575: Potentially The Next Big Commercial Opportunity In the Aesthetic Market</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-10T18:22:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-10T18:22:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pediatric High Risk Neuroblastoma Treatment Approved In The US</title>
	<pubDate>2015-03-10T18:17:50+01:00</pubDate>
	<wp:post_id>5963</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: United Therapeutics Corporation has announced today the US 
<ORG></ORG>approval of Unituxin™ (dinutuximab) Injection (formerly called 
ch14.<wbr>18), in combination with GM-CSF, interleukin-2 (IL-2), and 13-cis-retinoic 
acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma 
who achieve at least a partial response to prior first-line multiagent, 
multimodality therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Approval</STRONG> </div><div style="margin-bottom: 10px;">The approval was based on demonstration of improved event-free survival (EFS) 
and overall survival (OS) in a multicenter, open-label, randomized trial 
(ANBL0032) conducted by the <ORG>Children's Oncology Group</ORG> (COG).<wbr>  
The trial randomized (1:1) 226 patients to either the Unituxin/<wbr>13-cis-retinoic 
acid (RA) arm or the RA alone arm.<wbr>  Patients in each arm received six 
cycles of treatment.<wbr>  The Unituxin/<wbr>RA arm consisted of Unituxin in 
combination with granulocyte macrophage-colony stimulating factor and RA (cycles 
1, 3, and 5), Unituxin in combination with interleukin-2 and RA (cycles 2 and 
4), and RA (cycle 6).<wbr>  Patients were 11 months to 15 years of age (median 
age 3.<wbr>8 years).<wbr> </div><div style="margin-bottom: 10px;">The major efficacy outcome measure was investigator-assessed EFS, defined as 
the time from randomization to the first occurrence of relapse, progressive 
disease, secondary malignancy, or death.<wbr> </div><div style="margin-bottom: 10px;">At the seventh interim analysis, an improvement in EFS [HR 0.<wbr>57 (95% CI: 
0.<wbr>37, 0.<wbr>89); p = 0.<wbr>01, log-rank test] was demonstrated and four 
remaining patients undergoing treatment on the RA arm crossed over to receive 
Unituxin/<wbr>RA.<wbr>  The median EFS was not reached (3.<wbr>4 years, NR) in the 
Unituxin/<wbr>RA arm and was 1.<wbr>9 years (1.<wbr>3, NR) in the RA arm.<wbr> </div><div style="margin-bottom: 10px;">An analysis of overall survival (OS) conducted three years later documented 
an improvement in OS in the Unituxin/<wbr>RA arm compared to the RA arm [HR 0.<wbr>58 (95% 
CI: 0.<wbr>37, 0.<wbr>91)].<wbr>  At the time of this survival analysis, median OS had not 
been reached in either arm.<wbr> </div><div style="margin-bottom: 10px;">The most common serious adverse reactions (greater 
than or equal to 5%) are infections, infusion reactions, hypokalemia, 
hypotension, pain, fever, and capillary leak syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Collaborative Efforts That Facilitated Approval</STRONG> </div><div style="margin-bottom: 10px;">"This approval has been a collaborative effort between the <ORG value="ACORN:6000176586">National Cancer Institute</ORG> 
(NCI), the <ORG>Children's Oncology Group</ORG> and <ORG value="NASDAQ-NMS:UTHR">United Therapeutics</ORG> for the first approved therapy for 
pediatric high-risk neuroblastoma," said <PERSON value="APIN:3583957160">Roger 
Jeffs</PERSON>, Ph.<wbr>D.<wbr>, <ORG value="NASDAQ-NMS:UTHR">United 
Therapeutics'</ORG> President and Co-Chief Executive Officer.<wbr>  "We are 
grateful for the <ORG>FDA's</ORG> thorough review and collaboration on this 
program, and we look forward to expanding our research efforts in the area of 
pediatric oncology.<wbr>" </div><div style="margin-bottom: 10px;">"The <ORG>FDA</ORG> approval of dinutuximab represents the culmination of a 
remarkably productive collaboration between researchers of the 
<ORG>NCI-supported Children's Oncology Group</ORG>, the manufacturing and 
clinical research groups of NCI, and the oncology team at <ORG value="NASDAQ-NMS:UTHR">United Therapeutics</ORG>," said 
<PERSON>Malcolm Smith</PERSON>, MD, Ph.<wbr>D.<wbr>, Associate Branch Chief, Pediatrics in 
the Cancer Therapy Evaluation Program at NCI.<wbr>  Children with neuroblastoma 
will benefit from this collaboration, and the drug development pathway blazed by 
dinutuximab will likely be followed in the future to develop other novel agents 
directed against pediatric cancer therapeutic targets.<wbr>" </div><div>Source: <a href="http://www.ir.unither.com" class="defaultlink" title="www.ir.unither.com">ir.unither.com</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10630c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Following the approval in March by FDA, United Therapeutics announced its intention to sell the rare paediatric disease priority review voucher to Abbvie for $350M in cash.<wbr> The priority review voucher was issued due to the approval of Unituxin in high risk neuroblastoma that is classified as a rare paediatric disease.<wbr> And the voucher is usually received upon approval of a rare pasdiatric disease product and it might be sold or transferred without limitation.<wbr> The voucher can be used to obtain priority review for a new drug application or biologis license application submitted later.<wbr> This could lead to shortening the review timeframe ie faster approval.<wbr> On 21st  May 2015, EMA also adopted a positive opinion recommending a marketing authorisation in combination with GMCSF, IL2 and isotretinoin with likely post-marketing safety surveillance required  (source EMA  <A href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002800/smops/Positive/human_smop_000831.jsp&amp;mid=WC0b01ac058001d127">http:/<wbr>/<wbr>www.<wbr>ema.<wbr>europa.<wbr>eu/<wbr>ema/<wbr>index.<wbr>jsp?curl=pages/<wbr>medicines/<wbr>human/<wbr>medicines/<wbr>002800/<wbr>smops/<wbr>Positive/<wbr>human_smop_000831.<wbr>jsp&amp;mid=WC0b01ac058001d127</A>) </div><div style="margin-bottom: 10px;">United Therapeutics gained approval for Unituxin earlier this week in the EU for use in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and isotretinoin for the treatment of pediatric patients (aged 12 months to 17 years) suffering from high-risk neuroblastoma, who have previously received induction chemotherapy and achieved at least a partial response followed by myeloablative therapy and autologous stem cell transplantation.<wbr> However, Unituxin&rsquo;s approval in the EU came with special warnings and precautions related to allergic reactions and capillary leak syndrome among others.<wbr> The drug is subject to additional monitoring.<wbr> </div><div>Source: United Therapeutics Press Release </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10329">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-10T18:17:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-10T18:17:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Reversal Of Neurological Disability In Patients With MS With HSCT</title>
	<pubDate>2015-03-10T17:47:22+01:00</pubDate>
	<wp:post_id>5964</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Recently published and attracting attention in the press, is 
research that has been undertaken in Sheffield and the US which has used 
nonmyelobaltive hematopoietic stem cell transplantation (HSCT) to overcome 
the neurological disability associated with MS.<wbr> Whilst patient numbers 
evaluated to date have been small, some of the responses 
have resulted in "profound neurological improvement" 
and reportedly led as a consequence to active recruitment of a larger 
number of patients for an international trial.<wbr> </div><div style="margin-bottom: 10px;">The pilot findings are published in a recent issue of JAMA (see link 
below) </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The key endpoints in the 145 patient open study were as follows:- </div><div style="margin-bottom: 10px;"><UL><LI>Primary end point was reversal or progression of disability measured 
  by change in the Expanded Disability Status Scale (EDSS) score of 1.<wbr>0 or 
  greater (score range, 0-10).<wbr> </LI>
<LI>Secondary outcomes included changes in the Neurologic Rating Scale 
  (NRS) score of 10 or greater (score range, 0-100), Multiple Sclerosis 
  Functional Composite (MSFC) score, quality-of-life Short Form 36 questionnaire 
  scores, and T2 lesion volume on brain magnetic resonance imaging 
  scan</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">There was significant improvement in disability (decrease in EDSS score of 
≥1.<wbr>0) in 41 patients (50%; 95% CI, 39% to 61%) at 2 years and in 23 patients 
(64%; 95% CI, 46% to 79%) at 4 years.<wbr> Four-year relapse-free survival was 80% 
and progression-free survival was 87%.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The NRS scores improved significantly from a pretransplant median of 74 to 
  88.<wbr>0 (IQR, 77.<wbr>3 to 93.<wbr>0; n = 78) at 2 years and to 87.<wbr>5 (IQR, 75.<wbr>0 to 93.<wbr>8; 
  n = 34) at 4 years (<I>P</I> &lt; .<wbr>001 at each assessment).<wbr> </LI>
<LI>The median MSFC scores were 0.<wbr>38 (IQR, −0.<wbr>01 to 0.<wbr>64) at 2 years 
  (<I>P</I> &lt; .<wbr>001) and 0.<wbr>45 (0.<wbr>04 to 0.<wbr>60) at 4 years (<I>P</I> = .<wbr>02).<wbr> 
</LI>
<LI>Total quality-of-life scores improved from a mean of 46 (95% CI, 43 to 49) 
  pretransplant to 64 (95% CI, 61 to 68) at a median follow-up of 2 years 
  posttransplant (n = 132) (<I>P</I> &lt; .<wbr>001).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">Some of the individual patient stories of remarkable recoveries are 
highlighted in the Sunday Times (01/<wbr>03/<wbr>15).<wbr> Professor Sharrack is reported as 
saying that "Since we started treating patients some three years ago, some of 
the results we have seen have been miraculous.<wbr> This is not a word I would use 
lightly but we have seen profound neurological improvements.<wbr>" </div><div style="margin-bottom: 10px;">Sources: </div><div style="margin-bottom: 10px;"><A href="http://www.thesundaytimes.co.uk/sto/news/uk_news/Health/article1525354.ece">http:/<wbr>/<wbr>www.<wbr>thesundaytimes.<wbr>co.<wbr>uk/<wbr>sto/<wbr>news/<wbr>uk_news/<wbr>Health/<wbr>article1525354.<wbr>ece</A> </div><div><A href="http://jama.jamanetwork.com/article.aspx?articleid=2091305">http:/<wbr>/<wbr>jama.<wbr>jamanetwork.<wbr>com/<wbr>article.<wbr>aspx?articleid=2091305</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7940">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-10T17:47:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-10T17:47:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Canadian Real World Experience Study Suggests Benefit With Earlier Treatment With Abiraterone Before Performance Status Declines</title>
	<pubDate>2015-03-10T17:06:42+01:00</pubDate>
	<wp:post_id>5965</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: Azad et al have reported on the real world experience in Canada of mCRPC patients treated with abiraterone and prednisone.<wbr> The findings indicate advanced prostate cancer patients who have worse performance status derive less benefit from abiraterone.<wbr> The potential implication is that earlier treatment with abiraterone before performance status declines could improve outcomes.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Given abiraterone's approved label, abiraterone can be commonly used in broader populations in the real world than those included in the clinical trials.<wbr> For example, abiraterone can be given to patients with poorer performance status (PS &ge; 2) over chemotherapy due to the better tolerability profile.<wbr> Azad pointed out that only 10% of patients in the COU-AA-301 trial had PS &ge; 2, and no patients had poor performance status was allowed in the COU-AA-302 trial.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">In this Canadian study, a total of 519 patients were identified.<wbr> ECOG PS 0-1 patients (n=318) were significantly more likely than  to achieve a PSA decline of more than 50% from baseline and had significantly longer median time to PSA progression (5.<wbr>2 months vs 4.<wbr>1 months; p=0.<wbr>023), median treatment duration (7.<wbr>4 months vs 4.<wbr>5 months; p&lt;0.<wbr>001), and median OS (20.<wbr>0 months vs 9.<wbr>1 months; p&lt;0.<wbr>001).<wbr> </SPAN><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Both the docetaxel pretreated and docetaxel na&iuml;ve groups had inferior outcomes in patients with poor PS.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">"<EM><STRONG>Unfortunately one of the most interesting clinical questions - whether patients with PS</STRONG> <STRONG>&ge; 2 derive a survival benefit from abiraterone - cannot be answered by this study.<wbr> There was no comparator arm; thus the conclusion that these patients derived little or no benefit from abiraterone cannot be inferred from these data</STRONG></EM>" commented Dr.<wbr> Andrew Armstrong</SPAN> </div><div><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Source: Azad et al.<wbr> Eur Urol March 2015 p.<wbr>441-447 (<a href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare?Format_document=1&Mouvement=890936&Urlorigine=&Premier=0&Dernier=0&Doc4=3013309" class="defaultlink">PEARL Link</a>)<BR></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10327">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-10T17:06:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-10T17:06:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Has Accepted Captisol-enabled™ Melphalan NDA Filing For Its Use In Multiple Myeloma</title>
	<pubDate>2015-03-10T13:01:07+01:00</pubDate>
	<wp:post_id>5966</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: Spectrum announced FDA's acceptance of NDA filing for Captisol-enabled Melphalan (CE-Melphalan).<wbr> The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of October 23, 2015 for the CE-Melphalan NDA, which is 10 months from the filing date.<wbr> Spectrum is seeking FDA approval for its use as a high-dose conditioning treatment prior to autologous hematopoietic (progenitor) stem cell transplantation (AHCT) in patients with multiple myeloma (MM), an orphan drug designation.<wbr> Spectrum is also seeking approval for the palliative treatment of patients with MM for whom oral therapy is not appropriate.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.<wbr> Captisol was invented and initially developed by scientists in the laboratories of Dr.<wbr> Valentino Stella at the University of Kansas' Higuchi Biosciences Center for specific use in drug development and formulation.<wbr> This unique technology has enabled six FDA-approved products, including Onyx Pharmaceuticals' Kyprolis <SUP></SUP>, Baxter International's Nexterone <SUP></SUP> and Merck's NOXAFIL IV.<wbr> There are also more than 30 Captisol-enabled products currently in clinical development.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">CE-Melphalan's improved solubility and stability should make it an attractive treatment option for both transplant conditioning and the palliative treatment of patients with MM.<wbr> Eliminating the need for propylene glycol in the preparation of CE-Melphalan eliminates the risk of the toxicities associated with this excipient.<wbr> In addition, CE-Melphalan's increased stability simplifies the logistics for pharmacies and nursing staff, and is anticipated to allow for longer infusion times which may permit the administration of higher dose intensities.<wbr> We anticipate these characteristics of CE-Melphalan will facilitate rapid adoption.<wbr> We look forward to bringing this drug to market and providing additional treatment options to patients suffering with cancer.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">The Phase 2 pivotal trial evaluating CE-Melphalan was a multi-center trial evaluating safety and efficacy.<wbr> The primary objective of the study was to determine the overall safety and toxicity profile in MM patients receiving 200 mg/<wbr>m <SUP></SUP> of CE-Melphalan as myeloablative therapy prior to AHCT.<wbr> The secondary objectives evaluated the efficacy of CE-Melphalan in this patient population as measured by Multiple Myeloma Response Rate (according to International Myeloma Working Group [IMWG] criteria), and the rates of myeloablation and engraftment.<wbr> Study results support the safety and efficacy of high-dose CE-Melphalan as a high-dose conditioning treatment prior to AHCT in patients with MM.<wbr> CE-Melphalan led to successful myeloablation and subsequent engraftment in all (100%) of the MM patients studied with no mortality or unexpected transplant-related toxicity.<wbr> Overall, 95% of subjects (n=61) responded to high dose CE-Melphalan, and 67% VGPR or better responses were achieved in the subgroup of high risk patients (15%).<wbr> There were no deaths by Day 100, and the most common Grade 3 and 4 toxicities were the expected hematologic events (neutropenia, leukopenia, lymphopenia, thrombocytopenia and anaemia).<wbr> The most frequent non-hematologic adverse events included diarrhoea, nausea, and fatigue.<wbr> Importantly, the incidence of severe mucositis was low (Grade 3/<wbr>4; 10%).<wbr></SPAN> </div><div><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Source: Spectrum Pharmaceutical Press Release<BR></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10326">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-10T13:01:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-10T13:01:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Heat Biologics' HS-410 Has Been Granted Fast Track Designation In Combination with BCG for NMIBC</title>
	<pubDate>2015-03-10T12:45:17+01:00</pubDate>
	<wp:post_id>5967</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Heat Biologics announced that the FDA has granted Fast Track Designation for HS-410 for the treatment of non-muscle invasive bladder cancer.<wbr> HS-410 is currently being evaluated in a randomized Ph2 trial in combination with BCG and as monotherapy for the treatment of NMIBC.<wbr> </div><div style="margin-bottom: 10px;">The Company completed enrollment in a Phase 1 study and is expected to release interim data on 10 patients in the first half of 2015.<wbr> In January, the company presented positive immunological data from its Ph1 trial (<a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=10236" class="defaultlink">Oncology10236: Heat Biologics Presented Positive Immunological Data On HS-410 in NMIBC</a>).<wbr> A Phase 2 clinical trial is ongoing with a primary endpoint of recurrence-free survival.<wbr> FPI was initiated in October 2014 (<a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=10072" class="defaultlink">Oncology10072:</a><U></U> and the enrolment is expected to complete in Q3 2015, which would make topline data available in the second half of 2016.<wbr> </div><div>Source: Heat Biologics Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10323">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-10T12:45:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-10T12:45:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Appointments & Therapeutic Development Intent Noted On The Recent Revance Call</title>
	<pubDate>2015-03-09T16:03:43+01:00</pubDate>
	<wp:post_id>5968</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Strengthening its leadership team, management noted the addition of Dr.<wbr> Philip Vickers to its board of directors.<wbr> He is currently Global Head of R&amp;D at Shire and has experience in pre-clinical research, clinical development, and regulatory affairs.<wbr> Beyond this position, Revance noted it is also looking to recruit the best and brightest professionals in neurotoxin drug development, biologic manufacturing, clinical development, and regulatory affairs.<wbr> In addition to its recruitment ambitions, more detailed comment was made about plans to move its injectable formulation RT-002 into a movement disorder trial (CD or spasticity).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on delays with RT-001 &amp; the group's development intent with RT-002 L Daniel Brown Co-Founder, President, &amp; Chief Executive Officer made the following comments .<wbr></STRONG> </div><div style="margin-bottom: 10px;">"Over the last few months, we've made progress with our 01 drug product and related manufacturing process.<wbr> Today, we better understand our drug product as we've characterized it extensively and evaluated the clinical performance.<wbr> We've made adjustments designed to enhance the interaction of the peptide and the toxin.<wbr> Beyond that, we continue to deliver, develop and implement new analytic methods.<wbr> We believe these changes have the potential to lead for better clinical outcomes, enable us to deliver the results we need to gain regulatory approval of crow's feet lines.<wbr>" </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We expect to start the new open-label study incorporating these adjustments imminently and conclude it by mid this year.<wbr> Upon successful completion, we plan to initiate a Phase 3 pivotal study in the U.<wbr>S.<wbr> in crow's feet and expect to report efficacy results in the second half of 2015.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"In terms of topical 01 for the treatment of hyperhidrosis or excessive sweating, we plan to initiate a Phase 2 clinical trial mid-2015 and report preliminary efficacy data from this trail in the second half of this year.<wbr> We believe hyperhidrosis in the axillary or underarms is a highly underserved market and<STRONG> represents the most significant near-term therapeutic opportunity for topical 01.<wbr>" </STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Moving on to the injectable 02 product and aesthetic indication for glabellar or frown lines.<wbr> We are on track with our BELMONT Phase 2 active comparator clinical trial in glabellar lines.<wbr> Market research among key opinion leaders indicates that an injectable toxin with roughly double the duration of effect in frown lines and and potentially in other aesthetic and therapeutic indications could prove to be transformational in the neurotoxin market.<wbr> We expect to report interim duration results in late 2015.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>"Now, turning to injectable 02 for therapeutic </STRONG><STRONG>indications</STRONG>.<wbr> Injectable 02 has the potential to treat a number of therapeutic indications and botulinum toxin is already approved for eight medical conditions in the United States.<wbr> Globally, therapeutic use of botulinum toxin represents a larger market than the aesthetic market and it is predicted to grow faster over the next six years.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Muscle movement disorders account for roughly half of the 1.<wbr>7 billion in therapeutic neurotoxin sales globally.<wbr> They include conditions that affect a person's ability to control muscle activity, often due to nervous system damage caused by stroke, disease, or trauma.<wbr> While not life-threatening, muscle movement disorders can be painful and significantly impact quality of life.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"From a market access standpoint, similar to dermatology, neurology has a targeted manageable physician base, which we believe we can be easily accessed by a small specialty sales force.<wbr> As we look at the various muscle movement indications, we are focused on conditions where deeper, more targeted delivery is required and longer duration is desired.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Examples include cervical dystonia, characterized by excessive pulling of the muscles in the neck and shoulder; and upper limb spasticity, which affects muscles in the arms and can cause stiffness in the fingers, wrists and elbows.<wbr> While we are in the process of finalizing our clinical plans and currently expect to initiate a Phase 2 muscle movement disorder clinical trial and report clinical results in the second half of 2015.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Further comments made by Daniel Brown during the Q/<wbr>A</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Relative to RT002 and duration of action, in the case of glabellar lines, as we've spoken to the marketplace and clinicians, we find this <STRONG>doubling of the duration is potentially </STRONG><STRONG>game-changing</STRONG>.<wbr> <STRONG>It's expressed to us as the golden goose, if you will, for showing very clear differentiation to the current injectable products.<wbr></STRONG> As you start to look at some of the other therapeutic indications in the case of cervical dystonia, you're also beginning to look at not only extending the duration over the existing injectable products, but you're potentially also trying to look at safety.<wbr> By controlling the diffusion, you're looking at opportunities to reduce the adverse event rates as part of those.<wbr></P> </div><div><P class="pwrapper">But, right now, we're really focused on the most significant differentiation on duration.<wbr> And right now, we're at roughly seven months on the glabellar lines.<wbr> And as we move into these muscle movement disorders later this year, we'll start to get a look at safety and efficacy and ultimately with duration.<wbr> We think that it has to be meaningful and we'll certainly include that in our cost-effective arguments for supporting RT002.<wbr>"</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7938">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-09T16:03:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-09T16:03:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi's Planned A New Ph2 Study (PRIMCAB) To Evaluate Cabazitaxel Versus Enzalutamide/Abiraterone In Chemo Naive mCRPC Patients</title>
	<pubDate>2015-03-06T18:23:13+01:00</pubDate>
	<wp:post_id>5969</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A new Ph2 trial (<A class="study-link" href="http://clinicaltrials.gov/show/NCT02379390" title="Current version of study NCT02379390 on ClinicalTrials.gov"><U></U></A>) is registered by Sanofi to evaluate efficacy (measured by rPFS) of cabazitaxel versus abiraterone or enzalutamide in chemo na&iuml;ve mCRPC patient s who have developed primary resistance to abiraterone or enzalutamide.<wbr> The duration of the study per patient will be approximately 2 years.<wbr> Patient enrolment of this study has yet to initiate.<wbr> </div><div style="margin-bottom: 10px;">Definition of mCRPC patients developed primary resistance to abiraterone or enzalutamide is patients who have progressive disease while receiving abiraterone or enzalutamide within 6 months of treatment initiation.<wbr> </div><div style="margin-bottom: 10px;">Experimental Arm 1: Cabazitaxel 25 mg/<wbr>m^2 intravenously in 1 hour every three weeks + prednisone 10 mg orally given daily.<wbr> Treatment will continue until confirmed disease progression or unacceptable toxicity </div><div style="margin-bottom: 10px;">Experimental Arm 2:  Abiraterone acetate 1000 mg orally, once daily + prednisone 5 mg orally given twice daily OR Enzalutamide 160 mg orally, once daily.<wbr> Treatment will continue until confirmed disease progression or unacceptable toxicity </div><div>Source: ClinicalTrial.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10322">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-06T18:23:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-06T18:23:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: MSD to Start Registration Trial of VivaLAX (Constipation) in Russia</title>
	<pubDate>2015-03-06T16:54:24+01:00</pubDate>
	<wp:post_id>5970</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">MSD to Start Registration Trial of VivaLAX (Constipation) in Russia</span>&nbsp;<br><span style="font-size: 12px;">Comment: Sponsored by Merck Sharp &amp; Dohme (MSD), this pivotal trial will evaluate the complete resolution of constipation in participants taking VivaLAX compared to those taking Forlax.<wbr> PE has been designed to measure number of bowel movements per week.<wbr> </span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2122">...</a><br></div><div style="margin-bottom: 10px;">Last update from clinicaltrials.<wbr>gov indicates that the sponsor has changed to Bayer.<wbr> Start and completion timelines initially in November 2014 have been delayed for 13 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">End of 2014, Bayer closed acquisition of consumer care business of Merck&amp;Co </div><div style="margin-bottom: 10px;">Bayer becomes the OTC leader in North and Latin America and achieves top global positions in key OTC categories </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2281">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2122">View thread  GastroEnterology2122: MSD to Start Registration Trial of VivaLAX (Constipation) in Russia</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-06T16:54:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-06T16:54:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENDO 2015: Chiasma Presents New Data To Support Oral Octreotide</title>
	<pubDate>2015-03-06T16:40:43+01:00</pubDate>
	<wp:post_id>5971</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P align="left" dir="ltr">Comment: Chiasma, whici is developing octreotide capsules for adult acromegaly, has presented new data at ENDO2015 further supporting its intention to file an NDA to the FDA in 2015.<wbr> Further to Sholmo Melmed's (global Phase III study PI), presentation of the Phase III results, Christian Strasburger (Charite Universitasuch as phtsmedizin, Germany) gave a brief introduction to a poster that reported the outcome of a survey in acromegaly patients treated with SSAs (octreotide and lanreotide), a survey developed by leading endocrinologists composed mainly of questions evaluating injection-related issues such as phyical and emotional burden of the injection and injection administration and everyday treatment burden.<wbr> Patients were generally satisfied with theiri treatment but reported that an 'oral therapy' (48%), a treatment to avoid injections (44%) and a treatment with 'better symptom control' (41%) would be potential major improvement over their current treatments.<wbr> Also, self-injcetions or at-home injections were not considered major improvements by many patients (12% and 10% respectively)</P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><SPAN style="text-decoration: underline;"><STRONG>Poster (#THR-484), Patient Reported Outcomes Survey in Acromegaly Patients Treated with Parental SSAs</STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">The survey was conducted at 9 endocrinology centers specialized in acromegaly from Germany, Netherlands and England.<wbr> The patients were managed on SSAs administered parentally by IM or deep SC injections.<wbr> Of the patients surveyed, 57% received octreotide and 43% lanreotide, with results showing the injection burden was similar between the two medications.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Results showed:</P> </div><div style="margin-bottom: 10px;"><UL><LI>70% of patients reported acromegaly symptoms/<wbr>signs, with 52% reporting that symptoms became worse toward the end of the dosing interval.<wbr>
</LI>
<LI>70% of patients experienced pain during or after injection, while 36% experienced pain even days later.<wbr>
</LI>
<LI>The most frequently reported injection&ndash;related symptoms were hardness at injection site (48%), nodules (38%), swelling (28%), bruising (16%) and inflammation (7%).<wbr>
</LI>
<LI>36% of patients felt a loss of independence due to chronic injections.<wbr>
</LI>
<LI>16% of patients regularly miss work for injections (averaging 11 days per year).<wbr>
</LI>
<LI>44% of patients experienced problems with the preparations and administration of the injections.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Patients were generally satisfied with their treatment but reported that an &lsquo;oral therapy&rsquo; (48%), a treatment to &lsquo;avoid injections&rsquo; (44%) and a treatment with &lsquo;better symptom control&rsquo; (41%) would be a potential major improvement over their current treatment.<wbr> Self-injections at home were not considered major improvements by many patients (12% and 10% respectively).<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><SPAN style="text-decoration: underline;"><STRONG>Oral Presentation #OR09-3 (Abstract #21142) - Determinants of Oracl octreotide capsule effect in acromegaly</STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Results showed that octreotide capsule efficacy is reliably determined within 12 weeks of initiating treatment and is sustainable up to 13 months.<wbr> IGF-I and GH levels are well maintained over time.<wbr> 85% of the population demonstrating response at the beginning of fixed-dose phased maintained response for up to 13 months.<wbr> The octreotide capsule efficacy was shown to be portended by dose of injectable SRL and degree of baseline control.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><SPAN style="text-decoration: underline;"><STRONG>Soft Intelligence</STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">A Chiasma employer further confirmed the plan to file a NDA to the FDA this year and also commented that presenting an open label study with no US centres to the FDA would not be an obstacle for getting marketing authorization in the US.<wbr></P> </div><div><P align="left" dir="ltr">Note: Pictures of slides and Poster presented will be uploaded shorthly as the connection is proving difficult to upload images.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7978">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-06T16:40:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-06T16:40:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sandoz First to Receive Approval of a Biosimilar in the US Through the New Pathway</title>
	<pubDate>2015-03-06T16:11:00+01:00</pubDate>
	<wp:post_id>5972</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: FDA has approved Zarxio for all indications included in the reference product's (Neupogen) label.<wbr> This approval is likely to pave way for greater access to high-quality biologics in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The approval was based on a comprehensive package of analytical, nonclinical, and clinical data, which confirmed that Zarxio is highly similar to the US-licensed reference product.<wbr> The approval of Zarxio follows the unanimous positive vote in January by the Oncologic Drugs Advisory Committee (ODAC) </div><div style="margin-bottom: 10px;">The successful Sandoz pivotal head-to-head PIONEER study was the final piece of data contributing to the totality of evidence used by FDA to approve Zarxio as biosimilar to the reference product.<wbr> Importantly, the data demonstrating high similarity was sufficient to allow extrapolation of use of Zarxio to all indications of the reference product.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Marketed as Zarzio®, the Sandoz biosimilar filgrastim is available in more than 60 countries worldwide, has generated over 7.<wbr>5 million patient-days of exposure and is the most widely used filgrastim in Europe.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11117">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-06T16:11:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-06T16:11:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mesalamine and Amitriptyline Drugs on the Quality of Life of Patients with IBS-D</title>
	<pubDate>2015-03-06T14:08:37+01:00</pubDate>
	<wp:post_id>5973</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tillotts Pharma AG (part of the Zeria Group) and Teheran U.<wbr> of Medical Sciences started a few months ago a Ph4 RCT to assess the effects of Asacol (mesalamine 800mg) and Amitriptyline drugs on the Quality of Life (primary endpoint) and Symptom Severity Scale in patients with IBS-D.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Reference</U> NCT02190526 </div><div style="margin-bottom: 10px;"><U>Protocol 3-arm trial</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2280_1_ScreenCapture1.jpg">Timelines study to complete Dec 2015 /<wbr> Sept 2016 </div><div style="margin-bottom: 10px;"><U>Recruitment</U> approx 90 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Establishment of diagnosis of IBS by ROME-III criteria</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Age &gt; 18 years old and &lt; 65 years old</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Normal colonoscopy or sigmoidoscopy</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Negative celiac serologic markers</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Normal complete blood count (CBC) and stool exam and stool culture</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">The patient should not be administered Anti-inflammatory drugs such as Nonsteroidal Antiinflammatory Drugs(NSAIDs), oral or parenteral Antibiotics, Corticosteroids, Mast cell stabilizers, Narcotics, Antidepressants and Immunosuppressive Agents.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Normal thyroid-stimulating hormone (TSH )</LI>
</UL> </div><div><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Normal Serum Calcium</LI>
</UL> </div><!-- Comment details --><a name="gastroenterology2280attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2280_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2280">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-06T14:08:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-06T14:08:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lactobacillus Casei dg (Enterolactis Plus®) in Patient with IBS</title>
	<pubDate>2015-03-05T19:52:49+01:00</pubDate>
	<wp:post_id>5974</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by S.<wbr>O.<wbr>F.<wbr>A.<wbr>R.<wbr> the study has been designed to collect data for the assessment of the Lactobacillus casei DG (Enterolactis plus&reg;) effect on overall abdominal pain/<wbr>discomfort (as the primary endpoint), symptoms and gut microbiota composition.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>S.<wbr>O.<wbr>F.<wbr>A.<wbr>R.<wbr> GI Products</STRONG> <A href="http://www.sofarfarm.it/en/prodotti/area-gastrointestinale/">http:/<wbr>/<wbr>www.<wbr>sofarfarm.<wbr>it/<wbr>en/<wbr>prodotti/<wbr>area-gastrointestinale/<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG>Study Details</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Reference</SPAN> NCT02371499 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Timeline</SPAN> Study will complete in December 2015 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Location</SPAN> Italy (5 sites) </div><div style="margin-bottom: 10px;">Dietary Supplement: Lactobacillus casei DG - the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus&reg;) twice daily for 4 weeks (Other Name: Enterolactis plus&reg;) </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment</SPAN> approx.<wbr> 40 </div><div><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Age &gt; 18 years and &le; 65 years.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">A positive diagnosis of Irritable Bowel Syndrome regardless of bowel habit (both males and females), according to Rome III criteria.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Negative outcome of barium enema or left colonoscopy within the previous two years.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Negative relevant additional screening or consultation whenever appropriate.<wbr>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2278">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-05T19:52:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-05T19:52:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study of ZYTIGA Use in the Community Urology Setting in Canada</title>
	<pubDate>2015-03-05T19:27:37+01:00</pubDate>
	<wp:post_id>5975</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of the COSMiC study is to temporally evaluate the impact of ZYTIGA therapy on Patient Reported Outcomes (PROs) and on clinical outcomes in the chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) population.<wbr> Safety data, levels of health care resource utilization associated with abiraterone acetate (ZYTIGA) therapy will also be prospectively collected and analyzed.<wbr> </div><div style="margin-bottom: 10px;">Of note, the study started around Sept2014, was verified by Janssen Inc, and listed in clinicaltrials.<wbr>gov last month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Reference</SPAN> NCT02364531 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">PE</SPAN>: Functional Assessment of Cancer Therapy - Prostate (FACT-P) Score </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment</SPAN> Approx 500 </div><div style="margin-bottom: 10px;"><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Participants must have a confirmed diagnosis of metastatic castrate-resistant prostate cancer (mCRPC) according to medical history and have rising Prostate-Specific Antigen (PSA) levels or radiographic progression (documented by previous positive bone scan or metastatic lesions identified on CT or MRI) despite ongoing conventional Androgen deprivation therapy (ADT)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Participant (or legally accepted representative) must be able to sign an informed consent form (ICF) indicating that they understand the procedures for data collection and are willing to participate in the study
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Participant must be able to understand and complete study questionnaires
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Abiraterone Acetate (ZYTIGA) has been chosen as the treatment for mCRPC disease progression as part of standard of care
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Male participants aged greater than (&gt;) 18 years
</LI>
</UL> </div><div><SPAN style="text-decoration: underline;">Completion date</SPAN> August 2017 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10321">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-05T19:27:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-05T19:27:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GTx Update Progress Of Enrollment for GTx758 +ADT Ph2 Trial In CRPC Patients</title>
	<pubDate>2015-03-05T19:00:16+01:00</pubDate>
	<wp:post_id>5976</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During GTx 2014 year end financial results, GTx provides an update for GTx-758 that is currently being evautated as a secondary hormonal treatment in CRPC patients.<wbr> Both mCRPC and M0 CRPC patients are enrolling in the open-label Ph2 study.<wbr>The 125 mg arm is enrolled and the 250 mg dose is expected to be fully enrolled by the end of Q1 2015.<wbr> Men on androgen deprivation therapy (ADT) who fail to reach castrate levels of testosterone remain at high risk for progression of their prostate cancer.<wbr> GTx-758, in combination with ADT in these patients, may reduce this risk by lowering testosterone to accepted castrate levels, as well as ameliorating the estrogen deficiency side effects associated with ADT.<wbr> Completion of the trial will trigger GTx's decision to pursue partnership for funding of a Ph3 trial.<wbr> </div><div style="margin-bottom: 10px;">GTx reported financial results for the fourth quarter and year ended December 31, 2014, and highlighted recent accomplishments and upcoming milestones.<wbr> The Company remains focused on targeting the androgen receptor in women with advanced breast cancer using enobosarm, the Company&rsquo;s oral nonsteroidal selective androgen receptor modulator.<wbr> The Company also highlighted clinical progress with GTx-758, its oral nonsteroidal selective estrogen receptor alpha agonist, being studied for secondary hormonal therapy in men with castration resistant prostate cancer.<wbr> In terms of management changes, GTx annouced new CEO, Rob Wills, who was described as an industry executive with solid operational experience, to help us execute on our business objectives.<wbr> The breast cancer indication will remain company's priority: </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Enobosarm</STRONG></SPAN> is the Company&rsquo;s lead product candidate and is being developed for two breast cancer indications: as a targeted treatment for (i) estrogen receptor positive (ER+) and androgen receptor positive (AR+) breast cancer, and (ii) AR+ triple negative breast cancer (TNBC).<wbr> The results showed clinical benefit at six months that exceeded the pre-defined statistical threshold requiring that at least 3 of 14 AR+ patients demonstrate clinical benefit.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Q2 2015: initiation of an open-label, proof-of-concept Phase 2 clinical trial of enobosarm in patients with advanced AR+ TNBC.<wbr> The study will enroll up to 55 patients with the primary efficacy objective defined as clinical benefit at 16 weeks.<wbr>
</LI>
<LI>Q3 2015: initiation of an open-label Phase 2 clinical trial of enobosarm in patients with ER+/<wbr>AR+ advanced breast cancer.<wbr> The study will enroll up to 118 patients with the primary efficacy objective defined as clinical benefit at 24 weeks.<wbr><BR>For each of these two phase 2 clinical trials, clinical benefit is defined as a complete response, partial response or stable disease.<wbr>
</LI>
</UL> </div><div>Source: GTx Company Q4 2014 Earning Financial WebCast 4 March 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10320">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-05T19:00:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-05T19:00:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Lexicon Q4/FY14 Financial Results</title>
	<pubDate>2015-03-05T17:05:47+01:00</pubDate>
	<wp:post_id>5977</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lexicon reported revenues for Q4:14 of $21.<wbr>5 million (an increase from $1.<wbr>4 million in the prior year period).<wbr> For the year, revenues increased to $22.<wbr>9 million from $2.<wbr>2 million in 2013.<wbr> Upon having successful data from Ph3 of trelotristat, the company should then be in a position to file a NDA in Q1:16, with approval and launch in H2:16.<wbr> Management said that the plan is to prepare the NDA filing in parallel with the MAA filing "to be able to file them in very close proximity to one another".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Financial Figures</STRONG> </div><div style="margin-bottom: 10px;">R&amp;D expenses for the 2014 fourth quarter decreased 1%, to $20 million, from $20.<wbr>3 million in the prior year period.<wbr> For the year, R&amp;D expenses decreased to $89.<wbr>3 million from $89.<wbr>7 million in 2013 </div><div style="margin-bottom: 10px;"><STRONG>2015 Guidance</STRONG> </div><div style="margin-bottom: 10px;">Magagement expects contractual revenues from existing agreements in 2015 of approximately $2 million </div><div style="margin-bottom: 10px;">Operating expenses in 2015 will be in the range of $130 million to $140 million.<wbr> Non-cash expenses are expected to be approximately $11 million of this total, including $7 million in stock-based compensation, $3 million in an increase in fair value of Symphony Icon purchase liability, and $1 million in depreciation and amortization.<wbr> These operating expenses include R&amp;D expenses expected to be in the range between $100 million and $180 million, and selling, general and administrative expenses expected to be in a range between $30 million and $32 million.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Selected Q&amp;A From Analysts&amp;Management</STRONG> </div><div style="margin-bottom: 10px;">Management expects clinically meaningful benefit on the number of daily bowel movements ".<wbr>.<wbr>.<wbr> something in the range of 25% to 30%.<wbr> And that's really what we've powered our studies to be able to see.<wbr> As you probably remember, in Phase 2, we saw around a 40% reduction at week 11 and 12 compared to baseline.<wbr> So we feel like the study is quite well powered and expect it to show clinically meaningful results".<wbr> </div><div>Other requirements for the telotristat NDA submission " .<wbr>.<wbr>.<wbr> we've done Phase 1 studies that would allow us to file for approval.<wbr> So we're expecting to have the complete package ready to go and complete as soon as the pivotal studies are completed".<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7976">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-05T17:05:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-05T17:05:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pharmacyclics Is Up For A Sale?</title>
	<pubDate>2015-03-05T11:27:01+01:00</pubDate>
	<wp:post_id>5978</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pharmacyclics Is Up For A Sale?</span>&nbsp;<br><span style="font-size: 12px;">Comment: Pharmacyclics have Ibvruvica that is approved for four different haematological cancer indications and Pharmacyclics' ambition is to add one more uses every year.<wbr> In November 2014, the Company announced a clinical trial collaboration agreement with AstraZeneca to evaluate the efficacy and safety of anti-PD1 + Ibruvica in haematological cancers and solid tumours.<wbr> It is currently being valued at more than $15 billion  and murmurs amongst analysts suggest Pharmacyclics are exploring options including sale.<wbr> The market reacted and the company's shares rose 17% to $220.<wbr>22 at the close in New York.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11110">...</a><br></div><div>Comment: Rumours floating around on J&amp;J's interest in Pharmacyclics, Pharmacyclics jumps in apparent response to rumous that J&amp;J is close to making a premium bid for the $17B biotech.<wbr> The two companies have a history of working together.<wbr> The market had reacted positively with shares were up 6% in yesterday's session on double normal volume and are up another 2% after hours.<wbr> Today, the rumours were broken and it is now confrmed that AbbVie is to buy Pharmacyclics for about $21 billion This is the latest example of a pharma swooping on a biotech company to refill its pipeline.<wbr> Analysts are positive on AbbVie as they believe the Imbruvica would diversify the business beyond Humira.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11115">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11110">View thread  PharmaWorld11110: Pharmacyclics Is Up For A Sale?</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-05T11:27:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-05T11:27:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Strong Year-over-Year Revenue and Sales Growth for AMITIZA</title>
	<pubDate>2015-03-04T19:19:44+01:00</pubDate>
	<wp:post_id>5979</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Total revenues were <MONEY>$37.<wbr>8 million</MONEY> for Q4:14 compared to <MONEY>$24.<wbr>5 million</MONEY> in the same period in 2013, an increase of 54%.<wbr> Total revenues were <MONEY>$115.<wbr>5 million</MONEY> for the full year of 2014 compared to <MONEY>$89.<wbr>6 million</MONEY> in the same period in 2013, an increase of 29%.<wbr> Alongside those figures, management outlined significant progress on pipeline programs.<wbr> Early in 2015, the European Mutual Recognition Procedure (MRP) for AMITIZA for CIC was successfully completed, and last month, <LOCATION value="LC/ie;LB/neur">Ireland</LOCATION> became the first country to issue a marketing authorization.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2277_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2277_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In <CHRON>February 2015</CHRON>, the first patient was dosed in a phase 2 trial of cobiprostone for non-erosive reflux disease (NERD) in proton pump inhibitors refractory patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2277_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Unmet medical need in the ped constipation segment</STRONG> " .<wbr>.<wbr>.<wbr> Obviously there's a very large segment of the population in general, whether it be in the US or in ex-US territories, of kids between the ages of six months and 17 years.<wbr> Our best estimate is you're talking millions of patients, both in the US alone, that could be suffering from chronic constipation.<wbr> </div><div style="margin-bottom: 10px;">I will note that we need to continue to work-up and do -- not a better job but just get more specificity in the market on these patients by doing targeted market research, both with physicians and with the parents of these patients that are suffering from constipation.<wbr> But I think it's fair to say that it's a sizeable market opportunity if you just use the same correlates we use to the adult population and how many patients suffer from constipation in the adult population.<wbr> </div><div>Obviously the unmet medical need there is real.<wbr> These are kids.<wbr> That's why we're taking the path of the capsule studies but, more importantly, I would say the alternate formulation because a lot of these kids in the younger ages have an aversion or aren't able to swallow tablets.<wbr>" </div><!-- Comment details --><a name="gastroenterology2277attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2277_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2277_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(118,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2277_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(41,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2277">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-04T19:19:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-04T19:19:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AB-Biotics Enters the Chinese Ped Market with its Probiotics for Infantile Colic</title>
	<pubDate>2015-03-04T14:38:22+01:00</pubDate>
	<wp:post_id>5980</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AB-Biotics and Derbycare recently inked an agreement, whereas Derbycare 1/<wbr>will launch AB-Kolicare in China (H1:2015), and 2/<wbr>develop three new clinical trials with a minimum of 3,000 patients to further substantiate the proven health benefits of the product.<wbr> Of note, beginning of December 2014, AB-Biotics signed a deal with Matrix Health Foods for the distribution of AB-Kolicare in Pakistan (launch expected H1:2015).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Derbycare and AB-Biotics will also collaborate for the research and development of new probiotic formulas and food supplement rich in probiotics for infants to market in China and other markets </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ab-Biotics claims that the consumption of AB-Kolicare during only 14 days reduces the excessive daily crying in 67.<wbr>5 % in subjects with a daily crying duration between 60 and 240 minutes.<wbr> </div><div style="margin-bottom: 10px;">BI notes that this is the same claims as for AB-Biotics' Sanogermina (<A href="https://biotechspain.com/en/news_item.cfm?iid=ab-biotics-sanofi-gastropediatric-sanogermina">https:/<wbr>/<wbr>biotechspain.<wbr>com/<wbr>en/<wbr>news_item.<wbr>cfm?iid=ab-biotics-sanofi-gastropediatric-sanogermina</A>), and is wondering weither it is the same probiotics with different brand names.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Site: <A href="http://www.derbycare.com/#!science-to-love/c17di">http:/<wbr>/<wbr>www.<wbr>derbycare.<wbr>com/<wbr>#!science-to-love/<wbr>c17di</A> </div><div style="margin-bottom: 10px;">Chinese company focused on pregnant women and babies health nutritional food segment.<wbr> There are several key business departments in Derbycare, such as CI Clinical Medical Service, MIHC Scientific Laboratory, MIHC Medical Market, MIHC Health Application Product .<wbr>.<wbr>.<wbr> </div><div>In the probiotic field, the company commercializes in the Chinese market products from leading international companies such as Zmarto from Hutchinson Whampoa Limited, the No.<wbr> 1 brand for the pregnant women and infant products, which has been in the market for over 10 years; <STRONG>the probiotic BB12 from Christian Hansen.<wbr></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2273">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-04T14:38:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-04T14:38:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Valeant Announced Its Plan To Update 2015 Guidance To Reflect Two Major Acquistions - Dendreon And Salix</title>
	<pubDate>2015-03-04T12:34:29+01:00</pubDate>
	<wp:post_id>5981</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Valeant Announced Its Plan To Update 2015 Guidance To Reflect Two Major Acquistions - Dendreon And Salix</span>&nbsp;<br><span style="font-size: 12px;">Comment: During Valeant's Fourth Quarter 2014 Financial Results Conference Call, Valeant reported a total revenue of $8.<wbr>3 billion with an increase of 43% over the prior year.<wbr> A high restructuring and integration expense ($388M) was reported for 2014 due to a numbers of deals closed in 2014 - including Solta, ECR, Croma, Precision, Bescon, and MedPharm.<wbr> This has not yet reflected the confirmed acquisitions of Dendreon and Salix.<wbr> Two business units will be created for Dendreon and Salix operation and Valeant expect the minimum for restructuring and integration charges incurring for both.<wbr> Valeant also announced the plan to update their 2015 guidance on Q1 2015 call to reflect acquisitions of Dendreon and Salix.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11100">...</a><br></div><div>Shortly after confirmation of the Valeant's takeover in February, Valeant informed employment security that 77 employees, mostly from G&amp;A functions where there was overlap with Valent's existing business, will be laid off from Dendreon.<wbr> This reflects Valeant's aggressive nature and also Michael Pearson's (CEO, Valeant) ambition to raise the gross margins of the business to more than 65% by the end of 2015, and 80% gross margins in the loner term.<wbr> Source: Seattle times </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11114">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11100">View thread  PharmaWorld11100: Valeant Announced Its Plan To Update 2015 Guidance To Reflect Two Major Acquistions - Dendreon And Salix</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-04T12:34:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-04T12:34:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS' New Hope To Enter mCRPC : BMS Will In-License Bavarian Nordic's PROSTVAC for mCRPC</title>
	<pubDate>2015-03-04T09:37:20+01:00</pubDate>
	<wp:post_id>5982</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: Bavarian Nordic and BMS announced that BMS will have an exclusive option to license and commercialise PROSTVAC, that is currently being evaluated in Ph3 trial or e treatment of asymptomatic o minimally symptomatic mCRPC patients.<wbr> This could be a new entry point for BMS into prostate cancer market following disappointing outcome from ipilimumab's programmes in mCRPC.<wbr> BMS' likely strategic intention is to explore combination strategy with its immuno-oncology portfolio such as nivolumab.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><P style="margin: 1em 0cm;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small; mso-bidi-font-family: Arial;"></SPAN></P> </div><div><P style="margin: 1em 0cm;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small; mso-bidi-font-family: Arial;"></SPAN></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10315">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-04T09:37:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-04T09:37:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OPKO/Pfizer to Present Data from Ph2 LAhGH at ENDO</title>
	<pubDate>2015-03-03T18:36:38+01:00</pubDate>
	<wp:post_id>5983</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OPKO will be presenting two posters that will include 12 months data from its hGH-CTP in PGHD.<wbr> The data affirm the selection of an optimal dose that will potentially demonstrate non-inferiority compared to daily hGH in the upcoming phase 3 study in pediatric GHD patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>THR-148</U>: "Top Line Results of 12 Months of <ORG>Once-Weekly Administration of CTP-Modified Human Growth Hormone</ORG> (MOD-4023): Phase 2 Dose Finding Study in Children with Growth Hormone Deficiency (GHD)" </div><div style="margin-bottom: 10px;">Session details: <CHRON>Thursday, March 5</CHRON>; Time: 1:00 - <CHRON>3:00 PM</CHRON> </div><div style="margin-bottom: 10px;"><U>THR-151</U>: "Twelve Months Pharmacokinetics and Pharmacodynamics Profile of <ORG>Once-Weekly</ORG>, CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Study in Children with Growth Hormone Deficiency" </div><div style="margin-bottom: 10px;">Session details: <CHRON>Thursday, March 5</CHRON>; Time: 1:00 - <CHRON>3:00 PM</CHRON> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7973_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="endocrinology7973attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7973_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7973">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-03T18:36:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-03T18:36:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: US OD Designation Granted For Trofinetide In Rett Syndrome</title>
	<pubDate>2015-03-03T14:26:18+01:00</pubDate>
	<wp:post_id>5984</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">US OD Designation Granted For Trofinetide In Rett Syndrome</span>&nbsp;<br><span style="font-size: 12px;">Comment: Neuren Pharmaceuticals announced today that the US FDA has 
granted its drug trofinetide Orphan Drug designation for the treatment of Rett 
Syndrome.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7966">...</a><br></div><div style="margin-bottom: 10px;">Neuren has announced that the FDA agreed that Rett syndrome meets the criteria for a serious or life-threatening condition.<wbr> However, Breakthrough Therapy will not be granted at this time because the FDA considered that data from Neuren&rsquo;s exploratory Phase 2 trial provide insufficient evidence to demonstrate substantial improvement over existing therapies using conventional statistical methods.<wbr> The company will proceed as planned under the Fast Track designation that has already been granted by the FDA under its expedited programs for serious conditions.<wbr> As planned, management expects to meet with the FDA in 1H:15 to agree the remaining requirements for the development of trofinetide in Rett syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Fast Track designation</STRONG> is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously.<wbr> </div><div><STRONG>Breakthrough Therapy</STRONG> is intended to streamline drug development and regulatory review of innovative new medicines that address unmet medical needs for serious diseases or conditions.<wbr> The criteria for Breakthrough Therapy require preliminary clinical evidence indicating that the drug may demonstrate a substantial improvement over existing therapies on at least one clinically significant endpoint.<wbr> Breakthrough Therapy designation conveys all of the Fast Track program features, as well as a commitment that FDA will work closely with the sponsor on an efficient drug development program.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7972">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7966">View thread  Endocrinology7966: US OD Designation Granted For Trofinetide In Rett Syndrome</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-03T14:26:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-03T14:26:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Probi Digestis® for IBS to be Launched in Hong Kong and Macau</title>
	<pubDate>2015-03-03T10:47:29+01:00</pubDate>
	<wp:post_id>5985</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi and DKSH have signed a long-term agreement for the branding and launch of Probi’s gastrointestinal health product Probi Digestis® (based on Lactobacillus plantarum 299v, Probi’s clinically documented probiotic strain).<wbr> The agreement is an expansion of the agreement signed in 2013 between Probi and BiO-LiFE, a Malaysian subsidary of DKSH.<wbr> Also, to further strengthen its presence in Asia Pacific, Probi has expanded its Marketing and Sales organisation with a regional director based in Singapore.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The product will be marketed in a co-branded solution with BiO-LiFE and Probi Digestis® and will be positioned against Irritable Bowel Syndrom (IBS) symptom’s like abdominal pain, bloating, constipation and flatulence.<wbr> </div><div>DKSH will market, sell and distribute the product in both medical channels such as clinics and hospitals as well as in pharmacies in Hong Kong and Macau </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2272">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-03T10:47:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-03T10:47:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messgaes from Merck Serono and Consumer Health Businesses</title>
	<pubDate>2015-03-03T10:37:57+01:00</pubDate>
	<wp:post_id>5986</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Total revenues of the Merck Group rose by 3.<wbr>7% to € 11.<wbr>5 billion in 2014.<wbr> Sales grew by 5.<wbr>5% to € 11.<wbr>3 billion (2013: € 10.<wbr>7 billion).<wbr> Strategic drivers for Merck Serono were emerging markets, good performance of Erbitux and Fertility.<wbr> Emerging markets and Europe, the growth of strategic brands (Neurobion, Femibion and Floratil as well as local brands in Germany) drove the Consumer Healthcare business.<wbr> Focusing on Saizen, sales increased by 2% and 4% for Q4 and FY2014 respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_10_ScreenCapture10.jpg"> </div><!-- Comment details --><a name="pharmaworld11113attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(104,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(99,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(95,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(106,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(102,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(11,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(66,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(64,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11113_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(78,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11113">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-03T10:37:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-03T10:37:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>While Revenue Decreased Revance Reiterated Its 2015 Outlook</title>
	<pubDate>2015-03-03T08:35:35+01:00</pubDate>
	<wp:post_id>5987</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Loss from operations for the quarter ended December 31, 2014 was $M13.<wbr>8.<wbr> For the full year ended December 31, 2014, loss from operations was $M52.<wbr> Management outlined that infrastructure and product pipeline are now "in place to execute plans from a solid platform".<wbr> In parallel, the company presentation has been updated, and key information is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7936_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7936_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Research and development expenses</STRONG> for the fourth quarter and full year ended December 31, 2014 were $9.<wbr>1 million and $33.<wbr>4 million, respectively, compared to $6.<wbr>2 million and $27.<wbr>8 million for the same periods in 2013, respectively </div><div style="margin-bottom: 10px;"><STRONG>Sales, general, and administrative expenses</STRONG> for the fourth quarter and full year ended December 31, 2014 were $4.<wbr>8 million and $19.<wbr>0 million, respectively, compared to $3.<wbr>0 million and $11.<wbr>0 million for the same periods in 2013, respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7936_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="neurology7936attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7936_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(103,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7936_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7936_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(64,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7936">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-03T08:35:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-03T08:35:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from RedHill Financial Results</title>
	<pubDate>2015-03-02T18:55:40+01:00</pubDate>
	<wp:post_id>5988</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The revenues in 2014 were mainly from an upfront payment of $7.<wbr>0 million received from Salix (now part of Actavis) for the out-licensing of RedHill's RHB-106 encapsulated bowel preparation (which potential advantages are improved safety and no need to consume liquid solution).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Research and Development</U> Expenses for the year ended December 31, 2014 were approximately $12.<wbr>7 million, an increase of $4.<wbr>6 million, or approximately 57%, compared to $8.<wbr>1 million for the year ended December 31, 2013.<wbr> </div><div style="margin-bottom: 10px;"><U>General and Administrative Expenses</U> for the year ended December 31, 2014 were approximately $4.<wbr>0 million, an increase of $1.<wbr>3 million, or approximately 48%, compared to $2.<wbr>7 million for the year ended December 31, 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2271_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2271_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2271_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="gastroenterology2271attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2271_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(64,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2271_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2271_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(79,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2271">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-02T18:55:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-02T18:55:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</title>
	<pubDate>2015-03-02T17:21:28+01:00</pubDate>
	<wp:post_id>5989</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</span>&nbsp;<br><span style="font-size: 12px;">Comment: Eisai executive Ivan Cheung in an interview with the Wall Street Journal reportedly claimed that its top prospect in oncology, levantanib can bring in peak annual sales north of $1bn by 2020, starting with its imminent approval in the US for the treatment of radioactive refractory thyroid cancer and then expanding to other tumour types.<wbr> Analysts at Morgan Stanley are forecasting US sales  of $90m in 2019 for the thyroid indication alone and $300m at best.<wbr>.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10266">...</a><br></div><div>Eisai announced today that Lenvima has been launched in the US on February 26th as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.<wbr> The US is the first country in the world where Lenvima has been launched.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10314">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10266">View thread  Oncology10266: Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-03-02T17:21:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-03-02T17:21:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Raptor Huntington Path to Registration Program to Gain Clarity This Year</title>
	<pubDate>2015-02-27T15:49:11+01:00</pubDate>
	<wp:post_id>5990</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday alongside fiancial results, call with management highlighted a couple of strategic points on the Huntington's disease program from a clinical and regulatory perspectives (please see below).<wbr> On the business hand, PROCYSBI achieved Q4 and FY2014 net sales of $17.<wbr>3M (vs $10.<wbr>2M in Q4:13) and $69.<wbr>5M (vs $16.<wbr>9M for 2013)) respectively.<wbr> Growth was driven by continued market penetration in the U.<wbr>S.<wbr> (launch in June 2013) and the launch in Germany (April 2014).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Regulatory</U> </div><div style="margin-bottom: 10px;">Management outlined being in "active" discussions with both EMA and FDA to determine the path to registration, and expects to gain clarity this year.<wbr> </div><div style="margin-bottom: 10px;"><U>Clinical</U> </div><div style="margin-bottom: 10px;">CCyst-HD (Ph2/<wbr>3) - The company anticipates the last patient will complete the 36-month assessment in the trial this summer, with 36-month data available later this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Establishing 2015 global net product sales guidance for PROCYSBI of $80 to $90 million.<wbr> <BR></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Establishing non-GAAP operating expense, excluding non-cash stock-based compensation expense, guidance of between $115 and $125 million</LI>
</UL> </div><div>Source: Raptor </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7933">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-27T15:49:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-27T15:49:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Chiasma Raises $33.8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</title>
	<pubDate>2015-02-27T15:18:10+01:00</pubDate>
	<wp:post_id>5991</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Chiasma Raises $33.<wbr>8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</span>&nbsp;<br><span style="font-size: 12px;">Chiasma has today announced the appointment of David Stack (CEO and chairman of Pacira Pharmaceuticals) as Chairman of the Board, and John Scarlett (CEO and president of Geron Corporation) as a member of the board.<wbr> Roni Mamluk, CEO, on commenting the news stressed the "benefit from the deep experience and knowledge Dave and John will bring to Chiasma as we move oral octreotide toward a NDA submission by the middle of this year.<wbr>.<wbr>.<wbr>".<wbr> Once again Chiasma is confirming their intention on submitting an NDA to the FDA this year, with possible US approval in 2016.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7968">...</a><br></div><div style="margin-bottom: 10px;">Chiasma has announced today the closing of a $70 million financing round.<wbr> Participants in the financing included new investors Rock Springs Capital and Sofinnova Ventures, and an undisclosed blue chip public investment fund, as well as existing investors MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners.<wbr> Once again Chiasma has stated it will use the new capital to build its sales and marketing capabilities and prepare for the launch of octreotide capsules in the US.<wbr> The company intends to submit a NDA to the FDA in the second quarter of 2015 and, if the NDA is approved, to launch the product in the US in 2016.<wbr> Chiasma will also conduct additional clinical studies for octreotide capsules to support approval in the European Union and advance new product candidates based on its proprietary TPEA (Transient Permeability Enhancer) technology into preclinical development.<wbr> </div><div>Source: PR Newswire </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7970">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7902">View thread  Endocrinology7902: Chiasma Raises $33.<wbr>8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-27T15:18:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-27T15:18:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sirtex Reports Strong 1H Results With Study Results In Liver Metastastasis Associated With mCRC Expected Soon</title>
	<pubDate>2015-02-27T13:43:55+01:00</pubDate>
	<wp:post_id>5992</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sirtex reported half-year revenue growth of 37.<wbr>3% to $80.<wbr>5m and profit after tax growth of 58% to $17.<wbr>7m.<wbr> Preliminary results from the SIRFLOX study a trial undertaken with Sir- Spheres in the 1st line setting in CRC patients with metastatic liver cancer are due to be released in March, with final results and detailed analysis to appear at ASCO.<wbr> </div><div style="margin-bottom: 10px;">Sirtex sales revenues and dose sales demonstrate a consistent growth picture across all three major regions.<wbr> A key event in September was the release of the new European Society of Medical Oncology Clinical Guidelines recommending SIR-Spheres microspheres for the treatment of metastatic colorectal cancer in patients who have failed to respond to chemotherapy.<wbr> This it is believe should continue to improve access and awareness across Europe and other markets.<wbr> period.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">The slides below illustrates the full spectrum of trials being undertaken by Sirtex in patients with liver cancer associated with different causality and the companies plans in terms of sales/<wbr>marketing and data release and its means of creating long-term strategic value </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">The only study currently evaluating Sir-Spheres in Neuroendocrine tumours associated with liver metastases is being conducted by Emory University.<wbr>This is a small study (n=13), which should conclude later this year in terms of primary endpoint evaluating the spheres in combination with pasireotide and everolimus.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-top: 1ex;" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="padding-left: 1em;"><A class="study-link" href="http://clinicaltrials.gov/show/NCT01469572" title="Current version of study NCT01469572 on ClinicalTrials.gov">NCT01469572</A></TD>
</TR>
</TBODY>
</TABLE> </div><div>Source.<wbr><a href="http://www.sirtex.com" class="defaultlink" title="http://www.sirtex.com">sirtex.com</a> </div><!-- Comment details --><a name="oncology10310attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(142,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(176,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(112 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10310_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(94,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10310">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-27T13:43:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-27T13:43:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Positive Ph2 Data From Progenics PSMA-ADC Presented At ASCO GU</title>
	<pubDate>2015-02-27T11:43:46+01:00</pubDate>
	<wp:post_id>5993</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Progrenics presents the full results from its Ph2 study of PSMA ADC in mCRPC patients following progression from prior enzalutamide or abiraterone therapy.<wbr> The study includes both chemo na&iuml;ve and post-docetaxel cohorts (NCT01695044).<wbr> The data was presented as part of the general poster session on Thursday 26th Feb (11:30-1:00 PM).<wbr> The full surrogate biomarker and radiological data suggests a meaningful clinical benefit -shrinkage of patients' tumours.<wbr> The conversion of unfavourable levels of circulating tumour cells to favourable levels and the reduction in patients' PSA scores, all of which provide strong evidence of PSMA ADC anti-tumour activity.<wbr> Possible surrogate biomarkers (Low NE which can be easily done via blood tests) have been identified that Progenics believe will help to overcome future market access and reimbursement hurdle.<wbr> The full poster is available as attachment During the RBC Healthcare Conference held in New York, Marker Baker (CEO, Progenics) stated the PSMA-ADC programme is now ready to move into Ph3 and final decision on Ph3 position is expected in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Poster Title: A Phase 2 Study of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Following Abiraterone and/<wbr>or Enzalutamide</STRONG>The Phase 2 trial assessed the anti-tumour activity and tolerability of PSMA ADC, an antibody drug conjugate, in both taxane-experienced and chemo-na&iuml;ve patients that had progressed following treatment with abiraterone and/<wbr>or enzalutamide.<wbr> The study enrolled 119 patients with mCRPC that had progressed following treatment with abiraterone and/<wbr>or enzalutamide, including 84 taxane-experienced patients and 35 chemo-na&iuml;ve patients.<wbr> Patients in the trial received PSMA ADC 2.<wbr>5mg/<wbr>kg or 2.<wbr>3 mg/<wbr>kg intravenously three times weekly for up to 8 cycles.<wbr> Safety, antitumor activity, and exploratory biomarkers were assessed.<wbr> </div><div style="margin-bottom: 10px;">In the chemo-na&iuml;ve cohort (n=35), treatment with PSMA ADC reduced tumour size and levels of PSA and CTCs (circulating tumour cells) evidencing strong anti-tumour activity.<wbr> Among these chemo-na&iuml;ve patients, one (3%) had a complete radiological response, four (14%) had a partial radiological response, 22 (76%) showed stable disease, and two (7%) experienced progressive disease.<wbr>The safety data identified an appropriate dose of 2.<wbr>3 mg/<wbr>kg, which is generally well tolerated and appears to be better than the 2.<wbr>5 mg/<wbr>kg dose.<wbr> The most common adverse events were neutropenia, fatigue, electrolyte imbalance, anaemia and neuropathy.<wbr> Detailed radiological, CTC and PSA data is included below: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10306_1_1.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10306_2_2.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10306_3_3.JPG"> </div><div>Source: Progenics Press Release, RBC Healthcare Conference Feb 2015 </div><!-- Comment details --><a name="oncology10306attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10306_1_1.JPG">1.JPG</a>&nbsp;&nbsp;(38 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10306_2_2.JPG">2.JPG</a>&nbsp;&nbsp;(39,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10306_3_3.JPG">3.JPG</a>&nbsp;&nbsp;(72,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10306_4_PSMA%20ADC%20ASCO%20GU%202015%20Poster.pdf">PSMA ADC ASCO GU 2015 Poster.pdf</a>&nbsp;&nbsp;(1,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10306">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-27T11:43:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-27T11:43:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Appoints Shire Executive to its Board</title>
	<pubDate>2015-02-27T11:09:17+01:00</pubDate>
	<wp:post_id>5994</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Philip Vickers, Executive VP and Global Head of R&amp;D at Shire, will be responsible to move RT001 and RT002 toward regulatory approval, and expand the company's toxin pipeline into a 'wide variety of therapeutic areas'.<wbr> First Ph3 study of RT001 for LCL is expected to start 2H:15.<wbr> Mid-2015, the drug is set to enter Ph1/<wbr>2 for hyperhidrosis.<wbr> Results of the Belmont study with RT002 for GL is planned later this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">25 years of experience developing and commercializing innovative biologics, and small molecules.<wbr> </div><div style="margin-bottom: 10px;">Currently responsible for overseeing PC researchn clinical development, regulatory affairs, medical affairs and pharmacovigilance at Shire </div><div style="margin-bottom: 10px;">Member of Shire's executive and Pipeline Committees.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7932_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7932_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology7932attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7932_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7932_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7932">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-27T11:09:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-27T11:09:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pharmacyclics Is Up For A Sale?</title>
	<pubDate>2015-02-27T10:55:24+01:00</pubDate>
	<wp:post_id>5995</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pharmacyclics have Ibvruvica that is approved for four different haematological cancer indications and Pharmacyclics' ambition is to add one more uses every year.<wbr> In November 2014, the Company announced a clinical trial collaboration agreement with AstraZeneca to evaluate the efficacy and safety of anti-PD1 + Ibruvica in haematological cancers and solid tumours.<wbr> It is currently being valued at more than $15 billion  and murmurs amongst analysts suggest Pharmacyclics are exploring options including sale.<wbr> The market reacted and the company's shares rose 17% to $220.<wbr>22 at the close in New York.<wbr> </div><div style="margin-bottom: 10px;">According to Bloomberg, a deal of this size would value Pharmacyclics at more than 200 times the company&rsquo;s net income last year of $86 million.<wbr> However, sales of Imbruvica, the company&rsquo;s oncology treatment, will grow to $3.<wbr>56 billion in 2018 from $492 million last year.<wbr> </div><div style="margin-bottom: 10px;">&ldquo;<EM>I don&rsquo;t think this is a crazy valuation based on the peak sales of this thing.<wbr> I would call it a primarily one-asset company.<wbr> It&rsquo;s not surprising to see a buyout.<wbr> It&rsquo;s very clean and straightforward for a bigger company that can say, We can do a better job with our sales force</EM>.<wbr>&rsquo;&rdquo; Stefan Quenneville, an analyst at Morningstar commented </div><div style="margin-bottom: 10px;">Possible runners include J&amp;J and Novartis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>J&amp;J:</STRONG> Pharmacyclics already has a partnership with J&amp;J&rsquo;s Janssen Biotech Inc.<wbr> to manufacture Imbruvica, which last month received a fourth approval from the U.<wbr>S.<wbr> Food &amp; Drug Administration.<wbr>J&amp;J is seeking to replenish its product lineup as drugs such as hepatitis C treatment Olysio and blood thinner Xarelto face new competition.<wbr> Jami Rubin, an analyst at Goldman Sachs Group Inc.<wbr>, lowered her recommendation on J&amp;J to sell from neutral on Jan.<wbr> 15 because she sees the company bringing fewer new drugs to market this year than in previous years, she said in a note.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Novartis:</STRONG> Novartis has extensive experience in blood cancers, and pioneered Gleevec, one of the first targeted therapies for chronic myeloid leukemia.<wbr> Gleevec revolutionized treatment of the disease, and last year sales of the drug were $4.<wbr>75 billion, while a newer Novartis drug for the same type of leukemia, Tasigna, had $1.<wbr>53 billion in 2014 sales.<wbr> Imbruvica&rsquo;s use was expanded last year for patients with chronic lymphocytic leukemia patients who have tried at least one other treatment, three months after Roche&rsquo;s Gazyva was approved for the disease.<wbr> It will be a good fit in Novratis' current haematological portfolio.<wbr> </div><div style="margin-bottom: 10px;">Pharmacyclics, Inc.<wbr>, reported financial results for the quarter and year ended December 31, 2014: </div><div style="margin-bottom: 10px;">In the first full year of IMBRUVICA&reg; (ibrutinib) sales, the Company recorded total revenue of $730 million, driven by U.<wbr>S.<wbr> net product revenue of $492 million for the year ended December 31, 2014, compared to U.<wbr>S.<wbr> net product revenue of $14 million for the prior year.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Worldwide IMBRUVICA net product revenue of $548 million was recorded for the year ended December 31, 2014, including net product revenue of $56 million from outside of the U.<wbr>S.<wbr> as reported by our collaboration partner Janssen Biotech, Inc.<wbr> and its affiliates (Janssen).<wbr>
</LI>
<LI>Strong fourth quarter U.<wbr>S.<wbr> net product revenue of $185 million was reported, representing 31% quarter over quarter growth.<wbr>
</LI>
<LI>The fourth quarter represents the second profitable quarter under the worldwide collaboration and license agreement (Agreement) with Janssen.<wbr>
</LI>
<LI>IMBRUVICA received regular (full) U.<wbr>S.<wbr> Food and Drug Administration (FDA) approval on January 29, 2015, as the first and only treatment for patients with Waldenstrom's Macroglobulinemia (WM), and it is approved in all lines of therapy.<wbr> This is the fourth indication for IMBRUVICA in less than 15 months.<wbr> In the United States, approximately 1,500 people are diagnosed each year with WM, the prevalence is approximately 12,000 (G7 incidence estimated at 6,000 and prevalence at 23,000).<wbr>
</LI>
<LI>25 IMBRUVICA trials commenced in 2014 across a variety of hematologic histologies.<wbr>
</LI>
<LI>Research expansion with trials in several solid tumour types will begin in the first half of 2015.<wbr>
</LI>
</UL> </div><div>Source: Pharmacyclics financial statement.<wbr> Bloomberg </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld11115c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Rumours floating around on J&amp;J's interest in Pharmacyclics, Pharmacyclics jumps in apparent response to rumous that J&amp;J is close to making a premium bid for the $17B biotech.<wbr> The two companies have a history of working together.<wbr> The market had reacted positively with shares were up 6% in yesterday's session on double normal volume and are up another 2% after hours.<wbr> Today, the rumours were broken and it is now confrmed that AbbVie is to buy Pharmacyclics for about $21 billion This is the latest example of a pharma swooping on a biotech company to refill its pipeline.<wbr> Analysts are positive on AbbVie as they believe the Imbruvica would diversify the business beyond Humira.<wbr> </div></div><a name="PharmaWorld11289c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Ibrutinib (IMBRUVICA) is now being investigated for advanced carcinoid and pNETs, sponsored by H.<wbr>Lee Moffitt Cancer Center in collaboration with Pharmacyclis/<wbr>Abbvie (PI, J.<wbr> Strosberg).<wbr> The study, a Phase II prospective open-label trial, will enroll up to 51 patients in two cohorts, 30 carcinoids and 21 pNET patients.<wbr> ORR is the primary outcome with PFS being the secondary outcome measure.<wbr> The study is currently recruiting with estimated primary completion date in February 2017 (NCT02575300).<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11110">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-27T10:55:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-27T10:55:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Q4 2014 Earnings: Bayer Is Confident To Win Back Customer's Confidence With Xofigo In 2015</title>
	<pubDate>2015-02-26T19:25:11+01:00</pubDate>
	<wp:post_id>5996</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer held Q4 2014 earnings call this morning and reported Xofigo ended the year weaker than anticipated with &euro;157 million in sales due to temporary product shortages during Q4.<wbr>This related to a manufacturing issue that was identified and now resolved.<wbr> During the Q&amp;A session, Bayer commented that they do not foresee any long term impact related to the supply issue and expect Xofigo to reach &euro;300 m by end 2015.<wbr> They are working on regaining customer confidence by implementing additional marketing efforts to raise share of voice and reviewing their sales force coverage with a special focus on urologists.<wbr> The long term ambition for Xofigo's life cycle is to prolong treatment duration up to 12 months with higher doses.<wbr>  We know that Bayer in-licensed ODM-201 from Orion in June 2014 and initiated a Ph3 trial in M0 CRPC setting in Sept 2014.<wbr> However no further progress has been reported during the call.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10303_1_1.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10303_2_2.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10303_3_3.JPG"> </div><div>Source: Bayer Investor Relation </div><!-- Comment details --><a name="oncology10303attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10303_1_1.JPG">1.JPG</a>&nbsp;&nbsp;(123,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10303_2_2.JPG">2.JPG</a>&nbsp;&nbsp;(147,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10303_3_3.JPG">3.JPG</a>&nbsp;&nbsp;(151,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10303">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T19:25:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T19:25:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation 2014 Q4 Financial Statements: Emphasis On Xtandi's Growth From Both Volume And New Patient Initaition Perspectives And Future Programmes Involving Xtandi And Pidilizumab</title>
	<pubDate>2015-02-26T17:44:11+01:00</pubDate>
	<wp:post_id>5997</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif">Comment: <SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">During the Q4 2014 financial statement call yesterday, Medivation marked the first full quarter of sales in the US following the September approval of Xtandi's chemo naïve mCRPC indication.<wbr> <SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Medivation is confident for continuous urologists outreach in 2015 (hence growth) as market research showed urologists perceived Xtandi requiring less monitoring and without the need for steroids as pre-requisite to start the therapy.<wbr> The 2015 spend on SG&amp;A reflects the expansion of 30 sale force from 60 to 90 in 2014 (Astellas has similar size of SF) - most likely aligned with Medivation's additional efforts to focus on urologists and future vision to bring Xtandi into earlier prostate cancer setting.<wbr> </SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Planned 2015 medical congress presence for key data readout includes 1) PREVAIL final data in ASCO GU; 2) Ph2 TERRIAN (EU) in EAU; 3) Ph2 STRIVE (US) : most likely ASCO, but only speculation at this stage as it will depend on numbers of events reached.<wbr> Future long term growth is expected to come from future indications exploring combination strategy with pidilizumab that is in-licensed from Cure-Tech in Q4 2014.<wbr> Prostate Cancer is alluded during the Q&amp;A session as one of the indications to be explored.<wbr> </SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN style="TEXT-DECORATION: underline"><STRONG>2014 Financial Performance</STRONG></SPAN>: </SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10301_1_Fiancial.JPG"><BR></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10301_2_Fiancial2.JPG"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><EM><STRONG><SPAN style="TEXT-DECORATION: underline">Risks Envisaged that could negatively impact on Xtandi revenue</SPAN></STRONG></EM>: <BR></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><OL><LI><SPAN style="FONT-SIZE: small">Xtandi failed to compete effectively commercially with other approved products in the market - especially bigger established pharma players such as J&amp;J, Bayer, and Sanofi who have more resources, commercial and development experiences</SPAN> </LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Pricing pressure and pricing competition<BR></SPAN></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Competition from products that have similar MOA (eg ARN509)<BR></SPAN></SPAN></SPAN></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Competition from generic entry e.<wbr>g.<wbr> Zytiga's patent expiry<BR></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Unsuccessful marketing efforts to include urologists<BR></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Unexpected negative events arose from Astellas (e.<wbr>g.<wbr> Astellas' inadequate performance from both market access and marketing perspectives)<BR></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Failure to comply with post-marketing requirement or commitments <BR></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></SPAN></LI>
</OL> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small; TEXT-DECORATION: underline"><STRONG>Progress of Enzalutamide Programmes</STRONG> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small">TERRAIN Trial: </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small"></SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-SIZE: small"></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif"><SPAN style="TEXT-DECORATION: underline"><STRONG>Future Plan with in-licensed anti PD1: </STRONG></SPAN><STRONG>Medivation's ambition to build an immuno-oncology franchise</STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt"><SPAN style="FONT-SIZE: small; FONT-FAMILY: arial,helvetica,sans-serif"></SPAN></P> </div><div><P style="MARGIN: 0cm 0cm 0pt"></P> </div><!-- Comment details --><a name="oncology10301attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10301_1_Fiancial.JPG">Fiancial.JPG</a>&nbsp;&nbsp;(153,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10301_2_Fiancial2.JPG">Fiancial2.JPG</a>&nbsp;&nbsp;(190,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10301_3_Enzalutamide%20Programmes.JPG">Enzalutamide Programmes.JPG</a>&nbsp;&nbsp;(131,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10301">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T17:44:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T17:44:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring to Start a Ph3 Superiority Study of Pentasa Enema for UC in China</title>
	<pubDate>2015-02-26T17:17:32+01:00</pubDate>
	<wp:post_id>5998</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3 study which will investigate the efficacy and safety of 4-week double-blind treatment with PENTASA enema compared with placebo enema in Chinese patients with mild to moderate active left-sided ulcerative colitis.<wbr> PE will measure efficacy (clinical remission after 4 weeks treatment).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="https://clinicaltrials.gov/ct2/show/NCT02368717?term=NCT02368717&amp;rank=1">NCT02368717</A> </div><div style="margin-bottom: 10px;">The trial will be followed by a maximal 28-week open-label extension phase with PENTASA enema and/<wbr>or PENTASA tablets.<wbr> </div><div style="margin-bottom: 10px;"><U>Timelines </U>The study is expected to start next month and complete April 2016 (PE), and November 2016 (final data collection).<wbr> </div><div style="margin-bottom: 10px;"><U>Recruitment</U> approx 249 men/<wbr>women (18 to 70 years) </div><div><UL><LI>Newly diagnosed or recurrent mild to moderate left-sided active ulcerative colitis</LI>
<LI>Mayo score of at least 4 but not greater than 10 points and a score of ≥ 2 for colonoscopy</LI>
<LI>Extent of colonic involvement and endoscopy subscore of Mayo score as confirmed by colonoscopy</LI>
<LI>The patient is compliant with Patient Daily Diary by having adequately responded to the questions on ≥5 of the most recent full 7 days before the Randomization Visit</LI>
<LI>Negative stool test at screening to rule out parasites and bacterial pathogens</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2268">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T17:17:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T17:17:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Encouraging NICE Guidance Recommends Additional Techniques Such as Hexvix And NBI Should Be Used To Improve TURB For NMIBC</title>
	<pubDate>2015-02-26T16:19:46+01:00</pubDate>
	<wp:post_id>5999</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NICE has published a bladder cancer guidance to encourage the use of additional techniques such as Hexvix, NBI, a cytology or a urinary biomarker test along side with white light guided TURBT in order to improve TURB quality for non muscle invasive bladder cancer.<wbr> This has been identified as one the priorities for implementation in the NHS.<wbr> </div><div style="margin-bottom: 10px;">The details of the recommendations are: </div><div style="margin-bottom: 10px;"><P align="LEFT">Diagnosis</P> </div><div style="margin-bottom: 10px;"><UL><LI>
Consider CT or MRI staging before transurethral resection of bladder tumour (TURBT) if muscle-invasive bladder cancer is suspected at cystoscopy.<wbr>

</LI>
<LI>
Offer white-light-guided TURBT with one of photodynamic diagnosis, narrow-band imaging, cytology or a urinary biomarker test (such as UroVysion using fluorescence in-situ hybridization [FISH], ImmunoCyt or a nuclear matrix protein 22 [NMP22] test) to people with suspected bladder cancer.<wbr> This should be carried out or supervised by a urologist experienced in TURBT.<wbr>

</LI>
<LI>
Offer people with suspected bladder cancer a single dose of intravesical mitomycin C given at the same time as the first TURBT.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="LEFT">The full document is available via <a href="http://www.nice.org.uk/guidance/ng2/resources/bladder-cancer-diagnosis-and-management-of-bladder-cancer-51036766405" class="defaultlink" title="http://www.nice.org.uk/guidance/ng2/resources/bladder-cancer-diagnosis-and-management-of-bladder-cancer-51036766405">nice.org.uk/<wbr>guida&hellip;</a></P> </div><div><P align="LEFT">Source: NICE, Bryan Qvick (Global Medical Director, Hexvix)</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10300">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T16:19:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T16:19:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Oncobiologics' ONS-3010 (Humira® Biosimilar) Meets PK Endpoints in First Clinical Study</title>
	<pubDate>2015-02-26T11:35:17+01:00</pubDate>
	<wp:post_id>6000</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: U.<wbr>S based biotech firm Oncobiologics is actively working on 7 biosimilar assets, with several others under consideration for future development.<wbr> In this first clinical trial, healthy volunteers were enrolled in a 3-arm single-dose PK study for a comparison between ONS-3010 and Humira® reference products.<wbr> The researchers concluded that all the PK endpoints fulfilled the bioequivalency criteria of the established geometric mean ratios.<wbr> ONS-3010 has the same amino acid sequence as adalimumab, identical pharmaceutical dosage scheme and strength, though its formulation has a different composition.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">timelines/<wbr>location: Initiated in EU in Q2:14 </div><div style="margin-bottom: 10px;">collaborator: carried out by the <A href="http://www.chdr.nl/">Center for Human Disease Research </A>in Leiden, The Netherlands.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The model combines a team of leading scientists and engineers from the world’s top biopharmaceutical companies working in the agile, unencumbered environment of a start-up.<wbr> </div><div style="margin-bottom: 10px;">The team is equipped with the latest in analytical, development and manufacturing tools.<wbr> </div><div style="margin-bottom: 10px;">The BioSymphony model also includes symbiotic partnerships with external global specialists to leverage expertise so that quality, cost structure and timely execution are optimized to meet program needs.<wbr> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2265_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology2265attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2265_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(104,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2265">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T11:35:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T11:35:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer To Cut Jobs In Cambridge R&D Institute</title>
	<pubDate>2015-02-26T11:11:29+01:00</pubDate>
	<wp:post_id>6001</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Re-aligning its research efforts with its business priorities, 
Pfizer today announced select headcount reductions at its Cambridge 
Massachusetts research centre.<wbr> The R&amp;D hub was openend one year ago bringing 
together 1000 staff from 3 locations.<wbr> Whilst certain undisclosed areas will be 
cut expansion will occur eleswhere with a focus on gene therapy and cancer.<wbr> </div><div style="margin-bottom: 10px;">The Boston Globe reports that the company will not disclose how many 
employees are impacted by the cuts but it does refer to a  Pfizer 
statement notably "As the R&amp;D ecosystem evolves Pfizer will continue to 
ensure that it has the right talent and capabilities focused on the right areas 
in order to execute its strategy of advancing the next wave of innovation" </div><div>Source: The Boston Globe </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11108">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T11:11:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T11:11:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring Acquires New Technology for Oral Drug Delivery of Peptides and Proteins</title>
	<pubDate>2015-02-26T10:17:59+01:00</pubDate>
	<wp:post_id>6002</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Under the agreement involving an undisclosed up-front payment, milestone and royalty terms, Ferring and Seoul-based CTCBIO will collaborate to develop prototype formulations for <EM>in-vitro</EM> and <EM>in-vivo</EM> testing and the subsequent up-scaling required to manufacture the technology to meet worldwide GMP requirements.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- created in 1995, and listed in 2002 </div><div style="margin-bottom: 10px;">- HQ: Seoul </div><div style="margin-bottom: 10px;">- operates in pharmaceuticals, functional food and veterinary medicines </div><div style="margin-bottom: 10px;">- core technologies include microbial fermentation, drug coating and Drug Delivery System </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10297_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">- partners: BASF; Pfizer; NOVUS </div><div style="margin-bottom: 10px;">- location USA; Vietnam; China and JV in Australia </div><div style="margin-bottom: 10px;">- financial figures </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10297_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology10297attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10297_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10297_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(47 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10297_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10297">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T10:17:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T10:17:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Exelixis Financial Results</title>
	<pubDate>2015-02-26T09:23:30+01:00</pubDate>
	<wp:post_id>6003</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Net revenues for Q4:14 were <MONEY>$7.<wbr>4M, (compared to </MONEY><MONEY>$4.<wbr>3M for Q4:13) and for FY2014 were </MONEY><MONEY>$25.<wbr>1M (vs $31.<wbr>3M for 2013).<wbr> For 2015 company will focus its development efforts and financial resources on the opportunities for cabozantinib in mRCC and HCC, and to support Genentech as it prepares for the potential WW commercialization of cobimetinib.<wbr> One rapidly approaching milestones is the top-line data from cabozantinib's METEOR Ph3 trial in 2nd-line RCC (Q2:15).<wbr> Management reported it will share with the oncology community at ASCO GU the details of the top-line data of cabozantinb for mCRPC, which was discontinued in Q2:14.<wbr> A selection of key slides is provided below.<wbr></MONEY> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The <SPAN id="101" style="BACKGROUND-COLOR: rgb(255,255,0)">CELESTIAL</SPAN> trial for second-line HCC is the company's current enrollment priority.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_3_ScreenCapture3.jpg"></STRONG> </div><div style="margin-bottom: 10px;">In the next few weeks management is expecting the initiation of a new combination trial of cabozantinib with the PD1 inhibitor, nivolumab or the combination of nivolumab and ipilimumab in patients with genitourinary cancers including bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Total net revenue of $7.<wbr>4M in Q4:14 (17% increase vs Q3:14) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG>Management reported " .<wbr>.<wbr>.<wbr> Now I will note here that due to the potentially large breadth of opportunities for cabozantinib, both near-term for RCC and <SPAN id="103" style="BACKGROUND-COLOR: rgb(255,255,0)"></SPAN>, if our pivotal trials are positive and longer-term and other significant oncology indications including non-small cell lung cancer, breast cancer, bladder cancer and a variety of other tumor types that we have decided to seek a partner for ex-US territories to help us maximize the global commercial opportunity for cabozantinib without making the significant investment required to build an ex-US commercial infrastructure ourselves".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_6_ScreenCapture6.jpg"> </div><div>Source: Exelixis </div><!-- Comment details --><a name="oncology10294attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(70,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(93,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10294_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(60,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10294">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-26T09:23:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-26T09:23:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Small Study Showed Taxane Could Offer Alternative For ARV7+ve mCRPC Patients</title>
	<pubDate>2015-02-25T15:47:31+01:00</pubDate>
	<wp:post_id>6004</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The findings from a small prospective study that will be presented during ASCO GU 2015 in Orlando suggest that chemo naive mCRPC pateints habouring ARV7+ should be offered chemotherapy.<wbr> The data showed that unlike abiraterone or enzalutamide, AR-V7 does not affect treatment outcome following taxane chemotherapy.<wbr> Although this is still a very small study (ARV7 -ve n= 20; ARV7+ve n=17), the results are yet to be validated.<wbr> The success in validation of both ARV7 as a biomarker and the finding from this small study could mean the chemo naive space will become a much smaller patient segment.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">Session: General Session : Evolving Role of Multimodality Treatment in Low-Volume Hormone-Sensitive Metastatic Disease Type: General Session Time : Thursday February 26, 10:00 AM to 11:30 AM Location 1: Gatlin Ballroom C</P> </div><div style="margin-bottom: 10px;"><P align="left">This is the first clinical study to explore the association between AR-V7 status and outcomes after treatment with taxane chemotherapy (either docetaxel or cabazitaxel) in patients with mCRPC.<wbr> AR-V7 status was assessed through an experimental blood test that measures AR-V7 mRNA in circulating tumor cells.<wbr> Seventeen out of 37 men (46 percent) who were enrolled in the study were AR-V7 positive.<wbr></P> </div><div style="margin-bottom: 10px;">Study participants had comparable responses to therapy irrespective of their AR-V7 status.<wbr> PSA responses were achieved in 41 percent of AR-V7-positive men and in 65 percent of AR-V7-negative men (the difference was not statistically significant).<wbr> This 41 percent PSA response rate to taxane therapy is notable because the PSA response rate to abiraterone or enzalutamide in AR-V7-positive patients was 0 percent in the authors&acirc;&euro;&trade; prior study.<wbr> </div><div style="margin-bottom: 10px;">The median progression-free survival to taxane therapy was also comparable in AR-V7-positive (5.<wbr>1 months) and AR-V7-negative men (6.<wbr>9 months; the difference was not statistically significant).<wbr> </div><div>Source: <A href="http://abstracts.asco.org/159/AbstView_159_141642.html">http:/<wbr>/<wbr>abstracts.<wbr>asco.<wbr>org/<wbr>159/<wbr>AbstView_159_141642.<wbr>html</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10293">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-25T15:47:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-25T15:47:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: NICE Says "Provenge' Cost to NHS too high to be recommended in draft guidance"</title>
	<pubDate>2015-02-25T14:40:01+01:00</pubDate>
	<wp:post_id>6005</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: NICE Says "Provenge' Cost to NHS too high to be recommended in draft guidance"</span>&nbsp;<br><span style="font-size: 12px;">Comment: The final draft guidance issued by NICE on 13 Jan remains consistent with NICE's preliminary decision - Dendreon has so far been unable to show that it works better than other treatments currently available.<wbr> The final draft guidance is now with consultees, who have the opportunity to appeal against it.<wbr> Until NICE issues final guidance, NHS bodies should make decisions locally on the funding of specific treatments.<wbr> Given the current position of Dendreon as they are awaiting for bidders, the future of Provenge in European markets is questionable.<wbr> (Source: <a href="https://www.nice.org.uk/news/press-and-media/cost-to-nhs-of-providing-sipuleucel-t-too-high-to-be-recommended-in-draft-guidance" class="defaultlink">NICE PRESS RELEASE Jan 2015</a>)</span>&nbsp;<br></div><div>The final NICE guidance is being published with the final decision that Provenge is not recommended within its marketing authorisation for treating adults who have asymptomatic or minimally symptomatic metastatic non visceral hormone relapsed prostate cancer for which chemotherapy is not yet clinically indicated.<wbr> (Source:<A href="http://www.nice.org.uk/guidance/ta332/chapter/1-guidance">http:/<wbr>/<wbr>www.<wbr>nice.<wbr>org.<wbr>uk/<wbr>guidance/<wbr>ta332/<wbr>chapter/<wbr>1-guidance</A>) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10292">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10052">View thread  Oncology10052: NICE Says "Provenge' Cost to NHS too high to be recommended in draft guidance"</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-25T14:40:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-25T14:40:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: BMS Acquires Flexus for $1.25B And Partners With Rigel For $339M</title>
	<pubDate>2015-02-25T13:53:07+01:00</pubDate>
	<wp:post_id>6006</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">BMS Acquires Flexus for $1.<wbr>25B And Partners With Rigel For $339M</span>&nbsp;<br><span style="font-size: 12px;">Comment: BMS has entered today the final agreement to acquire Flexus Biosciences, a privately held biotechnology company, focused on the discovery and developments of novel anti-cancer therapeutics IDO/<wbr>TDO inhibitors which reduce kynurenine production enabling the immune system to attack tumors more effectively.<wbr> The deal inlcudes a $800 million upfront payment and a $450 million milestone development, for a potential of $1.<wbr>25 billion in total.<wbr> A very busy BMS, looking to aggressively expand its immuno-oncology work past the pioneering Yervoy and Opdivo, also today inked a $339 million partnership with Rigel.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10283">...</a><br></div><div>BMS is the third big pharma following AZ-Incyte, and Roche-New Genetics deal to enter the IDO pathway targeting within immuno-oncology space.<wbr> Within the immuno oncology space, the focus within medical community still has strong emphasis on CTLA-4 and PD1 or PD-L1 inhibitors.<wbr> These deals strongly validates the importance of modulating the immune system in treating cancer, and brings attention to other targets within immuno microenvironment.<wbr> More specifically, the fundamental importance of blocking the indolamine 2,3 deoxygenase (IDO) pathway as a means to reverse tumor immune suppression.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10291">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10283">View thread  Oncology10283: BMS Acquires Flexus for $1.<wbr>25B And Partners With Rigel For $339M</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-25T13:53:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-25T13:53:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>A Positive Synergy With Ipilimumab and PROSTVAC May Present A Future Oppoutunity Of First Immuno-Oncology Doublet Entry In mCRPC</title>
	<pubDate>2015-02-25T12:52:24+01:00</pubDate>
	<wp:post_id>6007</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bavarian Nordic will present updated overall survival data from combination of PROSTVAC + Ipilimumab at the ASCO GU 2015 in Orlando on Thursday 26th Feb (Board 8general poster session A 11:30am -1 pm).<wbr> The Ph1 Proof of Concept trial is led by NCI and ~20% of men with advanced prostate cancer treated with combination remain alive at 80 months after initating treatment.<wbr> The observed median OS was 31.<wbr>3 months for all doses cohotrts and 37.<wbr>2 months for ipi 10 mg/<wbr>kg cohort.<wbr> At the time of initiation, docetaxel was the only approved agent and the predicted OS was 18.<wbr>5 months.<wbr> A total of 30 pateints enrolled in the Ph1 tial was therefore randomised to receive either combination or Prostvac + Placebo.<wbr> The presentation will focus on the comparison of data from three independent trial (2 x Ph2 PRSTVAC montherapy trial and Ph1 PROTVAC+Ipi combination trial) and the authors conclude that the positive data warrnats pivitol trial to evaluate this potential synergy in mechamism action of two immuno-modulating agents.<wbr> Given chemo naive mCRPC space is getting very crowded, especially both abiraterone and enzalutamide have demonstrated <STRONG><SPAN style="text-decoration: underline;">significant survival benefit</SPAN></STRONG> , the critical challenge for Bavarian Nordic and BMS is to overcome the present competitive hurdle.<wbr> The strategic intention and progress of futrue pivitol trial needs to be closely followed.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">Session: General Poster Session A: Prostate Cancer</P> </div><div style="margin-bottom: 10px;"><P align="left">Type: General Poster Session</P> </div><div style="margin-bottom: 10px;"><P align="left">Time 1: Thursday February 26, 11:30 AM to 1:00 PM Location 1:Gatlin Ballroom B</P> </div><div style="margin-bottom: 10px;"><P align="left">Time 2: Thursday February 26, 5:15 PM to 6:45 PM Location 2:Gatlin Ballroom BThe detials of the abstract is below:</P> </div><div style="margin-bottom: 10px;"><STRONG>Background:</STRONG> </div><div style="margin-bottom: 10px;">Results of recent clinical trials have intensified interest in immunotherapy in oncology.<wbr> A number of cancer immunotherapies have been approved recently, while others are in late stage clinical development.<wbr> The poxvirus-based active immunotherapy, PROSTVAC is generally well tolerated and is currently being evaluated in a global Phase 3 randomized, placebo-controlled trial.<wbr> Ipilimumab, an approved immune checkpoint inhibitor in melanoma, is also being evaluated in a Phase 3 trial in chemo-na&Atilde;&macr;ve mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Methods: </STRONG> </div><div style="margin-bottom: 10px;">Results of two Phase 2 trials in men with mCRPC who were treated with PROSTVAC alone were compared with results from a Phase 1 combination study in mCRPC patients treated with PROSTVAC plus escalating doses of ipilimumab.<wbr> Patients were enrolled in the Phase 1 combination study when docetaxel was the only FDA-approved mCRPC treatment that improved overall survival (OS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results: </STRONG>In a multicenter Phase 2 trial, 125 men were randomized 2:1 to receive PROSTVAC or placebo.<wbr> Patients treated with PROSTVAC had improved OS compared to placebo (25.<wbr>1 vs 16.<wbr>6 months; HR 0.<wbr>56; 95% CI 0.<wbr>37-0.<wbr>85).<wbr>Similar data was seen in a second phase 2 trial of PROSTVAC, where 32 patients with mCRPC had a median OS of 26.<wbr>6 months (predicted median OS by the Halabi nomogram was 17.<wbr>4 months).<wbr> In a Phase 1 combination study of 30 mCRPC patients with similar baseline characteristics (predicted median OS of 18.<wbr>5 months), patients were treated with PROSTVAC plus escalating doses of ipilimumab.<wbr> The observed median OS was 31.<wbr>3 months for all dose cohorts and 37.<wbr>2 months for patients treated at 10 mg/<wbr>kg based on updated overall survival data.<wbr> Furthermore, there appears to be a tail on the curve with approximately 20% of patients at 10 mg/<wbr>kg alive at 80 months.<wbr> </div><div style="margin-bottom: 10px;">Clinical trial information: <A href="http://clinicaltrials.gov/show/NCT00113984">NCT00113984</A> </div><div>Source: Bevarian Nordic Press Release, <A href="http://abstracts.asco.org/159/AbstView_159_141599.html">http:/<wbr>/<wbr>abstracts.<wbr>asco.<wbr>org/<wbr>159/<wbr>AbstView_159_141599.<wbr>html</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10338c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: The study was presented as poster and interestingly the authors concluded that the study provides a strong rationale to combine PROSTVAC with anti-PD-1 or anti-PDL1, largely due to superior side effects profile compared to CTLA4 inhibition.<wbr> Pictures of the posters are kindly provided by Dr.<wbr> Patrick Cabri (Global Medical Affairs Director Decapeptyl/<wbr>Duphereline, Uro-Oncology Franchise) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10287">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-25T12:52:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-25T12:52:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Celltrion and Hospira to Sell First Copies of J&J's Remicade</title>
	<pubDate>2015-02-25T11:05:20+01:00</pubDate>
	<wp:post_id>6008</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Celltrion and Hospira to Sell First Copies of J&J's Remicade</span>&nbsp;<br><span style="font-size: 12px;">Comment: The European Commission should give the two companies approval to market their versions, called Remsima and Inflectra, for the same medical conditions for which Remicade is marketed.<wbr> The EMA’s recommendations are the final stage before the European Commission, the European Union’s executive arm, approves or rejects a drug for sale to patients in the 27-nation region.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=1899">...</a><br></div><div style="margin-bottom: 10px;">Mundipharma is launching its biosimilar Remsima in Germany, Italy, Britain, the Netherlands, Belgium and Luxembourg, following expiry of relevant Remicade patents.<wbr> Hospira is to sell its product Inflectra in markets including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain and Sweden.<wbr> Another test for biosimilars is looming in the United States, where a FDA advisory committee will decide on March 17 whether to recommend Celltrion's biosimilar version of Remicade.<wbr> </div><div style="margin-bottom: 10px;">Copies of Remicade have been on sale for several months in some smaller European markets, such as Norway, but the move into major economies is a big step forward for products that could disrupt the multibillion-dollar biotechnology industry.<wbr><BR><BR>Jorgen Jahnsen, professor of medicine and gastroenterology at the University of Oslo, said that in Norway the use of biosimilar infliximab had already enabled the healthcare system to make considerable savings.<wbr> </div><div>source: thomsonOne </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2262">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1899">View thread  GastroEnterology1899: Celltrion and Hospira to Sell First Copies of J&J's Remicade</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-25T11:05:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-25T11:05:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis Has Filed ANDA to Seek Approval of a Generic Version of Salix' Uceris®</title>
	<pubDate>2015-02-25T10:29:13+01:00</pubDate>
	<wp:post_id>6009</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Actavis believes it may be a first applicant to file an ANDA, and if approved by the FDA may be entitled to 180 days of generic market exclusivity.<wbr> </div><div>Uceris&reg; sales for 2014 were approx $123M in the US </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2261">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-25T10:29:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-25T10:29:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Chiasma Raises $33.8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</title>
	<pubDate>2015-02-24T15:29:21+01:00</pubDate>
	<wp:post_id>6010</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Chiasma Raises $33.<wbr>8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</span>&nbsp;<br><span style="font-size: 12px;">Comment: Israeli startup Chiasma has raised $33.<wbr>8 million of a planned $56.<wbr>3 million round to fund the oral octreotide project, according to regulatory filings.<wbr> The funds are believed to be for both completing the registration, with file submission to the FDA planned for mid-2015, and for setting up infrastructures for marketing the product.<wbr> Chiasma is clearly preparing to launch the oral octreotide for acromegaly on its own but, according to sources, is still keeping an open mindset to potential partnerships.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7902">...</a><br></div><div style="margin-bottom: 10px;">Chiasma has today announced the appointment of David Stack (CEO and chairman of Pacira Pharmaceuticals) as Chairman of the Board, and John Scarlett (CEO and president of Geron Corporation) as a member of the board.<wbr> Roni Mamluk, CEO, on commenting the news stressed the "benefit from the deep experience and knowledge Dave and John will bring to Chiasma as we move oral octreotide toward a NDA submission by the middle of this year.<wbr>.<wbr>.<wbr>".<wbr> Once again Chiasma is confirming their intention on submitting an NDA to the FDA this year, with possible US approval in 2016.<wbr> <a name="Endocrinology7994c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Further to new board members, Chiasma has now appointed Mark Leuchtenberger as CEO, a proven leader with successful track record in new products commercialization.<wbr> Leuchtenberger has 25 years experience in the pharmaceutical industry and from 1996 to 2002 was at Biogen, responsible for North America and the international commercial operations, including late-stage development, launch and marketing of Avonex, now a $3 billion product.<wbr> Roni Mamluk, previous CEO, will remain in the company as chief development officer.<wbr> Chiasma is also expanding its US operations in the Boston area.<wbr> The company is clearly pushing on a new strategy to ensure the best in-house capabilities and expertise to launch the first formulation of oral octreotide.<wbr> </div></div></div><div>Source: FirstWordPharma </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7970c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Chiasma has announced today the closing of a $70 million financing round.<wbr> Participants in the financing included new investors Rock Springs Capital and Sofinnova Ventures, and an undisclosed blue chip public investment fund, as well as existing investors MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners.<wbr> Once again Chiasma has stated it will use the new capital to build its sales and marketing capabilities and prepare for the launch of octreotide capsules in the US.<wbr> The company intends to submit a NDA to the FDA in the second quarter of 2015 and, if the NDA is approved, to launch the product in the US in 2016.<wbr> Chiasma will also conduct additional clinical studies for octreotide capsules to support approval in the European Union and advance new product candidates based on its proprietary TPEA (Transient Permeability Enhancer) technology into preclinical development.<wbr> </div><div>Source: PR Newswire </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7968">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7902">View thread  Endocrinology7902: Chiasma Raises $33.<wbr>8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-24T15:29:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-24T15:29:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Shire to Acquire NPS Pharmaceuticals for $5.2bn To Expand Its Rare Disease GI Franchise</title>
	<pubDate>2015-02-24T15:11:15+01:00</pubDate>
	<wp:post_id>6011</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Shire to Acquire NPS Pharmaceuticals for $5.<wbr>2bn To Expand Its Rare Disease GI Franchise</span>&nbsp;<br><span style="font-size: 12px;">Comment: Having escaped the clutches of Abbvie, Shire is now pursuing its own 
expansion plans through the acquisition of the specialty biopharmaceutical 
company NPS Pharmaceuticals.<wbr> The purchase will allow Shire to expand its rare 
dissease portfolio particularly in the GI area.<wbr> Shire is expecting to 
accelerate the growth of NPS's Gattex in the US by leveraging Shire's No 2 
ranked GI sales expertise and rare disease specialism.<wbr> The latter is based 
on sales of 5-ASA and enzyme replacement therapies respectively.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11064">...</a><br></div><div>After the $5 billion deal for NPS Pharma, Shire has announced today the acquisition of the Californian small biotech Meritage that includes a Phase III ready rare disease drug for $70 million upfront.<wbr> Meritage offers Shire an interesting portfolio on rare disease GI drugs, stressing once more Shire's committement to its GI franchise.<wbr> Shire acquired rights to purchase Meritage in 2014, in connection with its $4.<wbr>2 billion acquisition of rare disease specialist Viropharma.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11107">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld11064">View thread  PharmaWorld11064: Shire to Acquire NPS Pharmaceuticals for $5.<wbr>2bn To Expand Its Rare Disease GI Franchise</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-24T15:11:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-24T15:11:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PTC Therapeutics Up For Sale</title>
	<pubDate>2015-02-24T14:56:05+01:00</pubDate>
	<wp:post_id>6012</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Neuromuscular rare disease developer PTC Therapeutics is exploring a 
potential sale amid takeover interest from companies such as Shire 
&amp; BioMarin Pharmaceuticals.<wbr> Its lead candidate Translarna 
(ataluren) is a drug to treat Duchenne Muscular Dystrophy (DMD).<wbr> Biomarin 
recently acquired Prosensa which also has a drug to treat DMD for $840m.<wbr> </div><div style="margin-bottom: 10px;">PTC Therapeutics drug Translarna has received orphan drug status from the US 
&amp; EU regulatory authorities, EU approval and  is in the process of 
seeking FDA approval.<wbr> </div><div style="margin-bottom: 10px;">Shire could be interested in acquiring the company as a means of continuing 
to bolster its rare disease portoflio, itself having recently acquired NPS 
Pharmaceuticals for such purposes in January in a $4.<wbr>2bn deal </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_4_ScreenCapture4.jpg"> </div><div> </div><!-- Comment details --><a name="neurology7931attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(114,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(109 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(143,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7931_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(112,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7931">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-24T14:56:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-24T14:56:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' First-In-Market HDAC Inhibitor Approved For Multiple Myeloma</title>
	<pubDate>2015-02-24T12:14:39+01:00</pubDate>
	<wp:post_id>6013</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis received FDA approval of Farydak&reg; (Panobinostat) in combination with bortezomib and dexamethasone for relapsed multiple myeloma patients who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent This is the first HDAC inhibitor approved in multiple myeloma and Farydak is approved under FDA's accelerated approval programme based on its prolonged median PFS benefit when used with bortezomib and dexamethasone combination versus combination alone from 6 to 11 months.<wbr> Currently regulatory applications are underway in the EU, Japan and worldwide.<wbr> </div><div style="margin-bottom: 10px;">This FDA approval is based on efficacy and safety data in a pre-specified subgroup analysis of 193 patients who had received prior treatment with both bortezomib and an IMiD during the Phase III, randomized, double-blind, placebo-controlled, multicenter global registration trial, called PANORAMA-1 (<U class="hugin">PAN</U>obinostat <U class="hugin">ORA</U>l in Multiple <U class="hugin">M</U>yelom<U class="hugin">A</U>).<wbr> The trial found that the median PFS benefit increased in Farydak patients who had received prior treatment with both bortezomib and an IMiD (10.<wbr>6 months; n=94), as compared to the placebo arm (5.<wbr>8 months; n=99) (hazard ratio=0.<wbr>52 [95% confidence interval (CI): 0.<wbr>36, 0.<wbr>76], The FDA's decision overturned advice from a panel of medical experts who last year voted against recommending the combination's approval, saying its side effects, such as severe diarrhea and heart problems, outweighed its potential benefits.<wbr> The FDA usually follows the advice of advisory panels but is not obligated to do so.<wbr>The FDA has also approved a risk evaluation and mitigation strategy (REMS) for Farydak.<wbr> The REMS program serves to inform and educate healthcare professionals about the risks that may be associated with Farydak treatment.<wbr><BR><BR>The most common adverse reactions (incidence &gt;= 20%) in clinical studies are diarrhea, fatigue, nausea, peripheral edema, decreased appetite, pyrexia and vomiting[1].<wbr> The most common non-hematologic laboratory abnormalities (incidence &gt;= 40%) are hypophosphatemia, hypokalemia, hyponatremia and increased creatinine.<wbr> The most common hematologic laboratory abnormalities (incidence &gt;= 60%) are thrombocytopenia, lymphopenia, leukopenia, neutropenia and anemia[1].<wbr> Farydak can cause fatal and serious toxicities including severe diarrhea and cardiac toxicities.<wbr> Severe diarrhea occurred in 25% of Farydak-treated patients.<wbr> Severe and fatal cardiac ischemic events, including severe arrhythmias and ECG changes have occurred in patients receiving Farydak.<wbr> Serious adverse events (SAEs) occurred in 60% of patients treated with Farydak, bortezomib and dexamethasone compared to 42% of patients in the control arm.<wbr> The most frequent (&gt;= 5%) treatment-emergent SAEs reported for patients treated with Farydak were pneumonia (18%), diarrhea (11%), thrombocytopenia (7%), fatigue (6%) and sepsis (6%).<wbr> Additional serious adverse reactions included hemorrhage, myelosuppression, infections, hepatotoxicity and embryo-fetal toxicity.<wbr> </div><div>Source: Novartis Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10284">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-24T12:14:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-24T12:14:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Is To Divest Its BRAF And MEK Inhibitors As Part Of The GSK Oncology Transaction</title>
	<pubDate>2015-02-24T10:42:24+01:00</pubDate>
	<wp:post_id>6014</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis has won US antitrust approval to buy GSK's oncology assets ($ 16 billion deal) under the condition when Novartis are to divest assets to its BRAF and MEK inhibitor drugs.<wbr> If the transaction goes forward as proposed, Novartis will be forced to delay or terminate development of any programmes related to its BRAF and MEK inhibitors.<wbr> Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF and MEK inhibitor markets is not reduced.<wbr> Array Biopharm has been received approval as the buyer of Novartis' divested assets (<A class="title" href="traction/permalink/PharmaWorld11094" title="Permanent Link to PharmaWorld11094"><U></U></A> </div><div style="margin-bottom: 10px;">Physicians use BRAF and MEK inhibitors separately, and increasingly in combination, to treat melanoma.<wbr> Both products are also being developed to treat a variety of other cancers.<wbr> Novartis and GSK are two of a small number of companies with either a BRAF or MEK inhibitor currently on the market or in development, and two of only three companies marketing or developing a BRAF/<wbr>MEK combination product to treat melanoma.<wbr> For that reason, Novartis&rsquo;s acquisition of GSK&rsquo;s portfolio of cancer-treatment drugs would likely cause significant competitive harm in the U.<wbr>S.<wbr> markets for both the BRAF and MEK inhibitors, ultimately raising prices for consumers and depriving them of potentially superior products.<wbr> </div><div style="margin-bottom: 10px;">Throughout the investigation, Commission staff cooperated with staff of the antitrust agencies in Australia, Canada, and the European Union, working closely on the analysis of the proposed transaction and potential remedies.<wbr> This coordination led to compatible approaches on a global scale, and included FTC and European Commission approval of Array BioPharma as the buyer of the divested assets.<wbr> </div><div>Source: Reuters US </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11103">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-24T10:42:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-24T10:42:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS Acquires Flexus for $1.25B And Partners With Rigel For $339M</title>
	<pubDate>2015-02-23T20:40:40+01:00</pubDate>
	<wp:post_id>6015</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BMS has entered today the final agreement to acquire Flexus Biosciences, a privately held biotechnology company, focused on the discovery and developments of novel anti-cancer therapeutics IDO/<wbr>TDO inhibitors which reduce kynurenine production enabling the immune system to attack tumors more effectively.<wbr> The deal inlcudes a $800 million upfront payment and a $450 million milestone development, for a potential of $1.<wbr>25 billion in total.<wbr> A very busy BMS, looking to aggressively expand its immuno-oncology work past the pioneering Yervoy and Opdivo, also today inked a $339 million partnership with Rigel.<wbr> </div><div style="margin-bottom: 10px;">BMS gains full rights to Flexus pre-clinical IDO1 inhibitor F001287, targeted for IND filing in the second half of 2015, and the company broad IDO/<wbr>TDO discovery program, including its IDO-selective, IDO/<wbr>TDO dual and TDO-selective compound libraries.<wbr> </div><div style="margin-bottom: 10px;">The collaboration agreement with Rigel will focus on the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors.<wbr> </div><div>Source: FierceBiotech, BioSpace </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10291c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>BMS is the third big pharma following AZ-Incyte, and Roche-New Genetics deal to enter the IDO pathway targeting within immuno-oncology space.<wbr> Within the immuno oncology space, the focus within medical community still has strong emphasis on CTLA-4 and PD1 or PD-L1 inhibitors.<wbr> These deals strongly validates the importance of modulating the immune system in treating cancer, and brings attention to other targets within immuno microenvironment.<wbr> More specifically, the fundamental importance of blocking the indolamine 2,3 deoxygenase (IDO) pathway as a means to reverse tumor immune suppression.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10283">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-23T20:40:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-23T20:40:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chiesi's Holoclar Is The First Marketed Stem Cell Therapy In Europe</title>
	<pubDate>2015-02-23T19:59:19+01:00</pubDate>
	<wp:post_id>6016</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After 7 years of gaining orphan drug designation and more than 15 years for establising the proof of concept for the treatment method, the italian Chiesi has finally gained marketing approval for Holoclar, a pioneering stem cell therapy used to treat moderate to severe forms of limbal stem cell deficiency (LSCD), a rare eye condition caused by physical or chemical burns to the eye that can lead to blindness.<wbr> This is a significant milestone being the first stem-cell based therapy cleared in Western markets.<wbr> </div><div style="margin-bottom: 10px;">Holoclar, manufactured by Holostem Advanced Therapies, is created from a biopsy obtained from a small healthy area in the patient's cornea and grown in the laboratory using tissue culture techniques.<wbr> Looking similar to a contact lens, Holoclar can be transplanted into the patient and lead to a full recovery of visual activity without causing any rejection reaction, being the cells from the patient.<wbr> </div><div style="margin-bottom: 10px;">While excitement for stem-cell therapies started in the US long time ago, major developers stayed away from this field as too much investement was required to make these 'unique'  therapies a reality.<wbr> Chesi managed to succeed ensuring a close collaboration with academia (the University of Modena) and proving that cells can be cultured according to pharmaceutical standards appropriate to guarantee safety and efficacy.<wbr> </div><div style="margin-bottom: 10px;">The approval, for limbar stem-cell deficiency due to physical or chemical burns, arrives after a positive reccomendation by the EMA, in December 2014.<wbr> </div><div>Source: Chiesi PR, FirstWordPharma </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11102">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-23T19:59:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-23T19:59:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant Announced Its Plan To Update 2015 Guidance To Reflect Two Major Acquistions - Dendreon And Salix</title>
	<pubDate>2015-02-23T18:47:38+01:00</pubDate>
	<wp:post_id>6017</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During Valeant's Fourth Quarter 2014 Financial Results Conference Call, Valeant reported a total revenue of $8.<wbr>3 billion with an increase of 43% over the prior year.<wbr> A high restructuring and integration expense ($388M) was reported for 2014 due to a numbers of deals closed in 2014 - including Solta, ECR, Croma, Precision, Bescon, and MedPharm.<wbr> This has not yet reflected the confirmed acquisitions of Dendreon and Salix.<wbr> Two business units will be created for Dendreon and Salix operation and Valeant expect the minimum for restructuring and integration charges incurring for both.<wbr> Valeant also announced the plan to update their 2015 guidance on Q1 2015 call to reflect acquisitions of Dendreon and Salix.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_1_1.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_2_2.JPG"> </div><div style="margin-bottom: 10px;">About <SPAN style="text-decoration: underline;"><STRONG>Dendreon:</STRONG></SPAN> a platform for Valeant to gain cash and further establish a platform for additional "tuck-in" acquisitions.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_3_3.JPG"> </div><div style="margin-bottom: 10px;">About <SPAN style="text-decoration: underline;"><STRONG>Salix</STRONG></SPAN>: this acquisition offers a compelling opportunity for the company to create a strong platform for growth and business development The merger is expected to yield greater than $500 million in annual cost savings from the cost base of the combined company.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_4_4.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_5_5.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_6_6.JPG"> </div><div>Source: Valeant Q4 Earning Webcast 23 Feb 2015 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld11114c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Shortly after confirmation of the Valeant's takeover in February, Valeant informed employment security that 77 employees, mostly from G&amp;A functions where there was overlap with Valent's existing business, will be laid off from Dendreon.<wbr> This reflects Valeant's aggressive nature and also Michael Pearson's (CEO, Valeant) ambition to raise the gross margins of the business to more than 65% by the end of 2015, and 80% gross margins in the loner term.<wbr> Source: Seattle times </div></div><a name="pharmaworld11100attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_1_1.JPG">1.JPG</a>&nbsp;&nbsp;(202,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_2_2.JPG">2.JPG</a>&nbsp;&nbsp;(176,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_3_3.JPG">3.JPG</a>&nbsp;&nbsp;(168,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_4_4.JPG">4.JPG</a>&nbsp;&nbsp;(191,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_5_5.JPG">5.JPG</a>&nbsp;&nbsp;(172,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11100_6_6.JPG">6.JPG</a>&nbsp;&nbsp;(106,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11100">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-23T18:47:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-23T18:47:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Valeant to Explore Takeover of Salix</title>
	<pubDate>2015-02-23T17:40:21+01:00</pubDate>
	<wp:post_id>6018</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Valeant to Explore Takeover of Salix</span>&nbsp;<br><span style="font-size: 12px;">Comment: Reuters reported today that Valeant is in talks to buy Salix.<wbr> The US drugmaker has got a strategically focused sales force, a strong presence amongst gastroenterologists, as well as a powerful Xifaxan franchise.<wbr> Last year the company entered into an exclusive agreement with RedHill for the WW rights of the potential first encapsulated formulation for bowel cleansing.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2216">...</a><br></div><div style="margin-bottom: 10px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Valeant has bought Salix.<wbr> The transaction represents approximately $14.<wbr>5 Billion and will </STRONG>create a new Specialty Platform for Growth.<wbr> It is <SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 12px/20px HelveticaNeue-Light, 'Helvetica Neue Light', 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">expected to close in the second quarter of 2015.<wbr></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 12px/20px HelveticaNeue-Light, 'Helvetica Neue Light', 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The growing GI market has attractive fundamentals, and Salix has a portfolio of products that are outpacing the market in terms of volume growth and a promising near-term pipeline of innovative products.<wbr></SPAN></STRONG> </div><div><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 12px/20px HelveticaNeue-Light, 'Helvetica Neue Light', 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Salix's market-leading gastrointestinal franchise is an ideal strategic fit for Valeant's diversified portfolio of specialty products.<wbr></SPAN></STRONG> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2283c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>According to the Wall St Journal ENDO Pharmaceuticals has just submitted a competing bid for Salix of between $170 per share and $175 per share.<wbr>  Salix reached an agreement in February to be purchased by Valeant Pharmaceuticals for $158 per share.<wbr> Endo reportedly sent a private offer letter to Salix's board today.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2260">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2216">View thread  GastroEnterology2216: Valeant to Explore Takeover of Salix</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-23T17:40:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-23T17:40:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Probi AB Trial to Test Probiotics in Radiation-treated Gynecologic Cancer</title>
	<pubDate>2015-02-20T22:10:43+01:00</pubDate>
	<wp:post_id>6019</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The ProRad interventional randomized trial will study the efficacy <SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/19px arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">of a probiotic in reducing the symptoms of gastrointestinal toxicity linked to the irradiation of gynecologic cancer.<wbr> PE will assess <SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/19px arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Change in incidence of loose</SPAN></SPAN><SPAN style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/19px arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/19px arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">/<wbr></SPAN></SPAN><SPAN style="text-align: left; line-height: 19px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="hit_syn" style="text-align: left; line-height: 19px; widows: 2; text-transform: none; font-variant: normal; font-style: normal; text-indent: 0px; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">watery stool</SPAN><SPAN class="hit_syn" style="text-align: left; line-height: 19px; widows: 2; text-transform: none; font-variant: normal; font-style: normal; text-indent: 0px; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">s.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="text-align: left; line-height: 19px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="hit_syn" style="text-align: left; line-height: 19px; widows: 2; text-transform: none; font-variant: normal; font-style: normal; text-indent: 0px; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Trial Details</SPAN></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><SPAN style="text-align: left; line-height: 19px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="hit_syn" style="text-align: left; line-height: 19px; widows: 2; text-transform: none; font-variant: normal; font-style: normal; text-indent: 0px; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; text-decoration: underline; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Reference </SPAN></SPAN></SPAN><a href="https://clinicaltrials.gov/ct2/show/NCT02351089?term=BOTULINUM+OR+HUNTINGTON+OR+GROWTH+HORMONE+DEFICIENCY+OR+DIARRHEA&recr=Open&no_unk=Y&fund=2&rcv_s=01%2F20%2F2015&rank=2" class="defaultlink">NCT02351089</a> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><SPAN style="text-align: left; line-height: 19px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="hit_syn" style="text-align: left; line-height: 19px; widows: 2; text-transform: none; font-variant: normal; font-style: normal; text-indent: 0px; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; text-decoration: underline; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Timelines</SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: left; line-height: 19px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="hit_syn" style="text-align: left; line-height: 19px; widows: 2; text-transform: none; font-variant: normal; font-style: normal; text-indent: 0px; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Study planned to start next mont - completion date: Dec 2016</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: left; line-height: 19px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN class="hit_syn" style="text-align: left; line-height: 19px; widows: 2; text-transform: none; font-variant: normal; font-style: normal; text-indent: 0px; font-family: arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-decoration: underline;">Recruitment</SPAN> Approx 200</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><UL style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; margin-top: 1ex; text-indent: 0px; padding-left: 24px; font: 14px/19px arial, 'Nimbus Sans L', sans-serif; white-space: normal; orphans: 2; margin-bottom: 1ex; letter-spacing: normal; color: #000000; margin-left: 0px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><LI class="color-bullet" style="margin-top: 0.7ex; font: 14px/1.4em arial, 'Nimbus Sans L', sans-serif; margin-bottom: 4px; color: #8194bc;"><SPAN class="li-content" style="color: #000000;">Women diagnosed with cancer in the small pelvis and waiting to receive radiotherapy either as a primary or as a secondary treatment following surgery.<wbr> Chemotherapy may or may not be part of the treatment regimen.<wbr></SPAN>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex; font: 14px/1.4em arial, 'Nimbus Sans L', sans-serif; margin-bottom: 4px; color: #8194bc;"><SPAN class="li-content" style="color: #000000;">Age, older than 18 years old.<wbr></SPAN>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex; font: 14px/1.4em arial, 'Nimbus Sans L', sans-serif; margin-bottom: 4px; color: #8194bc;"><SPAN class="li-content" style="color: #000000;">Agreement for participation in the study by signed written informed consent.<wbr></SPAN>
</LI>
</UL> </div><div><P class="color-bullet" style="margin-top: 0.7ex; font: 14px/1.4em arial, 'Nimbus Sans L', sans-serif; margin-bottom: 4px; color: #8194bc;"><SPAN class="li-content" style="color: #000000;"><SPAN style="text-decoration: underline;">Location:</SPAN> Sweden - </SPAN><SPAN class="li-content" style="color: #000000;"><SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/19px arial, 'Nimbus Sans L', sans-serif; white-space: nowrap; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Maria Bjurberg, MD, PhD</SPAN></SPAN></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2257">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-20T22:10:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-20T22:10:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>REOLYSIN® Has Been Granted Orphan Drug Designation For Its Pancreatic Cancer Indication</title>
	<pubDate>2015-02-20T15:41:06+01:00</pubDate>
	<wp:post_id>6020</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncolytics Biotech's REOLYSIN&reg; has received FDA's orphan drug designation for pancreatic cancer.<wbr> This is the second indication (after ovarian cancer) for REOLYSIN&reg; to receive FDA's orphan drug designation.<wbr> Currently Oncolytics Biotech has 10 ongoing trials to evaluate REOLYSIN&reg; in various oncological indications including multiple myeloma, metastatic breast cancer, metastatic NSCLC, metastatic colorectal caner, mCRPC, pancreatic cancer, ovarian cancer, squamous cell lung cancer, and metastatic melanoma.<wbr> </div><div style="margin-bottom: 10px;">REOLYSIN<SUP id="yui_3_16_0_1_1424278142108_1645"></SUP> is Oncolytics' proprietary isolate of the reovirus.<wbr> Its primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/<wbr>or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF and KRAS.<wbr> Up to 70% of pancreatic cancers have activating Ras pathway mutations and/<wbr>or over-expressions.<wbr> </div><div>Source: Oncolytics Biotech Company Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10282">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-20T15:41:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-20T15:41:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Colon Capsule Maker to Raise $40-60M in IPO</title>
	<pubDate>2015-02-20T15:22:22+01:00</pubDate>
	<wp:post_id>6021</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Colon Capsule Maker to Raise $40-60M in IPO</span>&nbsp;<br><span style="font-size: 12px;">Comment: Check-Cap's disposable capsules which relies on X-ray technology is expected to be approved in 2015 (EU/<wbr>US).<wbr> The X-ray Radar technology is designed to image only the colon interior through which it travels.<wbr> It is self-administered, non-invasive and<STRONG> does not require</STRONG> <STRONG>preparation</STRONG>.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2022">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="color: #000000;"><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The company has announced p</SPAN>ricing of IPO, and expects to raise $24M in IPO and simultaneous private placement.<wbr> Next month, two new directors will be joining the company to help bringing the capsule to the market.<wbr></SPAN> </div><div style="margin-bottom: 10px;">Mr.<wbr> Yuval Yanai is a senior executive, bringing more than 25 years of cross-functional experience to Check-Cap Ltd<SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #2e4b80; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr> <SPAN style="color: #000000;">From 2005 through 2014, Mr.<wbr> Yanai served as Senior Vice President and Chief Financial Officer of Given Imaging Ltd.<wbr>, a developer and manufacturer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract (sold to Covidien for </SPAN></SPAN><SPAN style="color: #000000;"><SPAN class="xn-money" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">$1 billion</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> in 2014)</SPAN></SPAN> </div><div><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Mr.<wbr> Steven J.<wbr> Hanley is an experienced global business leader who has managed highly complex pharmaceutical and medical device operations with annual global revenue exceeding $1 billion<SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr> As the President of Covidien plc's Imaging Solutions business unit, he led a multifunctional organization that included sales, marketing, logistics, manufacturing, as well as research and development.<wbr> Internationally, his track record includes numerous new drug and device product introductions and sales force expansion in </SPAN><SPAN class="xn-location" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Eastern Europe</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">, </SPAN><SPAN class="xn-location" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">China</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> and </SPAN><SPAN class="xn-location" style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Latin America</SPAN><SPAN style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 14px/16px Calibri, Tahoma, Arial; white-space: normal; orphans: 2; float: none; letter-spacing: normal; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr></SPAN></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2256">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2022">View thread  GastroEnterology2022: Colon Capsule Maker to Raise $40-60M in IPO</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-20T15:22:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-20T15:22:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Top-Anti-aging Trends in Aesthetic for 2015 as Compiled by IAPAM</title>
	<pubDate>2015-02-20T14:52:49+01:00</pubDate>
	<wp:post_id>6022</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The International Association for Physicians in Aesthetic Medicine (IAPAM), in consultation with its members and associated industry experts, has compiled a list of the top5 anti-aging trends for 2015.<wbr> Botox/<wbr>Xeomin will continue to rise, with HA dermal fillers being close contender in the non-invasive cosmetic procedure race.<wbr> In third position, the IPL photo rejuvenation which is seen as an emerging and growing trend with an increase of 35%  in procedures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botulinum Toxin injections</STRONG> </div><div style="margin-bottom: 10px;">IAPAM indicates that men seem to be seeking injection procedures a lot more, ans in 2015 it estimates this trend likely to rise even further </div><div style="margin-bottom: 10px;"><STRONG>Derma Fillers</STRONG> </div><div style="margin-bottom: 10px;">HA dermal fillers <SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/23px helvetica, arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #444444; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">are close contenders in the race to being the top non invasive cosmetic procedure in 2015.<wbr> Popular hyaluronic acid fillers include Allergan's Juvederm and Voluma, and Merz's Boletero.<wbr> These new options will offer more facial contouring options for consumers in 2015.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 23px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: helvetica, arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #444444; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">IPL Photo Rejuvenation</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/23px helvetica, arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #444444; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">According to IAPAM, people now realize the positive results obtained with IPL treatment.<wbr> With ease of access, a great deal of safety and excellent outcomes the procedure is likely to remain popular in the year ahead.<wbr></SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/23px helvetica, arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #444444; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Source: <A href="http://www.prweb.com/releases/2015/02/prweb12524721.htm">http:/<wbr>/<wbr>www.<wbr>prweb.<wbr>com/<wbr>releases/<wbr>2015/<wbr>02/<wbr>prweb12524721.<wbr>htm</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7930">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-20T14:52:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-20T14:52:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ex-Bayer Joins Sanofi as New CEO</title>
	<pubDate>2015-02-20T12:41:17+01:00</pubDate>
	<wp:post_id>6023</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Olivier Brandicourt's immediate responsibilities will be to launch Toujeo, a replacement of Lantus (which will lose patent protection this year), and boost emerging markets portfolio (which represents a third of revenue).<wbr> Bayer said that executive board member Werner Baumann will replace Brandicourt as healthcare division head.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Mini Profile</STRONG> </div><div style="margin-bottom: 10px;"><P align="justify" class="hugin">Olivier Brandicourt has 28 years of global experience in the pharmaceutical industry, most recently as Chairman of the Board of Management of Bayer HealthCare AG and member of the Executive Council of Bayer AG.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="justify" class="hugin">Previously, Brandicourt held numerous positions of increasing responsibility within major global pharmaceutical groups, such as Parke-Davis/<wbr>Warner-Lambert and Pfizer.<wbr> Notably, Brandicourt served as a member of Pfizer's global Executive Leadership Team from 2010 - 2013.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="justify" class="hugin">A physician by training, Olivier Brandicourt's career includes several senior positions in Europe, Canada and the United States.<wbr> As the head of various key healthcare divisions, he has a broad range of expertise and knowledge of the pharmaceutical industry and has led the launch of numerous new medicines and the completion of strategic acquisitions and integrations.<wbr></P> </div><div><P align="justify" class="hugin">Source: Sanofi</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11098">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-20T12:41:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-20T12:41:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New PhII NMIBC Study After BCG Failure</title>
	<pubDate>2015-02-19T18:43:00+01:00</pubDate>
	<wp:post_id>6024</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing a new safety and efficacy study in high-grade non-muscle invasive bladder cancer with Cold Genesys Inc's oncolytic virus CG0070.<wbr> The patient population will have failed BCG therapy and refused cystectomy.<wbr> Interestingly, the trial will evaluate changes in PD-L1 status.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Endpoints</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Primary Outcome Measures: </STRONG> </div><div style="margin-bottom: 10px;"><UL style="margin-bottom: 1ex; margin-top: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Durable Complete Response Proportion (DCR) [ Time Frame: 18 months time point from the date of the first intravesical intervention ]
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;"><STRONG>Secondary Outcome Measures: </STRONG></P> </div><div style="margin-bottom: 10px;"><UL><LI><UL><LI><UL><LI class="color-bullet" style="margin-top: 0.7ex;">TimeFrame 18 months unless specified
<UL><LI class="color-bullet" style="margin-top: 0.7ex;">Cystectomy Free Survival
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Complete Response Survival
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Progression Free Survival
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Time to Progression to Muscle Invasive Disease
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Overall Survival
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">PD-L1 Status Changes [ Time Frame: changes between pre-intervention and post intervention at either cystectomy or at biopsy up to 24 months ]
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">PD-L1 status of cancer cells and immune cells at tumor site by IHC
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Organ Confined Disease Proportions [ Time Frame: at cystectomy ]
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patient proportions with no cancer cells in regional lymph nodes at cystectomy
</LI>
<LI>Complete Response Proportions [ Time Frame: 24 months after the first intravesical treatment ]
</LI>
</UL>
 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Proportions of patients with a complete response of at least 12 months' duration
</LI>
</UL>
</LI>
</UL>
</LI>
</UL>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="indent2" style="margin-top: 1ex;"><STRONG>Dosage &amp; Administration</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="indent2" style="margin-top: 1ex;">Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks.<wbr> Patients who achieved a partial response or a complete response at 6 month post first intravesical intervention will be maintained with the same induction cycle of weekly times six every six months until month 18.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="indent2" style="margin-top: 1ex;"><STRONG>Patient Nos &amp; Timleines</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="indent2" style="margin-top: 1ex;">Recruitment of 122 patients is due to start in March 2015.<wbr> Completion in terms of PE is due June 2017 and study completion June 2019.<wbr></P> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-top: 1ex;" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="padding-left: 1em;"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02365818" title="Current version of study NCT02365818 on ClinicalTrials.gov">NCT02365818</A></TD>
</TR>
</TBODY>
</TABLE> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-top: 1ex;" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">Other Study ID Numbers:</TD>
<TD headers="colData" style="padding-left: 1em;">BOND 2 version 3.<wbr>3</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10280">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-19T18:43:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-19T18:43:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Key Messages from Actavis Investor Meeting</title>
	<pubDate>2015-02-19T17:53:04+01:00</pubDate>
	<wp:post_id>6025</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Key Messages from Actavis Investor Meeting</span>&nbsp;<br><span style="font-size: 12px;">Comment: Alongside the financial results for Q4 and FY2014, management provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline.<wbr> It outlined 9 compounds currently in mid or late-stage development that have the potential to generate &gt;$6 billion in peak sales following launch.<wbr> In a separate PR Actavis has announced its intention to adopt 'Allergan' corporate name for its corporate name and for its global branded pharmaceutical portfolio.<wbr> Actavis name will retain for selected geographic regions and product portfolios.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2252">...</a><br></div><div>Allergan name is stronger than Actavis.<wbr>.<wbr>.<wbr>it makes sense </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2255">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2252">View thread  GastroEnterology2252: Key Messages from Actavis Investor Meeting</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-19T17:53:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-19T17:53:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Additional Information From Actavis Investor Day Re New Company Product Focus/Pipeline</title>
	<pubDate>2015-02-19T16:39:59+01:00</pubDate>
	<wp:post_id>6026</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The slides from yesterday's presentation provide greater clarity regarding pipeline specifics and the group's North American commercial focus.<wbr> Botox for Spasticity indications, for example, is highlighted as one of the new group's late stage CNS development candidates, whilst for Dermatology &amp; Aesthetic candidates Botox CFL for Asia and Botox Forehead lines are highlighted.<wbr> Product portfolio selection amongst earlier stage portfolio programs has yet to be announced; to date there is no comment on the status of the liquid toxin program.<wbr> </div><div style="margin-bottom: 10px;">What may be surprising to some is the strength of Actavis's own branded product portfolio and some of the key blockbuster drugs it has identified amongst these programmes.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key Business Areas Of Importance To Actavis' Brand Business</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Combined Actavis/<wbr>Allergan Late Stage Portfolio</STRONG> </div><div style="margin-bottom: 10px;">With 6 key therapy areas identified for development purposes, it is interesting to see Botox therapeutic activities aligned with the new group's CNS business, an area where Actavis's focus will be on psychosis given the perceived potential of cariprazine and where it has already expressed a significant interest in the headache market (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7857" class="defaultlink">Neurology7857: New Investor Report Focuses on Highlights Of Actavis Meeting With Brent Saunders</a>).<wbr> However, the potential of all the spasticity indications is at least captured.<wbr> </div><div style="margin-bottom: 10px;">When questioned at the investor event about the sustainability of Allergan's growth CEO Brent Saunders responded accordingly:- </div><div style="margin-bottom: 10px;"><EM>"My view of Allergan's performance is that it is sustainable.<wbr> I think where you saw a lot of the growth was in the expansion of Botox therapeutic, particularly migraine.<wbr> You saw in one of the areas I know quite well, the eye health category, particularly Restasis, Lumigan, other products grow very nicely.<wbr> And those are large and growing markets still.<wbr><BR><BR>The filler launch, the Voluma, Juvederm Voluma experienced the best launch in aesthetic history because it's a great product and there is great demand.<wbr> So I think as long as we can continue to focus on driving those brands, to continue to drive innovation to support the product flow, those businesses should maintain or even experience more robust growth.<wbr></EM> </div><div style="margin-bottom: 10px;">Commenting on the R&amp;D portfolio David Nicholson, Actavisplc - EVP, Brands R&amp;D noted the following:- </div><div style="margin-bottom: 10px;"><SPAN style="font-style: italic;">What is our R&amp;D strategy? As a standalone company, Actavis focuses energy on four key therapeutic areas: gastrointestinal disorders, CNS, infectious disease, and women's health.<wbr> And we are opportunistic in urology, dermatology, and cardiology.<wbr><BR><BR>Of course, this is Actavis as a standalone company.<wbr> We are all looking forward to bolting onto this the Allergan areas of expertise in ophthalmology, dermatology, and aesthetics, as well as their core research group in areas of ophthalmology and select agents.<wbr><BR><BR>Actavis as a standalone company has built and we continue to build our pipeline through collaborations and in-licensing.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_11_ScreenCapture12.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Actavis's North American Commercial Model</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Manufacturing Synergies</STRONG> </div><div style="margin-bottom: 10px;">Commenting on manufacturing synergies and looking at how the <SPAN id="114" style="background-color: #ffff00;">Allergan</SPAN> piece complements this Brent Saunders noted that there are two areas where Actavis didn't have actual manufacturing capability in-house.<wbr> On the inhalation side Actabis had R&amp;D capability, but it was relying on third parties to be able to produce the products.<wbr> Now with once the transaction closes it will have this capability.<wbr> <BR>Another area is likely to be ophthalmology.<wbr> There will be the ability to take that - effectively what was reliant on third parties to internally launch and execute R&amp;D strategies there.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_12_ScreenCapture13.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="neurology7927attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(120,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(93 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(105,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(131,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(97,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(107,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(137,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(69 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(118,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(91,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7927_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(108,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7927">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-19T16:39:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-19T16:39:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Heat Biologics And OncoSec Medical Announce Collaboration to Evaluate Combination of Immunotherapy Platforms</title>
	<pubDate>2015-02-18T16:42:20+01:00</pubDate>
	<wp:post_id>6027</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Heat Biologics and OncoSec Medical announced today that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.<wbr> The collaboration will evaluate the efficacy of <STRONG>Heat Biologics' proprietary gp-96-Ig platform (</STRONG>the two leading clinical programmes include HS110 in Ph2 NSCLC and HS410 in Ph2 non muscle invasive bladder cancer) and <STRONG>OncoSec Medical's ImmunoPulse Platform</STRONG> that is designed to use DNA 1L-12 to stimulate body's immune system.<wbr> The priority of indications of interest under this collaboration is yet unclear at this stage.<wbr> This may throw a hint on the momentum of the immuno-oncology combination strategy towards an earlier development collaboration between biotech clinical development companies.<wbr> </div><div style="margin-bottom: 10px;">Under the agreement, Heat and OncoSec will jointly evaluate the preclinical efficacy of Heat's proprietary gp-96-Ig based ImPACT immunotherapy platform using OncoSec's core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform.<wbr> Heat's ImPACT platform is a unique approach that specifically activates tumor specific cytotoxic T-cells.<wbr> OncoSec Medical Inc.<wbr> is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy.<wbr> OncoSec Medical's core technology is designed to enhance the local delivery and uptake of plasmid-encoded IL-12 and other DNA-based immune-targeting agents.<wbr> Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments.<wbr> OncoSec's lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers.<wbr> As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.<wbr> </div><div style="margin-bottom: 10px;">A summary of OncoSec Medical's key collaborations and pipelines is: </div><div style="margin-bottom: 10px;"><UL><LI>Reported Phase I Positive Long Term Survival Data
</LI>
<LI>Reported Phase II Positive Final Data
</LI>
<LI>Announced a combination trial with Merck&rsquo;s KEYTRUDA&reg;
</LI>
<LI>Initiation of a Phase II in Head &amp; Neck Cancer
</LI>
<LI>Announced a preclinical collaboration with Plexxikon&rsquo;s CSF-1R inhibitor
</LI>
<LI>Entered a Sponsored Research Agreement with the University of Washington to evaluate immunologic mechanisms
</LI>
<LI>Announced a collaboration with PerkinElmer and the University of California, Los Angeles to develop biomarker tests to evaluate a patient&rsquo;s immune response to cancer.<wbr> =&gt; OncoSec Medical published in the Nature of its finding on the role of PD-1/<wbr>L1 in adaptive immune resistance
</LI>
</UL> </div><div>Source: <A href="http://www.oncosec.com;">www.<wbr>oncosec.<wbr>com;</A> <A href="http://www.heatbio.com">www.<wbr>heatbio.<wbr>com</A> Press Release 18 Feb 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10276">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-18T16:42:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-18T16:42:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</title>
	<pubDate>2015-02-18T16:21:05+01:00</pubDate>
	<wp:post_id>6028</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</span>&nbsp;<br><span style="font-size: 12px;">Neurocrine Biosciences has announced that  the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting.<wbr> The presentation will take place on Thursday, March 5, 2015 from 11:30 am to 1:00 pm (PST) during the session entitled "HPA Axis and Adrenal: Receptors to Clinical Impact.<wbr>"</span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7929">...</a><br></div><div>Neurocrine Biosciences has announced on February 17th an underwritten public offering of shares to raise $225M to fund its R&amp;D efforts as well for preparing for commercialization of its lead assets.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7967">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7882">View thread  Endocrinology7882: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-18T16:21:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-18T16:21:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Actavis Investor Meeting</title>
	<pubDate>2015-02-18T15:52:16+01:00</pubDate>
	<wp:post_id>6029</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results for Q4 and FY2014, management provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline.<wbr> It outlined 9 compounds currently in mid or late-stage development that have the potential to generate &gt;$6 billion in peak sales following launch.<wbr> In a separate PR Actavis has announced its intention to adopt 'Allergan' corporate name for its corporate name and for its global branded pharmaceutical portfolio.<wbr> Actavis name will retain for selected geographic regions and product portfolios.<wbr> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7925" class="defaultlink">Neurology7925: re: Together Leading The Way In "Growth Pharma" - Actavis's New Slogan</a> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Selected Financial Data</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Arial; color: black; font-size: 0.62em;"><SPAN style="font-family: Arial; color: black; font-size: 8pt;"><STRONG>North America Brands Segment Information</STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Arial; color: black; font-size: 0.62em;"><SPAN style="font-family: Arial; color: black; font-size: 8pt;">For the full year 2014, this segment net revenue increased 336 percent to $4.<wbr>63 billion, driven by the acquisition of Forest and the full year impact of the Warner Chilcott acquisition</SPAN></P> </div><div style="margin-bottom: 10px;"><STRONG>EBITDA</STRONG> </div><div style="margin-bottom: 10px;">For the fourth quarter 2014, adjusted EBITDA increased 80% to $1.<wbr>5 billion, compared to $817 million for the fourth quarter 2013 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Pipeline - Selected Key Drugs in Key Areas</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><STRONG>Gastro</STRONG> </div><div style="margin-bottom: 10px;"><EM>Eluxadoline</EM><STRONG><EM> -</EM></STRONG> IBS-D (expected launch 2015/<wbr>2016) </div><div style="margin-bottom: 10px;"><EM>Relamorelin - </EM>diabetic gastroparesis (expected launch 2019) </div><div style="margin-bottom: 10px;"><STRONG>CNS</STRONG> </div><div style="margin-bottom: 10px;"><EM>Namzaric - </EM>moderate to severe Alzheimer's di<EM>sease (approved Dec.<wbr> 2014) </EM>Actavis expects to launch NAMZARIC in the U.<wbr>S.<wbr> in the second quarter of 2015.<wbr> </div><div style="margin-bottom: 10px;"><EM>Cariprazine</EM> -schizophrenia; bipolar disorder; bipolar depression; Adjunctive MDD </div><div style="margin-bottom: 10px;"><STRONG>Women's Health</STRONG> </div><div style="margin-bottom: 10px;"><EM>Esmya - uterine fibroids</EM>first-in-class, orally active selective progesterone receptor modulator for the treatment of abnormal uterine bleeding in women with uterine fibroids.<wbr> Approved in Canada in 2013, where it is marketed as FIBRISTAL, it is the first approved medication to reduce fibroid size as well as control symptoms.<wbr> ESMYA is currently in Phase [III] clinical trials, with results expected in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dermatology</STRONG> </div><div style="margin-bottom: 10px;"><EM>Sarecycline - </EM>acne vulgariscurrently in Phase 3 studies and results are expected in the 2016 (NDA approval in 2018) </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Full Year 2015 Standalone Financial Forecast</STRONG></SPAN> </div><div><UL type="disc"><LI>Total Net Revenue is expected to be approximately $15 billion
</LI>
<LI>Non-GAAP R&amp;D investment is expected to be approximately $1.<wbr>1 billion
</LI>
<LI>Non-GAAP Effective Tax Rate is expected to be approximately 16%
</LI>
<LI>Fully Diluted Shares Outstanding are expected to be approximately 270 million
</LI>
<LI>Non-GAAP earnings per diluted share is expected to be between $16.<wbr>30 and $17.<wbr>30
</LI>
<LI>SG&amp;A as a percent of Revenues is expected to be approximately 19%
</LI>
</UL> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2255c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Allergan name is stronger than Actavis.<wbr>.<wbr>.<wbr>it makes sense </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2252">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-18T15:52:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-18T15:52:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Together Leading The Way In "Growth Pharma" - Actavis's New Slogan</title>
	<pubDate>2015-02-18T14:47:14+01:00</pubDate>
	<wp:post_id>6030</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Together Leading The Way In "Growth Pharma" - Actavis's New Slogan</span>&nbsp;<br><span style="font-size: 12px;">Comment: Presenting at the JP Morgan H/<wbr>C Conference this week Brent 
Saunders presented his first expanded views on what the new combined 
Actavis/<wbr>Allergan "Growth Pharma" will look like (depicted in the slides below).<wbr> 
More was outlined about the combined culture of the organisation, its focus on 
tight SG&amp;A control and its key R&amp;D products.<wbr> 
Having already stated his aversion to discovery research it was of interest 
to note his comment "we're going to stay in discovery in those areas where 
we have a comparable advantage, that may be neuromodulators, it will probably be 
ophthalmology.<wbr>" Cutting its SG&amp; costs as part of its exercise to reduce 
costs while being pursued by Valeant, it was interesting to note the 
absence of an Allergan booth other than by name only at this week's TOXINS 
Congress.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7888">...</a><br></div><div style="margin-bottom: 10px;">Actavis has today announced the intention to adopt 'Allergan' corporate name for its corporate name and for its global branded pharmaceutical portfolio.<wbr>  Actavis name will retain for selected geographic regions and product portfolios.<wbr> Actavis' CEO commented on how the move to Allergan name speaks to the future strategic vision of the organization, focused on developing new medicines that support unmet medical needs in critical therapeutic areas (Allergan heritage) as well as increasing global access to high quality and affordable medicines (Actavis heritage).<wbr> Actavis will ask the shareholders to vote on this matter later in the year.<wbr> In the meantime Actavis will continue to operate and trade under its current name.<wbr> </div><div>Soucre: BioSpace, Actavis PR </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7925">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7888">View thread  Neurology7888: Together Leading The Way In "Growth Pharma" - Actavis's New Slogan</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-18T14:47:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-18T14:47:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Toxins 2015 Intelligence – Part 2: Key Presentations on Spasticity Treatment in Adults & Cerebral Palsy Patients Plus New Cervical Dystonia Data</title>
	<pubDate>2015-02-17T17:46:38+01:00</pubDate>
	<wp:post_id>6031</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><A href="http://www.sciencedirect.com/science/journal/10903798" title="Go to European Journal of Paediatric Neurology on ScienceDirect"><SPAN style="text-decoration: none; color: windowtext; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-language: EN-GB; mso-border-alt: none windowtext 0cm; text-underline: none; border: windowtext 1pt; padding: 0cm;"></SPAN></A> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_13_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"></EM></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"></EM></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"></EM></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Post-injection pain questionnaire, which evaluated whether CD caused neck pain or discomfort prior to treatment, whether neck pain was relieved within the first 2 weeks following treatment, and the time to relief of neck pain or discomfort.<wbr> Assessments occurred at phone interviews 1 and 2 and the final visit </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Pain subscale of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS),7 measured at baseline and visits 3 and 4 </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Pain Numeric Rating Scale (PNRS),8 assessed at all visits and phone interviews </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Pain and Discomfort subscale of the CD Impact Profile-58 (CDIP-58),9 measured at all visits and phone interviews </SPAN> </div><div style="margin-bottom: 10px;"><P class="Default" style="margin: 0cm 0cm 0pt;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">The charts below illustrate some of the important changes noted in pain parameters post treatment with the majority of patients noting significant pain relief one week after treatment with onabotulinumtoxinA.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P class="Default" style="margin: 0cm 0cm 0pt;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_25_ScreenCapture26.jpg"></SPAN></P> </div><div style="margin-bottom: 10px;"><P class="Default" style="margin: 0cm 0cm 0pt;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Differences in the management of CD in the US vs Europe: the patients&rsquo; perspective</SPAN></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="Default" style="margin: 0cm 0cm 0pt;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">This important poster (attached) highlights the results of a survey undertaken by Dystonia Europe and the Dystonia Medical Research Foundation conducted between March and December 2012.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P class="Default" style="margin: 0cm 0cm 0pt;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">Interestingly, the survey found that more patients in the US were satisfied with their treatment outcomes than in Europe (56% vs 49%), the reasons for which are unclear and merit further investigation.<wbr> The authors conclude that overall the results do point to the need for improvements in CD management.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P class="Default" style="margin: 0cm 0cm 0pt;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;">The Trudose Pilot Study &ndash; An evaluation of the dose of incobotulinumtoxinA and onabotulinumtoxinA in CD &amp; BEP (poster attached)</SPAN></STRONG></P> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="color: black; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="color: black; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_27_ScreenCapture28.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_28_ScreenCapture29.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_29_ScreenCapture30.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_30_ScreenCapture31.jpg"> </div><!-- Comment details --><a name="neurology7920attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(87,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(49,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(56,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(59,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(74,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(66 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(98,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(75,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(85,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_14_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(85,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_15_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(227,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_16_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(259,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_17_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(60,4 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_18_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(82,6 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_19_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(78,5 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_20_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(81,3 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_21_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(100,1 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_22_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(88,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_23_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(115,4 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_24_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(79,1 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_25_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(91,9 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_26_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(132,2 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_27_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(122 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_28_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(158,1 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_29_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(172,2 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_30_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(209,9 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_31_Botox%20Pain%20Releif%20In%20AUL%20spasticity.pdf">Botox Pain Releif In AUL spasticity.pdf</a>&nbsp;&nbsp;(116 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_32_Pain%20Relief%20in%20the%20CD%20PROBE%20study%20with%20Botox.pdf">Pain Relief in the CD PROBE study with Botox.pdf</a>&nbsp;&nbsp;(108,3 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_33_Trudose%20pilot%20dosing%20study%20comparing%20Botox%20and%20Xeomin%20in%20CD%20%26%20BEP.pdf">Trudose pilot dosing study comparing Botox and Xeomin in CD & BEP.pdf</a>&nbsp;&nbsp;(121 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7920_34_Literature%20Survey%20of%20Randomised%20Studies%20With%20Branded%20Toxins.pdf">Literature Survey of Randomised Studies With Branded Toxins.pdf</a>&nbsp;&nbsp;(320,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7920">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-17T17:46:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-17T17:46:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Study Supports Earlier Use Of Chemotherapy In Prostate Cancer</title>
	<pubDate>2015-02-17T17:25:34+01:00</pubDate>
	<wp:post_id>6032</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A study published in Clinical Cancer Research this week reported that cabazitaxel functions differently than docetaxel - <EM>in vitro</EM> model suggested that docetaxel and cabazitaxel should be considered as different class family as the results demonstrate the cellular consequences of cabazitaxel are distinct from docetaxel.<wbr> This supported the hypothesis of cabazitaxel could generate "superior" clinical benefit than docetaxel and explained the clinical efficacy observed with cabazitaxel following docetaxel failure (TROPIC Trial) .<wbr> Currently a H2H Ph3 FIRSTANA trial (NCT01308567) is ongoing to address this hypothesis and the study is estimated to complete in Q2 2015.<wbr> However, in recent Sanofi's 2014 financial webcast, there was no update given regarding to the progress of this trial and no indication of likely date for the data release yet.<wbr> Authors also reported that RB gene expression could be a valid biomarker to identify these will benefit from cabazitaxel - a Ph2 study (ABICABAZI NCT02218606) is funded by Sanofi to evaluate this.<wbr> Together with an interim analysis reported from CHAARTED that shows a striking benefit from addition of docetaxel to standard androgen deprivation therapy, positive outcomes reported form these trials could support chemotherapy utilisation in the earlier setting.<wbr> </div><div style="margin-bottom: 10px;">Typically taxane as a class is considered to attenuate the microtubule dynamicity and therefore inducing mitotic arrest and apoptosis (i.<wbr>e.<wbr> cell killing).<wbr> For years, docetaxel has been the only effective chemotherapy for men whose cancer was no longer responding to hormone treatments.<wbr> The next generation drug in the taxane family, cabazitaxel (Jevtana), was approved in 2010, but only for patients whose cancer no longer responded to hormone therapy or docetaxel treatment.<wbr> </div><div style="margin-bottom: 10px;">Knudsen and colleagues explored how cabazitaxel worked and demonstrated that it might be more effective sooner in treatment.<wbr> The researchers showed that cabazitaxel worked better than docetaxel in mCRPC human cell lineswhereas docetaxel has a greater impact on DNA transcription and repair.<wbr> </div><div style="margin-bottom: 10px;">"<EM>This difference in mechanism suggests that we should treat these two drugs less like members of the same family, and more like<SPAN style="color: #993300;"> two distinct therapies</SPAN> that may each have<SPAN style="color: #993300;"> distinct benefits</SPAN> for certain patients</EM>," says first author Ren&eacute;e de Leeuw, a postdoctoral researcher in the department of cancer biology at Thomas Jefferson University </div><div style="margin-bottom: 10px;">The collaborative research team also found a molecular marker that would help identify patients most likely to benefit from cabazitaxel treatment.<wbr> Knudsen and colleagues showed that tumors whose retinoblastoma (RB) gene no longer worked were likely to become hormone resistant, but remarkably were more likely to respond to cabazitaxel.<wbr> "This gene could give us a way to identify patients who would benefit from cabazitaxel earlier and reduce the trial and error of treating a <A class="textTag" href="http://medicalxpress.com/tags/cancer/" rel="tag"><U></U></A> patient," says Dr.<wbr> Knudsen.<wbr> </div><div style="margin-bottom: 10px;">A summary of key trials ongoing for Jevtana as below: </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" style="width: 1675px;"><COLGROUP><COL width="593">
</COLGROUP>
<COLGROUP><COL width="151">
</COLGROUP>
<COLGROUP><COL width="64">
</COLGROUP>
<COLGROUP><COL width="217">
</COLGROUP>
<COLGROUP><COL width="111">
</COLGROUP>
<COLGROUP><COL width="149">
</COLGROUP>
<COLGROUP><COL width="104">
</COLGROUP>
<COLGROUP><COL width="98">
</COLGROUP>
<COLGROUP><COL width="188">
</COLGROUP>
<TBODY><TR height="17"><TD height="17" width="593"><SPAN style="background-color: #888888;"><STRONG></STRONG></SPAN></TD>
<TD width="151"><SPAN style="background-color: #888888;"><STRONG></STRONG></SPAN></TD>
<TD width="64"><SPAN style="background-color: #888888;"><STRONG></STRONG></SPAN></TD>
<TD width="217"><SPAN style="background-color: #888888;"><STRONG> </STRONG></SPAN></TD>
<TD width="111"><SPAN style="background-color: #888888;"><STRONG> </STRONG></SPAN></TD>
<TD width="149"><SPAN style="background-color: #888888;"><STRONG></STRONG></SPAN></TD>
<TD width="104"><SPAN style="background-color: #888888;"><STRONG></STRONG></SPAN></TD>
<TD width="98"><SPAN style="background-color: #888888;"><STRONG></STRONG></SPAN></TD>
<TD width="188"><SPAN style="background-color: #888888;"><STRONG></STRONG></SPAN></TD>
</TR>
<TR height="34"><TD height="34" width="593"></TD>
<TD></TD>
<TD></TD>
<TD width="217"></TD>
<TD></TD>
<TD width="149"></TD>
<TD></TD>
<TD></TD>
<TD width="188"></TD>
</TR>
<TR height="34"><TD height="34" width="593"></TD>
<TD></TD>
<TD></TD>
<TD width="217"></TD>
<TD></TD>
<TD width="149"></TD>
<TD></TD>
<TD></TD>
<TD width="188"></TD>
</TR>
<TR height="34"><TD height="34" width="593"></TD>
<TD></TD>
<TD></TD>
<TD width="217"></TD>
<TD></TD>
<TD width="149"></TD>
<TD></TD>
<TD></TD>
<TD width="188"></TD>
</TR>
<TR height="102"><TD height="102" width="593"></TD>
<TD></TD>
<TD></TD>
<TD width="217"></TD>
<TD></TD>
<TD width="149"></TD>
<TD></TD>
<TD></TD>
<TD width="188"></TD>
</TR>
<TR height="68"><TD height="68" width="593"></TD>
<TD></TD>
<TD></TD>
<TD width="217"></TD>
<TD></TD>
<TD width="149"></TD>
<TD></TD>
<TD></TD>
<TD width="188"> <BR>  </TD>
</TR>
<TR height="51"><TD height="51" width="593"></TD>
<TD></TD>
<TD></TD>
<TD width="217"></TD>
<TD></TD>
<TD width="149"></TD>
<TD></TD>
<TD></TD>
<TD width="188"></TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: Leeuw et al.<wbr> CCR Feb 15, 2015 21;795 (Full text is available in <a href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare?Format_document=1&Mouvement=877568&Urlorigine=&Premier=0&Dernier=0&Doc1=2980201" class="defaultlink">PEARL</a>), ClinicalTrial.<wbr>Gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10274">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-17T17:25:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-17T17:25:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Program Launch for Epigenetic IBD Research</title>
	<pubDate>2015-02-17T15:46:11+01:00</pubDate>
	<wp:post_id>6033</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Crohn’s &amp; Colitis Foundation of America (CCFA) has partnered with the American Gastroenterological Association Institute and Janssen Biotech to launch a grant program promoting epigenetic research in inflammatory bowel disease (IBD).<wbr> The program will provide a 3-year grant of $100,000 per year to a junior investigator exploring the role of interrelated genetic and environmental factors involved in the development and treatment of IBD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>- to understand the complex interactions between genetic and environmental factors — for example, diet, bacteria, or medications — affecting the development and course of IBD.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2250">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-17T15:46:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-17T15:46:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>US OD Designation Granted For Trofinetide In Rett Syndrome</title>
	<pubDate>2015-02-16T18:48:12+01:00</pubDate>
	<wp:post_id>6034</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Neuren Pharmaceuticals announced today that the US FDA has 
granted its drug trofinetide Orphan Drug designation for the treatment of Rett 
Syndrome.<wbr> </div><div style="margin-bottom: 10px;">Additionally,  it notes in its press release that it has commenced 
the process of Orphan Drug applications to the EMA for both Rett syndrome and 
Fragile X syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>What is Trofinetide?</STRONG> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7972c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Neuren has announced that the FDA agreed that Rett syndrome meets the criteria for a serious or life-threatening condition.<wbr> However, Breakthrough Therapy will not be granted at this time because the FDA considered that data from Neuren&rsquo;s exploratory Phase 2 trial provide insufficient evidence to demonstrate substantial improvement over existing therapies using conventional statistical methods.<wbr> The company will proceed as planned under the Fast Track designation that has already been granted by the FDA under its expedited programs for serious conditions.<wbr> As planned, management expects to meet with the FDA in 1H:15 to agree the remaining requirements for the development of trofinetide in Rett syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Fast Track designation</STRONG> is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously.<wbr> </div><div><STRONG>Breakthrough Therapy</STRONG> is intended to streamline drug development and regulatory review of innovative new medicines that address unmet medical needs for serious diseases or conditions.<wbr> The criteria for Breakthrough Therapy require preliminary clinical evidence indicating that the drug may demonstrate a substantial improvement over existing therapies on at least one clinically significant endpoint.<wbr> Breakthrough Therapy designation conveys all of the Fast Track program features, as well as a commitment that FDA will work closely with the sponsor on an efficient drug development program.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7966">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-16T18:48:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-16T18:48:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biocodex Opens its 8th Subsidiary in Mexico</title>
	<pubDate>2015-02-16T18:36:18+01:00</pubDate>
	<wp:post_id>6035</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Biocodex's products are currently available in &gt;100 countries, with a network of 7 affiliates and 112 partners.<wbr> The PR indicates that this 8th subsidiary will market S.<wbr>boulardii in Mexico.<wbr> Additional details will be provided once the information is published in English.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2249_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology2249attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2249_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2249">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-16T18:36:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-16T18:36:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MCNA Bladder Cancer Submission Delayed By 3-months.</title>
	<pubDate>2015-02-16T17:39:39+01:00</pubDate>
	<wp:post_id>6036</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Telesta Therapeutics Inc.<wbr> issued its financial statements for the 6 month period ended December 31, 2014 providing alongside an update on the timetable for the submission of its US BLA for its bladder cancer treatment MCNA.<wbr> Negotiations with licensing partners are currently ongoing, with what is claimed to be "multiple non-binding offers" on the table.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" style="width: 100%;"><TBODY><TR><TD>&nbsp;</TD>
</TR>
<TR><TD>
<TABLE style="width: 100%;"><TBODY><TR align="left"><TD valign="top">
<DIV class="article_body"><STRONG>Filing delayed by 3-months to accommodate FDA feedback</STRONG></DIV>
<DIV class="article_body">On February 12th Telesta participated in a type C meeting with the US FDA is order to seek FDA feedback on questions that may relate to its manufacturing facility and to prepare for a FDA pre-license inspection.<wbr></DIV>
<DIV class="article_body">As a result of the FDA feedback, Telesta has amended it internal objection of filing the MCNA BLA by up to 3 months from March 31st to June 30th.<wbr></DIV>
<DIV class="article_body"><STRONG>Significant level of 3rd Party interest with multiple non-binding offers now received</STRONG></DIV>
<DIV class="article_body">The Company also reported that there is significant 3rd party interest in the MCNA program and that it is in receipt of multiple non-binding expressions of interest from a variety of public and private pharmaceutical and biotechnology companies.<wbr> Due to the confidential nature of the ongoing discussions, Telesta will only provide further updates to shareholders upon signature of a binding agreement.<wbr></DIV>
<DIV class="article_body"><STRONG>Market Assesment For MCNA Upgraded<BR></STRONG></DIV>
<DIV class="article_body">Finally, Telesta briefly highlighted the results of some market research undertaken by Medical Marketing Economis and the fact that it has upgraded its US peak sales assessment on the back of this data from sales of $200m to $400m.<wbr></DIV>
<DIV class="article_body">Source: <A href="http://www.telestatherapeutics.com">www.<wbr>telestatherapeutics.<wbr>com</A></DIV>
</TD>
</TR>
</TBODY>
</TABLE>
<TABLE style="width: 100%;"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE>
</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10270">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-16T17:39:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-16T17:39:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis Divests 'Aptalis Business' to TPG</title>
	<pubDate>2015-02-16T15:03:12+01:00</pubDate>
	<wp:post_id>6037</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: TPG, the global private investment firm, and Actavis have entered into definitive agreements, under which <ORG value="NYSE:ACT">Actavis</ORG> will divest to TPG the business currently known as Aptalis Pharmaceutical Technologies (Pharmatech).<wbr> No financial terms were disclosed.<wbr> Actavis will hold an Investor meeting on Feb.<wbr>18th, and may provide additional information on this operation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">COO of Actavis reported that the decision to divest the PharmaTech business " .<wbr>.<wbr>.<wbr> will enable our industry-leading Global Operations team to sharpen their focus on supporting our existing global supply chain, and on preparing for the expansion of our manufacturing network with the addition of the <ORG>Allergan</ORG> facilities following the close of the acquisition later this year".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Background</U>: Basically Aptalis returns to TPG.<wbr> On Jan 8th 2014, Forest agreed to acquire Aptalis from TPG for $2.<wbr>9bn, and on Feb.<wbr>18th Actavis acquired Forest for $25bn.<wbr> </div><div><U>Today</U>: John Fraher, current president of Aptalis Pharmaceutical Technologies, will become CEO of the new standalone company, and will be joined by others from his management team.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2247">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-16T15:03:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-16T15:03:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</title>
	<pubDate>2015-02-16T14:59:59+01:00</pubDate>
	<wp:post_id>6038</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</span>&nbsp;<br><span style="font-size: 12px;">Comment: Eisai executive Ivan Cheung in an interview with the Wall Street Journal reportedly claimed that its top prospect in oncology, levantanib can bring in peak annual sales north of $1bn by 2020, starting with its imminent approval in the US for the treatment of radioactive refractory thyroid cancer and then expanding to other tumour types.<wbr> Analysts at Morgan Stanley are forecasting US sales  of $90m in 2019 for the thyroid indication alone and $300m at best.<wbr>.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10266">...</a><br></div><div style="margin-bottom: 10px;">Eisai has announced today the FDA approval of its in-house developed Lenvima (lenvatinib mesylate) as a treatment for locally recurrent ore metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.<wbr> Lenvima was granted priority review status by the FDA and the approval comes in only six months from the submission of the NDA, in August 2014.<wbr> US is the first market where Lenvima has granted authorization.<wbr> </div><div>Source: Eisai website </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10345c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>During the CHMP meeting held on 23-26 March, the European Medicine Agency recommended Lenvima (lenvatinib) for approval and granted marketing authorization for the treatment of adults with progressive, locally, advanced or metastatic differentiated thyroid carcinoma, whose disease has progressed despite receiving radioactive iodine.<wbr> Lenvima was reviewed under EMA's accelerated assessment program being a drug that would significantly improve the treatment for this serious condition.<wbr>  The European approval arrives just over a month the US approval.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10269">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10266">View thread  Oncology10266: Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-16T14:59:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-16T14:59:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Celltrion and Hospira to Sell First Copies of J&J's Remicade</title>
	<pubDate>2015-02-16T14:09:58+01:00</pubDate>
	<wp:post_id>6039</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Celltrion and Hospira to Sell First Copies of J&J's Remicade</span>&nbsp;<br><span style="font-size: 12px;">Comment: The European Commission should give the two companies approval to market their versions, called Remsima and Inflectra, for the same medical conditions for which Remicade is marketed.<wbr> The EMA’s recommendations are the final stage before the European Commission, the European Union’s executive arm, approves or rejects a drug for sale to patients in the 27-nation region.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=1899">...</a><br></div><div style="margin-bottom: 10px;">On Feb.<wbr>16th Hospira announced additional launches of Inflectra, the 1st biosimilar mAb, in major EU markets (Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, Netherlands, Spain and Sweden).<wbr> The drug has already been launched in CEE, and some smaller Western European markets due to earlier patent expiry, and has already been prescribed to treat patients in all its licensed indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The drug covers several indications, and is indicated for the treatment of RA, psoriatric arthritis, ankylosing spondylitis, adult and ped IBD (Crohn's disease and ulcerative colitis), and plaque psoriasis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Europe - With the launch of the product in these new markets, Inflectra is now available in 24 EU countries </div><div>USA - Hospira's partner, Celltrion, has also submitted an application to the U.<wbr>S.<wbr> Food and Drug Administration for biosimilar infliximab.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2246">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1899">View thread  GastroEnterology1899: Celltrion and Hospira to Sell First Copies of J&J's Remicade</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-16T14:09:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-16T14:09:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ironwood Provides Strategic Milestones for Linzess (linaclotide)</title>
	<pubDate>2015-02-13T16:46:47+01:00</pubDate>
	<wp:post_id>6040</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results for the year, management reported that Ph3 trial of Linzess in China for IBS-C has completed enrollment (data expected in 2H15).<wbr> Partner AstraZeneca anticipates a launch in 2017.<wbr> Ironwood and Actavis continue to evaluate opportunities to strengthen linaclotide's clinical utility in its indicated patient population, as well as to develop and seek approval of linaclotide in CIC and OIC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Future Milestones</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">PhIII data of Linzess in CIC is expected in 2016</P> </div><div style="margin-bottom: 10px;"><P align="left">PhII data of Linzess in OIC in 2H15</P> </div><div style="margin-bottom: 10px;"><STRONG>Collaborative Arrangements Revenue</STRONG> </div><div style="margin-bottom: 10px;">Collaborative arrangements revenue was approximately $38.<wbr>1 million in the fourth quarter of 2014 compared with approximately $16.<wbr>9 million in the third quarter of 2014.<wbr> </div><div>For the full year 2014, collaborative arrangements revenue was approximately $76.<wbr>4 million </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2244">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-13T16:46:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-13T16:46:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Eisai Makes Strong Claims About The Blockbuster Potential Of Its New Thyroid Cancer Drug</title>
	<pubDate>2015-02-13T12:52:55+01:00</pubDate>
	<wp:post_id>6041</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Eisai executive Ivan Cheung in an interview with the Wall Street Journal reportedly claimed that its top prospect in oncology, levantanib can bring in peak annual sales north of $1bn by 2020, starting with its imminent approval in the US for the treatment of radioactive refractory thyroid cancer and then expanding to other tumour types.<wbr> Analysts at Morgan Stanley are forecasting US sales  of $90m in 2019 for the thyroid indication alone and $300m at best.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Publication Of The SELECT Tiral</STRONG> </div><div style="margin-bottom: 10px;">PhIII results from the SELECT study were published in The New England Journal Of Medicine yesterday demonstrating that oral treatment can significantly improve PFS compared to placebo in patients with thyroid cancer.<wbr> </div><div style="margin-bottom: 10px;">The SELECT study was a multicenter, randomized, double-blind, placebo-controlled Phase III study of 392 patients with progressive Radioiodine -refractory differentiated thyroid cancer.<wbr> In the study's primary endpoint of PFS, lenvatinib demonstrated a statistically significant extension in PFS compared to placebo (p&lt;0.<wbr>001；median PFS in the lenvatinib group: 18.<wbr>3 months, median PFS in the placebo group: 3.<wbr>6 months; Hazard Ratio (HR) 0.<wbr>21 [99% CI: 0.<wbr>14-0.<wbr>31]).<wbr> In addition, lenvatinib showed a statistically significant improvement in response rate (sum of complete and partial responses) compared to placebo (p&lt;0.<wbr>001; lenvatinib: 64.<wbr>8%, placebo: 1.<wbr>5%).<wbr> In particular, complete response was observed in 1.<wbr>5% (4 patients) of the lenvatinib group and zero in the placebo group.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10266_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The most common lenvatinib treatment-related adverse events of any grade, which occurred in more than 40% of patients in the lenvatinib group, were hypertension (67.<wbr>8%), diarrhea (59.<wbr>4%), fatigue or asthenia (59.<wbr>0%), decreased appetite (50.<wbr>2%), weight loss (46.<wbr>4%) and nausea (41.<wbr>0%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regulatory Status</STRONG> </div><div style="margin-bottom: 10px;">Eisai submitted regulatory applications for lenvatinib seeking approval for refractory thyroid cancer to health authorities firstly in Japan in June 2014, both the US and the EU in August 2014, and is filing subsequent applications in other countries worldwide.<wbr> </div><div style="margin-bottom: 10px;">Lenvatinib was granted Orphan Drug Designation for thyroid cancer by regulatory authorities in Japan, the United States and Europe.<wbr> In addition, lenvatinib was granted priority review status in the US and accelerated assessment in Europe.<wbr>Due to its priority review in theUS approval is expected in the coming months.<wbr> </div><div style="margin-bottom: 10px;">Differentiated thyroid cancer is the most common form of thyroid cancer and accounts for approximately 95% of all thyroid cancers.<wbr> Among differentiated thyroid cancers, some are radioiodine-refractory (RR-DTC) and cannot easily be cured with surgery and radioactive iodine treatment </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Eisai is conducting a global Phase III trial of lenvatinib in hepatocellular carcinoma and as well as Phase II studies of lenvatinib in several other tumor types such as renal cell carcinoma and non-small cell lung cancer.<wbr> </div><div>source <A href="http://www.wsj.com/articles/eisai-expects-new-cancer-drug-to-bring-in-1-billion-a-year-by-2020-1423735517">http:/<wbr>/<wbr>www.<wbr>wsj.<wbr>com/<wbr>articles/<wbr>eisai-expects-new-cancer-drug-to-bring-in-1-billion-a-year-by-2020-1423735517</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10269c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Eisai has announced today the FDA approval of its in-house developed Lenvima (lenvatinib mesylate) as a treatment for locally recurrent ore metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.<wbr> Lenvima was granted priority review status by the FDA and the approval comes in only six months from the submission of the NDA, in August 2014.<wbr> US is the first market where Lenvima has granted authorization.<wbr> </div><div>Source: Eisai website </div><span style="font-weight: bold; font-style: italic;"></span><a name="Oncology10345c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>During the CHMP meeting held on 23-26 March, the European Medicine Agency recommended Lenvima (lenvatinib) for approval and granted marketing authorization for the treatment of adults with progressive, locally, advanced or metastatic differentiated thyroid carcinoma, whose disease has progressed despite receiving radioactive iodine.<wbr> Lenvima was reviewed under EMA's accelerated assessment program being a drug that would significantly improve the treatment for this serious condition.<wbr>  The European approval arrives just over a month the US approval.<wbr> </div></div></div><a name="Oncology10314c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Eisai announced today that Lenvima has been launched in the US on February 26th as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.<wbr> The US is the first country in the world where Lenvima has been launched.<wbr> </div></div><a name="oncology10266attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10266_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(179,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10266">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-13T12:52:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-13T12:52:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Jevtana's Patent Is Being Challenged In US</title>
	<pubDate>2015-02-12T19:05:41+01:00</pubDate>
	<wp:post_id>6042</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sanofi's Jevtana's patent is being challenged by the announcement today by Breckenridge Pharmaceutical, Inc.<wbr> with its filing an ANDA with a Paragraph IV certification for cabazitaxel solution; IV (infusion) in 60 mg/<wbr>1.<wbr>5 mL (40 mg/<wbr>mL) strength.<wbr> On January 14, 2015, Sanofi filed a Paragraph IV lawsuit against Breckenridge in the United States District Court for the District of New Jersey.<wbr> Breckenridge filed its Paragraph IV ANDA on the first-possible submission date and expects to be entitled to 180-day exclusivity.<wbr> The progress of this event needs to be carefully monitored.<wbr> </div><div style="margin-bottom: 10px;">The ANDA was developed and will be manufactured by Breckenridge's partner, Natco Pharma Limited.<wbr> Nacto Pharm is an Indian generic company.<wbr> Breckenridge&rsquo;s latest patent challenge regarding cabazitaxel is a continuing part of its larger strategy to focus on injectable products.<wbr> Breckenridge&rsquo;s current injectable portfolio consists of oncology and general injectable products in liquid, lyophilized and pre-filled syringe forms.<wbr> </div><div>Source: Globaldata Feb 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10263">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-12T19:05:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-12T19:05:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Patent Challenges Put Pressure on Acorda's Share Price</title>
	<pubDate>2015-02-12T16:40:26+01:00</pubDate>
	<wp:post_id>6043</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acorda share price fell by 10% yesterday as another patent challenge to Ampyra was disclosed and filed as an IPR petition by the Coalition for Affodable Drugs Analysts are becoming more cautious about Ampyra's life-cycle outlook &amp; early stage pipeline, particularly as the company has encountered recent setbacks with a once-daily formulation, a formulation it plans to take into phIII trials for chronic post-stroke walking disorder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Ampyra is currently blocked by ODE and five Orange Book listed patents the first of which expire in mid.<wbr>2018.<wbr> ODE expires in January 2017.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Sales of Ampyra are growing but the pace of growth has slowed.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Whilst remaining confident about the patent challenge, Acorda is continuiing with the development of its pipeline which includes the phIII develompent of dalfampridine for chronic post-stroke walking difficulty following a postive PhII POC study.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="neurology7916attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(95 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(95,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7916_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(80,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7916">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-12T16:40:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-12T16:40:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revenues of Recordati Increased by 5% in 2014</title>
	<pubDate>2015-02-12T16:39:10+01:00</pubDate>
	<wp:post_id>6044</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revenue for 2014 increased by +4.<wbr>9% to €987.<wbr>4M (vs €941.<wbr>6M in 2013).<wbr> Corporate products including drug for rare diseases and OTC accounted for 51% and 17.<wbr>6% of revenue respectively.<wbr> Italy and France still drove revenues, with Spain and North Africa having performed the biggest growth vs the previous year (100% and 78.<wbr>5% respectively).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2242_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2242_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2242_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2242_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2242_1_ScreenCapture1.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2242">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-12T16:39:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-12T16:39:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NovaMedica Gets Russsian Rights for Three Line of OTC GI Products</title>
	<pubDate>2015-02-12T13:17:16+01:00</pubDate>
	<wp:post_id>6045</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to the PR, NovaMedica started last month the marketing of three Perrigo/<wbr>Omega Pharma's products, namely Benegast Reduflux (for the relief of heartburn and indigestion, Benegast Redugas (for the reduction of bloating) and Benegast Regulamine.<wbr> The company's GI portfolio include Aptalis' Panzytrate and Lacteol as well as VenterPharma's Lactest.<wbr> Established in 2012, NovaMedica strategy is to trigger innovations and bring companies and novel products to the Russian and Eurasian markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Established in 2012</LI>
<LI>Shareholders: Domain associates; Rusnano</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Management Team</STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2238_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2238_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="gastroenterology2238attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2238_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(65,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2238_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(106,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2238_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(124,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2238_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(170,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2238">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-12T13:17:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-12T13:17:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BioGaia's FY2014 and Q4 Results Show Double Digit Growth</title>
	<pubDate>2015-02-12T12:31:04+01:00</pubDate>
	<wp:post_id>6046</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: CEO outlined that the BioGaia brand is becoming increasingly established, particularly among paediatricians, as the safest and most effective probiotic on the market.<wbr> Net sales in this segment performed better than the adult one.<wbr> BioGaia has got a strong network of distribution partners such as Ferring and Nestlé in Iran (BioGaia ProTectis drops and chewable tablets and Nestlé Infant formula), and Achè in Brazil (ProVance chewable tablets; ColiKids drops and BioGaia ProTectis chewable tablets).<wbr> Of note, the future launches of ProDentis chewing gum which will position the company in the Dental Science segment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">For the FY2014, net sales amounted to SEK 481.<wbr>8 million (315.<wbr>9), an increase of SEK 165.<wbr>9 million (53%).<wbr> Net sales include license revenue of SEK 95.<wbr>4 million from Nestlé.<wbr> Excluding license revenue from Nestlé, net sales totalled SEK 386.<wbr>4 million, an increase of 22% (excluding foreign exchange effects, 18%).<wbr> </div><div style="margin-bottom: 10px;">Net sales in the Paediatrics Business Unit reached SEK 313.<wbr>7 million (238.<wbr>6), up by SEK 75.<wbr>1 million (31%).<wbr> </div><div style="margin-bottom: 10px;">Net sales in the Adult Health Business Unit amounted to SEK 69.<wbr>4 million (75.<wbr>6), a decrease of SEK 6.<wbr>2 million (-8%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Net sales reached SEK 121.<wbr>4 million (90.<wbr>2), an increase of SEK 31.<wbr>2 million (35%) (excluding foreign exchange effects, 28%).<wbr> </div><div style="margin-bottom: 10px;">Net sales in the Paediatrics Business Unit totalled SEK 97.<wbr>8 million (65.<wbr>6), an improvement of SEK 32.<wbr>2 million (49%).<wbr> </div><div>Net sales in the Adult Health Business Unit amounted to SEK 23.<wbr>0 million (24.<wbr>1), a decrease of SEK 1.<wbr>1 million (-4%).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2237">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-12T12:31:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-12T12:31:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gene Therapy Company Voyager Attracts Sanofi's Interest With A Proposed Up-Front of $100m For Its Early Stage Programs</title>
	<pubDate>2015-02-11T19:21:23+01:00</pubDate>
	<wp:post_id>6047</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sanofi embarks into the hot field of gene therapy with a $845m 
proposed partnership with Voyager Therapeutics.<wbr> Voyager will take the lead on 
programs for Parkinson's disease, Friedreich's ataxia and Huntington's 
disease as well as other CNS disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms </STRONG> </div><div style="margin-bottom: 10px;">Voyager is getting $65m in cash up-front together with $30m for an equity 
stake and "addtional in-kind contributions" in the deal.<wbr> Genzyme gets the option 
to lisence several programs following completion of an initial POC human trial 
but Voyager is retaining all US rights to its lead product programs in PD 
(VY-AADC01) which is in PhI and Friedreich's Ataxia (V~Y-FXN01).<wbr> Voyager 
will split US profits with Genzyme for its Huntington's disease program 
VY-HTT01.<wbr> </div><div style="margin-bottom: 10px;">Additionally, Voyager's lead ALS program with VY-SOD101 is not part of the 
collaboration.<wbr> Voyager retains W/<wbr>W rights to this program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Voyager Pipeline Status</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7915_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Background &amp; Interest In Gene Therapy</STRONG> </div><div style="margin-bottom: 10px;">Voyager received its initial backing from Third Rock Ventures and quickly 
focused on existing AAV technology to get started on its clinical 
programs.<wbr> </div><div style="margin-bottom: 10px;">In the last few months a number of companies have strengthened their 
gene therapy programs either through collaborations 
(Pfizer) or by backing their internal programs 
(Biogen-Idec).<wbr> </div><div>Source: <A href="http://www.voyagertherapeutics.com">www.<wbr>voyagertherapeutics.<wbr>com</A> </div><!-- Comment details --><a name="neurology7915attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7915_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(51,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7915">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T19:21:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T19:21:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Dendreon Can Be Valuable for Valeant</title>
	<pubDate>2015-02-11T18:30:22+01:00</pubDate>
	<wp:post_id>6048</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Dendreon Can Be Valuable for Valeant</span>&nbsp;<br><span style="font-size: 12px;">Valeant has reported that "in response to competing bids," it has raised its offer to $400 million in cash.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10257">...</a><br></div><div style="margin-bottom: 10px;">Valeant has apparently scooped up Dendreon and its prostate cancer immunotherapeutic Provenge for $400m in cash after no further qualified bids came forward by the Tuesday deadline.<wbr> A competing joint bid by United WorldMeds &amp; Deerfield Management, a New York based investment firm was made but the bid did not match that of Valeant's proposition.<wbr> Valeant will seek court approval on the 20th February and hopes to close the purchase by the end of the month.<wbr> </div><div>.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10262">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10238">View thread  Oncology10238: Dendreon Can Be Valuable for Valeant</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T18:30:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T18:30:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sangamo Reports Ambitious Goal for the Progress of its Huntington Program</title>
	<pubDate>2015-02-11T16:10:45+01:00</pubDate>
	<wp:post_id>6049</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results for 2014, the company outlined a busy end of 2014 and beginning of 2015 with its ZFP therapeutic pipeline for Huntington's disease.<wbr> Data of this program will be presented at the 10th Annual Huntington's Disease Therapeutics Conference (Feb.<wbr> 23-26 2015 in Palm Springs).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">CEO announced that Sangamo remains on track to file an IND at the end of 2015 or at the very beginning of 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>with Shire</U> </div><div style="margin-bottom: 10px;"><A href="http://investor.sangamo.com/releasedetail.cfm?ReleaseID=644499">http:/<wbr>/<wbr>investor.<wbr>sangamo.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=644499</A> </div><div style="margin-bottom: 10px;"><U>with CHDI</U> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=5658" class="defaultlink">Neurology5658: Collaboration Expands Sangamo's ZFP Therapeutics(R) for Huntington</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7914">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T16:10:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T16:10:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Reckitt Benckiser Guides 2015 Similar to 2014</title>
	<pubDate>2015-02-11T13:36:35+01:00</pubDate>
	<wp:post_id>6050</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The year ended with Q4 registring 5% like-for-like (LFL) growth, and 4% LFL growth for the FY14.<wbr> The FY performance was driven by a strong 11% LFL growth from RUMEA (Russia, Middle East and Africa).<wbr> The group has a confident outlook, announcing new medium-term cost savings, and strong cash returns for 2015.<wbr> According to Morgan Stanley analysts, RB remains well positioned to continue to pursue acquisitions – in line with its stated strategy of being a consolidator in the Consumer Health space.<wbr> Selected financial figures from Indivior (spun off from RB in December) are also provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Despite solid positions in opioid addiction, Indivior is essentially a one-product company facing increasing competition (tablets' generic, branded film), margin pressure and patent challenges.<wbr> </div><div style="margin-bottom: 10px;">The company posted a 8% fall, mainly due to: </div><div style="margin-bottom: 10px;">- Austerity pressures in Europe </div><div style="margin-bottom: 10px;">- The loss of patent exclusivity for the Suboxone opiate addiction drug in 2009 has gradually eorded market share </div><div style="margin-bottom: 10px;"><UL><LI>The U.<wbr>S.<wbr> market share for Suboxone Film, which is sold on prescription and administered orally, fell to 58% from 67% even though overall demand in the market.<wbr></LI>
<LI>The U.<wbr>S accounted for 78% of sales in 2013</LI>
</UL> </div><div style="margin-bottom: 10px;">- Management said new treatments under development would begin to generate revenue in 2016 /<wbr> 2017: </div><div style="margin-bottom: 10px;"><UL><LI>
Naloxone, an opioid overdose treatment administered nasally, is due to be launched in 2016.<wbr></LI>
<LI>An injectable form of the opiate addiction treatment is due to be launched in 2017.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Profit by Segment</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">RB targets savings from the 'supercharge' program of £100-150M with full impact by 2017, through a combination of organisational simplification (including moving from 3 to 2 reporting regions), reduction of indirect costs and optimising the manufacturing network, with the cost of the program at £200M over this period.<wbr> </div><div style="margin-bottom: 10px;">Management did not provide any details on the phasing of savings, but in 2015 this will partly go to enabling the stepped up 2014 margin profile to be sustainable.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Targets</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_5_ScreenCapture5.jpg"> </div><div>RB guides to LFL sales growth of 4% in 2015, with a moderate to 'nice EBIT margin improvement.<wbr> </div><!-- Comment details --><a name="gastroenterology2231attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(20,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(27,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(26,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(18 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(50,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2231_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(6,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2231">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T13:36:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T13:36:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cortendo Has High Expectations For Its Novel Ketoconazole Formulation In Cushings</title>
	<pubDate>2015-02-11T12:10:52+01:00</pubDate>
	<wp:post_id>6051</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cortendo's latest presentation highlights its strategic "Orphan Specialty Biopharm Model.<wbr> The differenitated profile of COR-003 (a single enantiomer formulation of ketoconazole) is addressed and the market potential for the product explained.<wbr> A market research survey undertaken by LEK is indicating a significant switch potential for COR-003 post launch (a switch from ketoconazole, Signifor, Korlym and carbergoline to COR-003) based on the drug's current TPP.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Proposed Business Model</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Cllinical Differentiation of COR-003 vs ketoconazole</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Ongoing Clinical Development Programme</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Treatment Algorithm &amp; Perceived Market Potential</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Company Calendar, Financial Position &amp; Company Valuation</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_7_ScreenCapture7.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="endocrinology7960attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(98,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(93,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(91 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(63 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(89,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(64,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(97,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(96,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(88,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(74,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(94,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7960_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(77,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7960">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T12:10:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T12:10:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nestlé Markets New Product with BioGaia's Probiotic</title>
	<pubDate>2015-02-11T11:59:28+01:00</pubDate>
	<wp:post_id>6052</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Since the end of 2014, Nestlé has started the launch of L.<wbr>reuteri Protectis (powder formula) for children &gt;1 year in emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">As scientific support for the new range of products are clinical studies, such as Pedro Gutierrez’ study published in 2014 in <EM><A href="http://pediatrics.aappublications.org/content/133/4/e904.short">Pediatrics</A></EM> showing that Lactobacillus reuteri Protectis could prevent infections in children older than one year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The collaboration gave Nestlé the exclusive rights to use BioGaia's patented probiotic strain Lactobacillus reuteri Protectis in an additional range of products.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.dairyreporter.com/Ingredients/BioGaia-Nestle-sign-new-probiotic-supply-and-licence-deal">http:/<wbr>/<wbr>www.<wbr>dairyreporter.<wbr>com/<wbr>Ingredients/<wbr>BioGaia-Nestle-sign-new-probiotic-supply-and-licence-deal</A> </div><div style="margin-bottom: 10px;"><A href="http://www.biogaia.com/press/biogaia-signs-agreement-nestl%C3%A9-new-category-products">http:/<wbr>/<wbr>www.<wbr>biogaia.<wbr>com/<wbr>press/<wbr>biogaia-signs-agreement-nestl%C3%A9-new-category-products</A> </div><div style="margin-bottom: 10px;">(<A href="http://www.biogaia.com/press/biogaia-enters-new-extended-agreement-nestl%C3%A9">http:/<wbr>/<wbr>www.<wbr>biogaia.<wbr>com/<wbr>press/<wbr>biogaia-enters-new-extended-agreement-nestl%C3%A9</A>) </div><div>Source: BioGaia </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2230">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T11:59:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T11:59:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Scottish Medicines Consortium Said "No" To J&J's Zytiga For Chemo Naive mCRPC Patients</title>
	<pubDate>2015-02-11T11:11:58+01:00</pubDate>
	<wp:post_id>6053</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Scottish Medicines Consortium (SMC) said this week it would not endorse the drug&rsquo;s use earlier in the treatment pathway despite the fact that patient groups and clinicians who participated in the process spoke strongly about the improved quality of life it offers men in the early stages of prostate cancer.<wbr> This decision is mainly due to the substantial cost (even after discount agreement under a patient access scheme) with lack of evidence to support overall benefits.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0px; font-family: Helvetica;">Zytiga is recommended as an option in Scotland for treating patients post chemotherapy, but the Committee felt there was &ldquo;insufficient evidence&rdquo; on the overall benefits of its use at an earlier stage.<wbr> Also, while a confidential discount to NHS Scotland under a Patient Access Scheme has been agreed, the drug&rsquo;s cost is &ldquo;still substantial,&rdquo; the SMC said.<wbr> The Institute of Cancer Research (ICR) is calling on the Scottish Medicines Consortium to reconsider its decision to bar patients with prostate cancer from access to Janssen&rsquo;s <STRONG>Zytiga</STRONG> (abiraterone) before they have had chemotherapy.<wbr> The ICR argues that the SMC appraisal itself acknowledges data showing that the drug extends life by an average of more than four months when given before chemotherapy, but failed to include these findings in the cost analysis.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px; font-family: Helvetica;">Janssen said it is disappointed with the decision, which echos a rejection by the National Institute for Health and Care Excellence in August last year, but said it would work closely with the SMC in the hope of agreeing a way to make Zytiga routinely available in Scotland for pre-chemo patients.<wbr></P> </div><div><P style="margin: 0px; font-family: Helvetica;">Source: Scottish Medicines Consortium Advice (<a href="https://www.scottishmedicines.org.uk/SMC_Advice/Advice/873_13_abiraterone_Zytiga/abiraterone_Zytiga" class="defaultlink" title="https://www.scottishmedicines.org.uk/SMC_Advice/Advice/873_13_abiraterone_Zytiga/abiraterone_Zytiga">scottishmedicines&hellip;</a>)</P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10396c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Following the earning release yesterday, Janssen UK also made the press release statement in response to the Scottish Medicines Consortium's (SMC) decision not to recommend the use of Zytiga&reg; (abiraterone acetate) before chemotherapy for men with advanced prostate cancer in Scotland.<wbr> Janssen has requested an Independent Review Panel for the decision.<wbr> (Source: J&amp;J Press Release) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10261">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T11:11:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T11:11:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Improvement of Abdominal Pain/Discomfort with S. cerevisiae CNCM I-3856 in IBS Patients</title>
	<pubDate>2015-02-11T10:58:43+01:00</pubDate>
	<wp:post_id>6054</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Given the preclinical evidence of the analgesic effect of CNCM I-3856 in the gut, the aim of this study was to investigate whether oral administration of CNCM I-3856 is effective in alleviating IBS symptoms.<wbr> The 13-week single-centre double-blind placebo-controlled clinical study, sponsored by Lesaffre International, randomized 2 parallel groups of 100 IBS patients.<wbr> Recruitment was monitored in one investigative site at Biofortis, in Nantes (France).<wbr> Authors conclude that Saccharomyces cerevisiae may be a new promising candidate for improving abdominal pain in subjects with irritable bowel syndrome (IBS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="https://clinicaltrials.gov/ct2/show/NCT01613456?term=Saccharomyces+cerevisiae&amp;rank=3&amp;submit_fld_opt=">NCT01613456</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2228_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key Results</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2228_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.sciencedirect.com/science/article/pii/S1590865814007920">http:/<wbr>/<wbr>www.<wbr>sciencedirect.<wbr>com/<wbr>science/<wbr>article/<wbr>pii/<wbr>S1590865814007920</A> -  </div><div style="margin-bottom: 10px;"><P class="smh5">Guillaume Pineton de Chambrun<A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0005" id="baff0005" title="Affiliation: a"><SUP>a</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0010" id="baff0010" title="Affiliation: b"><SUP>b</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0015" id="baff0015" title="Affiliation: c"><SUP>c</SUP></A>, Christel Neut<A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0010" id="baff0010" title="Affiliation: b"><SUP>b</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0015" id="baff0015" title="Affiliation: c"><SUP>c</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0020" id="baff0020" title="Affiliation: d"><SUP>d</SUP></A>, Amélie Chau<A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0010" id="baff0010" title="Affiliation: b"><SUP>b</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0015" id="baff0015" title="Affiliation: c"><SUP>c</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0025" id="baff0025" title="Affiliation: e"><SUP>e</SUP></A>, Murielle Cazaubiel<A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0030" id="baff0030" title="Affiliation: f"><SUP>f</SUP></A>, Fanny Pelerin<A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0035" id="baff0035" title="Affiliation: g"><SUP>g</SUP></A>, Peter Justen<A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0035" id="baff0035" title="Affiliation: g"><SUP>g</SUP></A>, Pierre Desreumaux<A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0005" id="baff0005" title="Affiliation: a"><SUP>a</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0010" id="baff0010" title="Affiliation: b"><SUP>b</SUP></A><SUP>, </SUP><A class="intra_ref auth_aff" href="http://www.sciencedirect.com/science/article/pii/S1590865814007920#aff0015" id="baff0015" title="Affiliation: c"><SUP>c</SUP></A><SUP>,</SUP></P> </div><div><UL class="authorGroup noCollab svAuthor" style="DISPLAY: block"><LI class="smh5plus" id="aff0005"><SUP>a</SUP> CHU Lille, Department of Gastroenterology, Claude Huriez Hospital, Lille, France</LI>
<LI class="smh5plus" id="aff0010"><SUP>b</SUP> Lille University North of France, Lille, France</LI>
<LI class="smh5plus" id="aff0015"><SUP>c</SUP> INSERM U995, Lille, France</LI>
<LI class="smh5plus" id="aff0020"><SUP>d</SUP> Department of Microbiology, Faculty of Pharmacy, University of Lille, France</LI>
<LI class="smh5plus" id="aff0025"><SUP>e</SUP> CHU Lille, Department of Surgery, Claude Huriez Hospital, Lille, France</LI>
<LI class="smh5plus" id="aff0030"><SUP>f</SUP> Biofortis-Mérieux NutriSciences, Nantes, France</LI>
<LI class="smh5plus" id="aff0035"><SUP>g</SUP> Lesaffre International, Lesaffre Human Care, France</LI>
</UL> </div><!-- Comment details --><a name="gastroenterology2228attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2228_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2228_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2228_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(22,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2228">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-11T10:58:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-11T10:58:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Topline Results from Ph1b Show SYN-004 Protects the Microbiome and Prevents C.difficile Infections</title>
	<pubDate>2015-02-10T18:39:04+01:00</pubDate>
	<wp:post_id>6055</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Synthetic Biologics plans to initiate Ph2a studies in Q1:15 to further evaluate the prophylactic approach to preventing <I>C.<wbr> difficile</I> infection by protecting the gut microbiome from the collateral damage caused by antibiotics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2227_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2227_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The randomized, double-blind, placebo-controlled Phase 1b study was designed to further evaluate the safety, tolerability and pharmacokinetics of escalating doses of oral SYN-004 in healthy adult volunteers.<wbr> </div><div style="margin-bottom: 10px;">In all, the study enrolled 24 healthy adult volunteers in three cohorts, with six participants in each cohort receiving increasing doses of SYN-004 up to four times a day over a seven-day period and two participants in each cohort receiving placebo </div><div><STRONG>Results from Ph1a </STRONG>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2166" class="defaultlink">GastroEnterology2166: Synthetic Biologics's C.<wbr>difficile Drug Sets to Enter Ph2 Testing in Q1:15</a> </div><!-- Comment details --><a name="gastroenterology2227attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2227_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2227_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(50,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2227_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(68,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2227">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-10T18:39:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-10T18:39:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biomarker Research Study of Radium-223 Chloride for mCRPC</title>
	<pubDate>2015-02-10T18:21:51+01:00</pubDate>
	<wp:post_id>6056</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This Ph2 study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard testing in an attempt to gain insight about how the drug works and how best to track patients who are receiving the drug.<wbr> PE will be assessing change from baseline in bone scan index at 2 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="https://clinicaltrials.gov/ct2/show/NCT02346526?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=01%2F10%2F2015&amp;rank=187">NCT02346526</A> </div><div style="margin-bottom: 10px;">Timelines From January 2015 to January 2021 </div><div style="margin-bottom: 10px;">Recruitment Approx 22 </div><div>PI: Philip J Saylor, MD Massachusetts General Hosp.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10260">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-10T18:21:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-10T18:21:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis Refines Its Dermatology Business With The Sale Of Acne Drug</title>
	<pubDate>2015-02-10T13:50:43+01:00</pubDate>
	<wp:post_id>6057</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As part of a restructuring programme pre the closure of the Allergan 
deeal, Actavis has sold its US risht to its acne treatment Doryx and other 
assets related to the acne brand to Mayne Pharma in a deal worth $50.<wbr> The deal 
follows closely on the back of divestiture of its respiratory business to 
AstraZeneca for $600m earlier this month.<wbr> </div><div style="margin-bottom: 10px;">Actavis currently holds the license for the distribution of Doryx in the US 
under a partnership between Warner Chilcott Plc which was acquired by Actavis in 
2013, and Mayne Pharma Group Ltd, an Australian specialty pharmaceutical.<wbr> The 
company agreed to hand over the US rights for Doryx to Mayne, before the 
partnership ends this year.<wbr> </div><div style="margin-bottom: 10px;">As per the deal, Actavis will be packaging, distributing, and promoting the 
brand until May 2, after which Mayne Pharma will establish its <STRONG>own US 
specialty brands unit</STRONG> for its commercial operations.<wbr> Mayne’s US 
specialty brands division will have a staff of 66 employees including Andy 
McClenaghan, the former vice president of Warner Chilcott’s US commercial 
operations.<wbr> </div><div>Source: <A href="http://www.actavis.com">www.<wbr>actavis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7913">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-10T13:50:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-10T13:50:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chiasma Publishes Phase III Study For Oral Octreotide</title>
	<pubDate>2015-02-10T09:55:25+01:00</pubDate>
	<wp:post_id>6058</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chiasma has published the results of a multicenter Phase III trial for oral octreotide in acromegaly ahead of print on the Journal of Clinical Endocrinology &amp; Metabolism (JCEM).<wbr> Based on these results, Chiasma intends to submit a NDA to the FDA later this year.<wbr> If approved, octreotide capsules would be the first oral somatostatin analog, and would give people with acromegaly an alternative to chronic injections, the current standard treatment for this lifelong disease.<wbr> </div><div style="margin-bottom: 10px;">The <a href="http://press.endocrine.org/doi/10.1210/jc.2014-4113" class="defaultlink">data published,</a> confirmed previous presented data (ECE 2014), when Chiasma was still collaborating with Roche on the development of this novel formulation.<wbr> </div><div style="margin-bottom: 10px;">155 patients were evaluated for biochemical and asymptomatic disease control over 13 months period following treatment with octreotide capsules, twice a day dose (morning and evening administration, &gt;1h before meal and &gt;2h after meal).<wbr> </div><div style="margin-bottom: 10px;">Result showed: </div><div style="margin-bottom: 10px;"><UL><LI>62% of patients achieved disease control at the end of treatment.<wbr>
</LI>
<LI>85% of responders, at the end of the dose-titration phase, had sustained response up to 13 months.<wbr>
</LI>
<LI>80% of patients who entered the fixed-dose phase, improved or maintained their acromegaly symptoms (54% improved, 26% maintained), at the end of treatment.<wbr>
</LI>
<LI>86% who completed the core treatment period of seven months opted to participate in the voluntary six-month extension phase and continued using octreotide capsules.<wbr>
</LI>
<LI>89% of patients experienced an adverse event (AE); 92% of the events were mild to moderate.<wbr> The most common AEs were reported in the gastrointestinal system, nervous system, and musculoskeletal system, consistent with the known safety profile of octreotide and the disease burden of acromegaly, with no AEs related to the oral route of administration.<wbr> The majority of the gastrointestinal AEs reported in the study were mild to moderate, occurring within the first two months of treatment and resolved on treatment (median duration 13 days).<wbr>
</LI>
<LI>23 patients (14.<wbr>8%) discontinued treatment due to AEs.<wbr> Of these, 16 (69.<wbr>6%) discontinued during the dose-titration phase.<wbr> The most common AEs leading to discontinuation of the study drug were gastrointestinal symptoms, including nausea, diarrhea and abdominal pain.<wbr> The incidence of AEs significantly decreased from the dose-titration phase to the fixed-dose phase and continued to decrease as exposure increased up to 13 months.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Please find <a href="https://ipsengroup.sharepoint.com/sites/root20/MyEndoCommunity/SitePages/Market%20environment/War%20Games.aspx?RootFolder=%2Fsites%2Froot20%2FMyEndoCommunity%2FWar%20games%20Documents%2Fwargame%20Octreolin&FolderCTID=0x012000E475C893C0FD4640B28FEA2CD9844D0A&View=%7BDA820965-C847-4410-9669-359B61D3B6C3%7D" class="defaultlink">here</a> (MyEndoCommunity on SharePoint) more info on a wargame Ipsen carried out last year to weight the threat that oral octreotide would represent.<wbr> </div><div>Source: FirstWordPharma, PS Newswire, JCEM </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7956">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-10T09:55:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-10T09:55:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lallemand Health Solutions' Researchers Presented New Findings During Probiota Conference</title>
	<pubDate>2015-02-09T18:13:47+01:00</pubDate>
	<wp:post_id>6059</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr P.<wbr> Burguière presented a new method of quantifying probiotic content in products, and DR C.<wbr> MacPherson showed how a DNA micro-array was helping understand differing mechanisms of actions in different strains.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Application of Flow Cytometry for specific quantification and viability assessment of probiotic bacteria in multi-strain products - Camille Chiron, Thomas A.<wbr> Tompkins and Pierre Burguière </div><div style="margin-bottom: 10px;">See <A href="http://www.probiotaevent.com/page.cfm/link=64">http:/<wbr>/<wbr>www.<wbr>probiotaevent.<wbr>com/<wbr>page.<wbr>cfm/<wbr>link=64</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Dr MacPharson said that "immune pathways are diverse and complex, and we have spent several years fine-tuning a specific DNA microaarray to this aim".<wbr> </div><div>See <A href="http://aem.asm.org/content/80/5/1692.full">http:/<wbr>/<wbr>aem.<wbr>asm.<wbr>org/<wbr>content/<wbr>80/<wbr>5/<wbr>1692.<wbr>full</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2225">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-09T18:13:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-09T18:13:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK's Announcement Of Its Postive Result Generates Confidence For Its Shareholders</title>
	<pubDate>2015-02-09T12:19:58+01:00</pubDate>
	<wp:post_id>6060</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK and Novartis' transcaction last year was one of the biggest headlines within pharmaceutical industry, and the objectives for the 3 part transcactions with Novartis were to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders.<wbr> GSK annouced the positive results for the COMBI-d (GSK's BRAF and MEK inhibitor combination) that is an important breakthrough as it establishes the importance of the combined treatment impact on metastatic melanoma patients compared to a monotherapy, and in analysts' view "this reflects no additional risks to GSK's performance".<wbr> This positive milestone will prompt $1.<wbr>5 billion payment from Novartis as part of the agreement from the trasactions.<wbr> GlaxoSmithKline Plc shares rose to the highest in six months.<wbr> In parallel, this will trigger the final decision on Novartis to return its Binimetinib (MEK inhibitor) worldwide right back to Array.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="text-decoration: underline;">GSK and Novartis Transection</SPAN></STRONG> </div><div style="margin-bottom: 10px;">The Ph3 Combi-d trial success will yield a $1.<wbr>5 billion payout from Novartis, on top of the $14.<wbr>5 billion the company agreed to pay for GSK Oncology business and results will be submitted to regulators for approval in the coming months.<wbr>Glaxo rose as much as 2.<wbr>1 percent and was up 1.<wbr>5 percent at 1,524 pence as of 10:36 a.<wbr>m.<wbr> in London, the third-biggest increase among stocks on the FTSE 100 Index.<wbr> Novartis rose 0.<wbr>8 percent to 90.<wbr>80 Swiss francs in Zurich.<wbr> </div><div style="margin-bottom: 10px;">The 3-part inter-conditional transaction with Novartis AG involves GSK's Consumer Healthcare, Vaccines and Oncology businesses (the "Transaction").<wbr> In summary: </div><div style="margin-bottom: 10px;"><UL><LI>GSK and Novartis will create a new world-leading Consumer Healthcare business with 2013 pro forma revenues of &pound;6.<wbr>5 billion.<wbr> GSK will have majority control with an equity interest of 63.<wbr>5%
</LI>
<LI>GSK will acquire Novartis' global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.<wbr>25 billion with subsequent potential milestone payments of up to $1.<wbr>8 billion and ongoing royalties
</LI>
<LI>GSK will divest its marketed Oncology portfolio, related R&amp;D activities and rights to its AKT inhibitor and also grant of commercialisation partner rights for future oncology products to Novartis for an aggregate cash consideration of $16 billion (of which up to $1.<wbr>5 billion depends on the results of the COMBI-d trial)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Novartis and Array Licnesing Deal</STRONG> </SPAN> </div><div style="margin-bottom: 10px;">Array BioPharma reached a definitive agreement with Novartis in Dec 2014 to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials.<wbr> This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval.<wbr> Array had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be superseded by a new set of agreements between the parties.<wbr> Binimetinib is currently advancing in three Phase 3 clinical trials and, we expect to file for our first regulatory approval during the first half of 2016.<wbr> </div><div style="margin-bottom: 10px;">Upon deal close, Array will receive up to $85 million and Novartis' global, exclusive license to binimetinib will terminate with all rights reverting to Array.<wbr> Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign to Array patent and other intellectual property rights it owns to the extent relating to binimetinib.<wbr> All clinical trials involving binimetinib, including the COLUMBUS, NEMO and MILO pivotal trials, will continue to be conducted as currently contemplated.<wbr> </div><div style="margin-bottom: 10px;">Novartis will be responsible for continued conduct and funding of the COLUMBUS trial.<wbr> This obligation will transfer to any future owner of LGX818 (encorafenib).<wbr> Following deal close, Novartis will reimburse Array for all remaining out-of-pocket expenses and half of all remaining fully-burdened full time equivalent (FTE) costs associated with MILO, which Array will continue to conduct.<wbr> For NEMO and all other ongoing and planned clinical trials, Novartis will conduct and solely fund each trial, until a mutually agreed-upon transition date to Array.<wbr> Following this transition, Novartis will reimburse Array for all remaining out-of-pocket expenses and half of all remaining fully-burdened FTE costs required to complete these studies.<wbr> </div><div style="margin-bottom: 10px;">Novartis will remain responsible for conducting and funding development of the NRAS melanoma companion diagnostic until Premarket Approval is received from the U.<wbr>S.<wbr> Food and Drug Administration.<wbr> Following approval, Novartis will transfer the product and Premarket Approval to a diagnostic vendor of Array's designation.<wbr> </div><div>Source: Array Press Release, GSK Press Release </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11094">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-09T12:19:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-09T12:19:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMTTS Effective in the Protection and Delivery of Lactobacillus acidophilus</title>
	<pubDate>2015-02-09T10:57:49+01:00</pubDate>
	<wp:post_id>6061</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Recently published in the <EM>Journal of Pharmacy and Pharmacology</EM>, the study focuses on the use of gastro-resistant denatured ovalbumin for the targeted delivery of <EM>L</EM><EM>actobacillus acidophilus</EM> to simulated human intestinal and colon conditions through a bi-layered mini-tablet-in-tablet system (BMTTS).<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><DIV class="section" id="jphp12389-sec-0002">
<DIV class="para">
<P></P></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="section" id="jphp12389-sec-0003">
<H4></H4>
<DIV class="para">
<P></P></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="section" id="jphp12389-sec-0004">
<H4></H4>
<DIV class="para">
<P></P></DIV></DIV> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><DIV id="articleTitle">
<H1 class="articleTitle"></H1></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2223">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-09T10:57:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-09T10:57:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Simcere Takes Full Control of its JV with Merck</title>
	<pubDate>2015-02-09T10:23:31+01:00</pubDate>
	<wp:post_id>6062</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Estalished in 2011, the JV initially focused on cardiovascular and metabolic diseases.<wbr> Simcere stated today that the JV will remain an independent business unit in the future.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Estblished in July 2011, the JV focused on a combined portfolio of medicines from both companies.<wbr> <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=9440" class="defaultlink">PharmaWorld9440: Merck's Affiliate and Simcere Establish Strategic JV in China</a> </div><div style="margin-bottom: 10px;">In August 2013, Simcere went private.<wbr> <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=10585" class="defaultlink">PharmaWorld10585: China's Simcere To Be Taken Private</a> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Simcere have montmorillonite mine in Sichuan China.<wbr> </div><div>The API materials and preparations of Montmorillonite are both successfully passed and received EU GMP certification.<wbr> Each year, Simcere sold more than 20 million boxes of montmorillonite preparation (<EM>source: Simcere</EM>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2222">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-09T10:23:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-09T10:23:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: J&J's Indirect Effort To Overcome Market Access Hurdle In UK For Abiraterone In Chemo Naive mCRPC</title>
	<pubDate>2015-02-06T19:18:01+01:00</pubDate>
	<wp:post_id>6063</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">J&J's Indirect Effort To Overcome Market Access Hurdle In UK For Abiraterone In Chemo Naive mCRPC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Zytiga has been struggling to get a positive nod from NICE for its use in chemo na&iuml;ve metastatic castration resistant prostate cancer.<wbr> Currently NICE is re-considering the appeal that J&amp;J submitted last year and the appraisal process is currently ongoing following the final analysis demonstrated Zytiga provides overall survival benefit in the chemo na&iuml;ve setting.<wbr> Today BBC reported a story to advocate abiraterone's "striking" benefit in chemo na&iuml;ve setting and this is likely to be J&amp;J's indirect effort via patient advocacy group to influence UK payer's decision.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10256">...</a><br></div><div>The second study referred to the new results published in <EM>Clinical Cancer Research</EM>, shows it is possible to identify a subgroup of men with very aggressive prostate cancer who may benefit particularly strikingly from abiraterone pre chemotherapy.<wbr> These data represent a subgroup of patients with a very aggressive form of prostate cancer may benefit the most from treatment with abiraterone from COU-AA-302 trial.<wbr>.<wbr>The researchers cross-referenced data on how well 348 men on the trial responded to either abiraterone or a placebo &acirc;&euro;&ldquo; as defined by a halt in the progress in their cancer &acirc;&euro;&ldquo; with a detailed genetic analysis of their tumours.<wbr> They looked in particular at whether changes to a gene called <EM>ERG</EM>, which are often associated with faster cancer progression, correlated with abiraterone response.<wbr> They found a clear link between major <EM>ERG</EM> mutations and response to abiraterone.<wbr> Although abiraterone improved survival generally regardless of <EM>ERG</EM> mutations, a subset of patients with the most pronounced mutations to the gene &acirc;&euro;&ldquo; accounting for 15 per cent of the men studied &acirc;&euro;&ldquo; responded particularly well.<wbr> These men lived for an average of 22 months without their disease progressing, compared with 5.<wbr>4 months for men with the same <EM>ERG</EM>status who received a placebo.<wbr> Source: Attard et al.<wbr> CCO Jan 2015 (the full text is availabile in PEARL <A href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare?Format_document=1&amp;Mouvement=871717&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc1=2964872">http:/<wbr>/<wbr>cis12103:8080/<wbr>qesipsen/<wbr>servlet/<wbr>QESServlet_prepare?Format_document=1&amp;Mouvement=871717&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc1=2964872</A>) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10259">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10256">View thread  Oncology10256: J&J's Indirect Effort To Overcome Market Access Hurdle In UK For Abiraterone In Chemo Naive mCRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-06T19:18:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-06T19:18:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Divests Dental Business</title>
	<pubDate>2015-02-06T16:42:00+01:00</pubDate>
	<wp:post_id>6064</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merz Pharma has entered an agreement with the Japanese dental materials and equipment manufacturer SHOFU.<wbr> This deal reflects Merz clear focus of its activities in the areas of Aesthetics, Neurotoxins and regional products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial terms not disclosed </div><div style="margin-bottom: 10px;">SHOFU aims to leverage this acquisition to strengthen its German market presence.<wbr> To achieve that, the company considers it important to maintain and heighten the autonomy of Merz Dental.<wbr> The head office will be kept in Lütjenburg, and Friedhelm Klingenburg will be staying on as CEO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- entity based in Lütjenburg, near Kiel in Northern Germany </div><div style="margin-bottom: 10px;">- in German-speaking countries, Merz Dental is one of the market leaders in its business </div><div style="margin-bottom: 10px;">- workforce of slightly under 200 </div><div style="margin-bottom: 10px;">- objective: supplier to dentists and dental technicians </div><div>Source: Merz </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7912">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-06T16:42:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-06T16:42:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer Call with Investors Puts Acquisition of Hospira in Context</title>
	<pubDate>2015-02-06T14:18:22+01:00</pubDate>
	<wp:post_id>6065</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Participants included 15 investors and a pannel of 5 Pfizer's senior executive managers.<wbr> Management said that the deal, which represents ~8% of Pfizer's market cap, brings together Pfizer's GEP's portfolio of leading branded off-patent with Hospira's leading generic sterile injectables business, and will definitely boost the GEP business.<wbr> The combination will make the GEP segment a more attractive play for investors should Pfizer eventually spin it off or sell it, a decision expected end of 2017.<wbr> It was outlined that Hospira biosimilars adds significant marketed recombinant proteins, an attractive biosimilars pipeline, and broad commercialization experience in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7954_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Generic Sterile Injectables - Large and Growing Segment</STRONG> </div><div style="margin-bottom: 10px;">Pfizer said the $37 billion global market for sterile injectables in 2013 will double to $70 billion by 2020.<wbr> Such products include cancer drugs delivered by infusion pump, intravenous medicines, pre-filled syringes, bags and vials used by hospitals.<wbr> </div><div style="margin-bottom: 10px;">They are harder, and more expensive, to manufacture with the proper quality controls than traditional pills, and the number of companies that specialize in their production has dropped dramatically in recent years due to a wave of consolidation among generics companies.<wbr> </div><div style="margin-bottom: 10px;">Hospira had a series of quality control problems beginning in 2010 at its plant in North Carolina and later facilities in India and elsewhere, since fixed, as well as several product recalls, contributing to shortages.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7954_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Biosimilars - Attractive Growth Opportunity</STRONG> </div><div style="margin-bottom: 10px;">J young reported: " .<wbr>.<wbr>.<wbr> <A class="link" id="L110">we see the emerging biosimilars marketplace as being an extremely attractive market in terms of size and potential.<wbr></A><A class="link" id="L111"> As I mentioned again in my comments, Jami, we are seeing certainly regulators becoming clearer on the regulatory pathway and also IP considerations also becoming clearer.<wbr><BR><BR></A><A class="link" id="L112">We are excited by Hospira's significant marketed and pipeline biosimilars portfolio, because it will complement Pfizer's evolving biosimilars portfolio and our world-class development capabilities.<wbr></A><A class="link" id="L113"> Obviously we will work closely with regulators in their review in order to obtain the necessary approvals going forward</A>".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7954_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7954_1_ScreenCapture1.jpg"> </div><div>I Read's conclusion outlined that : " .<wbr>.<wbr>.<wbr> this deal will make us a top-tier player with leading positions in highly attractive and growing market segments.<wbr> It will add durable growth opportunities to our business over the long term.<wbr> It will accelerate the growth trajectory of the Global Established Pharma business and will provide a strong element of robustness to its portfolio.<wbr> It brings to us additional expertise and talent in key areas and it has compelling financial impact which we believe will result in shareholder value creation".<wbr> </div><!-- Comment details --><a name="endocrinology7954attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7954_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(99,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7954_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(65,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7954_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7954">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-06T14:18:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-06T14:18:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novartis and U. North Carolina to Assess Combination of Everolimus and Pasireotide LAR for 1st-line HCC</title>
	<pubDate>2015-02-06T12:55:05+01:00</pubDate>
	<wp:post_id>6066</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis and U.<wbr> North Carolina to Assess Combination of Everolimus and Pasireotide LAR for 1st-line HCC</span>&nbsp;<br><span style="font-size: 12px;">Comment: The purpose of this Phase 2 trial is to estimate the time to disease progression when the drugs are given together in patients with advanced or metastatic HCC (stage III; stage IV).<wbr> Should this regimen demonstrate efficacy, this will support a Phase 3 RCT of this combination therapy.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=7965">...</a><br></div><div style="margin-bottom: 10px;">Despite promising early efficacy signals, researchers found no benefit for the combination of everolimus and pasireotide in HCC (Invest New Drugs.<wbr> 2015 Jan 23.<wbr> [Epub ahead of print].<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results</STRONG> </div><div style="margin-bottom: 10px;">After 24 patients were enrolled, results of a randomized trial showing no benefit of everolimus in HCC were released prompting an unplanned interim analysis that found the conditional probability of rejecting the null hypothesis based on events in those patients was 0.<wbr>08.<wbr> </div><div style="margin-bottom: 10px;">Therefore accrual was halted.<wbr> </div><div style="margin-bottom: 10px;">Patients had a median age of 59 years, 21 (88 %) had BCLC stage C cancer, and 11 (46 %) metastatic disease.<wbr> Median TTP was 3.<wbr>5 months (95 % CI 2-5.<wbr>8) and median survival 6.<wbr>7 months (95 % CI 6-infinity).<wbr> Best response was stable disease in ten patients.<wbr> Grade 3 hyperglycemia occurred in 6 (25 %).<wbr> There were no grade 4 treatment-emergent events.<wbr> </div><div>Source: <A href="http://rd.springer.com/article/10.1007%2Fs10637-015-0209-7">http:/<wbr>/<wbr>rd.<wbr>springer.<wbr>com/<wbr>article/<wbr>10.<wbr>1007%2Fs10637-015-0209-7</A> Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.<wbr> Sanoff HK<SUP>1</SUP>, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10258">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology7965">View thread  Oncology7965: Novartis and U.<wbr> North Carolina to Assess Combination of Everolimus and Pasireotide LAR for 1st-line HCC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-06T12:55:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-06T12:55:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Dendreon Can Be Valuable for Valeant</title>
	<pubDate>2015-02-06T12:37:02+01:00</pubDate>
	<wp:post_id>6067</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Dendreon Can Be Valuable for Valeant</span>&nbsp;<br><span style="font-size: 12px;">Comment: Valeant 'stalking horse' deal announced today is subject to higher and better bid.<wbr> Assuming additional qualified bids are submitted, an auction would be held on Feb.<wbr> 12.<wbr> BMO Capital sees the deal attractive and valuable for Valeant, who wants to pay $296MM to buy a cancer drug with $300M in sales (2014), $66M of raw materials inventory, and property and equipment worth about $108M.<wbr> Key points from the analyst report are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10238">...</a><br></div><div style="margin-bottom: 10px;">Valeant has reported that "in response to competing bids," it has raised its offer to $400 million in cash.<wbr> </div><div style="margin-bottom: 10px;">Competitors have not been disclosed so far.<wbr> </div><div>The deadline for parties to submit bids is February 10, with an auction to be held on February 12 if Dendreon receives other offers.<wbr> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10262c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Valeant has apparently scooped up Dendreon and its prostate cancer immunotherapeutic Provenge for $400m in cash after no further qualified bids came forward by the Tuesday deadline.<wbr> A competing joint bid by United WorldMeds &amp; Deerfield Management, a New York based investment firm was made but the bid did not match that of Valeant's proposition.<wbr> Valeant will seek court approval on the 20th February and hopes to close the purchase by the end of the month.<wbr> </div><div>.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10257">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10238">View thread  Oncology10238: Dendreon Can Be Valuable for Valeant</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-06T12:37:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-06T12:37:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's Indirect Effort To Overcome Market Access Hurdle In UK For Abiraterone In Chemo Naive mCRPC</title>
	<pubDate>2015-02-05T19:21:03+01:00</pubDate>
	<wp:post_id>6068</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Zytiga has been struggling to get a positive nod from NICE for its use in chemo na&iuml;ve metastatic castration resistant prostate cancer.<wbr> Currently NICE is re-considering the appeal that J&amp;J submitted last year and the appraisal process is currently ongoing following the final analysis demonstrated Zytiga provides overall survival benefit in the chemo na&iuml;ve setting.<wbr> Today BBC reported a story to advocate abiraterone's "striking" benefit in chemo na&iuml;ve setting and this is likely to be J&amp;J's indirect effort via patient advocacy group to influence UK payer's decision.<wbr> </div><div style="margin-bottom: 10px;">The full story is below : </div><div style="margin-bottom: 10px;"><P class="introduction" id="story_continues_1">The drug abiraterone can add four months to the lives of men with advanced prostate cancer if given before chemotherapy, evidence suggests.<wbr> Currently given to NHS patients after chemotherapy, the drugs regulator had rejected expanding its use, partly over questions about survival.<wbr> Charities say the medicine should now be given to all patients who need it.<wbr> The Institute of Cancer Research said the drug might be more beneficial for patients with very aggressive cancer.<wbr></P> </div><div style="margin-bottom: 10px;"><DIV class="story-feature narrow">
<H2 class="quote"><SPAN style="font-size: small;"><EM>&ldquo;The latest trial evidence strengthens the already powerful case for it to be accepted for NHS use earlier in the course of treatment&rdquo; Prof Paul Workman Institute of Cancer Research</EM></SPAN></H2>
</DIV> </div><div style="margin-bottom: 10px;">Last year the National Institutes of Health and Care Excellence (NICE) rejected its use before chemotherapy.<wbr> A previous analysis had suggested it could slow cancer progression, but did not lengthen people's lives.<wbr> But now, a study, published in Lancet Oncology, suggests it can add an average of four months.<wbr>A second piece of research, published in Clinical Cancer Research, suggests doctors could use a genetic test to identify people with a particularly aggressive form of prostate cancer.<wbr> The study found men with this form of cancer had an extra 17 months of life when given abiraterone compared with those given a dummy pill.<wbr> Prof Paul Workman, chief executive of the Institute of Cancer Research, said: "Abiraterone has already transformed care for patients with advanced prostate cancer, but the latest trial evidence strengthens the already powerful case for it to be accepted for NHS use earlier in the course of treatment.<wbr>"Not only do the overall results find that abiraterone significantly extends lives when used before chemotherapy, but the second study shows it is possible to pick out a subgroup of men who benefit especially strikingly.<wbr>" Owen Sharp, chief executive of charity Prostate Cancer UK, said: "This data further confirms the huge benefits of abiraterone for men with incurable prostate cancer who haven't yet received chemotherapy.<wbr>"We want to see this additional evidence swiftly lead to this use of abiraterone being routinely available for all men who need it in the UK.<wbr>" Following an appeal last year, NICE began to relook at decisions regarding this drug.<wbr> The regulator says this appraisal is ongoing.<wbr> </div><div>Source: <a href="http://www.bbc.co.uk/news/health-31146920" class="defaultlink">BBC,</a> Ipsen's Public Affairs (Jan Swiderski) </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10259c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The second study referred to the new results published in <EM>Clinical Cancer Research</EM>, shows it is possible to identify a subgroup of men with very aggressive prostate cancer who may benefit particularly strikingly from abiraterone pre chemotherapy.<wbr> These data represent a subgroup of patients with a very aggressive form of prostate cancer may benefit the most from treatment with abiraterone from COU-AA-302 trial.<wbr>.<wbr>The researchers cross-referenced data on how well 348 men on the trial responded to either abiraterone or a placebo &acirc;&euro;&ldquo; as defined by a halt in the progress in their cancer &acirc;&euro;&ldquo; with a detailed genetic analysis of their tumours.<wbr> They looked in particular at whether changes to a gene called <EM>ERG</EM>, which are often associated with faster cancer progression, correlated with abiraterone response.<wbr> They found a clear link between major <EM>ERG</EM> mutations and response to abiraterone.<wbr> Although abiraterone improved survival generally regardless of <EM>ERG</EM> mutations, a subset of patients with the most pronounced mutations to the gene &acirc;&euro;&ldquo; accounting for 15 per cent of the men studied &acirc;&euro;&ldquo; responded particularly well.<wbr> These men lived for an average of 22 months without their disease progressing, compared with 5.<wbr>4 months for men with the same <EM>ERG</EM>status who received a placebo.<wbr> Source: Attard et al.<wbr> CCO Jan 2015 (the full text is availabile in PEARL <A href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare?Format_document=1&amp;Mouvement=871717&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc1=2964872">http:/<wbr>/<wbr>cis12103:8080/<wbr>qesipsen/<wbr>servlet/<wbr>QESServlet_prepare?Format_document=1&amp;Mouvement=871717&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc1=2964872</A>) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10256">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T19:21:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T19:21:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Achieved A Record Increase In Dollar Sales In Its Fourth Quarter</title>
	<pubDate>2015-02-05T18:49:27+01:00</pubDate>
	<wp:post_id>6069</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Reporting its last set of figures as an independent entity, Allergan 
beat earnings consensus delivered 15% (16.<wbr>5% l.<wbr>c.<wbr>)  sales growth and 
89% gross margins essentially demonstrating it has been operating at the top of 
its game.<wbr> It did not host a call or provide future guidance so in essence we are 
lacking the granularity regarding performance that we previously had.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strong Cuts In SG&amp;A &amp; R&amp;D Enhanced Earnings</STRONG> </div><div style="margin-bottom: 10px;">The company experienced the strongest increase in dollar sales in 
any quarter in the company's history (total product sales were up 17.<wbr>2% on a 
constant currency basis.<wbr> to $1.<wbr>9bn.<wbr> Specialty pharmaceutical sales increased 
12.<wbr>4% (15.<wbr>3% l.<wbr>c.<wbr>), whilst core medical devices advanced 0.<wbr>7% (26.<wbr>9% 
l.<wbr>c.<wbr>).<wbr> </div><div style="margin-bottom: 10px;">For the full year Botox sales reached $2.<wbr>23bn +12.<wbr>5% (14.<wbr>2% l.<wbr>c.<wbr>),  
Facial Aesthetics grew by 38.<wbr>6% (41.<wbr>8% l.<wbr>c.<wbr>) and Eye Care by 12.<wbr>7% (14.<wbr>1%).<wbr> 
Domestic sales represented 63.<wbr>4% of total.<wbr> </div><div style="margin-bottom: 10px;">In general Allergan's outperfromance was due to strong product 
growth, a change in product mix and strict cost control (SG&amp;A &amp; 
R&amp;D fell far short of analysts expectations).<wbr> The former was noticeable 
at both TOXINS 2015 and IMCAS 2015 where Allergan had little sales and amrketing 
presence.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Therapeutic Sales/<wbr>Growth Outstripped Aesthetic 
Sales</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>2014 Botox therapeutic sales accounted for approximately 55% of sales and 
  increased approximately 15% compared to 2013, </LI>
<LI>2014 Botox aesthetic sales accounted for approximately 45% of 
  total and  increased approximately 10% compared to 2013.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px"><STRONG>Next Steps</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px">On <CHRON>January 26, 2015</CHRON>, Actavis and 
<ORG value="NYSE:AGN">Allergan</ORG> announced that they have 
set <CHRON>March 10, 2015</CHRON> as the date of their respective special 
meetings of stockholders to be held in connection with Actavis' pending 
acquisition of <ORG value="NYSE:AGN">Allergan</ORG>.<wbr> </P> </div><div><P style="MARGIN-BOTTOM: 10px">Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7910">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T18:49:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T18:49:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Good Performance for Lundbeck's Xenazine in the US</title>
	<pubDate>2015-02-05T17:39:17+01:00</pubDate>
	<wp:post_id>6070</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7909_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7909_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology7909attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7909_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7909_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(56,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7909">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T17:39:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T17:39:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SOFT trial and Merck's Permbrolizumab Featured The Top News In Oncology Times</title>
	<pubDate>2015-02-05T16:57:48+01:00</pubDate>
	<wp:post_id>6071</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In the Oncology Times' February issue, a few developments in breast cancer have been featured including a comment article on SOFT study solving part of ovarian suppression riddle for premenopausal breast cancer patients as this could create a new algorithm for treating high risk breast cancer patients who are less than 35.<wbr> Also as data reported on the KEYNOTE-12 study, it is the first anti-PD-1 (MSD's pembrolizumab) starts showing promise in triple negative breast cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>For Premenopausal Breast Cancer Patients, Part of Ovarian-Suppression Riddle Solved with New SOFT Study (by Susman) </STRONG></SPAN> </div><div style="margin-bottom: 10px;">At the San Antonio Breast Cancer Symposium, Dr.<wbr> Prudence Francis (Associate Professor of Medicine at the University of Melbourne/<wbr>Peter MacCallum Cancer Centre) reported data from the SOFT trial in a plenary session that women at low risk did well whether they were on tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression.<wbr> However, for women at sufficient risk of recurrence to warrant adjuvant chemotherapy and who retained pre-menopausal estradiol, the addition of ovarian function suppression to tamoxifen reduced recurrence.<wbr> The benefit from ovarian function suppression is most striking in women under the age of 35.<wbr> Professor Hope Rugo (MD, Professor of Medicine at the University of California, San Francisco) cautioned interpretation of the results as she thinks the trial is still at the early stage and attention must clearly be made to management of toxicities such as hypertension and bone health.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>PD-1 Inhibitor Active in Triple-Negative Breast Cancer (by Carlson) </STRONG></SPAN> </div><div style="margin-bottom: 10px;">Another recent breakthrough featured in the news is the data reported from the KEYNOTE-12 study of pembrolizumab in women with ER-, PR-, HER2-negative tumours that were positive for PD-1.<wbr> A total of 58% of women screened for the study who had triple-negative breast cancer had PD-L1-positive tumours.<wbr> Tripe negative breast cancer patients have been historically considered as one of the breast cancer patient population with highest unmet medical need.<wbr> Dr Rita Nanda (MD, Assistant Professor of Medicine and Associate Director of the Breast Medical Oncology Program at the University of Chicago) presented at the San Antonio Breast Cancer Symposium and focused on the durability of responses in women with are being treated with pembrolizumab.<wbr> At the time of this analysis three of the five responders had been on therapy for at least 48 weeks.<wbr> Four patients came off study due to disease progression, and two of those had been on treatment for 40 weeks.<wbr> Interestingly at the news conference, the response rate was criticised as it doesn't seem to be comparable to what has been reported in other diseases such as Hodgkin lymphoma and melanoma.<wbr> Dr.<wbr> Edith A.<wbr> Perez, MD, (Deputy Director at Large for the Mayo Clinic Cancer Center and Professor at Mayo Clinic College of Medicine, Jacksonville, Florida) on the panel at the news conference commented that this is still a proof-of-concept study and a further study should be warranted to understand the "true" clinical value of immuno-modulating agents in breast cancer.<wbr> </div><div>Source: Oncology Times Feb 10 2015 Vol 37 Issue 3 (Full Text is available in PEARL: <A href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare?Format_document=1&amp;Mouvement=867429&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc1=2959922">http:/<wbr>/<wbr>cis12103:8080/<wbr>qesipsen/<wbr>servlet/<wbr>QESServlet_prepare?Format_document=1&amp;Mouvement=867429&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc1=2959922</A>;  <A href="http://cis12103:8080/qesipsen/servlet/QESServlet_prepare?Format_document=1&amp;Mouvement=867429&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc2=2959923">http:/<wbr>/<wbr>cis12103:8080/<wbr>qesipsen/<wbr>servlet/<wbr>QESServlet_prepare?Format_document=1&amp;Mouvement=867429&amp;Urlorigine=&amp;Premier=0&amp;Dernier=0&amp;Doc2=2959923</A>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10251">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T16:57:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T16:57:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages on Teva's Results</title>
	<pubDate>2015-02-05T16:20:03+01:00</pubDate>
	<wp:post_id>6072</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results, management highlighted that key priorities for 2015 will be to generate $500M in net cost reductions, further maintain the Copaxone franchise and manage the LCM of key specialty products.<wbr> Among the pivotal clinical event in 2015, we have noted the Ph2/<wbr>3 results of pridopidine for Huntington's disease (expected late 2015/<wbr>early 2016), and the Ph2 results of <A href="https://clinicaltrials.gov/ct2/show/NCT02092077?term=TV1106-IMM-20001&amp;rank=1">albutropin for Ped GHD</A>.<wbr> In 2015, the company intends to put a strong focus on business development activities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Quaterly Revenues by Segment</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Quaterly Revenues by Market</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Annual Revenues by Segment</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Annual Revenues by Market</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="pharmaworld11092attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(65,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(13,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(30,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(25,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(13,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(30,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(26,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11092_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(71,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11092">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T16:20:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T16:20:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer to Buy Hospira For $17 Billion</title>
	<pubDate>2015-02-05T14:10:11+01:00</pubDate>
	<wp:post_id>6073</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfizer agreed to buy Hospira, a maker of injectable drugs and infusion technologies, for approximately $17 billion.<wbr> Hospira is one of the first US drug makers providing biosimilars to patients in Europe and Australia.<wbr>  Pfizer is clearly trying to enhance its portfolio in a highly profitable and growing market: the global market for generic sterile injectables is expected to reach$70 billion in 20202, while the biosimilars market may be $20 billion by that time.<wbr> </div><div style="margin-bottom: 10px;">According to sources, the transaction will be financed two-thirds in cash and one-third in new debt.<wbr> Hospira shareholders will receive $90 a share in cash, a 39% premium to Wednesday's market close.<wbr> </div><div>Source: Bloomberg, WSJ </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11091">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T14:10:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T14:10:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca's Growth Platform Up 15% in 2014</title>
	<pubDate>2015-02-05T13:33:13+01:00</pubDate>
	<wp:post_id>6074</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Growth platforms represented 53% of total revenue for 2014 with dougle digit increase in all segment except Japan (-3%).<wbr> Management outlined Oncology emerging as sixth growth platform.<wbr> From a product perspective, we have noted Zoladex sales were $227M in Q4 (down 2% as 50% growth in China was offset by overall declines), and 2014 global revenue was $924m, down 4%.<wbr> Separately the company has announced the $600M acquisition of Actavis' respiratory portfolio, which essentially brings fully in-house the global rights to Tudorza and the former-Almirall brands.<wbr> CEO states it is on-line to hit a return to growth in 2017 and positioned to meet its long-term targets $45bn in sales in 2023.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>- Recent Highlights</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key Milestones</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Product Sales</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Zoladex FY2014 Sales by Region</STRONG> </div><div style="margin-bottom: 10px;"><TABLE border="1" cellpadding="2" cellspacing="2" cols="2" id="TractionHTMLTable2" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " width="50%"><TBODY><TR><TD id="Row0 Col0" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="5" width="50%">US</TD>
<TD id="Row0 Col1" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="6" width="50%">$26M +13%</TD>
</TR>
<TR><TD id="Row1 Col0" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="8" width="50%">Europe</TD>
<TD id="Row1 Col1" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="9" width="50%">$226M (12)</TD>
</TR>
<TR><TD id="Row2 Col0" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="11" width="50%">Established ROW</TD>
<TD id="Row2 Col1" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="12" width="50%">$322M (6)</TD>
</TR>
<TR><TD id="Row3 Col0" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="14" width="50%">Emerging Markets</TD>
<TD id="Row3 Col1" style="BORDER-TOP-COLOR: ; BORDER-LEFT-COLOR: ; BORDER-BOTTOM-COLOR: ; BORDER-RIGHT-COLOR: " tabindex="15" width="50%">$350M +4%</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_6_ScreenCapture6.jpg"> </div><!-- Comment details --><a name="oncology10248attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(96,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(84,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(44,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(24,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10248_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(25,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10248">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T13:33:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T13:33:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Sanofi FY2014 Results</title>
	<pubDate>2015-02-05T12:51:40+01:00</pubDate>
	<wp:post_id>6075</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Full-year sales reached €33,770 million, an increase of 2.<wbr>5%, and grew 4.<wbr>4% to €27,720 million for Pharmaceuticals.<wbr> In the Consumer Healthcare, sales of Enterogermina increased by 24.<wbr>6% (CER) to €156 million.<wbr> In the Innovative part of the business, sales of Jevtana increased by 19.<wbr>5% (CER) to €273 million.<wbr> Alongside the reporting of the results, S Weinber indicated that the name of the new CEO could be published in Q1.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Consumer Healthcare</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11089_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Innovative Products</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11089_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Geographic Region</STRONG> </div><div style="margin-bottom: 10px;">Emerging Markets region represents a third of Sanofi’s worldwide sales.<wbr> Management reported: " .<wbr>.<wbr>.<wbr> The economies of these fast developing countries will remain a key growth engine for Sanofi and we have decided to dedicate additional resources to Emerging Markets in order to leverage our leadership position.<wbr> New initiatives are underway to further expand our footprint in these markets".<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11089_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="pharmaworld11089attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11089_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11089_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11089_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(61,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11089">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T12:51:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T12:51:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Announces Enhancement of Management Structure and Appointment of New Head of Global Development</title>
	<pubDate>2015-02-05T11:58:14+01:00</pubDate>
	<wp:post_id>6076</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Top Management committees, top management structure and global functions will be enforced and reorganized to respond to accelerating and elaborating environmental changes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Bernie Zeiher will be newly appointed as Head of Global Development as of April 1, 2015.<wbr> (The current Head of Global Development, Sef Kurstjens, will continue to serve in his role as Chief Medical Officer).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The “Executive Committee (EC)” will be newly established for decision on significant matters in global management of the Astellas group.<wbr> The EC consists of CEO, as chairperson, CAO &amp; CCO, CFO, CSTO and CMO.<wbr> </div><div style="margin-bottom: 10px;">The Heads of Drug Discovery Research, Global Development, Technology, Japan Sales &amp; Marketing, Asia/<wbr>Oceania Business, EMEA operations and Americas operations will join the EC as the extended member for discussion on its related matters upon the chairperson’s request.<wbr>  </div><div style="margin-bottom: 10px;">The “Japan Management Committee (JMC)” will be newly established for decision-making on the significant corporate governance matters of Astellas Pharma Inc.<wbr> and its affiliates in Japan.<wbr> The JMC consists of CAO &amp; CCO, as chairperson, and Corporate Vice Presidents of Corporate Planning, Corporate Finance &amp; Control, Human Resources and Legal &amp; Compliance.<wbr>  </div><div style="margin-bottom: 10px;">The Global Management Committee, the Corporate Administration &amp; Finance Committee and Global Human Resources Committee will be dismantled accordingly.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10247_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10247_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Global Marketing Strategy Global Marketing Strategy under Product &amp; Portfolio Strategy will move directly under CEO and the position of Head of Global Marketing Strategy will be newly established.<wbr> We will provide the patients with the maximized value by enhancing the global market access function, and by promoting the internal collaboration with Medical Affairs, Global Development and regional Marketing.<wbr> Yukio Matsui will be appointed to Head of Global Marketing Strategy as of April 1, 2015 and Head of Global Marketing Strategy will be located in Illinois, the United States </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A single transaction execution function will be created in Business Development, Astellas Pharma Inc.<wbr> so that we can align the globally consistent transactional operation.<wbr> The alliance management function will be split clearly between global and regional.<wbr> The global alliance management function will be established in Business Development, Astellas Pharma Inc.<wbr> and will become a primary contact to global/<wbr>multi-regional strategic partners.<wbr> This function will also be responsible for control of issues related to global alliances.<wbr> The regional alliance management function will be established under the sales and marketing organization in each region and the Japan regional alliance management function will be under Japan Sales &amp; Marketing, Astellas Pharma Inc.<wbr> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><a name="oncology10247attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10247_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10247_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(18,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10247">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T11:58:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T11:58:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lesaffre Targets Middle East Markets with its Probiotics Business</title>
	<pubDate>2015-02-05T08:06:32+01:00</pubDate>
	<wp:post_id>6077</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lesaffre Human Care, the human health and nutrition division of the French group Lesaffre, will be showcasing its probiotic yeasts and bacteria marketed under the Lynside Pro and Probisis brands at the next edition of Arab Health-Medlab to be held in Dubai (from 26 to 29 January 2015).<wbr> The company intends to use its first participation at this exhibition to gain insight into the business practices of the region and secure new opportunities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Lynside Pro</STRONG> </div><div style="margin-bottom: 10px;">Lynside Pro SCB, Saccharomyces cerevisiae var.<wbr> boulardii, is the world's most widely studied and documented probiotic yeast.<wbr> It reduces diarrhoea and reinforces intestinal health.<wbr> </div><div style="margin-bottom: 10px;">Lynside Pro GI+, is a Saccharomyces cerevisiae strain, selected and patented by Lesaffre, from amongst thousands of proprietary strains, for its effects against abdominal pain and intestinal bloating and its ability to reduce intestinal discomfort.<wbr> The many successful preclinical and clinical trials carried out on Lynside Pro GI+ will lead to communications in scientific conferences and publications in international journals.<wbr> </div><div style="margin-bottom: 10px;">Lesaffre Human Care will also be displaying Probisis BS, a new specific probiotic strain, patented and clinically tested to strengthen the body's natural defences against harmful external factors.<wbr> This Bacillus subtilis was specially selected and studied for its immune-stimulating properties.<wbr> </div><div style="margin-bottom: 10px;"><H3>Lesaffre in brief</H3> </div><div style="margin-bottom: 10px;"><UL><LI>A group founded in 1853, and still owned by the Lesaffre family </LI>
<LI>A turnover of 1,56 billion euros in 2013 </LI>
<LI>7 700 employees </LI>
<LI>More than 80 subsidiaries in over 40 countries </LI>
<LI>49 production plants </LI>
<LI>39 sales offices </LI>
<LI>30 Baking Center facilities </LI>
<LI>and  Culinary Centers </LI>
<LI>Lesaffre products and services are sold in more than 180 countries </LI>
</UL> </div><div><EM>Source: Lesaffre</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2217">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-05T08:06:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-05T08:06:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>QR Pharma Starts Collaboration on Posiphen for HD</title>
	<pubDate>2015-02-04T17:20:18+01:00</pubDate>
	<wp:post_id>6078</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The collaboration with Rockefeller U.<wbr> will focus on PC research involving Posiphen.<wbr> The drug inhibits amyloid precursor protein (APP) and therefore a major pathway leading to Alzheimer’s disease.<wbr> It also inhibits α-Synuclein, an important player in a pathway linked to Parkinson’s disease.<wbr> Recently, it was shown to inhibit huntingtin, the protein that is seen at high levels in HD.<wbr> </div><div style="margin-bottom: 10px;">Investigators at Rockefeller will conduct experiments in stem cell culture models of HD to determine, if Posiphen lowers the levels of the toxic huntingtin protein in these cells, if it promotes differentiation into neuronal cells and, if it prolongs the cell life of the HD cells.<wbr> </div><div style="margin-bottom: 10px;">Results from the collaboration could lead to clinical studies in HD patients.<wbr> </div><div><EM>Source: QR Pharma</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7908">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-04T17:20:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-04T17:20:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's Promising Breast Cancer Approved by the FDA</title>
	<pubDate>2015-02-04T16:39:37+01:00</pubDate>
	<wp:post_id>6079</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: FDA has approved Pfizer's <PFE.N>Ibrance (palbociclib) for use with Letrozole as 1st-line treatment of postmenopausal women with ER+/<wbr>HER2- metastatic breast cancer.<wbr> The regulatory decision came earlier than expected.<wbr> The drug works through a new mechanism of action, by blocking two enzymes involved in cell division, CDK4 and CDK6.<wbr></PFE.N> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Cowen and Co has estimated the drug could generate annual sales of $3 billion by 2020, and JP Morgan $4 billion </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The accelerated approval was based on data from Ph2 PALOMA-1 trial, a study on 165 postmenopausal women with metastatic breast cancer classified as estrogen receptor-positive, human epidermal receptor 2-negative, who hadn’t received previous treatment for the advanced disease.<wbr> The study found Ibrance stopped tumors from growing for a median of more than 20 months, about twice as long as the current treatment alone.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 13px; FONT-FAMILY: Helvetica, Arial, sans-serif; COLOR: rgb(68,68,68); LINE-HEIGHT: 20px"> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 13px; FONT-FAMILY: Helvetica, Arial, sans-serif; COLOR: rgb(68,68,68); LINE-HEIGHT: 20px"></SPAN> </div><div><SPAN style="FONT-SIZE: 13px; FONT-FAMILY: Helvetica, Arial, sans-serif; COLOR: rgb(68,68,68); LINE-HEIGHT: 20px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10245">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-04T16:39:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-04T16:39:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Lists New Phase IIIb Study For Pasireotide In Acromegaly</title>
	<pubDate>2015-02-04T16:18:21+01:00</pubDate>
	<wp:post_id>6080</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A Phase IIIb study to evaluate pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin analogues, has been newly listed on Clinical Trials site (<a href="https://clinicaltrials.gov/ct2/show/NCT02354508?term=NCT02354508&rank=1&submit_fld_opt=" class="defaultlink">NCT02354508</a>).<wbr>  The study is not yet opened for participant recruitment (estimated enrollment ~112).<wbr> </div><div style="margin-bottom: 10px;">This is a phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first generation somatostatin analogues.<wbr> The study is planning to enroll inadequately controlled patients by high doses (maximal approved) of first-generation somatostatin analogues given for at least 3 months.<wbr> Patients will receive pasireotide LAR 40 mg or 60 mg during 36 week core study phase.<wbr> </div><div style="margin-bottom: 10px;">Primary Endpoints: </div><div style="margin-bottom: 10px;"><UL><LI>Patients achieving GH &lt;1&mu;g/<wbr>L and IGF-1
</LI>
<LI>Proportion of patients who achieve biochemical control defined as GH &lt;1&mu;g/<wbr>L and IGF-1
</LI>
<LI>Patients achieving GH &lt;1&mu;g/<wbr>L and IGF-1
</LI>
<LI>Supportive analysis for primary outcome measure: Proportion of patients achieving GH &lt;1&mu;g/<wbr>L and IGF-1 2.<wbr>5 &mu;g/<wbr>L
</LI>
</UL> </div><div>Source: ClinicalTrials.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7949">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-04T16:18:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-04T16:18:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Neuromusuclar Orphan Drug Sepcialist Catalyst Pharmaceutical Partners Annouces IPO</title>
	<pubDate>2015-02-04T15:31:51+01:00</pubDate>
	<wp:post_id>6081</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Catalyst is focused on developing and commercializing innovative 
therapies for people with rare debilitating neuromuscular and 
neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), 
infantile spasms, and Tourette Syndrome.<wbr> Its lead candidate, Firdapse™ for 
the treatment of LEMS, recently completed a pivotal Phase 3 trial resulting in 
positive top-line data with a potential filing date now set for Q315.<wbr> </div><div style="margin-bottom: 10px;">Firdapse™ for the treatment of LEMS has received Breakthrough Therapy 
Designation from the <ORG>U.<wbr>S.<wbr> Food and Drug Administration</ORG> (FDA).<wbr> and is 
the first and only European approved drug for symptomatic treatment in adults 
with LEMS.<wbr> </div><div style="margin-bottom: 10px;">Based on recent pre-NDA discussions with the US FDA  regarding 
Firdapse™ for the treatment of LEMS.<wbr> Catalyst believes that its Phase 3 clinical 
program will provide acceptable support for submission of an NDA for 
Firdapse<I>™</I> for LEMS.<wbr> Hence, the Company plans to complete a full NDA 
submission during the 3rd quarter of 2015 </div><div style="margin-bottom: 10px;"><STRONG>Licensing Situation</STRONG> </div><div style="margin-bottom: 10px;">North America rights to Firdapse™ were licensed to Catalyst in October 2012 
from BioMarin which retained rights to the ROW.<wbr> BioMarin has a 10% equity stake 
in the company.<wbr> A joint development agreement is in place with future milestone 
payments of up to $10m and royalty payments in the low teens.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commercialisation Plans</STRONG> </div><div style="margin-bottom: 10px;">Catalyst plans to build its own sales force of 15-20 reps in Q315 (to address 
750 neuromuscular specialists).<wbr> anticipating an NDA approval and launch in 2016.<wbr> 
Management have pointed towards a $200-$500 orphan drug opportunity 
for Firdapse™ in the US based on 1st line therapy approval for 
LEMS and life cycle expansion to 
other opportunities such as congenital myasthemic syndrome (CMS) and 
myasthemia gravis.<wbr> Price assumptions have also been modest.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Catalyst's Pipeline</STRONG> </div><div style="margin-bottom: 10px;">In addtiion to  Firdapse™ Catalyst is also developing CPP-115 to treat 
infantile spasms, epilepsy and other neurological conditions associated with 
reduced GABAergic signaling, like post-traumatic stress disorder and Tourette 
Syndrome.<wbr> </div><div style="margin-bottom: 10px;">CPP-115 has been granted U.<wbr>S.<wbr> orphan drug designation for the treatment of 
infantile spasms by the <ORG>FDA</ORG> and has been granted E.<wbr>U.<wbr> orphan 
medicinal product designation for the treatment of West Syndrome by the 
<ORG>European Commission</ORG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7907_1_ScreenCapture1.jpg"> </div><div>A recent presentation from the 2014 Bio Investor Forum is available for those 
interested.<wbr> </div><!-- Comment details --><a name="neurology7907attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7907_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(164,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7907">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-04T15:31:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-04T15:31:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant to Explore Takeover of Salix</title>
	<pubDate>2015-02-03T19:16:30+01:00</pubDate>
	<wp:post_id>6082</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Reuters reported today that Valeant is in talks to buy Salix.<wbr> The US drugmaker has got a strategically focused sales force, a strong presence amongst gastroenterologists, as well as a powerful Xifaxan franchise.<wbr> Last year the company entered into an exclusive agreement with RedHill for the WW rights of the potential first encapsulated formulation for bowel cleansing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2216_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=9501" class="defaultlink">Oncology9501: Salix In-licenses 1st Encapsulated Bowel Cleanser</a> </div><div style="margin-bottom: 10px;"><STRONG>Focused Sales Force</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2216_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Robust Xifaxan Franchise</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2216_2_ScreenCapture2.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2260c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Valeant has bought Salix.<wbr> The transaction represents approximately $14.<wbr>5 Billion and will </STRONG>create a new Specialty Platform for Growth.<wbr> It is <SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 12px/20px HelveticaNeue-Light, 'Helvetica Neue Light', 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">expected to close in the second quarter of 2015.<wbr></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 12px/20px HelveticaNeue-Light, 'Helvetica Neue Light', 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The growing GI market has attractive fundamentals, and Salix has a portfolio of products that are outpacing the market in terms of volume growth and a promising near-term pipeline of innovative products.<wbr></SPAN></STRONG> </div><div><STRONG style="text-align: left; widows: 2; text-transform: none; text-indent: 0px; font: 14px/20px HelveticaNeueLTStd75Bold; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 12px/20px HelveticaNeue-Light, 'Helvetica Neue Light', 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Salix's market-leading gastrointestinal franchise is an ideal strategic fit for Valeant's diversified portfolio of specialty products.<wbr></SPAN></STRONG> </div><span style="font-weight: bold; font-style: italic;"></span><a name="GastroEnterology2283c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>According to the Wall St Journal ENDO Pharmaceuticals has just submitted a competing bid for Salix of between $170 per share and $175 per share.<wbr>  Salix reached an agreement in February to be purchased by Valeant Pharmaceuticals for $158 per share.<wbr> Endo reportedly sent a private offer letter to Salix's board today.<wbr> </div></div></div><a name="gastroenterology2216attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2216_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2216_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(118,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2216_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(68,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2216">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-03T19:16:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-03T19:16:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Highlights Its Response To New Data Transparency Regulation</title>
	<pubDate>2015-02-03T16:29:21+01:00</pubDate>
	<wp:post_id>6083</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas has announced that the company will now make trial data available through <A href="http://www.clinicalstudydatarequest.com">www.<wbr>clinicalstudydatarequest.<wbr>com</A> an independent Web site that will eanable research proposals by an independent review panel.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11083_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on this development Sef Kurstjens, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, chief medical officer of Astellas Pharma, Inc stated </STRONG> </div><div style="margin-bottom: 10px;">"Transparency in the conduct of clinical trials is an important issue for the scientific and medical community today.<wbr> By making our clinical trial data more widely available, we further its potential to increase understanding of disease and, ultimately, to address the unmet needs of patients around the globe.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>Objective of the new site</STRONG> </div><div style="margin-bottom: 10px;">The new site, <A href="http://www.clinicalstudydatarequest.com">www.<wbr>clinicalstudydatarequest.<wbr>com</A><INS>, </INS>was developed to enable researchers to request data from clinical studies and perform further research that could help advance medical science or improve patient care.<wbr> A research proposal will be reviewed and approved by an independent review panel, and Astellas will not be involved in decisions made by the independent review panel.<wbr> <STRONG>What is Astellas Prepared To Provide</STRONG> </div><div style="margin-bottom: 10px;">It will provide access to anonymized patient-level data from interventional clinical trials in patients completed after January 2010 for products and indications that have been approved in the U.<wbr>S.<wbr> and/<wbr>or in the E.<wbr>U.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Trial Data Disclosure</STRONG> </div><div>Additionally Astellas has recently revised and expanded its Global Policy on Clinical Trial Data Disclosure, which details the company&rsquo;s principles regarding registration of clinical trials, posting and publication of trial results and scientific community access to trial data.<wbr> The policy is now available at :- <A href="http://www.astellas.com/en/corporate/disclosure/clinicalstudies.html">www.<wbr>astellas.<wbr>com/<wbr>en/<wbr>corporate/<wbr>disclosure/<wbr>clinicalstudies.<wbr>html</A> </div><!-- Comment details --><a name="pharmaworld11083attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11083_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(189,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11083">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-03T16:29:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-03T16:29:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Janssen Secures UC Sales of Simponi on the Italian Market</title>
	<pubDate>2015-02-03T12:18:12+01:00</pubDate>
	<wp:post_id>6084</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Italian Medicines Agency (AIFA) has granted reimbursement to Janssen's Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC).<wbr> Simponi is used in patients who have not responded adequately to, or cannot use, conventional treatment – including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The medicine is already reimbursed by the National Health Service as a class H drug (medicine for inpatient use) in Italy for the treatment of active rheumatoid arthritis, active and progressive psoriatic arthritis and severe active ankylosing spondylitis.<wbr> </div><div style="margin-bottom: 10px;">The ulcerative colitis extension of the reimbursement in Italy follows the approval by the European Commission in September 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The medicine is reimbursed for hospital use at a maximum ex-manufacturer price of EUR1,157 (USD1,307) and EUR1,909.<wbr>51 (retail price) for 50 mg.<wbr> </div><div style="margin-bottom: 10px;">The contract is valid for 24 months.<wbr> </div><div style="margin-bottom: 10px;">The drug has been approved under the condition of a payment-by-results deal.<wbr> In addition, the manufacturer is required to apply a mandatory discount to public facilities.<wbr> </div><div><EM>Source: IHSGlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2214">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-03T12:18:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-03T12:18:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Starts Collaboration With 23andMe on Parkinson's Disease</title>
	<pubDate>2015-02-03T11:00:46+01:00</pubDate>
	<wp:post_id>6085</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: DNA testing company 23andMe, which is backed by millions of dollars of investment from Google, has yet struck another Pharma deal with Genentech to identify new therapeutic targets for treating Parkinson's disease.<wbr> The deal's financials have not been disclosed but rumors report  Roche's biotech arm will pay $10 million upfront and up to $50 million in milestones for genomes acquired from 23andMe customers.<wbr> </div><div style="margin-bottom: 10px;">Approximately 3,000 23andMe customers suffering from Parkinson's disease agreed for their anonymous genetic information to be used and shared for medical research.<wbr>  Roche has gained access to the largest Parkinson's disease community of its kind through this multi-year collaboration.<wbr>  This supports Roche's effort to grow its portfolio beyond oncology, immunology and ophthalmology and to focus on innovative solutions for early detection and treatment of diseases.<wbr> </div><div style="margin-bottom: 10px;">This is yet another collaboration example on how Pharma companies are broadening their vision of improving the human condition through genetic research.<wbr> </div><div>Source: PharmaTimes, BioSpace, Reuters, FirstWordPharma </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11082">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-03T11:00:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-03T11:00:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly & NET</title>
	<pubDate>2015-02-03T10:25:31+01:00</pubDate>
	<wp:post_id>6086</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly & NET</span>&nbsp;<br><span style="font-size: 12px;">Comment: A new phII open-label randomised PK, PD efficacy &amp; safety study with CAM2029 is now listed by Camurus on the EU Clinical Trial Register.<wbr> The trial will evaluate the drug in both acromegaly and NET patients.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7770">...</a><br></div><div>Status of trial <a href="https://clinicaltrials.gov/ct2/show/NCT02299089" class="defaultlink">NCT02299089</a> has changed to "recruiting" OnJan 25th, with 2 sites recruiting: CHU Rouen (France), RCCS Azienda Ospedaliera Universitaria San Martino IST (Italy) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7948">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7770">View thread  Endocrinology7770: EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly & NET</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-03T10:25:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-03T10:25:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Botulinum Toxin Studied as Treatment for Scleroderma</title>
	<pubDate>2015-02-02T18:29:19+01:00</pubDate>
	<wp:post_id>6087</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Johns Hopkins Researchers are currently enrolling patients for the first Ph3 RCT to determine whether botulinum toxin can relieve symptoms of Raynaud’s syndrome in people with scleroderma.<wbr> The trial, co-sponsored by Allergan, began enrolling participants in late January 2015, and is expected to complete by December 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Objective: <A href="https://clinicaltrials.gov/ct2/show/NCT01233999"></A>to determine whether botulinum toxin can relieve symptoms of Raynaud’s syndrome in people with scleroderma </div><div style="margin-bottom: 10px;">PI: Dr Scott Lifchez </div><div style="margin-bottom: 10px;">Intervention: Each subject will be injected with Botulinum toxin A (Botox) in one hand, and the opposite hand will be injected with sterile saline (placebo).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">According to the study report, presented at AAHS ASPN ASRM Annual Meetings in 2011 by Kelli N Webb and colleagues of Southern Illinois University School of Medicine: “Twenty-three out of 29 patients (79%) reported pain-reduction after a single injection…Tissue perfusion results demonstrated a marked change in blood flow (-48.<wbr>15 to +425%) to the digits.<wbr> Fifteen out of 17 patients (88%) with finger ulcers healed within 60 days.<wbr>” </div><div>Source: scleroderma.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7906">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-02T18:29:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-02T18:29:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Interventional Trial to Assess Blend of Berries and Probiotics in the Elderly</title>
	<pubDate>2015-02-02T18:08:56+01:00</pubDate>
	<wp:post_id>6088</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is a three-arm study evaluating placebo (maltodextrine), only probiotics (freezedried bacteria at 10 billions cfu/<wbr>daily dose and maltodex) and blend of berries and probiotics).<wbr> Probi AB in collaboration with Lund U.<wbr> will evaluate the ability of the blend in reducing low-grade inflammation and intestinal permeability in approx.<wbr> 60 participants (aged &gt;75 years).<wbr> </div><div style="margin-bottom: 10px;">Principal Investigator Bengt Jeppsson, Prof.<wbr> </div><div style="margin-bottom: 10px;">Trial ID <A href="https://clinicaltrials.gov/ct2/show/NCT02342496?term=probiotic&amp;recr=Open&amp;no_unk=Y&amp;rank=45">NCT02342496 </A> </div><div style="margin-bottom: 10px;">Duration: one month </div><div style="margin-bottom: 10px;"><U>Endpoints</U> </div><div>Blood and fecal samples will be collected for analysis at baseline and at the end of the intervention with the aim to analyse possible changes in different parameters at the two timepoints.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2213">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-02T18:08:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-02T18:08:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: AAA Filed with the SEC to Raise $100M in an IPO</title>
	<pubDate>2015-02-02T17:12:55+01:00</pubDate>
	<wp:post_id>6089</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">AAA Filed with the SEC to Raise $100M in an IPO</span>&nbsp;<br><span style="font-size: 12px;">Comment: AAA which plans to list on the NASDAQ under the symbol AAAP, iniitially filed confidentially on August 4, 2014.<wbr> Today, management announced its results for the first nine months of 2014, with sales of &euro;50.<wbr>2M (+28.<wbr>9% vs 9 months 2013).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7862">...</a><br></div><div style="margin-bottom: 10px;">AAA announced the terms of its IPO last Tuesday plans to raise $75 million by offering 5.<wbr>4 million shares at a price range of $13 to $15.<wbr> At the midpoint of the proposed range, Advanced Accelerator Applications would command a fully diluted market value of $538 million.<wbr> </div><div style="margin-bottom: 10px;">Source: </div><div><P style="background: white; margin: 0cm 0cm 0pt;"><STRONG><SPAN lang="EN-US" style="color: black; font-family: 'Arial',sans-serif; mso-ansi-language: EN-US;"><A href="http://renaissancecapital.com/news/Nuclear-therapy-biotech-Advanced-Accelerator-Apps-sets-terms-for-$75-millio-22862.html"><U></U></A></SPAN></STRONG></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7947">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7862">View thread  Endocrinology7862: AAA Filed with the SEC to Raise $100M in an IPO</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-02T17:12:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-02T17:12:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Astellas' Results for 3Q/FY2014</title>
	<pubDate>2015-02-02T14:12:38+01:00</pubDate>
	<wp:post_id>6090</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sales increased to 952.<wbr>8 millions of Yen (+9.<wbr>7% vs 3Q/<wbr>FY2013), driven by Vesicare/<wbr>Mirabegron (+22.<wbr>5%), and Xtandi (+58.<wbr>1%).<wbr> Regionally, Japan continues to struggle (mainly due to NHI drug price reduction, and generic impact), but the US and EU are still doing better than the firm expected (+14.<wbr>9% in US$ and +16.<wbr>1% in lc respectively YoY).<wbr> Strategic priorities include the enhancement of business base in EMs (establishment of Astellas MENA/<wbr>SSA), and the extension of growth drivers (maximize OAB franchise, enhance Xtandi sales growth and label expansion).<wbr> Of note, degarelix 3M is listed as still being in Ph3 in Japan.<wbr> A selection of key slides is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>Analysis of change in Sales</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management commented on the conference call that volume growth accounted for 20ppt of the 27% QoQ increase in US Xtandi sales.<wbr> </div><div style="margin-bottom: 10px;">Currently, Xtandi is primarily used in post-chemo patients, but management looks for usage by pre-chemo patients to increase going forward.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">- Astellas announced an alliance with Dana-Farber Cancer Institute (DFCI) in November 2014 to take up the challenge of developing inhibitors of KRAS mutations, a target that has eluded pharmaceutical companies for a long time.<wbr> Specifically, they are targeting G12C mutations, which are commonly observed in most cancers.<wbr> If successful, this could lead to a blockbuster drug.<wbr> Competition includes a group from University of California, San Francisco that published similar findings and partnered with Araxes Pharma and Johnson &amp; Johnson.<wbr> </div><div style="margin-bottom: 10px;">- Astellas established a joint research chair with Osaka U.<wbr> for R&amp;D on cell therapy headed by Professor Yoshiki Sawa, the foremost authority in Japan on cardiovascular-related cell therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>Focus in Onco</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>Enzalutamide Development Progress</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_8_ScreenCapture8.jpg"> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><a name="oncology10243attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(163,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(120,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(94 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(66,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(202,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(167,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(200,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10243_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(99,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10243">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-02-02T14:12:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-02-02T14:12:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cortendo To Present Study Protocol Of Global Phase III NormoCort For Cushing Disease At Endo 2015</title>
	<pubDate>2015-01-30T16:23:24+01:00</pubDate>
	<wp:post_id>6091</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cortendo has announced today that it will present the study protocol of its global Phase III study of COR-003, NormoCort, in patient's with endogenous Cushing's Syndrome at ENDO 2015 (San Diego, March).<wbr> The trial, started in August 2014, is currently recruting participants, and is expected to be completed in January 2016.<wbr>  However Cortendo has issued a press release stating that the aim is to generate final Phase III data in 2017, before potentially submitting a NDA to the FDA.<wbr> </div><div style="margin-bottom: 10px;">NormoCort will possibly launch in the US in the second half of 2018 and in the 5EU in the second half of 2019 at the earliest.<wbr> Cortendo is planning to commercialize COR-003 in the US but will seek a partner to commercialize and develop the drug in Europe.<wbr>There are high expectations for NormoCort as it is supposed to be more efficient and less toxic than racemic ketoconazole, whose availability is becoming increasingly limited.<wbr> NormoCort has received orphan drug status in US and EU.<wbr> </div><div>Source: BioSpace, ClinicalTrials.<wbr>gov, Cortendo Website, GlobalData </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7945">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-30T16:23:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-30T16:23:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Nodisk Operating Profit Increased by 13% in 2014</title>
	<pubDate>2015-01-30T15:20:30+01:00</pubDate>
	<wp:post_id>6092</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sales increased by 8% (in lc) and 6% in Danish kroner (Dk).<wbr> Geographical growth drivers were N.<wbr>America (+11%), International Operations (+14%) and Region China (+13%).<wbr> Sales of Norditropin increased bu 10% (in lc).<wbr> For 2015, the company expects sales to grow 6-9% (in lc).<wbr> The LA hGH has been progressing well (Ph3 development for AGHD initiated) and, with hemophilia, now belongs to the company's "promising pipeline".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7941_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7941_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7941_1_ScreenCapture1.jpg"> </div><div><EM>Source: Novo Nordisk</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7941">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-30T15:20:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-30T15:20:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon Can Be Valuable for Valeant</title>
	<pubDate>2015-01-30T13:10:48+01:00</pubDate>
	<wp:post_id>6093</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Valeant 'stalking horse' deal announced today is subject to higher and better bid.<wbr> Assuming additional qualified bids are submitted, an auction would be held on Feb.<wbr> 12.<wbr> BMO Capital sees the deal attractive and valuable for Valeant, who wants to pay $296MM to buy a cancer drug with $300M in sales (2014), $66M of raw materials inventory, and property and equipment worth about $108M.<wbr> Key points from the analyst report are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Historical Background: In November 2014, Dendreon filed for bankruptcy (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10091" class="defaultlink">Oncology10091: Dendreon Is In Chapter 11 - Dendreon's Share Fell 75% After Filing For Bankruptcy</a>) </div><div style="margin-bottom: 10px;">Although an increase of competition in the immunotherapy-oncology (IO) the treatment of advanced prostate cancer, analysts believe Valeant could maintain annual sales of roughly $300MM for the next 5-6 years, offsetting potential volume declines with price increases (Since PROVENGE&reg; has been shown to improve overall survival in this setting, it has some pricing leverage </div><div style="margin-bottom: 10px;">Analysts also expect Valeant to quickly cut Dendreon&rsquo;s SG&amp;A from 53% of sales to "its preferred 20%".<wbr> This is seen as a risk as such cut in SG&amp;A could "lower sales" </div><div style="margin-bottom: 10px;">BMO Capital report emphasizes that " .<wbr>.<wbr>.<wbr> Clearly there won&rsquo;t be many operating synergies with the rest of Valeant&rsquo;s business;however, it appears that after 4 years, PROVENGE&reg; has established a niche in its market and may not require significant marketing to maintain current sales </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Attractive TA : ' .<wbr>.<wbr>.<wbr> strong growth, high durability, strong patient and physician loyalty, and a terrific reimbursement regime'.<wbr>
</LI>
<LI>Profitable Deal: ' .<wbr>.<wbr>.<wbr> with the unique dynamics of this situation, we believe that this transaction will create significant shareholder value'.<wbr>
</LI>
</UL> </div><div><EM>Source: Valeant; Dendreon; BMO Capital (Flash report Jan 30 2015)</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10257c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Valeant has reported that "in response to competing bids," it has raised its offer to $400 million in cash.<wbr> </div><div style="margin-bottom: 10px;">Competitors have not been disclosed so far.<wbr> </div><div>The deadline for parties to submit bids is February 10, with an auction to be held on February 12 if Dendreon receives other offers.<wbr> </div><span style="font-weight: bold; font-style: italic;"></span><a name="Oncology10262c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Valeant has apparently scooped up Dendreon and its prostate cancer immunotherapeutic Provenge for $400m in cash after no further qualified bids came forward by the Tuesday deadline.<wbr> A competing joint bid by United WorldMeds &amp; Deerfield Management, a New York based investment firm was made but the bid did not match that of Valeant's proposition.<wbr> Valeant will seek court approval on the 20th February and hopes to close the purchase by the end of the month.<wbr> </div><div>.<wbr> </div></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10238">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-30T13:10:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-30T13:10:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Corcept's Financial Results Outline Korlym Growth and Future Potential</title>
	<pubDate>2015-01-30T12:43:54+01:00</pubDate>
	<wp:post_id>6094</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J.<wbr> Belanoff (President &amp; CEO) reported that revenue for 2014 was $26.<wbr>6M, an increased of 156% compared to 2013.<wbr> He estimates 2015 net revenue to be between $47-53M (roughly the double).<wbr> He outlined plans and expectations for the Cushing's syndrome franchise (please see below).<wbr> When it come to pipeline, he outlined the progress of the Ph1/<wbr>2 targeted therapy trial (Korlym with eribulin) for triple negative breast cancer.<wbr> Early 2016, he expects for CORT125134, the next generation selective GR antagonist, to advance to Ph2 for both oncology indication and Cushing's syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Status: Ph1 to complete Q2:15, with Ph2 to start by end of 2015.<wbr> </div><div style="margin-bottom: 10px;">In PC assays of triple-negative breast cancer " .<wbr>.<wbr>.<wbr> Mifepristone actually looks quite good relative to chemotherapeutic agent like Taxol, in combination it produces a superior result to Taxol alone.<wbr> CORT 125134 produces an even better result than Mifepristone".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Steady Growth Since Launch in April 2012</U> </div><div style="margin-bottom: 10px;">Sales were $3.<wbr>3M for the nine months of commercial activities in 2012, $10.<wbr>3M in 2013, and $26.<wbr>6M in 2014.<wbr> </div><div style="margin-bottom: 10px;"><U>Multiple indications Assessed in Clinical Studies</U> </div><div style="margin-bottom: 10px;">Korlym is currently being used in clinical studies of triple-negative breast cancer, castrate-resistant prostate cancer, alcohol dependence, post-traumatic stress disorder, and central serous retinopathy.<wbr> Korlym's development for these and other indications has the advantage of being able to proceed relatively rapidly and inexpensively, because any new approval is a label extension, utilizing the toxicology, carcinogenicity and CMC work that is already being completed and accepted by the US FDA.<wbr> </div><div style="margin-bottom: 10px;"><U>Patient Pipeline</U> </div><div style="margin-bottom: 10px;">Belanoff emphasized that " .<wbr>.<wbr>.<wbr> it is important to note that there are more than 10,000 patients with Cushing's syndrome who could benefit with Korlym, and only a small percentage of them have been treated with it.<wbr>" </div><div style="margin-bottom: 10px;"><U>Commercial Priorities</U> </div><div style="margin-bottom: 10px;"><UL><LI>Specificity of the Sales Force</LI>
</UL> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> We're <U>very, very</U> selective based on what we learned about who are the likely people who are sophisticated enough to be able to develop the appropriate messages for physicians to feel comfortable using the medication".<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>50% increase in recruitment</LI>
</UL> </div><div style="margin-bottom: 10px;">When asked on Korlym detailing, CEO reported " .<wbr>.<wbr>.<wbr>  we have established that 25 sales territories across the country are the right number, and at this point in time we have representatives covering 17 of them.<wbr> The next time we talk we'll have representatives in all 25.<wbr>" </div><div style="margin-bottom: 10px;"><UL><LI>Focus on New Prescribers</LI>
</UL> </div><div style="margin-bottom: 10px;">Key growth drivers for Korlym highlighted by management include the adding of new first time prescribers " .<wbr>.<wbr>.<wbr> the real growth for both 2015 and 2016 will be that we will add new prescribes, because we're confident that once we have a prescriber who writes their first prescription, it gets much easier having seen the effects to write second and third prescriptions".<wbr> </div><div>Source: Korlym </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7940">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-30T12:43:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-30T12:43:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Impact of Probiotic Treatment in Children with Acute Gastroenteritis</title>
	<pubDate>2015-01-29T18:35:50+01:00</pubDate>
	<wp:post_id>6095</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A non-industry sponsored RCT Ph3 trial started Q4:14 to assess Lacidofil in a large cohort of pediatric patients (3 months to 48 months) in Canada.<wbr> PE will measure development of moderate to severe disease in the 2 weeks after the index visit.<wbr> Of note, in the description of the study, it is indicated that the results will enable guidelines to either clearly endorse or recommend against the routine use of a probiotic in this setting.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ref <A href="https://clinicaltrials.gov/ct2/show/NCT01853124?recr=Open&amp;no_unk=Y&amp;cond=gastroenteritis&amp;phase=012&amp;fund=2&amp;rank=3">NCT01853124</A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 886 </div><div style="margin-bottom: 10px;">Timelines: completion June 2017 /<wbr> July 2017 </div><div style="margin-bottom: 10px;">Intervention </div><div style="margin-bottom: 10px;">Lacidofil Arm: </div><div style="margin-bottom: 10px;">All patients in this arm of the study will take 1 sachet twice daily for 5 days.<wbr> Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L.<wbr> helveticus Rosell-52 (5%).<wbr> The total weight of all ingredients is 1 gm.<wbr> </div><div>Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/<wbr>drink.<wbr> If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.<wbr> Total daily dose = 8 billion CFU x 5 days </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2212">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-29T18:35:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-29T18:35:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Synergy Pharm Updates its Chronic Idiopathic Constipation (CIC) Program</title>
	<pubDate>2015-01-29T18:09:50+01:00</pubDate>
	<wp:post_id>6096</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Synergy Pharm Updates its Chronic Idiopathic Constipation (CIC) Program</span>&nbsp;<br><span style="font-size: 12px;">Comment: The company has completed patient enrollment in the first of two pivotal Ph3 trials evaluating the safety and efficacy of two plecanatide doses (3.<wbr>0 and 6.<wbr>0 mg) in patients with CIC.<wbr> Management expects top-line data results from the first phase 3 CIC trial in 2Q 2015.<wbr> The company plans to file its first NDA with plecanatide in the CIC indication in 4Q 2015.<wbr> Of note, plecanatide 3.<wbr>0 and 6.<wbr>0 mg doses are also being evaluated in the ongoing Ph3 registration program for IBS-C (FDA approval in 2017).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2188">...</a><br></div><div style="margin-bottom: 10px;">Today Synergy  announced that it has successfully completed patient enrollment in the second of two pivotal ph3 trials evaluating the safety and efficacy of two plecanatide doses (3.<wbr>0 and 6.<wbr>0 mg) in patients with chronic idiopathic constipation (CIC).<wbr> Patient enrollment in the first phase 3 CIC trial completed on January 8, 2015.<wbr> </div><div style="margin-bottom: 10px;">Each of the two randomized, 12-week, double-blind, placebo-controlled phase 3 trials are evaluating plecanatide, once-daily oral tablets, in approximately 1350 adult patients with CIC.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint is the proportion of patients who are <EM>Overall Responders</EM> during the 12-week treatment period.<wbr> </div><div style="margin-bottom: 10px;">An <EM>Overall Responder</EM> is a patient who fulfills both &ge; 3 complete spontaneous bowel movements (CSBMs) per week plus an increase of &ge; 1 CSBM from baseline in the same week, for 9 out of the 12 weeks, including &ge; 3 of the last 4 weeks.<wbr> </div><div>Plecanatide has met this endpoint and demonstrated statistical significance at the 3.<wbr>0 mg dose in a phase 2b CIC trial evaluating 951 patients with CIC.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2211">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2188">View thread  GastroEnterology2188: Synergy Pharm Updates its Chronic Idiopathic Constipation (CIC) Program</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-29T18:09:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-29T18:09:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>RedHill Updates on Progress with RHB-104 Ongoing Registration Program for CD</title>
	<pubDate>2015-01-29T13:55:20+01:00</pubDate>
	<wp:post_id>6097</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Increasing evidence supports the hypothesis that Crohn's Disease (CD) is caused by MAP infection in suceptible patients.<wbr> Based on FDA's feedback, RedHill and Quest Diagnostics plan to start a Ph3 MAP US trial of approx.<wbr> 40 patients in Q2-Q3/<wbr>2015 to assess the clinical utility of a diagnostic test.<wbr> The RHB-104 Phase III MAP US study for CD is one of RedHill's 3 ongoing Ph3 studies in the U.<wbr>S.<wbr> targeting gastrointestinal diseases, together with the RHB-105 Ph3 study (the ERADICATE Hp study) for the treatment of <I>H.<wbr> pylori</I> infection (top-line results expected during Q2:15) and the RHB-102 (BEKINDA<SUP>(TM)</SUP>) Ph3 study (the GUARD Study) for gastroenteritis and gastritis (top-line results expected H2/<wbr>2015).<wbr> The company business model is to primarily commercilaize its products through partnerships.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">RedHill further announced that a protocol amendment has been filed with the FDA to the approved IND in relation to the ongoing Phase III MAP US study with RHB-104 for the treatment of CD.<wbr> As part of the amendment, the number of subjects planned to be enrolled in the study has been increased from 240 to 270 in order to account for potential drop-outs from the study.<wbr> </div><div style="margin-bottom: 10px;">Additionally, the amendment allows for the inclusion of Crohn's disease patients with moderate to severe disease despite current treatment with anti-Tumor Necrosis Factor (anti-TNF) therapies infliximab (Remicade<SUP>(R)</SUP>) and adalimumab (Humira<SUP>(R)</SUP>).<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>The inclusion of these concomitant medications significantly increases the number of Crohn's disease patients potentially eligible to enroll in the ongoing Phase III <A href="https://clinicaltrials.gov/ct2/show/NCT01951326?term=Redhill+AND+MAP&amp;rank=1">MAP US </A>study.<wbr> </P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">With 66 clinical sites actively enrolling patients, RedHill also plans to increase the number of clinical sites in the Phase III MAP US study, currently ongoing in the U.<wbr>S.<wbr>, Canada and Israel, from 100 to 120, including new sites in Australia, New Zealand and Europe.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2210_1_ScreenCapture1.jpg"> </div><div><EM>Source: RedHill</EM> </div><!-- Comment details --><a name="gastroenterology2210attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2210_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(91,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2210">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-29T13:55:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-29T13:55:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's Q4 Earnings - Key Takeaways</title>
	<pubDate>2015-01-28T19:19:58+01:00</pubDate>
	<wp:post_id>6098</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfizer's Q4 webcast focused on many points with some of the more interesting comments directed towards whether the company will pursue a large acquisition or not, the consideration it may be giving to splitting up the company in 2015 and the scope of its immuno-oncology development programme with Merck KGaA.<wbr> Key product sales of interest to Ipsen are Somavert (pegvisomant acromegaly) which recorded sales of $229m +6% and Genotropin (growth hormone) sales were $723m -6%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ian Reid's (Chairman &amp; CEO) Comments Regarding Pfizer's Partnership with Merck KGaA</STRONG> </div><div style="margin-bottom: 10px;">"Through our partnership with Merck KGaA and their anti-PD-L1, avelumab, we are able to accelerate our participation in the immuno-oncology space, enabling both companies to participate in the first wave of potential single agent monotherapy treatment regimens of several tumor types, some of which we expect to be first or second to market </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="color: black; margin: 0cm 0cm 0pt; mso-list: l0 level2 lfo2; tab-stops: list 72.0pt;">Additionally, through this partnership we are positioned to be a potential leader in the next wave of I-O combination therapies
</LI>
<LI style="color: black; margin: 0cm 0cm 0pt; mso-list: l0 level2 lfo2; tab-stops: list 72.0pt;">We expect to be amongst the first three companies in certain cancer indications with monotherapy and a leader with combinations of PD-L1 avelumab with targeted agents, for example, Inlyta, Xalkori and second-generation ALK or dual I-O combinations example, 4-1BB, OX40, ADCs, et cetera and in various cancer indications
</LI>
<LI style="color: black; margin: 0cm 0cm 0pt; mso-list: l0 level1 lfo4; tab-stops: list 36.0pt;">This year we will be collaborating on up to 20 studies with Merck KGaA with registrational intent on up to six of these studies
</LI>
<LI style="color: black; margin: 0cm 0cm 0pt; mso-list: l0 level2 lfo5; tab-stops: list 72.0pt;">In addition, through the collaboration, we expect to have five different I-O drugs in the clinic this year and up to ten by 2016"
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif;"><STRONG>Regarding Generating Shareholder Returns</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><H3><SPAN style="font-family: arial,helvetica,sans-serif;"><SPAN style="font-size: small;">n 2015, Pfizer will continue its efforts to finish the ground work required to be in a position to operationalize a potential split of the company For 2015, its anticipate the effort that will be required for this work will result in approximately $400mm in one-time costs on a pre-tax basis.<wbr> At this point the board has not yet made a final decision that this will occur.<wbr></SPAN></SPAN></H3> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black; font-family: arial,helvetica,sans-serif; font-size: small; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black; font-family: arial,helvetica,sans-serif; font-size: small;"><STRONG>"</STRONG>So on the price, willing sellers &ndash; price always determines whether you have a willing seller or not normally; it&rsquo;s just a matter of what value you want to transfer.<wbr> What I would say is I think the starting point of the prices are somewhat &ndash; buoyant, shall we say, given where the marketplace is, so that does give you some concern when you look at paying the type of prices or premiums you need off what we see as high valuations to begin with.<wbr> So we are being disciplined in how we look at that.<wbr>"</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;"><STRONG>Sales Breakdown For Somavert &amp; Genotropin</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;"><STRONG>Somavert (12 month breakdown)</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">Total $m 229 vs 217 +6%</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">US $m 57 vs 52 +8%</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">ROW $m 172 vs 165 +5%</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">Europe $m 141 vs 134 +5%</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;"><STRONG>Genotropin (12 month breakdown)</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">Total $m 723 vs 772 -6%</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">US $m 184 vs 199 -7%</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">ROW $m 539 vs 573 -6%</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="color: black;">Europe $m 251 vs 268 -6%</SPAN> </div><div><SPAN lang="EN-US" style="color: black;">Source: Pfizer's Q4 Earnings Webcast</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11075">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-28T19:19:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-28T19:19:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takehome Messages from Roche's Results</title>
	<pubDate>2015-01-28T19:03:26+01:00</pubDate>
	<wp:post_id>6099</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Group sales increased by 5% (at CER), and Pharma Division by 4%, driven by oncology (HER2, Avastin), and strong growth in immuology (Actemra, Xolair).<wbr> The 2015 milestones chart indicates expansion in cancer immunotherapy (PD-L1: Bladder, Lung, Renal, Triple Negative BC - NMEs: OX40, CD40, CEA-IL2, CSF1R, IDO, CEA-CD3), and entries into Hemophilia and multiple sclerosis.<wbr> Roche faces increased competition in the field of oncology.<wbr> BMS <BMY.N>and Merck &amp; Co <MRK.N>have taken the lead, gaining approval for 2 immunotherapy drugs to treat advanced melanoma.<wbr> Roche Management expects pivotal data for its PD-L1 drug in lung cancer this year, with a potential filing for approval scheduled for 2016.<wbr> A selection of key slide is provided below.<wbr></MRK.N></BMY.N> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>2014</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>As of 2014 year end</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Additional trials</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_6_ScreenCapture6.jpg"> </div><!-- Comment details --><a name="oncology10237attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(73 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(93,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(80,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(116,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(98,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10237_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(35,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10237">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-28T19:03:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-28T19:03:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NICE Gives Green Light To An Ultra Orphan Drug Costing £340,000 Per Year</title>
	<pubDate>2015-01-28T18:28:39+01:00</pubDate>
	<wp:post_id>6100</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NICE known for its recent practice of refusing life-extending treatments particularly in the oncology field, has surprised many by agreeing that the drug eculizumab (Soliris) from Alexion can be made available to kidney patients with atypical haemoliytic uraemic syndrome on the NHS claiming that the drug offers gains " of a magnitude that is rarely seen for any new drug treatment" in this instance seemingly 25 years of good quality life.<wbr> </div><div style="margin-bottom: 10px;">It appears that when such small populations are involved, as in this case (patient population is around 200 in the UK with 30 new cases diagnosed each year), NICE's QALY calculations breakdown and it allows itself more discretion.<wbr> </div><div style="margin-bottom: 10px;">Without such treatment many patients with aHUS have to have routine dialysis and often die soon after diagnosis.<wbr> </div><div style="margin-bottom: 10px;">Patients treated will have to remain on the drug for life.<wbr> Hence the annual budget for treatment is expected to be of the order of &pound;82m.<wbr> About 56 patients are currently receiving the drug through an interim agreement with the NHS, which will now fund the drug permanently.<wbr> </div><div style="margin-bottom: 10px;">Reportedly, NICE is considering at least one other highly expensive drug under a special regime set up two years ago for very rare conditions.<wbr> If approved it could cost the NHS similar amounts.<wbr> </div><div style="margin-bottom: 10px;">Source: The Times 28th January </div><div><a href="https://www.nice.org.uk/news/press-and-media/first-nice-highly-specialised-technologies-guidance-recommends-eculizumab-soliris-for-treating-very-rare-life-threatening-blood-disorder" class="defaultlink" title="https://www.nice.org.uk/news/press-and-media/first-nice-highly-specialised-technologies-guidance-recommends-eculizumab-soliris-for-treating-very-rare-life-threatening-blood-disorder">nice.org.uk/<wbr>news/<wbr>&hellip;</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11073">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-28T18:28:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-28T18:28:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Strength of Norditropin® FlexPro® to Reach the US Market</title>
	<pubDate>2015-01-28T14:47:37+01:00</pubDate>
	<wp:post_id>6101</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Strength of Norditropin® FlexPro®  to Reach the US Market</span>&nbsp;<br><span style="font-size: 12px;">Comment: Available from April 2015, the FlexPro<SUP>®</SUP> 30 mg/<wbr>3.<wbr>0 mL device will complement the existing portfolio of Norditropin<SUP>®</SUP> FlexPro<SUP id="yui_3_16_0_1_1422360195916_1412">®</SUP> products available in 5 mg/<wbr>1.<wbr>5 mL, 10 mg/<wbr>1.<wbr>5 mL and 15 mg/<wbr>1.<wbr>5 mL pens.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7930">...</a><br></div><div>Elaine Arnold (Commercial Manager Pediatric Endocrinology, UK) has commented this information.<wbr> She would rate it as "an important one.<wbr> The FlexPro device is a good one, already with a very strong range of presentation sizes, and particularly for paediatrics, a 30mg size would be an advantage.<wbr> It gives a positive message to the market as well with regards to commitment and development.<wbr> If this new size comes to Europe, it will strengthen further the extremely compelling offer from Novo".<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7936">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7930">View thread  Endocrinology7930: New Strength of Norditropin® FlexPro®  to Reach the US Market</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-28T14:47:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-28T14:47:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Probi's End-Year Results</title>
	<pubDate>2015-01-28T14:39:10+01:00</pubDate>
	<wp:post_id>6102</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In 2014, CEO reported net sales rose 32% to MSEK135.<wbr> Of note, during this period, sales more than doubled in the US.<wbr> Management has outlined the launch this year of a well documented product that increases the body's ability to absord iron.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sharp growth was the result of Probi's partnership with Pharmavite and NBTY (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2038" class="defaultlink">GastroEnterology2038: Probi and Pharmavite Expand Probiotic Product Partnership in the US and International Markets</a>), and launch in Korea (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=1966" class="defaultlink">GastroEnterology1966: Sanofi Korea to Launch Probi Digestis® for IBS</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Fourth Quarter of 2014</U> </div><div style="margin-bottom: 10px;">NET SALES amounted to MSEK 39.<wbr>9 (26.<wbr>2).<wbr>  </div><div style="margin-bottom: 10px;">OPERATING PROFIT totalled MSEK 6.<wbr>6 (3.<wbr>1).<wbr> </div><div style="margin-bottom: 10px;">CASH FLOW amounted to MSEK 10.<wbr>6 (neg: 0.<wbr>1).<wbr> </div><div style="margin-bottom: 10px;"><U>FY2014</U> </div><div style="margin-bottom: 10px;">NET SALES amounted to MSEK 135.<wbr>2 (102.<wbr>2).<wbr> </div><div style="margin-bottom: 10px;">OPERATING PROFIT totalled MSEK 27.<wbr>0 (18.<wbr>1 </div><div>CASH FLOW amounted to MSEK 16.<wbr>9 (4.<wbr>0).<wbr> Probi paid dividends of MSEK 6.<wbr>8 (6.<wbr>8).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2208">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-28T14:39:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-28T14:39:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</title>
	<pubDate>2015-01-28T14:36:39+01:00</pubDate>
	<wp:post_id>6103</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</span>&nbsp;<br><span style="font-size: 12px;">Neurocrine Biosciences has announced that  the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting.<wbr> The presentation will take place on Thursday, March 5, 2015 from 11:30 am to 1:00 pm (PST) during the session entitled "HPA Axis and Adrenal: Receptors to Clinical Impact.<wbr>"</span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7929">...</a><br></div><div>This is an interesting approach from the endocrinological perspective.<wbr> The patients will still, however, need to take hydrocortisone replacement therapy.<wbr> The advantage of Chronocort is that it does both - controls ACTH secretion and also provides replacement therapy.<wbr>  Chronocort is also going into Phase III, so it is way ahead </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7935">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7882">View thread  Endocrinology7882: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-28T14:36:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-28T14:36:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Q4 2014 Financial Results</title>
	<pubDate>2015-01-27T22:23:15+01:00</pubDate>
	<wp:post_id>6104</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis Q4 and full 2014 year results were announced today.<wbr> Mr Jiminez, CEO, called 2014 as the year of delivering operational excellence through strengthening innovation and transforming the company and in particular the portfolio.<wbr> Endocrinology products appear to be playing a key role in the next 5 years pipeline with approval of Signifor in acromegaly in EU and US (end of 2014) followed by Afinitor key results in NET expected for 2015.<wbr> In the financial report RADIANT-4 pivotal trial results in non-functioning GI/<wbr>lung NET are listed for Q2 2015 (confirming previous intelligence).<wbr> Also increasing interest in Cushing disease, with Signofor LAR planning to file in 2016 and LCI699 in 2017.<wbr> </div><div style="margin-bottom: 10px;">Group net sales increased 1%(+3%cc) to $58 billion in the full year 2014.<wbr> Growth products contributed to $18.<wbr>6 billion or 32% of group net sales, up 18%($) over 2013.<wbr> Loss of exclusivity, including Diovan, impacted sales by approximately $2.<wbr>4 billion.<wbr> </div><div style="margin-bottom: 10px;">R&amp;D budget was up by about 1% to $9.<wbr>9 billion in 2014 to strongly support innovation.<wbr> Innovation for pharma was strongly driven by the US approval of Zykadia in NSCLC and by two drugs to be launched in 2015, LCZ696 for chronic heart failure and Cosentyx (approved in January 2015) for psoriasis.<wbr> Novartis is working towards being the first company to launch the anti-IL17A Cosentyx with three indications in the label (psoriasis, psoriatic arthritis and ankylosing spondylitis).<wbr> In the second half of 2015 Novartis is also expecting FDA decisions on the cancer therapy LDE225 and the QVA149 and NVA237 combination for COPD.<wbr> </div><div style="margin-bottom: 10px;">The key products for growth of the pharma division included Afinitor, representing 22% of the full year growth.<wbr> </div><div style="margin-bottom: 10px;">Signifor approval was also highlighted as a new long acting release formulation for the treatment of acromegaly and described as a product that gives the opportunity to the patients 'to get their disease under control' and 'should add few hundred million dollars to Novartis overall analogue franchise', said David Epstein (Division Head, Pharma).<wbr> </div><div style="margin-bottom: 10px;">As of January 2015 the pharma division has the following structure including the listed areas: oncology, immunology and dermatology, cardio-metabolic, retina, neuroscience, respiratory, cell and gene therapies and established medicines.<wbr> </div><div style="margin-bottom: 10px;">Source: Novartis Financial Results, Novartis PR </div><div style="margin-bottom: 10px;">Note: For all the relevant presentation slides, please make sure you open the 'Related Content' attachments </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_7_Novartis%255f1.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_8_Novartis%255f5.JPG"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_10_Novartis%255f7.JPG"> </div><!-- Comment details --><a name="endocrinology7932attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_7_Novartis%255f1.JPG">Novartis_1.JPG</a>&nbsp;&nbsp;(108,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_8_Novartis%255f5.JPG">Novartis_5.JPG</a>&nbsp;&nbsp;(89,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_9_Novartis%255f7.JPG">Novartis_7.JPG</a>&nbsp;&nbsp;(126,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_11_Novartis%255f8.JPG">Novartis_8.JPG</a>&nbsp;&nbsp;(117,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_13_Novartis%255f3.JPG">Novartis_3.JPG</a>&nbsp;&nbsp;(87,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7932_14_Novartis%255f6.JPG">Novartis_6.JPG</a>&nbsp;&nbsp;(93,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7932">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-27T22:23:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-27T22:23:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Strength of Norditropin® FlexPro® to Reach the US Market</title>
	<pubDate>2015-01-27T13:53:35+01:00</pubDate>
	<wp:post_id>6105</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Available from April 2015, the FlexPro<SUP>®</SUP> 30 mg/<wbr>3.<wbr>0 mL device will complement the existing portfolio of Norditropin<SUP>®</SUP> FlexPro<SUP id="yui_3_16_0_1_1422360195916_1412">®</SUP> products available in 5 mg/<wbr>1.<wbr>5 mL, 10 mg/<wbr>1.<wbr>5 mL and 15 mg/<wbr>1.<wbr>5 mL pens.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">To offer an additional option for patients who may require a higher dose of treatment, and better address the unique needs of appropriate patients on treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">EU timelines were not provided in the PR.<wbr> So please let us know if you happen to hear or read information on this subject.<wbr> </div><div>Source: NNordisk PR </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7936c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Elaine Arnold (Commercial Manager Pediatric Endocrinology, UK) has commented this information.<wbr> She would rate it as "an important one.<wbr> The FlexPro device is a good one, already with a very strong range of presentation sizes, and particularly for paediatrics, a 30mg size would be an advantage.<wbr> It gives a positive message to the market as well with regards to commitment and development.<wbr> If this new size comes to Europe, it will strengthen further the extremely compelling offer from Novo".<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7930">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-27T13:53:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-27T13:53:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Heat Biologics Presented Positive Immunological Data On HS-410 in NMIBC</title>
	<pubDate>2015-01-27T10:55:25+01:00</pubDate>
	<wp:post_id>6106</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Heat Biologics presented positive immunological data on HS-410 in non-muscle invasive bladder cancer at the Annual Phacilitate Immunotherapy Forum 2015, Washington USA.<wbr> From its Ph1 trial, HS-410 substantially increased tumour infiltrating lymphocytes in non muscle invasive bladder cancer (NMIBC) patients.<wbr> Observation of a highly polarized immune response in favour of CD8+ T cells in a patient where residual disease was eliminated is encouraging.<wbr> HS-410 is an immunotherapy that is engineered to specifically stimulate antigen specific cytotoxic T-cells (CD8+).<wbr> The data supports the mechanism of action of the <EM>ImPACT</EM>vaccines, and may represent a treatment effect.<wbr> An interim analysis of the 10 patients in Phase 1 is expected in the first half of 2015, and the Phase 2 study is still ongoing with a primary endpoint of recurrence-free survival.<wbr> The enrolment of the Phase 2 study is expected to complete in Q3 2015, and topline data from the Ph2 study will be  available in the 2016 2H.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block">The Phase 1 trial enrolled patients who have had Ta, T1, or Tis NMIBC (tumour removed).<wbr> For the open-label Phase 1 trial to assess safety and tolerability, 10 patients received 5-6 weekly doses of BCG before HS-410 administration.<wbr> After BCG treatment, patients received a low dose of HS-410.<wbr> Patients were given 12 weekly injections followed by 3 monthly injections.<wbr> HS-410 was well-tolerated with no serious adverse events, allowing Heat Biologics to initiate its current Phase 2 trial.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="copy-paste-block">Biopsies were collected at baseline and at the appearance of suspicious lesions from all patients enrolled in the Phase 1 trial.<wbr> Analysis of tumor-infiltrating lymphocytes (TILs) in one patient after surgery and induction BCG (<EM>bacillus Calmette-Guerin</EM>) followed by 6 weeks of HS-410 demonstrated an approximately 70-fold increase in CD8 expression (a marker for CD8+ killer T cells) within the tumor, which was not associated with any increase in CD4 expression (a marker for CD4+ helper T cells).<wbr> When this patient returned at week 21, the trend continued and an approximate 750-fold increase in CD8 was observed, without any increase in CD4 expression.<wbr> This high degree of specific immune infiltrate is consistent with Heat Biologics' preclinical findings and the known mechanism of action for its gp96-Ig based vaccines.<wbr> This patient currently remains disease-free.<wbr>

<DIV class="copy-paste-block">The increase in levels of tumor infiltrating lymphocytes appeared to correlate with the clinical response observed with HS-410.<wbr> In a second patient, a non-specific immune infiltrate was noted on week 7 to be slightly increased as compared to baseline, but which consisted of both CD4+ and CD8+ T cells.<wbr> This patient returned with recurrent disease at week 13, when the repeat biopsy showed no further increase in the immune infiltrate.<wbr></DIV>
</DIV> </div><div><DIV class="copy-paste-block">Source: Heat Biologics Press Release 26 January 2015<BR></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10236">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-27T10:55:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-27T10:55:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</title>
	<pubDate>2015-01-27T10:11:51+01:00</pubDate>
	<wp:post_id>6107</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</span>&nbsp;<br><span style="font-size: 12px;">Comment: Neurocrine Biosciences announced today the start of a new clinical programme with a proprietary CRF-1 antagonist NBI-77860 to address congenital adrenal hyperplasia (CAH).<wbr>The Company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately fifteen adolescent females with classic CAH.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7882">...</a><br></div><div style="margin-bottom: 10px;">Neurocrine Biosciences has announced that  the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting.<wbr> The presentation will take place on Thursday, March 5, 2015 from 11:30 am to 1:00 pm (PST) during the session entitled "HPA Axis and Adrenal: Receptors to Clinical Impact.<wbr>" </div><div><TABLE style="width: 100%;"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7935c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>This is an interesting approach from the endocrinological perspective.<wbr> The patients will still, however, need to take hydrocortisone replacement therapy.<wbr> The advantage of Chronocort is that it does both - controls ACTH secretion and also provides replacement therapy.<wbr>  Chronocort is also going into Phase III, so it is way ahead </div></div><a name="Endocrinology7967c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Neurocrine Biosciences has announced on February 17th an underwritten public offering of shares to raise $225M to fund its R&amp;D efforts as well for preparing for commercialization of its lead assets.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7929">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7882">View thread  Endocrinology7882: First Report Of Clinical Activity With A New CRF-1 antagonist in Congenital Adrenal Hyperplasia</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-27T10:11:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-27T10:11:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis to Become Largest UK Generics Supplier</title>
	<pubDate>2015-01-26T15:32:25+01:00</pubDate>
	<wp:post_id>6108</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: With the acquisition of Auden Mckenzie for approx £306M ($459M) in cash, Actavis will add about 175 new generic and branded products as well as a pipeline of approximately 40 additional products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- inception in 2000 </div><div style="margin-bottom: 10px;">- privately owned- notable position among the UK niche generic businesses </div><div style="margin-bottom: 10px;">- <A href="http://www.audenmckenzie.com/products">product portfolio </A>includes a borad range of molecules in various dosage forms, for treatments across a broad spectrum of TAs.<wbr> </div><div>Source: <A href="http://finance.yahoo.com/news/actavis-acquire-auden-mckenzie-306m-123000022.html">http:/<wbr>/<wbr>finance.<wbr>yahoo.<wbr>com/<wbr>news/<wbr>actavis-acquire-auden-mckenzie-306m-123000022.<wbr>html</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11072">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-26T15:32:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-26T15:32:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Yissum and PhytoTech Medical to Develop Advanced Cannabis Based Therapeutic Products</title>
	<pubDate>2015-01-26T14:58:14+01:00</pubDate>
	<wp:post_id>6109</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Through this exclusive research and licensing agreement PhytoTech, which became on Jan 22 the first Australian listed medicinal marijuana company,  is strategically positioned to become a key player in the global Medical Grade Cannabis market.<wbr> Companies will be developing an improved, oral capsule formulation and transbuccal delivery system that consists of a flexible, muco-adhesive patch that will release the active ingredients of cannabis in a controlled manner.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On January 22 2015, the company raised AUS$5.<wbr>9 million dollars (approximately US$4.<wbr>7 million) at a share price of $0.<wbr>20 per share.<wbr> </div><div style="margin-bottom: 10px;">PhytoTech aims to grow proprietary strains of MGC in California, Uruguay and other jurisdictions.<wbr> </div><div style="margin-bottom: 10px;">Using proprietary technology, PhytoTech's vision is to administer ground breaking health benefits of cannabinoids in "<STRONG>oral preparations, vapour form, and other routes of administration in safe and effective ways"</STRONG>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">It estimates the global cannabis industry is worth up to $US100 billion.<wbr> </div><div><EM>Source: </EM><A href="http://www.abnnewswire.net/press/en/79151/PhytoTech_Medical_Limited_(ASX:PYL)_First_Medical_Cannabis_Company_to_List_on_the_Australian_Stock_Exchange.html">http:/<wbr>/<wbr>www.<wbr>abnnewswire.<wbr>net/<wbr>press/<wbr>en/<wbr>79151/<wbr>PhytoTech_Medical_Limited_(ASX:PYL)_First_Medical_Cannabis_Company_to_List_on_the_Australian_Stock_Exchange.<wbr>html</A>;  <A href="http://www.watoday.com.au/wa-news/perth-medicinal-marijuana-company-phytotech-starts-trading-on-a-high-20150122-12w06a.html">http:/<wbr>/<wbr>www.<wbr>watoday.<wbr>com.<wbr>au/<wbr>wa-news/<wbr>perth-medicinal-marijuana-company-phytotech-starts-trading-on-a-high-20150122-12w06a.<wbr>html</A>) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7904">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-26T14:58:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-26T14:58:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key PhII Trial In Ultra-orphan Endocrine Cancer Resumes under SPA</title>
	<pubDate>2015-01-26T12:55:39+01:00</pubDate>
	<wp:post_id>6110</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Progenics Pharmaceuticals has announced that it has dosed the first 
subject in the re-launched pivotal Phase 2 clinical study of the 
radiopharmaceutical Azedra™ in patients with malignant pheochromocytoma and 
paraganglioma.<wbr>an ultra-orphan cancers with limited treatment options.<wbr> The trial 
is being conducted under an SPA agreed with the US FDA and is planned to 
complete enrollment by the end of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Facts</STRONG> </div><div style="margin-bottom: 10px;">Progenics acquired Azedra, a novel targeted cancer radiotherapy, in 
conjunction with its 2013 acquisition of Molecular Insight Pharmaceuticals 
(MIP).<wbr> The drug has received Orphan Drug and Fast Track designations 
from the FDA for the treatment of phaeochromocytoma and paranganglioma.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the resumption of the trial principal 
investigator Dr.<wbr> Daniel Pryma,</STRONG> Associate Professor of Radiology and 
Clinical Director of Nuclear Medicine and Molecular Imaging at the University of 
Pennsylvania, stated:- </div><div style="margin-bottom: 10px;">"Relaunching this study is a very important milestone for patients with 
metastatic and/<wbr>or recurrent pheochromocytoma/<wbr> paraganglioma, this treatment has 
been generally well tolerated and the data emerging from the trial to date has 
been encouraging.<wbr> I am pleased to be resuming this study and feel that Azedra 
could represent the best treatment in malignant  pheochromocytoma/<wbr> 
paraganglioma in the future.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Study Design<BR></STRONG><BR>The study is designed to evaluate the 
efficacy and safety of the administration of two therapeutic doses of Azedra in 
patients with malignant relapsed/<wbr>refractory pheochromocytoma or paraganglioma, 
The primary objective of the study is to determine the clinical benefit of 
Azedra based on the proportion of study participants with a reduction of all 
antihypertensive medication by at least 50% for at least six months.<wbr> The SPA 
requires that 25% of 58 evaluable patients achieve the primary endpoint.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background to the trial suspension in 2010<BR></STRONG><BR>MIP 
suspended enrollment in the trial to seek additional funding  At this 
point, 41 patients had been treated  and 32% of those patients have 
achieved the primary endpoint.<wbr> The most common adverse events observed had been 
gastroenterological and hematologic disorders.<wbr> </div><div>Source: <A href="http://www.progenics.com">www.<wbr>progenics.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7928">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-26T12:55:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-26T12:55:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Next Big Opportunity In The Aesthetics Market Up For FDA Review</title>
	<pubDate>2015-01-26T12:41:48+01:00</pubDate>
	<wp:post_id>6111</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: KYTHERA Biopharmaceuticals, has announced that 
the Dermatology and Ophthalmic Drugs Advisory Committee of the US FDA 
is scheduled to review the group's NDA for ATX-101 (deoxycholic acid) for 
improvement in the appearance of moderate to severe submental fullness on the 
morning of March 9, 2015.<wbr> </div><div>KYTHERA submitted the ATX-101 NDA to the 
FDA on May 12, 2014.<wbr> The NDA has a PDUFA action date of May 13, 2015.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7903">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-26T12:41:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-26T12:41:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Albany Molecular to Manufacture Glide's Octreotide for Use in Bioequivalence Study</title>
	<pubDate>2015-01-26T11:07:20+01:00</pubDate>
	<wp:post_id>6112</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a PR issued today, Glide Technologies reported that Albany Molecular Research (AMRI) has been appointed to manufacture its octreotide formulation for use in a human bioequivalence study to be conducted in Q4:2015.<wbr> The study is designed to confirm that Glide's solid dose formulation has an equivalent pharmacokinetic profile to Sandostatin®.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
AMRI will install the clinical production line developed by Glide into its GMP facility, and will produce sterile octreotide solid doses for clinical study.<wbr></LI>
<LI>
Glide's clinical trial planned for later this year is AMRI will produce the novel formulation at its state-of-the-art facility in Glasgow, UK.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Glide SDI®, is an innovative approach for the parenteral administration of drugs, which uses a novel solid dose formulation delivered using the company's proprietary injector.<wbr> </div><div style="margin-bottom: 10px;">Glide SDI® offers comfort, ease-of-use for self-administration and improved product stability.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7925_1_ScreenCapture1.jpg"> </div><div><EM>Source: Glide</EM> </div><!-- Comment details --><a name="endocrinology7925attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7925_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7925">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-26T11:07:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-26T11:07:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Ph3 Details of DWP-450 (Botulinum purified neurotoxin, Type A)</title>
	<pubDate>2015-01-23T17:11:58+01:00</pubDate>
	<wp:post_id>6113</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Ph3 Details of DWP-450 (Botulinum purified neurotoxin, Type A)</span>&nbsp;<br><span style="font-size: 12px;">Comment: <EM>Clinicaltrials.<wbr>gov</EM> is listing two US registration trials of DWP-450 to treat glabellar lines.<wbr> Both studies (EV001 and EV002) will enroll approx.<wbr> 324 subjects each, be randomly assigned 3:1 to receive DWP-450 or placebo, and have same timelines and PE (reduction in GL as assessed by investigator and subject).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7880">...</a><br></div><div style="margin-bottom: 10px;">Ahead of IMCAS this week, ALPHAEON issued a press release yesterday noting that enrolment in its PhIII glabellar lines programme began on January 14th.<wbr> Whilst we believe it is still waiting for FDA inspection of its toxin manufacturing plant, clearly its IND data and EMA cGMP approval of its plant is proving adequate for it to initiate its phIII programme.<wbr> </div><div><P align="LEFT">Commenting on this development Chris Marmo President of ALPHAEON Beauty stated &ldquo;The agreement with the FDA on our phase III pivotal study protocol marks another key milestone on the execution of our neuromodulator development plan.<wbr> Access to EVOSYAL (DW450 BoNT-A) as noted previously was gained through the acquisition of Evolus last year which had previously in-licensed global aesthetic and therapeutic rights to the product from Daewoong in Korea.<wbr> At IMCAS last year Strathspey Crown the holding company for ALPHAEON noted that it was not intending to focus on the development of the toxin for aesthetic purposes only.<wbr></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7900">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7880">View thread  Neurology7880: Ph3 Details of DWP-450 (Botulinum purified neurotoxin, Type A)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-23T17:11:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-23T17:11:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dicerna Announced Positive Preclinical HCC/CRC Data At The Recent AACR Meeting</title>
	<pubDate>2015-01-23T16:49:31+01:00</pubDate>
	<wp:post_id>6114</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dicerna highlighted new preclinical data on its Dicer substrate short interfering RNA therapeutics targeting MYC &amp; B-cantenin oncogenes in models of HCC and CRC respectively.<wbr> Dicerna's DCR-MYC oncology program is on track in human proof-of-concept clinical studies, with initial clinical data expected by the end of 2015.<wbr> </div><div style="margin-bottom: 10px;">The poster (abstract #358), titled, <A href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dicerna.com%2Fpdf%2FAACR_MYC_v5.pdf&amp;esheet=51016814&amp;newsitemid=20150112005458&amp;lan=en-US&amp;anchor=EnCore-LNP+mediated+tumor+delivery+of+MYC+and+CTNNB1+Dicer+substrate+RNAs+%28DsiRNAs%29&amp;index=1&amp;md5=a8baa4e7a5bb1c10969eecb0cda3215f" rel="nofollow"><EM></EM></A> highlighted data from multiple preclinical models in HCC and CRC.<wbr> </div><div style="margin-bottom: 10px;">The new data included:- </div><div style="margin-bottom: 10px;"><OL><LI>A pharmacokinetic (PK) study, which demonstrated that the PK properties of EnCore can be optimized to increase the tumor bioavailability of DsiRNAs.<wbr>
</LI>
<LI>A robust, quantitative way to measure target engagement and the mode of action of MYC DsiRNA in a mouse model of HCC.<wbr> Using a quantitative RNAi target engagement assay and next-generation sequencing (NGS) technology, researchers showed that more than 90% of MYC messenger RNA (mRNA) fragments in the tumor match the predicted DsiRNA target site.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;">Dicerna plans to apply this technology in the clinic, along with fluorodeoxyglucose positron emission tomography (FDG-PET) as a more conventional radiology marker to determine if silencing the MYC oncogene results in a favorable reduction of tumor metabolic activity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is DCR-MYC?</STRONG> </div><div style="margin-bottom: 10px;">Dicerna's investigational Dicer substrate siRNA (DsiRNA) molecule, is a synthetic double-stranded RNA delivered via the company's proprietary EnCore&trade; LNP delivery system.<wbr> </div><div style="margin-bottom: 10px;">DCR-MYC is designed to serve as a potent and specific inhibitor of the MYC oncogene, MYC being a key target in oncology because it has been demonstrated to cause or promote cancer when abnormally expressed or activated.<wbr> The MYC oncogene encodes for a small intracellular protein that lacks a good binding site, making it a challenging target for monoclonal antibodies or traditional small molecules.<wbr> However, DsiRNA therapeutics may be able to overcome these challenges by "silencing" the MYC oncogene in cancer cells.<wbr> </div><div>Source: <A href="http://www.dicerna.com">www.<wbr>dicerna.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10234">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-23T16:49:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-23T16:49:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on the Prostate Cancer DataBase (C-CaP) in China</title>
	<pubDate>2015-01-23T12:30:14+01:00</pubDate>
	<wp:post_id>6115</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Yan Yusu (Sr Product Manager) we have more granularity on this database, and learnt that the project was initiated in 2013, with Takeda as a sponsor.<wbr> Additional details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On December 23 2014, Wu Jieping Medical Foundation (lead by Pr Na Yanqun) announced the launch of the database.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<DIV class="ii" id="oncology10224.07ii">- Objective: to collect information on diagnosis and treatment to track its incidence and development.<wbr></DIV></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">Takeda reported it would suppport the Chinese database jointly with the Japanese one to create an Asian prostate cancer database.<wbr> </div><div style="margin-bottom: 10px;"> </div><div><U>Reference in Traction</U>: Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10224" class="defaultlink">Oncology10224: J&J's CEO Complains on Drugs' Path to China</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10232">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-23T12:30:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-23T12:30:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Reported Postive Result For Ph2 TERRAIN Trial (Enzlutamide vs Bicalutamide In Metastatic Setting)</title>
	<pubDate>2015-01-22T22:41:56+01:00</pubDate>
	<wp:post_id>6116</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Commet: Today Astellas/<wbr>Medivation announced positive results for enzalutamide phase 2 Terrain and enzalutamide demonstrated statistically significant Increase in PFS as compared to bicalutamide in metastatic prostate cancer.<wbr> The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared to bicalutamide (Hazard Ratio = 0.<wbr>44; 95% Confidence Interval, 0.<wbr>34-0.<wbr>57; p &lt; 0.<wbr>0001).<wbr> Median PFS was 15.<wbr>7 months in the enzalutamide group compared to 5.<wbr>8 months in the bicalutamide group.<wbr> The median time on treatment in TERRAIN was 11.<wbr>7 months in the enzalutamide group versus 5.<wbr>8 months in the bicalutamide group.<wbr> This may place Xtandi a step ahead of Zytiga to enter prostate cancer in the earlier setting, and more importantly, to shape the choice of ADT thearpy in metasatic setting.<wbr> </div><div style="margin-bottom: 10px;">TERRAIN trial (Ph2) enrolled 375 patients in North America and Europe.<wbr> The trial involved patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration.<wbr> The primary endpoint of the trial was progression-free survival, defined as time from randomization to centrally confirmed radiographic progression, skeletal related event, initiation of new anti-neoplastic therapy or death, whichever occurs first.<wbr> The trial was designed to evaluate enzalutamide at a dose of 160 mg taken once daily versus bicalutamide at a dose of 50 mg taken once daily, the approved dose in combination with a LHRH analogue.<wbr> Targeted enrollment was completed in July 2013.<wbr> The results of this study showed that enzalutamide provides a longer duration of disease control in the studied patient population compared to bicalutamide.<wbr> Additional data from the Phase 2 TERRAIN trial, including the secondary endpoints and further safety data, will be submitted for presentation at an upcoming medical conference.<wbr> Serious adverse events were reported in 31.<wbr>1% of enzalutamide-treated patients and 23.<wbr>3% of bicalutamide-treated patients.<wbr> Grade 3 or higher cardiac adverse events were reported in 5.<wbr>5% of enzalutamide-treated patients versus 2.<wbr>1% of bicalutamide-treated patients </div><div>Source: Medivation Press Release 22nd Janurary 2015 .<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10229">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-22T22:41:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-22T22:41:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from AbbVie at JP Morgan H/C Conference</title>
	<pubDate>2015-01-22T16:40:44+01:00</pubDate>
	<wp:post_id>6117</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bill Chase, Executive VP, Finance and CFO outlined that growth in 2015 will be driven by continued strong growth from Humira, and the launch of Viekira (interferon‐free HCV regimen).<wbr> Oncology was reported being an emerging strength for the company, with promising assets in mid-late stage development.<wbr> When it comes to Elagolix (Ph3/<wbr>endometriosis; Ph2b for UF), management highlighted that its goal with the drug is to bring to market an oral short-acting therapy that provides a high level of efficacy with minimal menopausal side effects while preserving bone health.<wbr> Please see more details below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Important Development upcoming</U> </div><div style="margin-bottom: 10px;">In 2014, AbbVie completed a clinical program evaluating Humira as a treatment for hidradenitis suppurativa (HS), a chronic inflammatory skin disease.<wbr> The company reported positive results from two Ph3 studies and the US and EU regulatory applications are currently under review.<wbr> Given disease prevalence and the lack of effective treatment options, management believes HS has the potential to be a meaningful indication with peak year sales that could approach $1 billion.<wbr> </div><div style="margin-bottom: 10px;">AbbVie is also exploring Humira as a possible treatment for uveitis, a sight threatening inflammatory eye disease.<wbr> Management expects to complete a Ph3 program and submit regulatory applications later this year.<wbr> </div><div style="margin-bottom: 10px;"><U>Drug Positionning</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10227_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">To consolidate its leadership position in CD, AbbVie recently entered a microbiome-based collboaration with Enterome (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2114" class="defaultlink">GastroEnterology2114: AbbVie and Enterome Enter Microbiome-Based Collaboration in Crohn's Disease</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10227_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10227_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Last week, positive top-line results from the first of two ongoing Ph3 clinical trials were announced (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10195" class="defaultlink">Oncology10195: Positive  Top-Line Results of Elagolix (GnRH antagonist) for Endometriosis</a>).<wbr> </div><div style="margin-bottom: 10px;">Initial results from the study showed that after 6 months of treatment both evaluated doses of the drug met the study's co-primary endpoints of reducing scores of non-menstrual pelvic pain and menstrual pain associated with endometriosis relative to placebo control.<wbr> </div><div style="margin-bottom: 10px;">Additional efficacy and safety data from this ongoing trial will be reported later this year.<wbr> </div><div style="margin-bottom: 10px;">Results from the mid-stage trial in uterine fibroids are expected later this year as well.<wbr> </div><div><EM>Source: AbbVie</EM> </div><!-- Comment details --><a name="oncology10227attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10227_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10227_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10227_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(19,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10227">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-22T16:40:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-22T16:40:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MAA for AZ' Gout Treatment Accepted by EMA</title>
	<pubDate>2015-01-22T11:50:57+01:00</pubDate>
	<wp:post_id>6118</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Agency has accepted the Marketing Authorisation Application for lesinurad 200mg tablets, setting it up for a possible approval later this year.<wbr> Lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The MAA filing was based on data from the CLEAR1, CLEAR2 and CRYSTAL pivotal Ph3 combination therapy studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>CLEAR1 and CLEAR2</STRONG> were 12-month, multicentre, randomised, placebo-controlled studies that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with allopurinol versus allopurinol alone, in symptomatic gout patients not achieving target serum uric acid (sUA) levels on their current allopurinol therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>CRYSTAL</STRONG> was a 12-month, multicentre, randomised, placebo-controlled study that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with febuxostat compared to febuxostat alone in gout patients with tophi (deposits of uric acid crystals in joints and skin).<wbr> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=10930" class="defaultlink">PharmaWorld10930: AZ Announces Positive Top-Line PhIII Gout Data</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Lesinurad works by inhibiting the uric acid transporter URAT1 in the kidney, thereby increasing uric acid excretion resulting in lower sUA.<wbr> </div><div style="margin-bottom: 10px;">Combination therapy with lesinurad and an XO inhibitor provides a dual mechanism approach targeting both excretion and production of uric acid which effectively lowers sUA and enables significantly more patients to achieve and maintain target treatment goals to control their disease.<wbr> </div><div><EM>Source: AstraZeneca PR</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2706c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">In a letter sent to the US FDA, Public Citizen has asked the agency to reject the advice of its advisory commitee and not approve lesinurad.<wbr> </div><div style="margin-bottom: 10px;">Public Citizen maintains that multiple FDA-approved gout medications already are on the market and lesinurad does not offer any major benefits compared to these approved therapies.<wbr> Clinical trials of lesinurad showed that it provides at best meager benefits, but is associated with very troubling safety concerns, the most significant being compelling evidence of kidney toxicity and serious cardiac adverse events.<wbr> </div><div>“FDA approval of lesinurad — even with reliance on warnings in the product labeling, a risk evaluation and mitigation strategy, and postmarket safety studies — would be a reckless approach and would not be in the interests of public health,” said Dr.<wbr> Michael Carome, director of Public Citizen’s Health Research Group.<wbr> </div></div><a name="GastroEnterology2718c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorisation of lesinurad 200mg tablets.<wbr> Lesinurad, in combination with a xanthine oxidase inhibitor (XOI), is recommended for the adjunctive treatment of hyperuricaemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid levels (sUA) with an adequate dose of a XOI alone.<wbr> </div><div style="margin-bottom: 10px;">The CHMP&rsquo;s positive opinion on lesinurad will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).<wbr> The final decision will be applicable to all 28 EU member countries plus Iceland, Norway and Liechtenstein.<wbr> AstraZeneca anticipates a final decision by the EC in the first quarter of 2016.<wbr> If approved, lesinurad will be the first selective uric acid reabsorption inhibitor (SURI) to treat patients with inadequately controlled gout in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>US Situation</STRONG> </div><div>Lesinurad is also under review in the United States.<wbr> On 23 October 2015, the US Food and Drug Administration&rsquo;s Arthritis Advisory Committee recommended the approval of lesinurad 200mg tablets for the treatment of hyperuricemia associated with gout, in combination with an XOI.<wbr> The Prescription Drug User Fee Act (PDUFA) target goal date is 29 December 2015.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2204">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-22T11:50:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-22T11:50:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Ad-sig-hMUC-1/ecdCD40L Vector Vaccine Has Entered Ph1</title>
	<pubDate>2015-01-22T11:12:04+01:00</pubDate>
	<wp:post_id>6119</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This particular cancer vaccine encodes one of the most common proteins, MUC-1 (expressed on many cancers such as ovarian, breast, prostate, colon, pancreas and lung cancer, but not expressed on normal cells) to the potent immune stimulating molecule CD40L.<wbr> It has been developed by a US biotech company, MicroVAX.<wbr> In preclinical studies, the vaccine was found to induce a potent immune response that surpassed that induced by other immunological strategies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="https://clinicaltrials.gov/ct2/show/NCT02140996">NCT02140996</A> </div><div style="margin-bottom: 10px;">Recruitment: approx 24 </div><div style="margin-bottom: 10px;"><UL><LI>Of the 4 patients treated to date, two are diagnosed breast cancer and the remaining two have ovarian cancer.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">MoA: the vaccine is injected under the patient's skin.<wbr> </div><div style="margin-bottom: 10px;">Sponsor: the Singapore Clinical Research Institute (SCRI), and conducted by Dr Toh Han Chong, Senior Consultant and Deputy Director at the National Cancer Centre Singapore (NCCS).<wbr> </div><div style="margin-bottom: 10px;">Main objective: to assess the safety and benefit of the vaccine, which aims to target a common protein on many of the commonest cancers such as colon cancer, breast cancer and ovarian cancer, and provide a specific extra boost to the immune system against cancer at the same time.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The MicroVAX cancer vaccine is comprised of the attachment of the target protein MUC-1, expressed on the surface of the cancers mentioned, to the potent immune stimulating molecule CD40L.<wbr> </div><div style="margin-bottom: 10px;">This novel combination aims to further power up the body’s full immune system to attack the surface cancer protein, MUC1, thereby killing the cancer cells themselves.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>MicroVAX is a clinical stage biotech company located in Manassas, Prince William County, VA, dedicated to the development of potent vaccines, for treatment and preventive purposes, having application to the areas of cancer and infectious diseases for which effective solutions have not yet been developed.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10226">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-22T11:12:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-22T11:12:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's CEO Complains on Drugs' Path to China</title>
	<pubDate>2015-01-22T10:38:47+01:00</pubDate>
	<wp:post_id>6120</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Interviewed by<EM> Bloomberg</EM>, Paul Stoffels reported that the Chinese pharmaceutical market is becoming increasingly difficult for drug companies because of how long regulators in the country take to approve new medicines.<wbr> In parallel <EM>Xinhua </EM>reported that the country has established its first database on prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Foreign pharmaceutical companies in China have expressed concerns that regulations are slowing approvals.<wbr> At least thirty-four applications from multinational drug companies have been or will be delayed after Chinese regulators began requiring an added administrative procedure before drugs can be approved, according to R&amp;D-Based Pharmaceutical Association Committee, or RDPAC, an industry group.<wbr> </div><div style="margin-bottom: 10px;">Previously, Chinese approval for drugs developed through international trials took about two years, and may now take twice as long, according to RDPAC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Initiated by Wu Jieping Medical Foundation, the Chinese Prostate Cancer Database (C-CaP) opened on Monday in Zhejiang Cancer Hospital in Hangzhou, east China's Zhejiang Province.<wbr> </div><div style="margin-bottom: 10px;">Objective: to collect information on diagnosis and treatment to track its incidence and development.<wbr> </div><div style="margin-bottom: 10px;">Epidemiology: The second most common cancer in men globally, prostate cancer is on the increase in China.<wbr> Data from the Chinese Anti-cancer Association show the cancer's incidence in China increased more than tenfold in the past two decades.<wbr> </div><div><EM>Source: Bloomberg; Xinhuanet</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10224">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-22T10:38:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-22T10:38:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: 4d Pharma Progresses with New Treatment for IBS and Crohn</title>
	<pubDate>2015-01-21T18:11:46+01:00</pubDate>
	<wp:post_id>6121</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">4d Pharma Progresses with New Treatment for IBS and Crohn</span>&nbsp;<br><span style="font-size: 12px;">Comment: The company has reported its "live biotherapeutics", Blautix for IBS and Thetanix for ped CD, are set to enter clinical studies in Q2:15.<wbr> On Aug.<wbr> 7th, Rosburix, its UC drug for ped patients won orphan drug designation from the FDA.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2019">...</a><br></div><div style="margin-bottom: 10px;">4D Pharma has raised &pound;34m through a shares placing.<wbr> 4D discovers and develops new live biotherapeutic candidates using its MicroRx platform.<wbr> This technology allows for the rapid screening of the Company's library of commensal bacteria, isolated from the human gut, for therapeutic effect.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial Background</STRONG> </div><div style="margin-bottom: 10px;">The Manchester company  floated on AIM London Stock Exchange in February last year, raising &pound;16.<wbr>5m.<wbr> </div><div style="margin-bottom: 10px;">Only a few months later the company raised an additional &pound;21.<wbr>5m because of the conditional placing of more than 14m new shares at a price of 150p.<wbr> </div><div>Its latest fundraising, through broker Zeus Capital of 8,475,610 new ordinary shares at a placing price of 410p, will be used to step-up its research efforts </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2203">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2019">View thread  GastroEnterology2019: 4d Pharma Progresses with New Treatment for IBS and Crohn</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-21T18:11:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-21T18:11:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study Has Started to Compare Guidance Techniques for Botox Injections for Limb Spasticity and Focal Dystonia</title>
	<pubDate>2015-01-21T18:02:15+01:00</pubDate>
	<wp:post_id>6122</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Under the responsibility of David Simpson, MD the study, sponsored by Mount Sinai School of Medicine, has been designed to compare electrophysiologic guidance, using electrical stimulation, and ultrasound.<wbr> PE will measure change in patient global impression of change.<wbr> Allergan will be providing the toxin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reference: <A href="https://clinicaltrials.gov/ct2/show/NCT02334683?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=12%2F21%2F2014&amp;rank=206">NCT02334683</A> </div><div style="margin-bottom: 10px;">Timelines: completion is expected Jan 2016 /<wbr> May 2016 </div><div style="margin-bottom: 10px;">Recruitment Approx 30 participants </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Confirmed diagnosis of focal upper extremity dystonia (FHD) or upper limb spasticity</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Stable onabotulinumtoxinA dose regimen with a stable response as judged by the physician and patient for at least 2 treatment sessions.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Design: The study will consist of four visits: </div><div style="margin-bottom: 10px;"><UL><LI><U>Visit 1</U> consists of screening subjects who will then be consented and randomized to one of the two treatment techniques for their ona-BoNT injection: 1) Electrophysiologic guidance using electrical stimulation or 2) ultrasound.<wbr> </LI>
<LI><U>Visit 2</U> will occur at week 4 where the subjects will return for a follow up visit to have blinded evaluator measurements of efficacy and strength and capture safety data.<wbr> </LI>
<LI><U>Visit 3</U> will be at week 12 when subjects will cross over and have the alternate treatment technique during their ona-BoNT injection.<wbr> </LI>
<LI><U>Visit 4</U> will occur at week 16 as the final assessment where subjects will have measurements of efficacy and strength and capture safety data by the blinded evaluator.<wbr></LI>
</UL> </div><div>Recruitment: </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7899">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-21T18:02:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-21T18:02:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Q4 And Full Year 2014 Earnings Highlight</title>
	<pubDate>2015-01-20T18:24:34+01:00</pubDate>
	<wp:post_id>6123</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Today J&amp;J reports 2014 Q4 and full year results - although overall strong growth is seen with Zytiga, this is mainly driven by new launches internationally (approved in 95 countries WW).<wbr> However, Zytiga's growth in US has slowed down and J&amp;J reported Zytiga share was approximately 31% of the market, down approximately 2 points on a sequential basis due to competition (i.<wbr>e.<wbr> Xtandi's entry in chemo na&iuml;ve mCRPC space).<wbr> In terms of long term growth, Alex Gorsky (CEO) used Zytiga and ARN-509 as the examples to demonstrate J&amp;J's success to identify new innovative products early and ensured the investors J&amp;J's strategic focus to continue identifying new compounds through M&amp;A deals.<wbr> ARN-509's filing in M0 CRPC setting and daratumumab's filing in Multiple Myeloma in the next two years are being highlighted as the two oncology examples to maintain J&amp;J market leadership position in respective markets.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_1_1.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_6_Capture.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_4_4.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_2_2.JPG"> </div><div>Source: J&amp;J Press Release 20 January </div><!-- Comment details --><a name="oncology10220attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_1_1.JPG">1.JPG</a>&nbsp;&nbsp;(156,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_2_2.JPG">2.JPG</a>&nbsp;&nbsp;(106,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_3_Capture.JPG">Capture.JPG</a>&nbsp;&nbsp;(56,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_4_4.JPG">4.JPG</a>&nbsp;&nbsp;(55,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_5_Capture.JPG">Capture.JPG</a>&nbsp;&nbsp;(52,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10220_6_Capture.JPG">Capture.JPG</a>&nbsp;&nbsp;(42,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10220">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-20T18:24:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-20T18:24:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Toxins 2015 - Part 1 Merz Focus On Patient Satisfaction & Shortened Injection Intervals</title>
	<pubDate>2015-01-20T18:09:26+01:00</pubDate>
	<wp:post_id>6124</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: One of the themes highlighted by the Toxins meetings and in particular by Merz/<wbr>affiliated KOLS was patient satisfaction with botulinum toxins treatment (all toxin types) and the potential for individualised patient dosing based on preliminary evidence.<wbr> Support for this concept led to the suggestion that the Inernational Neurotoxins Association should publish a consensus statement on the preliminary proof of concept, something that might start to sway payers who at this juncture will not pay for toxin treatment more frequently than every 3 months.<wbr> However, contrasting views were also expressed during the meeting indicating that the patient interest in more frequent injections centres more around durable symptom control until reinjection rather than more frequent injections and the logistics that go with this.<wbr> </div><div style="margin-bottom: 10px;">The first lunch-time symposia entitled "Botulinum neuotoxin revisited: An individualised, patient centric approach for the treatment of patients suffering from dystonia and spasticity, was hosted by the Centro de Medicina de Reabilitiacao de Alcoitao with the assistance of an educational grant from Merz.<wbr> </div><div style="margin-bottom: 10px;">Studies highlighted included a CD patient satisfaction survey published by Skethi KD et al in J Med Econ 2012 and two spasticity surveys published by Bensmail et al in the J Med Econ Sept 2014.<wbr> These studies were sponsored by Merz and have been reported at previous meetings largely in poster form.<wbr> Collectively, what they illustrated is a level of discrepacy that exists between patient and doctors when it comes to assessing treatment satisfaction and individualised patient dosing needs.<wbr> This situation has evolved because of the lack of treatment effect appraisal between peak effect and treatment effect at the time of reinjection together with regulatory recommendations and labelling which cite usage should not be more frequent than every 12 weeks (10 in the case of incoboutlinumtoxin).<wbr> Moreover, the bulk of clinical trials utilising botulinum toxins have been performed using these limitations.<wbr> Hence, in the absence of much clinical trial data to the contrary (shorter duration) the likes of the FDA are likely to require long-term adequate exposure trial data evaluating the safety (including immunogenicity) of more frequent administration before any agreement is reached to change labelling.<wbr> </div><div style="margin-bottom: 10px;">In addition to the symposium, Merz presented some US survey satisfaction data Kapil et al (see attached) in poster form and there was a plenary talk focusing on the same topic given by Hubert Fernandez (a KOL closely affiliated with Merz).<wbr> Interestingly, he tried to present the data in more of a clinical context making compairsons with other forms of therapy and highlighting the diminishing concerns about neutralising antibodies.<wbr> Some of the key slides he highlighted are shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_12_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_13_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_14_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_15_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_16_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_17_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_18_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_19_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_20_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_21_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_22_ScreenCapture25.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_23_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_24_ScreenCapture27.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_25_ScreenCapture29.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_26_ScreenCapture31.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_27_ScreenCapture32.jpg"> </div><div style="margin-bottom: 10px;">Merz's focus on shorter duration treatment in part is linked to Xeomin's widely recognsied shorter of duration of activity compared to Botox and Dysport, something that it may contest but something that does have financial implications.<wbr> Highlighting this point was a poster presented by Allergan on the so-called TRUDOSE study, a pilot study evaluating dose and duration of incobotulinumtoxinA vs onabotulinumtoxinA in patients with CD and blepharospasm.<wbr> A copy of the full poster is attached.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_28_ScreenCapture33.jpg"> </div><div style="margin-bottom: 10px;">Finally, it was of interest to note the change in promotional focus at the meeting both by Merz and by Allergan with the former presenting a much more patient centric marketing campaign, whilst as you will see below, there was a notable absence in terms of Allergan of any booth material.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_29_ScreenCapture34.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_30_ScreenCapture35.jpg"> </div><!-- Comment details --><a name="neurology7896attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(98,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(101,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(82,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(91,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(75,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(77,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(83,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(164,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(149,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(164,9 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_14_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(144,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_15_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(167,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_16_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(140,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_17_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(166,8 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_18_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(153 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_19_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(172,6 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_20_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(168,2 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_21_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(170,2 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_22_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(191,7 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_23_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(169,9 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_24_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(150,2 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_25_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(207,9 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_26_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(183,4 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_27_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(144,9 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_28_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(422,2 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_29_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(140,2 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_30_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(166,4 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_31_Kapil%20et%20al%20Satisfaction%20survey%20in%20CD%20post%20stroke%20spasticity%20and%20blepharospasm.pdf">Kapil et al Satisfaction survey in CD post stroke spasticity and blepharospasm.pdf</a>&nbsp;&nbsp;(489,6 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7896_32_Trudose%20pilot%20dosing%20study%20comparing%20Botox%20and%20Xeomin%20in%20CD%20%26%20BEP.pdf">Trudose pilot dosing study comparing Botox and Xeomin in CD & BEP.pdf</a>&nbsp;&nbsp;(121 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7896">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-20T18:09:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-20T18:09:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Acromegaly Therapy Area Landscape</title>
	<pubDate>2015-01-20T17:16:44+01:00</pubDate>
	<wp:post_id>6125</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div>Comment: You will find attached an updated competitive landscape for Acromegaly.<wbr> This slide deck provides a disease overview, including treatment options, epidemiology data and market analysis.<wbr> Further it lists the competitive landscape based on the different mechanism of actions.<wbr> We welcome any contribution to our Key Intelligence Questions (KIQs) to ensure the utility of the tool.<wbr> A special thank you to the Endo franchise and market access team's contribution to this edition.<wbr> </div><!-- Comment details --><a name="endocrinology7923attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7923_2_Acromegaly%255fTherapy%20Area%20Landscape%255fJanuary2015.pptx">Acromegaly_Therapy Area Landscape_January2015.pptx</a>&nbsp;&nbsp;(853,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7923">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-20T17:16:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-20T17:16:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medac GmbH Supports Guideline on Intravesical Instillations of BCG/MMC</title>
	<pubDate>2015-01-20T16:32:52+01:00</pubDate>
	<wp:post_id>6126</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has provided the European Association of Urology Nurses (EAUN) with an unrestricted educational grant to support the creation of a booklet “Guideline on intravesical instillations of BCG/<wbr>MMC<STRONG>”.<wbr> </STRONG>With this grant Medac is widening its support to encompass other healthcare professionals in the area of NMIBC striving to support optimal patient care Europe wide.<wbr><BR>
The new Guideline will be presented during the EAUN Annual meeting in Madrid as a part of the EAUN congress program.<wbr> </div><div style="margin-bottom: 10px;">The “Guideline on intravesical instillations of BCG/<wbr>MMC“ will also be available as pocket book.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">BCG-medac, powder and solvent for suspension for intravesical use.<wbr> </div><div style="margin-bottom: 10px;">Mitomycin powder for solution for infusion /<wbr> Mitomycin 1 mg/<wbr>ml, powder (and solvent) for solution for intravesical use.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Date: March 21-23 2015 in Madrid, Spain </div><div style="margin-bottom: 10px;"><P class="bodytext">The EAUN is a direct result of the 1st nursing conference, which was organised at the XVth congress of the European Association of Urology in Brussels, April 2000.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="bodytext">The 1st International Meeting of the EAUN was held with an attendance of 110 participants from 11 different countries.<wbr> In 2014, the EAUN meeting was attended by around 400 nurses from over 35 countries.<wbr></P> </div><div><P class="bodytext"><EM>Source: <A href="http://www.medac.de/medac_international/txt_files/opennews/142165244647180.htm">Medac PR</A>; EAUN website</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10219">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-20T16:32:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-20T16:32:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis Reinforces Its CNS Commitment Through FDA Filing Of Schizophrenia Drug Cariprazine</title>
	<pubDate>2015-01-20T12:52:26+01:00</pubDate>
	<wp:post_id>6127</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Hungarian drugmaker Gideon Richter and its partner Actavis 
announced today positive phIII results from a study with Richter's 
anti-psychotic drug Cariprazine to treat relapse in schizophrenia 
patients.<wbr> </div><div style="margin-bottom: 10px;">Treatment with Cariprazine, a potent D3/<wbr>D2 receptor partial 
agonist resulted in a 55% reduction in the risk of relapse versus placebo 
according to top-line results released on the Budapest stock exchange.<wbr> </div><div style="margin-bottom: 10px;">On January 6th the FDA acknowledged receipt of Actavis's NDA resbumission.<wbr> 
The PDUFA is expected in the second quarter of 2015.<wbr> </div><div style="margin-bottom: 10px;">Actavis has US &amp; Canadian rights to this product through an agreement 
negotated between Richter and Forest back in 2004.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7895">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-20T12:52:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-20T12:52:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex Partners with Dystonia Medical Research Foundation to Explore Dipraglurant in the Treatment of Dystonia</title>
	<pubDate>2015-01-20T10:26:22+01:00</pubDate>
	<wp:post_id>6128</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of the collaboration is to design a detailed development plan and regulatory path as well as identifying KOLs and patients for a Ph2 clinical trial.<wbr> In addition, Addex recently reported on Jan 9, plans to start clinical testing of the therapeutic effect of dipraglurant in patients with cervical dystonia in collaboration with Professor Dirk Dressler of The Hannover Medical School.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Dystonia Medical Research Foundation (<a href="http://www.dystonia-foundation.org" class="defaultlink" title="www.dystonia-foundation.org">dystonia-foundati&hellip;</a>) is a 501c3 non-profit organization dedicated to advancing research for improved dystonia treatments and ultimately a cure, promoting awareness, and supporting the well-being of affected individuals and families.<wbr> </div><div>Since 1976, the DMRF has supported and stimulated the dystonia research field.<wbr> Work supported by the DMRF has led to an overall better understanding of dystonia as well as breakthroughs in genetics and therapeutics.<wbr> The Foundation also provides patient education and support resources.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7894">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-20T10:26:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-20T10:26:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Favorable Topline Results From Thorough QT Clinical Trial of Auspex' SD-809 for Huntington's Disease</title>
	<pubDate>2015-01-19T16:52:55+01:00</pubDate>
	<wp:post_id>6129</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The thorough QT (TQT) clinical trial has been evaluating the effects of SD-809 on cardiac repolarization, based on placebo-corrected, time-matched changes from baseline in the corrected QT (QTc) interval.<wbr> The TQT clinical trial demonstrated that at two different dose levels, SD-809 had no clinically significant effect on cardiac repolarization as assessed by the QT interval.<wbr> A tetrabenazine arm was included for comparison and demonstrated an increase in QTc that is consistent with the effect reported in the FDA label for Xenazine®.<wbr> The clinical trial's assay sensitivity was established by the observation of characteristic QTc prolongation following dosing with moxifloxacin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The key outcome measure in this active- and placebo-controlled crossover study was to determine the effect of single doses of SD-809 on the QTc interval.<wbr> </div><div style="margin-bottom: 10px;">Assay sensitivity was established with a moxifloxacin arm, and a tetrabenazine arm was also included for comparison.<wbr> A 50 mg dose of tetrabenazine was selected as this was the maximal dose employed in the TQT study for Xenazine that led to the warning and precaution in the product label.<wbr> </div><div style="margin-bottom: 10px;">A 24 mg dose of SD-809 was selected as it provides comparable systemic exposure (AUC) to 50 mg of tetrabenazine, but with a lower peak concentration (Cmax).<wbr> </div><div style="margin-bottom: 10px;">For SD-809, a 12 mg dose led to a maximal increase in the QTc of approximately 0.<wbr>8 msec and a 24 mg dose led to maximal increase in the QTc of approximately 2.<wbr>6 msec.<wbr> </div><div style="margin-bottom: 10px;">The placebo-corrected time-matched maximal increases in QTc for the 12 and 24 mg doses of SD-809 were 2.<wbr>8 msec (90% two-sided Confidence Interval (CI): 0.<wbr>7 to 4.<wbr>8) and 4.<wbr>5 msec (90% two-sided CI: 2.<wbr>4 to 6.<wbr>5), respectively.<wbr> A 50 mg dose of tetrabenazine led to a maximal increase in QTc of approximately 7.<wbr>2 msec, with a placebo-corrected time-matched maximal increase in QTc of 7.<wbr>6 msec (90% two-sided CI: 5.<wbr>6 to 9.<wbr>5).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Phase 1 TQT study was conducted in 48 healthy volunteers.<wbr> </div><div style="margin-bottom: 10px;">This was a single-center, randomized, double-blind, placebo- and positive-controlled six-period crossover study to evaluate the effects of low-dose (12 mg) and high-dose (24 mg) SD-809 on cardiac repolarization, based on placebo-corrected, time-matched changes from baseline in the QTcF interval.<wbr> </div><div style="margin-bottom: 10px;">Assay sensitivity was established by using moxifloxacin as the positive control.<wbr> In addition, the effects of tetrabenazine on cardiac repolarization (also based on placebo-corrected, time-matched changes from baseline in the QTc interval) were evaluated in this study.<wbr> </div><div><EM>Source: PharmaeTrack</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7893">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-19T16:52:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-19T16:52:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ITG Receives Manufacturing Approval For Its New Ge 68/Ga-68 Generator</title>
	<pubDate>2015-01-19T15:39:21+01:00</pubDate>
	<wp:post_id>6130</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ITG has announced it has obtained manufacturing authorization for 
its pharmaceutical grade non metallic GE-68/<wbr>Ga-68 Generator for PET scan 
procedures (such as used in NET) from the Upper Bavaria Government.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the approval Steffen Schuster, CEO of ITG</STRONG> 
stated: "We feel proud to have set yet another important milestone in order to 
further strengthen the role of Gallium-68 as a next generation radioisotope for 
diagnostics.<wbr> The shelf-shielded iQS Ga-68 Fluidic Labeling Module also 
contributes to our innovative Gallium-68 platrom as it makes the preparation of 
Gallium-68 labelled tracers as fast and convenient as never before".<wbr> </div><div style="margin-bottom: 10px;"><P align="left">It is also noted that the group is boosting its development of 
therapeutic radioisotope treatments based on its no-carrier added (n.<wbr>c.<wbr>a.<wbr>) 
Lutetium-177, a radioistope now starting to be more widely used in the context 
of  both PET scanning and therapy for neuroendocrine tumour diagnosis 
and treatment.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Partnering Intent</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">ITG claims that it is in the prcess of strenghtening its 
innovative theranositc platofirm by reaching strategic alliance with leading 
partners in industry.<wbr> For example, we know that it has an agreement with 
RADIOMEX in the US (see below).<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7922_1_ScreenCapture1.jpg"></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Competitive Positioning</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">It as far as we understand the second company to gain approval for 
a modern Ga-68 Genreator in Europe with Eckert &amp; Zeigler the first in June 
2014</P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7922_2_ScreenCapture2.jpg"></P> </div><div><P align="left">Source: <A href="http://www.itg-garching.de/">http:/<wbr>/<wbr>www.<wbr>itg-garching.<wbr>de/<wbr></A></P> </div><!-- Comment details --><a name="endocrinology7922attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7922_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(162,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7922_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(195,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7922">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-19T15:39:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-19T15:39:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves Antria to Continue Testing Stem Cells in Plastic Surgery</title>
	<pubDate>2015-01-19T10:47:48+01:00</pubDate>
	<wp:post_id>6131</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinical research company Antria expects to start Ph2 facial grafting trial in Q1:15.<wbr> Antria's patent-pending process uses liposuction to extract the patient's own fat and then stem cells are prepared from the material.<wbr> Clinicians inject the stem cells under the patient's facial skin to reduce the appearance of wrinkles, scars and sagging skin.<wbr> By combining fat grafting with a patient’s own stem cells Antria’s process hopes to create a more natural appearance which lasts longer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In Ph2 Antria will expand the clinical trial to include a much larger group of participants.<wbr> </div><div style="margin-bottom: 10px;">Location: Gainesville Florida </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">One of the critical components of Antria’s process to isolate stem cells from adult fat cells is its proprietary product AdipolyxTM a collegenase-based reagent.<wbr> AdipolyxTM has potential applications to help patients suffering from arthritis wound healing ischemic limbs multiple sclerosis impotence and urinary incontinence.<wbr> </div><div style="margin-bottom: 10px;">Antria expects its next clinical trial to use ADSCs for breast augmentation procedures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Focus: discovery and development of new products and treatments with stem cells derived from adult patients’ own fat cells known as autologous derived stem cells (ADSCs) to help patients with various chronic and acute medical conditions.<wbr> </div><div style="margin-bottom: 10px;">- Founded in 2010 </div><div style="margin-bottom: 10px;">- HQ: Indiana Pennsylvania with additional offices in Gainesville Florida </div><div><EM>Source: Antria</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7891">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-19T10:47:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-19T10:47:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: OncoGenex Regains Rights to Custirsen from Teva</title>
	<pubDate>2015-01-19T10:31:30+01:00</pubDate>
	<wp:post_id>6132</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">OncoGenex Regains Rights to Custirsen from Teva</span>&nbsp;<br><span style="font-size: 12px;">Comment: During Q2:15, the companies announced that the Ph3 SYNERGY trial with custirsen in mCRPC failed to demontrate an improvement over strandard chemotherapy in terms of OS.<wbr> Survival results of the Ph3 AFFINITY mCRPC trial are expected late 2015/<wbr>early 2016.<wbr> OncoGenex will now have greater control of custirsen's development, including the modification of the ENSPIRIT statistical analysis plan to involve a more rigorous second interim futility analysis to be completed in Q2:15.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10191">...</a><br></div><div>Comment: Following recent agreement with Teva that OncoGenex has regained rights to custirsen, OncoGenex confirmed on 16th January that their prostate cancer development programme will continue.<wbr> Based upon completion of the interim futility analysis and recommendation of the Independent Data Monitoring Committee (IDMC), OncoGenex is committed to continue Ph3 AFFINITY that is evaluating combination strategy of custirsen and cabazitaxel in post-docetaxel mCRPC setting (Source: PR Newswire, OncoGenex Press Release 16 January) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10218">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10191">View thread  Oncology10191: OncoGenex Regains Rights to Custirsen from Teva</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-19T10:31:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-19T10:31:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Buys Trophos for Up to $120M</title>
	<pubDate>2015-01-16T16:49:49+01:00</pubDate>
	<wp:post_id>6133</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Rationale for Roche is to expand its portfolio, and gain access to Trophos' olesoxime, which has completed pivotal study for spinal muscular atrophy (SMA).<wbr> If approved, olesoxime could be the first treatment specifically developed for SMA patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement Trophos will receive an upfront payment of 120 million euros ($140 million), plus further payments based on certain predetermined milestones worth up to 350 million euros.<wbr><BR><BR><STRONG>About the Drug</STRONG> </div><div style="margin-bottom: 10px;">Olesoxime (TRO19622) is the lead compound of Trophos' proprietary cholesterol-oxime compound family of mitochondrial pore modulators.<wbr> </div><div style="margin-bottom: 10px;">Olesoxime, which has been granted orphan drug status by regulators in the US and EU, works by protecting the health of motor nerve cells.<wbr> </div><div style="margin-bottom: 10px;">Results of a Ph2 study found the drug showed a beneficial effect on the maintenance of neuromuscular function and also helped reduce medical complications associated with the disease.<wbr> </div><div>Olesoxime is also being investigated in an ongoing Ph1, as a potential add-on therapy to Interferon beta for the treatment of multiple sclerosis </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7890">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-16T16:49:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-16T16:49:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Together Leading The Way In "Growth Pharma" - Actavis's New Slogan</title>
	<pubDate>2015-01-16T10:35:10+01:00</pubDate>
	<wp:post_id>6134</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Presenting at the JP Morgan H/<wbr>C Conference this week Brent 
Saunders presented his first expanded views on what the new combined 
Actavis/<wbr>Allergan "Growth Pharma" will look like (depicted in the slides below).<wbr> 
More was outlined about the combined culture of the organisation, its focus on 
tight SG&amp;A control and its key R&amp;D products.<wbr> 
Having already stated his aversion to discovery research it was of interest 
to note his comment "we're going to stay in discovery in those areas where 
we have a comparable advantage, that may be neuromodulators, it will probably be 
ophthalmology.<wbr>" Cutting its SG&amp; costs as part of its exercise to reduce 
costs while being pursued by Valeant, it was interesting to note the 
absence of an Allergan booth other than by name only at this week's TOXINS 
Congress.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Summing up the culture of what the new Actavis will be about Brent 
Saunders stated the following:-</STRONG> </div><div style="margin-bottom: 10px;">"We have a very strong culture predicated in innovation, speed, efficiency, 
quality and compliance, and we have a continuous, but disciplined innovation 
approach.<wbr> This idea of internal, external thinking to refresh internal thinking.<wbr> 
This idea that it doesn't matter at Actavis if it was invented here or outside, 
we embrace all ideas.<wbr> We are the first to admit, we don't have monopoly on all 
the greatest ideas, and in fact the best ideas generally come from fresh 
thinking.<wbr> We just like to execute.<wbr>" </div><div style="margin-bottom: 10px;">"Our whole company and Allergan as well, was predicated on how do we service 
our customers whether that'd be a physician, whether that'd be a health plan, 
whether that'd be a regulatory agency, whether that'd be a partner.<wbr> And so we're 
going to maintain that very sharp external focus as we move forward.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Commenting on the pipeline, Brent Saunders noted:- </div><div style="margin-bottom: 10px;">"Obviously, we have some very important ones.<wbr> We've got the fixed-dose 
combination approved already CAZ-AVI which I'm going to struggle with saying 
AVI-CAZ.<wbr> AVI-CAZ, we expect an approval in the second quarter, I believe, as we 
look at eluxadoline later this year for IBS-D; cariprazine later in the year; 
Esmya for uterine fibroids could be very interesting.<wbr> Clearly when you look at 
Lumigan SR, SEMPRANA for headaches, and then, of course, earlier in the pipeline 
is DARPin and RESTASIS X that are very important to our future growth and to our 
future leadership in eye health.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_8_ScreenCapture8.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_9_ScreenCapture9.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_10_ScreenCapture10.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7925c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Actavis has today announced the intention to adopt 'Allergan' corporate name for its corporate name and for its global branded pharmaceutical portfolio.<wbr>  Actavis name will retain for selected geographic regions and product portfolios.<wbr> Actavis' CEO commented on how the move to Allergan name speaks to the future strategic vision of the organization, focused on developing new medicines that support unmet medical needs in critical therapeutic areas (Allergan heritage) as well as increasing global access to high quality and affordable medicines (Actavis heritage).<wbr> Actavis will ask the shareholders to vote on this matter later in the year.<wbr> In the meantime Actavis will continue to operate and trade under its current name.<wbr> </div><div>Soucre: BioSpace, Actavis PR </div></div><a name="neurology7888attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(104,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(115,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(137 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(138,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(107,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(149 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(110,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(123,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(164,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7888_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(140 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7888">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-16T10:35:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-16T10:35:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Article in Korean Newspaper Indicates Nabota Better than Botox</title>
	<pubDate>2015-01-16T01:48:32+01:00</pubDate>
	<wp:post_id>6135</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Article in Korean Newspaper Indicates Nabota Better than Botox</span>&nbsp;<br><span style="font-size: 12px;">Comment: The today online issue of <EM>Business Korea</EM> reported findings from a 268 patient study assessing Botox or Nabota for wrinkles.<wbr> The clinical trial was done in collaboration with Asan Medical Center and St.<wbr> Paul's Hospital of Catholic University.<wbr> The results are going to be published in the upcoming issue of <EM>International Journal of Dermatology.<wbr></EM></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7884">...</a><br></div><div style="margin-bottom: 10px;">Daewoong is using the attached Nabota brochure to show the result of the study.<wbr> (Page 4) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_1_Nabota%20brochure%201,2.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_2_Nabota%20brochure%203,4.JPG"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_3_Nabota%20brochure%205,6.JPG"> </div><!-- Comment details --><br><a name="neurology7887attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_1_Nabota%20brochure%201,2.JPG">Nabota brochure 1,2.JPG</a>&nbsp;&nbsp;(61 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_2_Nabota%20brochure%203,4.JPG">Nabota brochure 3,4.JPG</a>&nbsp;&nbsp;(64,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_3_Nabota%20brochure%205,6.JPG">Nabota brochure 5,6.JPG</a>&nbsp;&nbsp;(74,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7887">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7884">View thread  Neurology7884: Article in Korean Newspaper Indicates Nabota Better than Botox</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-16T01:48:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-16T01:48:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Despite Restructuring Dendreon Reports Major Milestones</title>
	<pubDate>2015-01-15T17:48:13+01:00</pubDate>
	<wp:post_id>6136</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In an article published today in OncLive online, Thomas Amick (CEO) reported that the company is optimistic that Europe will hold the key to future revenue growth.<wbr> He outlined that in early January 2015, the first patient in Europe was treated with Povenge.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>2014 Key Figures</STRONG> </div><div style="margin-bottom: 10px;">Major milestone reached: a $20.<wbr>1M improvement in total revenue in 2014 when compared with 2013.<wbr> </div><div style="margin-bottom: 10px;">Total revenue: $303.<wbr>8M (vs $283.<wbr>7M in 2013) </div><div style="margin-bottom: 10px;"><STRONG>European Situation</STRONG> </div><div style="margin-bottom: 10px;">The European Commission granted marketing authorization for sipuleucel-T as a treatment for chemotherapy ineligible men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) in September 2013.<wbr> </div><div style="margin-bottom: 10px;">Approximately 6 months after this, Dendreon announced plans to make sipuleucel-T available in Germany and the United Kingdom through the manufacturer PharmaCell.<wbr> </div><div>Source: <A href="http://www.onclive.com/web-exclusives/Dendreon-Revenue-Rises-Despite-Restructuring">http:/<wbr>/<wbr>www.<wbr>onclive.<wbr>com/<wbr>web-exclusives/<wbr>Dendreon-Revenue-Rises-Despite-Restructuring</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10216">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-15T17:48:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-15T17:48:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revive Signs Research Collaboration with Rettsyndrome.org</title>
	<pubDate>2015-01-15T16:21:44+01:00</pubDate>
	<wp:post_id>6137</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revive will supply the drug to conduct the study under the Rettsyndrome.<wbr>org Scout Program.<wbr> The objective of the study is to run a behavioral battery of tests to screen and assess the potential for REV-003 (Tianeptine) for Rett syndrome in a mouse model.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7918_1_ScreenCapture1.jpg">Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s.<wbr> </div><div style="margin-bottom: 10px;">Drug used primarily in the treatment of major depressive disorder, although it may also be used to treat asthma or irritable bowel syndrome.<wbr> Chemically it is a tricyclic antidepressant (TCA), but it has different pharmacological properties, for one it is known to serve as a selective serotonin reuptake enhancer, although more recent research suggests that tianeptine produces its antidepressant effects through indirect alteration of <ABBR title="α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor">AMPA</ABBR> and <ABBR title="''N''-methyl-D-aspartate">NMDA</ABBR> glutamate receptor activity and altered neuroplasticity and release of <ABBR title="brain-derived neurotrophic factor">BDNF.<wbr></ABBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Assessments will include body weight, grip strength, gait analysis, and neurologic/<wbr>behavioral parameters.<wbr> </div><div style="margin-bottom: 10px;">All raw data, samples and specimens arising from the performance of this study will remain the property of Revive.<wbr> </div><div style="margin-bottom: 10px;">The study will be funded and managed by Rettsyndrome.<wbr>org.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Rettsyndrome.<wbr>org aims to accelerate more discoveries to the clinic and committed over $600,000 towards the Scout Program, a Drug Discovery Screen in a mouse model of Rett syndrome.<wbr> </div><div>The Scout Program will aggressively accelerate the testing of compounds, whether new or repurposed, through standardized preclinical studies in the Rett mouse model.<wbr> This program will test many novel compounds and small molecules through a contract with the CRO, PsychoGenics, Inc.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8036c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Revive has announced positive study results of REV-003 (Tianeptine) from its research collaboration with Rettsyndrome.<wbr>org.<wbr> The study results assessed body weight, grip strength, gait analysis, and neurologic and behavioral parameters.<wbr> The drug was well-tolerated and had no effects on body weight, improved motor coordination in the rotarod test, reduced clasping to almost normal levels, normalized prepulse inhibition of startle at the higher dose, and significantly improved gait features, in particular the positioning of the paws.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Full results</STRONG> of the study, including replication and expansion to other functional domains, will soon be published.<wbr> </div><div>As part of the research collaboration, Revive supplied the drug to conduct the study, and all raw data, samples and specimens arising from the performance of this study remain properties of Revive.<wbr> The study was performed by PsychoGenics Inc.<wbr>, funded and managed by Rettsyndrome.<wbr>org.<wbr> </div></div><a name="endocrinology7918attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7918_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7918">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-15T16:21:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-15T16:21:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Lexicon's Presentation at JP Morgan H/C Conference</title>
	<pubDate>2015-01-15T14:13:12+01:00</pubDate>
	<wp:post_id>6138</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management outlined that Ph3 trial TELESTAR is more than 90% enrolled (completion enrollment in early 2015), and that US commercial preparations are underway.<wbr> It is expected Ph3 top-line data in Q3:15 and a poential NDA filing in Q1:16.<wbr> The other part of the presentation focused on Sotagliflozin (Ph3 in preparation for T1DM).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7917_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7917_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7917_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="endocrinology7917attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7917_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(114,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7917_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7917_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(80,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7917">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-15T14:13:12+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-15T14:13:12+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ironwood Outlined GI Strategy Plan for its GC-C Franchise at JP Morgan H/C Conference</title>
	<pubDate>2015-01-15T12:42:47+01:00</pubDate>
	<wp:post_id>6139</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Linzess is a core product for the company's growth.<wbr> It is the only FDA-approved GC-C agonist in the US for adults with IBS-C or CIC, and has significant future development opportunities in colonic release, colon cancer prevention (OTC/<wbr>Rx laxative market), OIC, and pediatrics.<wbr> Five clinical programs are currently ongoing with linaclotide, with multiple data readouts expected over the next 24 months.<wbr> The company strategy is focused on the acceleration of value creation through innovation and the in-licensing of drugs.<wbr> Key slides and comments are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">Management outlined the rationale for the 'colonic release': .<wbr>.<wbr>.<wbr> "We're excited about this program, because we think it will help us to separate the two modes of pharmacology of linaclotide.<wbr> Linaclotide start to work two ways; to treat both the constipation symptoms and the pain symptoms separately.<wbr> And what's need about that from the, from the physiology's aspect is the two aspects of the mechanism can be separated geographically in the GI tract.<wbr> So the secretion effects are mostly in the small intestine, whereas the pain effects mostly affect the efferent neurons in the colon.<wbr> So we believe that with a colonic release version, a delayed release version of linaclotide, we'll be able to enhance the pain affect bring us either faster onset or deeper pain relief and we're already seeing quite, quite good effects with linaclotide, with less effect on the fluid secretion.<wbr> </div><div style="margin-bottom: 10px;">And importantly that will give us novel intellectual property coverage to the mid 2030s and it's an interesting situation because, because it's a novel formulation.<wbr> And I should have mentioned linaclotide has no exposure outside the GERD.<wbr> So it's very challenging to do bioequivalent studies.<wbr> So for this program, we've had to develop a commercial form of linaclotide in Phase II, normally you can continue to do your final development in Phase III and so it's held us up a little bit.<wbr> We'll start that Phase IIb study in the middle of this year with data in 2016".<wbr><BR>
<STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported " .<wbr>.<wbr>.<wbr> In Europe, we're partnered with Almerol; in China with AstraZeneca and in Japan with Astellas.<wbr> </div><div>" .<wbr>.<wbr>.<wbr> Astellas has the linaclotide program in a Phase III now initiated in IBS-C and they've entered into Phase II now in chronic constipation as well.<wbr> Together with AstraZeneca, the program is in a Phase III study and actually quite substantially enrolled now in China and Almerol has approval and it's launched now in a dozen countries in Europe.<wbr> <STRONG>There are a number of territories and countries I didn't mention.<wbr> Those remain unpartnered territories and we're open to discussion about them".<wbr></STRONG> </div><!-- Comment details --><a name="gastroenterology2202attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(89,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(107,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2202_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(85,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2202">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-15T12:42:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-15T12:42:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Bowel Cleansing Effects on the Microbiota</title>
	<pubDate>2015-01-15T11:57:32+01:00</pubDate>
	<wp:post_id>6140</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Bowel Cleansing Effects on the Microbiota</span>&nbsp;<br><span style="font-size: 12px;">Comment: Published end of last year in <EM>Gut</EM>, the results show that the bowel cleansing using two separate dosages introduces fewer alterations to the intestinal microbiota than a single dose and hence may be preferred in clinical practice.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2185">...</a><br></div><div>The gut flora modifications shown in this small study on healthy subjects are transient (14 days with Moviprep split dose, 1 month with single dose) .<wbr> Another article  in a small number of healthy volunteers has also shown that flora modifications are transient  and that the gut flora reconstitutes after colonic lavage (O'Brien, PLOSPLoS ONE 8(5): e62815.<wbr> doi:10.<wbr>1371/<wbr>journal.<wbr>pone.<wbr>0062815).<wbr> It should be kept in mind that colonoscopies have been routinely performed for over 30 years now and have not been linked to long-term abdominal symptoms or disease.<wbr> .<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2201">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2185">View thread  GastroEnterology2185: Bowel Cleansing Effects on the Microbiota</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-15T11:57:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-15T11:57:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Presents Top Priorities for 2015 at JP Morgan H/C Conference</title>
	<pubDate>2015-01-15T11:30:52+01:00</pubDate>
	<wp:post_id>6141</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Joe Jimenez started the presentation with a projection of the healthcare landscape for 2015-2025, outlining the big impact of the demographic changes, and the increase burden of chronic diseases (70% of all illnesses).<wbr> He pointed out that non-traditional competitors such as tech companies are likely to emerge as the digitization of medicine starts to occur.<wbr> He finished his talk by highlighting Novartis priorities for 2015 from an innovation standpoint (key slides are provided below).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management would expect HC spending in the 10 years to double, and significant pressure on the HC systems around the world (reimbursememnt to better therapies to get harder, pricing being pushed down) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Novartis Implication</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><U>Novartis Strategy</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><U>Back-Office Functions into a Separate Group</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Management reported " .<wbr>.<wbr>.<wbr> in 2014 is we created a group called Novartis Business Services (NBS).<wbr> So think about the three big divisions at Novartis each with separate back-office operations in 60 countries across the world.<wbr> Well, in a tougher environment where you can expect cost containment, we better get our cost structure right and that's what NBS is all about.<wbr> We have taken the back-office functions such as information technology, procurement, financial reporting and accounting, and we put them into a separate group, they'll be consolidated on a country-by-country basis.<wbr> So, think about three divisions consolidating back-office across 60 countries and we see this as a source of margin improvement for the Company over the next five years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><U>Strenthen Innovation</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Two very important launches coming up with LCZ696 and with AIN457, which will be under the brand name Cosentyx in psoriasis.<wbr> </div><div style="margin-bottom: 10px;">Good progress made on CTL019; pivotal trial in acute lymphoblastic leukemia expected to start in 2015 "with the eye towards filing in 2016".<wbr><BR> </div><div style="margin-bottom: 10px;"><U>Complete the Portfolio Transformation</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">Novartis is in the final discussions with anti-trust authorities and on track to close the entire GSK transaction in 1H2015.<wbr> "This means that a lot of work follows and 2015 is going to be a lot about execution with the integration of oncology and the separation of vaccines and the start-up of the over-the-counter drug JV".<wbr> </div><div style="margin-bottom: 10px;"><U>Capture Cross-Divisional Synergies</U> </div><div style="margin-bottom: 10px;">N°4 priority is to capture cross-divisional synergies in 60 countries with Novartis Business Services.<wbr> </div><div style="margin-bottom: 10px;"><U>Build a</U> <U>High-Performing Organization</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_8_ScreenCapture8.jpg"> </div><div><EM>Source: Novartis</EM> </div><!-- Comment details --><a name="endocrinology7916attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(19,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(21,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(26,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(31,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(29,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(26,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7916_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(28,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7916">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-15T11:30:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-15T11:30:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Topical BBI-4000 to Enter POC Trial for Primary Axillary Hyperhidrosis</title>
	<pubDate>2015-01-14T18:00:28+01:00</pubDate>
	<wp:post_id>6142</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Preliminary results of a pilot study which were announced last September support the potential for BBI-4000 a "soft anticholinergic" to become a safe and effective treatment option for HH.<wbr> The Ph2 is planned to start next month in approx.<wbr> 180 participants (both genders from 18 to 65 years).<wbr> PE will measure proportion of subjects achieving at least 2-point improvement in HDSS from baseline to Week 4.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ph2 Details</STRONG> </div><div style="margin-bottom: 10px;">Ref <a href="https://clinicaltrials.gov/ct2/show/NCT02336503?cond=hyperhidrosis&fund=2&rcv_s=12%2F14%2F2014&rank=1" class="defaultlink">NCT02336503</a> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Inclusion Criteria</SPAN> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Primary axillary hyperhidrosis of at least 6 months's duration
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Hyperhidrosis disease severity score of 3 or 4 at baseline
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Gravimetric test at baseline indicating at least 50 mg of sweat production at rest in each axilla, in 5 minutes (room temperature)
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Willing to refrain from using any other antiperspirant agent for the duration of the study
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Timelines</SPAN> Final data estimated in March 2016 </div><div style="margin-bottom: 10px;"><STRONG>Ph1 Findings</STRONG> </div><div style="margin-bottom: 10px;">Trial (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7420" class="defaultlink">Neurology7420: Novel Topical Soft Anticholingeric for Hyperhidrosis</a>).<wbr> </div><div style="margin-bottom: 10px;">In the parallel group part of this double-blind clinical study, 18 subjects with primary axillary hyperhidrosis were randomized to a high topical concentration of BBI-4000, a low topical concentration of BBI-4000, or to topical vehicle, with 6 subjects in each group.<wbr> </div><div style="margin-bottom: 10px;"><P align="left" style="padding-left: 30px;">- The preliminary data show that <STRONG></STRONG>achieved more than 50% sweat reduction compared to 33% (2/<wbr>6) of the subjects in the vehicle group.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" style="padding-left: 30px;">-  In addition, <STRONG></STRONG>substantial (Scale, in comparison with 33% (2/<wbr>6) of subjects in the vehicle group.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">These endpoints are considered clinically relevant and have been used in the regulatory evaluation and product labeling of an approved product for hyperhidrosis.<wbr></P> </div><div><P align="left">Additionally, there were no treatment-related adverse effects or discontinuations due to adverse events.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7886">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-14T18:00:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-14T18:00:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Modified Version Of Temozolomide Overcomes Resistance To Current Formulation</title>
	<pubDate>2015-01-14T17:09:32+01:00</pubDate>
	<wp:post_id>6143</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cancer Research UK Scientists have reported in the journal <EM>Molecular Cancer Therapeutics</EM> success with a modified version of the drug temozolomide, a drug which is used as 1st line treatment for glioblastoma but also has utility in the treatment of pNET.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New formulation</STRONG> </div><div style="margin-bottom: 10px;">The revamped drug DP68 appears in vitro to be better at killing cancer cells than temozolomide and significantly reduces the re-growth in cells that have become resistant to temozolomide.<wbr> </div><div style="margin-bottom: 10px;">Cancer Research UK led the original development of temozolomide.<wbr> </div><div style="margin-bottom: 10px;">Study author, Dr Richard Wheelhouse, based at the University of Bradford, said: &ldquo;Temozolomide is a widely-used treatment for patients with glioblastoma.<wbr> But, when resistance to the drug develops, the tumours often grow back more aggressively so it&rsquo;s crucial to find new ways of outmanoeuvring the cancer cells.<wbr> </div><div style="margin-bottom: 10px;">&ldquo;DP68 could become a vital treatment for glioblastoma patients who&rsquo;ve developed resistance to the first-line treatment.<wbr> It&rsquo;s still early days but, unlike temolozomide that&rsquo;s only used to treat gliomas, we hope this new version of the drug may benefit patients with other cancer types.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>New pNET study with temozolomide</STRONG> </div><div style="margin-bottom: 10px;">At the UKINET meeting pre Christmas, we learnt that a new phIII pNET trial called SCORPION is planned with adjuvant temozolomide vs.<wbr> observation following resection of well differentiated pNET at high risk of relapse.<wbr> </div><div><P style="margin-bottom: 0pt; unicode-bidi: embed; word-break: normal; direction: ltr; text-align: left; margin-left: 0in; margin-top: 0pt; language: en-GB; mso-line-break-override: none; punctuation-wrap: hanging;">Source:Cancer Research UK</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7913">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-14T17:09:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-14T17:09:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pharma Mar to Distribute GP Pharm's Politrate® (leuprorelin) in Italy</title>
	<pubDate>2015-01-14T16:48:47+01:00</pubDate>
	<wp:post_id>6144</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pharma Mar to Distribute GP Pharm's Politrate® (leuprorelin) in Italy</span>&nbsp;<br><span style="font-size: 12px;">Comment: The agreement designates Pharma Mar S.<wbr>R.<wbr>L.<wbr> as the sole distributor of Politrate&reg; in Italy; the product will be supplied to Pharma Mar S.<wbr>R.<wbr>L.<wbr> by GP Pharm.<wbr> Pharma Mar plans to begin distributing Politrate&reg; in Italy in October.<wbr> Initially the 1M dosage will be distributed, with plans to subsequently add the 3M dose.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20150331&edate=20150101&rec=250">...</a><br></div><div style="margin-bottom: 10px;">Thanks to Michela Maraschi we have been informed that  </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0px; font: 15px wf_segoe-ui_normal, 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #212121; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0px; font: 15px wf_segoe-ui_normal, 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #212121; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></DIV> </div><div><DIV style="widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0px; font: 15px wf_segoe-ui_normal, 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #212121; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"></DIV> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20150331&edate=20150101&rec=258">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids250">View thread  DKPHybrids250: Pharma Mar to Distribute GP Pharm's Politrate® (leuprorelin) in Italy</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-14T16:48:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-14T16:48:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: NICE Says "Provenge' Cost to NHS too high to be recommended in draft guidance"</title>
	<pubDate>2015-01-14T15:55:11+01:00</pubDate>
	<wp:post_id>6145</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NICE Says "Provenge' Cost to NHS too high to be recommended in draft guidance"</span>&nbsp;<br><span style="font-size: 12px;">Comment: NICE has issued preliminary draft guidance not recommending sipuleucel-T for prostate cancer in people whose disease has spread, who have few symptoms and when chemotherapy would not yet have been given.<wbr>The available evidence showed that the price the NHS is being asked to pay for the drug is too high for the benefit it may provide - Sir Andrew Dillon commented that although Sipeuleucel-T dose show significant overall survival benefit, it was also not proven to delay the progression of the disease unlike current treatments.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10052">...</a><br></div><div>Comment: The final draft guidance issued by NICE on 13 Jan remains consistent with NICE's preliminary decision - Dendreon has so far been unable to show that it works better than other treatments currently available.<wbr> The final draft guidance is now with consultees, who have the opportunity to appeal against it.<wbr> Until NICE issues final guidance, NHS bodies should make decisions locally on the funding of specific treatments.<wbr> Given the current position of Dendreon as they are awaiting for bidders, the future of Provenge in European markets is questionable.<wbr> (Source: <a href="https://www.nice.org.uk/news/press-and-media/cost-to-nhs-of-providing-sipuleucel-t-too-high-to-be-recommended-in-draft-guidance" class="defaultlink">NICE PRESS RELEASE Jan 2015</a>) </div><!-- Comment details --><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10292c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The final NICE guidance is being published with the final decision that Provenge is not recommended within its marketing authorisation for treating adults who have asymptomatic or minimally symptomatic metastatic non visceral hormone relapsed prostate cancer for which chemotherapy is not yet clinically indicated.<wbr> (Source:<A href="http://www.nice.org.uk/guidance/ta332/chapter/1-guidance">http:/<wbr>/<wbr>www.<wbr>nice.<wbr>org.<wbr>uk/<wbr>guidance/<wbr>ta332/<wbr>chapter/<wbr>1-guidance</A>) </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10212">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10052">View thread  Oncology10052: NICE Says "Provenge' Cost to NHS too high to be recommended in draft guidance"</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-14T15:55:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-14T15:55:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Article in Korean Newspaper Indicates Nabota Better than Botox</title>
	<pubDate>2015-01-14T11:48:01+01:00</pubDate>
	<wp:post_id>6146</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The today online issue of <EM>Business Korea</EM> reported findings from a 268 patient study assessing Botox or Nabota for wrinkles.<wbr> The clinical trial was done in collaboration with Asan Medical Center and St.<wbr> Paul's Hospital of Catholic University.<wbr> The results are going to be published in the upcoming issue of <EM>International Journal of Dermatology.<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG>About the Findings</STRONG> </div><div style="margin-bottom: 10px;">After 4 weeks, patients that were injected with Nabota showed that their skin contracted up to 93.<wbr>9%, higher than the 88.<wbr>6% shown by those who used Botox.<wbr> </div><div style="margin-bottom: 10px;">No adverse drug reactions were reported.<wbr> </div><div>Source: <A href="http://www.businesskorea.co.kr/article/8558/wrinkle-treatment-local-botulinum-toxin-formula-reportedly-better-botox">http:/<wbr>/<wbr>www.<wbr>businesskorea.<wbr>co.<wbr>kr/<wbr>article/<wbr>8558/<wbr>wrinkle-treatment-local-botulinum-toxin-formula-reportedly-better-botox</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7887c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Daewoong is using the attached Nabota brochure to show the result of the study.<wbr> (Page 4) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_1_Nabota%20brochure%201,2.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_2_Nabota%20brochure%203,4.JPG"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7887_3_Nabota%20brochure%205,6.JPG"> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7884">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-14T11:48:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-14T11:48:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS and Lilly Enter Clinical Collaboration To Evaluate Combination Strategy Of anti-PD1 And TGF Inhibitor In Glioblastoma, HCC, And NSCLC</title>
	<pubDate>2015-01-14T11:24:35+01:00</pubDate>
	<wp:post_id>6147</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BMS and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of BMS anti-PD1 - Nivolumab (Opdivo) - in combination with Lilly's tumour growth factor kinase inhibitor - Galunisertib (LY2157299).<wbr> The Ph 1/<wbr>2 trial will recruit patients with advanced glioblastoma, hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC).<wbr> This proof of concept is to address the hypothesis that co-inhibition of PD-1 and TGF beta negative signals may lead to enhanced anti-tumour immune responses than inhibition of either pathway alone.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Opdivo (Nivolumab) - anti-PD1</STRONG> </SPAN> </div><div style="margin-bottom: 10px;">The U.<wbr>S.<wbr> Food and Drug Administration (FDA) approved <EM>Opdivo </EM>(nivolumab) injection, for intravenous use.<wbr> <EM>Opdivo</EM> is a PD-1 blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following <EM>Yervoy </EM>(ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor.<wbr> This indication is approved under accelerated approval based on tumor response rate and durability of response.<wbr> Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.<wbr> Bristol-Myers Squibb has a broad, global development program to study <EM>Opdivo</EM> in multiple tumor types consisting of more than 50 trials &ndash; as monotherapy or in combination with other therapies &ndash; in which more than 7,000 patients have been enrolled worldwide.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Galuniserib (LY2157299) - TGF beta R1 Kinase Inhibitor</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Galunisertib is currently under investigation as an oral treatment for advanced/<wbr>metastatic malignancies, including Phase 2 evaluation in hepatocellular carcinoma, myelodysplastic syndromes (MDS), glioblastoma, and pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;">Galuniserib<EM> in vitro </EM>selectively blocks TGF beta signaling.<wbr> TGF beta promotes tumors growth, suppresses the immune system, and increases the ability of tumors to spread in the body.<wbr> Immune function is suppressed in cancer patients, and TGF beta worsens immunosuppression by enhancing the activity of immune cells called T regulatory cells.<wbr> TGF beta also reduces immune proteins, further decreasing immune activity in patients.<wbr> </div><div>Source: Bristol-Myers Squibb Press Release 13 January 2015 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10211">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-14T11:24:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-14T11:24:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Presented Xtandi's Remarkable Performance And Discussed Its Future Vision To Become An Immuno-Oncology Player</title>
	<pubDate>2015-01-13T18:59:17+01:00</pubDate>
	<wp:post_id>6148</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medivation presented at the 33rd Annual JPMorgan Healthcare Conference (12-15th January 2015).<wbr> David Hung (Founder, President and CEO of Medivation) opened the company presentation by emphasizing Xtandi's strong growth in 2014 - WW net sales at $1.<wbr>2B annualized run rate in Q3 2014 and representing 149% growth vs 2013 9 months YTD.<wbr> David Hung also expressed Medivation's ambition to expand Xtandi's market potential by 1) bringing enzalutamide to earlier setting including M0 and high risk prostate cancer - TERRAIN, STRIVE, PROSPER, and Ph3 Biochemical Recurrence Trial; 2) further developing in advanced triple negative breast cancer; and capitalise its recent acquisition of pidilizumab (anti-PD1 monoclonal antibody licensed from CureTech) to strengthen its immuno-oncology franchise.<wbr> Pidilizumab is expected to enter Ph3 for haematologic malignancy in 2015 and there is a hint of Mediation will consider evaluating combination with Xtandi in breast, prostate and potentially other indications.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Strong performance in US and becoming the preferred novel hormonal agent for treating mCRPC patients</STRONG>: Xtandi is covered by Medicare and in Q3 2014 prescriptions were written for approximately 21,500 bottles by over 6,800 physicians in the US
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_1_1.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_2_2.JPG"> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Four trials (TERRAIN, STRIVE, PROSPER, and Ph3 BCR trial) are aimed to evaluate Xtandi in the earlier stage of prostate cancer to further establish Xtandi's leadership position</STRONG>: TERRAIN's unblinding readout is expected in Q1 2015 and STRIVE's readout is to follow.<wbr> 
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_3_3.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_4_4.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_5_5.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_6_6.JPG"> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Strong rationale and early clinical evidence to support Xtandi's breast cancer programmes</STRONG>: publications suggesting triple negative breast cancer (TNBC) could be driven by AR pathway.<wbr> 
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_7_7.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_8_8.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_9_9.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_10_10.JPG"> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Ambition to become an immuno-oncology player: </STRONG>Preclinical evidences suggest enzalutamide may have immuno-modulatory properties.<wbr> Combination of enzalutamide with pidlizumab could become a future strategy focus for Medivation
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_11_11.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_12_12.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_13_13.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_14_14.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_15_15.JPG"> </div><div>Source: Medivation Company Website 2015 January </div><!-- Comment details --><a name="oncology10210attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_1_1.JPG">1.JPG</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_2_2.JPG">2.JPG</a>&nbsp;&nbsp;(58,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_3_3.JPG">3.JPG</a>&nbsp;&nbsp;(66,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_4_4.JPG">4.JPG</a>&nbsp;&nbsp;(67,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_5_5.JPG">5.JPG</a>&nbsp;&nbsp;(50,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_6_6.JPG">6.JPG</a>&nbsp;&nbsp;(56 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_7_7.JPG">7.JPG</a>&nbsp;&nbsp;(72,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_8_8.JPG">8.JPG</a>&nbsp;&nbsp;(73,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_9_9.JPG">9.JPG</a>&nbsp;&nbsp;(48,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_10_10.JPG">10.JPG</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_11_11.JPG">11.JPG</a>&nbsp;&nbsp;(55,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_12_12.JPG">12.JPG</a>&nbsp;&nbsp;(53,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_13_13.JPG">13.JPG</a>&nbsp;&nbsp;(59 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_14_14.JPG">14.JPG</a>&nbsp;&nbsp;(44,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10210_15_15.JPG">15.JPG</a>&nbsp;&nbsp;(42,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10210">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T18:59:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T18:59:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Selective Inhibitor of GPR84 to be Studied in Humans</title>
	<pubDate>2015-01-13T18:54:26+01:00</pubDate>
	<wp:post_id>6149</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GPR84 is crucial in IBD as it participates in the regulation of macrophages, monocytes, and neutrophils in the human immune system.<wbr> Galapagos NV has started a POC study to evaluate GLPG1205 for Ulcerative Colitis (UC).<wbr> PE will measure change in Mayo score at week 8.<wbr> Top line results are expected to be release during 1H2016.<wbr> In December 2014, the company regained full rights to its GPR84 program as part of a new agreement with partner Janssen Pharm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="https://clinicaltrials.gov/ct2/show/NCT02337608?term=Galapagos&amp;rank=2">NCT02337608</A> </div><div style="margin-bottom: 10px;">Recruitment: approx 60 with moderate to severe ulcerative colitis </div><div style="margin-bottom: 10px;">Timelines: completion Feb 2016 /<wbr> April 2016 </div><div style="margin-bottom: 10px;">Location: Galapagos is recruiting patients in Belgium, Hungary, Czech Republic, Germany, Poland and Russia, and has already received full approvals to do so in the first four countries, while the last two should be approved during the first quarter of the year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2199_1_ScreenCapture1.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2784c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Galapagos said today its experimental drug had failed to prove its efficacy, and it would discontinue the programme for that indication.<wbr> While the drug GLPG1205 was well tolerated, it did not perform better than the placebo given to another group of patients.<wbr><BR> </div><div>Galapagos will evaluate whether GLPG1205 will be developed in alternative indications, likely to be chronic pain.<wbr> </div></div><a name="gastroenterology2199attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2199_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2199">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T18:54:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T18:54:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revive's Oral REV-002 (Bucillamine) to Enter POC Study for Gout</title>
	<pubDate>2015-01-13T18:34:02+01:00</pubDate>
	<wp:post_id>6150</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bucillamine, as a repurposed drug, benefits from 20 + years of safety and contraindication data.<wbr> The drug belongs to a different class of drugs and has a different mechanism of action resulting in a potential unique dual-therapeutic action based on gout animal studies.<wbr> In addtion to Gout, Revive is focused on underserved medical needs such as Rett syndrome (REV-003 to enter Ph1 this year), and postoperative pain management (REV-001 available for out-licensing).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="https://clinicaltrials.gov/ct2/show/NCT02330796?cond=GOUT+OR+PROSTATE+OR+BOTULINUM+OR+BOWEL+OR+HUNTINGTON&amp;phase=012&amp;fund=2&amp;rcv_s=12%2F13%2F2014&amp;rcv_e=01%2F13%2F2015&amp;rank=4&amp;submit_fld_opt=">NCT02330796</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2198_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Founded in 2012</LI>
<LI>Validate asset in Ph2, and seek partner</LI>
<LI>Cash and cash equivalents at September 30, 2014 totaled $982,360 (June 30, 2014 - $1,188,919).<wbr> The net loss for the three months ended September 30, 2014 was $398,588 (September 30, 2013 - $37,752).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Near-Term Catalysts</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2198_1_ScreenCapture1.jpg"> </div><div><EM>Source: Revive</EM> </div><!-- Comment details --><a name="gastroenterology2198attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2198_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2198_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2198">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T18:34:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T18:34:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis's Acquisition of Allergan May Now Proceed Very Rapidly With a "Seamless" Integration Planned</title>
	<pubDate>2015-01-13T18:25:45+01:00</pubDate>
	<wp:post_id>6151</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday the US Federal Trade Commission granted early termination 
of a federal regulatory waiting period.<wbr> As a result 
a "shareholder-of-record date" of the 22nd January  has been set to 
determine eligibility to vote at a special shareholders meeting to approve 
the proposed $68bn acquisition of Allergan.<wbr> </div><div style="margin-bottom: 10px;">The FTC granted early termination of the waiting period under the Hart-Scott 
-Rodino antitrust legislation.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, ahead of its presentation at the JP Morgan meeting Actavis 
announced an exceptional preliminary fourth quarter performance.<wbr> Full results 
are anticipated on February 18th alongside an overview of its R&amp;D 
pipeline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on Q4 CEO Brent Saunders stated:-</STRONG> </div><div style="margin-bottom: 10px;">"2014 was an exceptional year for our Company.<wbr> There were a number of 
significant highlights across our brand, generic, OTC and Anda distribution 
businesses during the fourth quarter.<wbr> In addition to strong sales growth in the 
U.<wbr>S.<wbr> and key International markets, we were pleased to announce the FDA approval 
of Namzaric, our fixed-dose combination (FDC) of memantine hydrochloride 
extended-release and donepezil hydrochloride for the treatment of moderate to 
severe dementia of the Alzheimer's type in patients stabilized on memantine 
hydrochloride and donepezil hydrochloride.<wbr> We were also pleased to report the 
favorable FDA Advisory Committee recommendation for our AVYCAZ anti-infective 
and that we have filed the NDA for our Cariprazine antipsychotic.<wbr> In our 
generics business, we ended 2014 having submitted more than 40 ANDAs in the U.<wbr>S" </div><div>"While delivering strong results in the quarter, we also continued to 
make significant progress in business development activities, completing the 
<STRONG>acquisition of Durata Therapeutics</STRONG>, which added the 
<STRONG>Dalvance antibiotic to our portfolio</STRONG>, and acquiring an 
<STRONG>exclusive option to Rhythm Health, Inc.<wbr>'s RM-131 (relamorelin) GI 
candidate.<wbr></STRONG> Finally, just prior to year-end, we announced the proposed 
combined executive leadership team following the close of the proposed 
acquisition of Allergan, and we are <STRONG>continuing to make extensive 
progress in pre-integration planning activities</STRONG> that will ensure we can 
seamlessly operate as one combined company following <STRONG>close, which is now 
anticipated late in the first quarter or early in the second quarter of 
2015.<wbr>" <BR></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7883">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T18:25:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T18:25:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Analysts Believe Salix Remains a Potential Takeout Target</title>
	<pubDate>2015-01-13T17:27:51+01:00</pubDate>
	<wp:post_id>6152</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After a today meeting with Salix management, Cantor analysts have highlighted that the company "remains" a potential takeout target due to its robust Xifaxan franchise, and strong presence amongst gastroenterologists.<wbr> Xifaxan could be approved for IBS-D around Q2:15 (and launched 2H15).<wbr> Last month, Deutsche Bank commissioned a survey to know how much Xifaxan is already used off-label for IBS-D, and what a formal approval/<wbr>indication could bring to the franchise (please see details below).<wbr> Of note, Actavis' eluxalodine (launch planned late 2015/<wbr>early 2016) has been identified as a key competitor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported it will likely benefit from the significant DTC promotion in the IBS-C space, which will raise awareness about the disease state.<wbr> </div><div style="margin-bottom: 10px;">The company identified under-dosing in current off-label treatment of IBS-D and management indicated that on-label use should drive more revenue growth as well.<wbr> </div><div style="margin-bottom: 10px;">Most importantly, the company is engaged in an active dialogue with FDA about IBS-D and has started to discuss modifying easier label sections such as pregnancy and PK (but not IBS-D indications or clinical data which may be last).<wbr> </div><div style="margin-bottom: 10px;">Management confirmed there are no CMC concerns at this time.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Population</U> </div><div style="margin-bottom: 10px;">67 gastroenterologists (GIs) and 33 Primay Care Doctors (PCPs) </div><div style="margin-bottom: 10px;"><U>Key Takeaways</U> </div><div style="margin-bottom: 10px;">1) awareness of the Xifaxan IBS-D data is high, </div><div style="margin-bottom: 10px;">2) the docs already prescribe Xifaxan for 17% of their IBS-D patients, </div><div style="margin-bottom: 10px;">3) payer access is a key hurdle to prescribing, and </div><div style="margin-bottom: 10px;">4) FDA approval should trigger a modest to significant increase in prescribing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Novel, orally active investigational compound being developed for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant irritable bowel syndrome or IBS-D.<wbr> </div><div style="margin-bottom: 10px;">The drug has shown success in two ph3 clinical trials.<wbr> </div><div style="margin-bottom: 10px;">Two double-blind, placebo-controlled, trials (IBS3001 and IBS3002) randomized patients meeting Rome III criteria for IBS-D to treatment with eluxadoline (75 mg or 100 mg twice daily) or placebo.<wbr> </div><div style="margin-bottom: 10px;">Both trials assessed efficacy through 26 weeks.<wbr> Thereafter, IBS3001 included an additional 26 weeks of double-blind treatment for long-term safety evaluations while IBS3002 included a 4-week placebo withdrawal phase </div><div><EM>Source: Cantor Report; Salix PR; Actavis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2197">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T17:27:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T17:27:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UCB's New CEO Introduces Executive Team</title>
	<pubDate>2015-01-13T16:26:35+01:00</pubDate>
	<wp:post_id>6153</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jean-Christophe Tellier has taken up the role as CEO of UCB on 1 January 2015, succeeding Roch Doliveux, and announced new leadership team effective February 1, 2015.<wbr> End of Q4:14, management highlighted 5 strategic priorities being 1/<wbr>grow Cimzia, Vimpat and Neupro; 2/<wbr>build emerging markets and Japan; 3/<wbr>advanced late-stage pipeline (such as brivaracetam); deliver breakthrough medicines to the clinic and 5/<wbr>reach competitive profitability.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11067_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld11067attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11067_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(109,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11067">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T16:26:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T16:26:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Janssen Signs First Agreement on Potential Microbiome Therapeutic</title>
	<pubDate>2015-01-13T15:56:03+01:00</pubDate>
	<wp:post_id>6154</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Janssen has signed a $241M license agreement with Vedanta Biosciences for the company's VE202, which in published PC studies has demonstrated efficacy in models of autoimmune disease.<wbr> The terms of the collaboration indicate that Janssen will develop and seek to commercialize the investigational drug in IBD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Upfront: $241M + possible additional considerations related to commercialization </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Vedanta was founded by PureTech Ventures and a team of world renowned experts in immunology and microbiology.<wbr> Vedanta is pioneering development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2195">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T15:56:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T15:56:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Revance's 2015 Milestones for RT001 and RT002 for Aesthetic and Cosmetic Indications</title>
	<pubDate>2015-01-13T13:37:38+01:00</pubDate>
	<wp:post_id>6155</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday management reported the advancement of both drugs, highlighting RT002, its injectable one, to be 'game-changing'.<wbr> In addition it was oultined that Revance expects cash burn for 2015 to be in the range of $74 to $84 million (vs $69 to $71M in 2014).<wbr> Details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Revance expects to start its first Ph3 pivotal study in the U.<wbr>S.<wbr> and report efficacy results in the second half of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Revance expects to initiate a Ph1/<wbr>2 clinical study using topical RT001 for the treatment of hyperhidrosis in mid-2015.<wbr> The company is currently completing the final design of the trial and expects to report preliminary efficacy results from this trial in the second half of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="https://clinicaltrials.gov/ct2/show/NCT02303002?term=revance&amp;rank=2&amp;submit_fld_opt=">BELMONT</A> Ph2 trial ongoing - Revance expects to report interim duration results from this study in late 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company plans to provide information on the selected indication Ph1/<wbr>2 clinical trial design in the first half of 2015 and to report the related clinical results in the second half of 2015.<wbr> </div><div><EM>Source: Revance PR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7882">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-13T13:37:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-13T13:37:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph3 Details of DWP-450 (Botulinum purified neurotoxin, Type A)</title>
	<pubDate>2015-01-12T18:18:56+01:00</pubDate>
	<wp:post_id>6156</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <EM>Clinicaltrials.<wbr>gov</EM> is listing two US registration trials of DWP-450 to treat glabellar lines.<wbr> Both studies (EV001 and EV002) will enroll approx.<wbr> 324 subjects each, be randomly assigned 3:1 to receive DWP-450 or placebo, and have same timelines and PE (reduction in GL as assessed by investigator and subject).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ref <A href="https://clinicaltrials.gov/ct2/show/NCT02334423?recr=Open&amp;no_unk=Y&amp;phase=0123&amp;fund=2&amp;rcv_s=12%2F01%2F2014&amp;rcv_e=01%2F12%2F2015&amp;rank=46">NCT02334423</A> - Ref <A href="https://clinicaltrials.gov/ct2/show/NCT02334436?recr=Open&amp;no_unk=Y&amp;phase=0123&amp;fund=2&amp;rcv_s=12%2F01%2F2014&amp;rcv_e=01%2F12%2F2015&amp;rank=38">NCT02334436</A> </div><div style="margin-bottom: 10px;"><STRONG>Description</STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx 324 each </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subjects is an adult, of at least 18 years of age</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject is able to provide informed consent and comply with study instructions</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject has moderate to severe glabellar lines at maximum frown as assessed by the investigator using the GLS</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject has moderate to severe glabellar lines at maximum frown as assessed by the subject using the GLS</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject is willing and able to complete the entire course of the study</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Timelines </P> </div><div style="margin-bottom: 10px;">Timelines Start in January 2015 /<wbr> completion July /<wbr> October 2015 </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">EV001 Steven Fagien, MD
<TD headers="locStatus">&nbsp;</TD> </div><div style="margin-bottom: 10px;"><TR><TD colspan="2" nowrap="" style="PADDING-LEFT: 4em">Boca Raton, Florida
 </div><div style="margin-bottom: 10px;"><P>EV002 The Clinical Testing Center of Beverly Hills</P> </div><div></TD>
</TR> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7900c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Ahead of IMCAS this week, ALPHAEON issued a press release yesterday noting that enrolment in its PhIII glabellar lines programme began on January 14th.<wbr> Whilst we believe it is still waiting for FDA inspection of its toxin manufacturing plant, clearly its IND data and EMA cGMP approval of its plant is proving adequate for it to initiate its phIII programme.<wbr> </div><div><P align="LEFT">Commenting on this development Chris Marmo President of ALPHAEON Beauty stated &ldquo;The agreement with the FDA on our phase III pivotal study protocol marks another key milestone on the execution of our neuromodulator development plan.<wbr> Access to EVOSYAL (DW450 BoNT-A) as noted previously was gained through the acquisition of Evolus last year which had previously in-licensed global aesthetic and therapeutic rights to the product from Daewoong in Korea.<wbr> At IMCAS last year Strathspey Crown the holding company for ALPHAEON noted that it was not intending to focus on the development of the toxin for aesthetic purposes only.<wbr></P> </div></div><a name="Neurology7994c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><P align="left">ALPHAEON has completed enrollment of the two pivotal studies which marks a significant milestone for the Ph3 development program.<wbr></P> </div><div><P align="left">Recruitment for the two U.<wbr>S.<wbr>-based studies began on January 2015 and was completed in March.<wbr></P> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7880">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T18:18:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T18:18:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Pfizer Supports Translational Research for IBD</title>
	<pubDate>2015-01-12T17:46:31+01:00</pubDate>
	<wp:post_id>6157</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pfizer Supports Translational Research for IBD</span>&nbsp;<br><span style="font-size: 12px;">Comment: Crohn&rsquo;s &amp; Colitis Foundation of America (CCFA) and Pfizer have entered into an agreement to identify and support the development and translation of research in the area of IBD.<wbr> This new agreement reinforces Pfizer's comitment in the field of IBD.<wbr> A couple of weeks ago, the company inked a deal with 23andME to map the DNA of 10,000 patients who have forms of the disease, in order to identify genetic similarities which could eventually guide development of new targeted drugs.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2015">...</a><br></div><div>Pfizer and 23andMe have expanded their IBD agreement to enable research, clinical trial recruitment for the treatment of lupus.<wbr> Nearly 4,000 patients have been enrolled in the IBD initiative since August 2014.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2194">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2015">View thread  GastroEnterology2015: Pfizer Supports Translational Research for IBD</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T17:46:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T17:46:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TASQ Therapy Area Landscape 2015 Update</title>
	<pubDate>2015-01-12T17:30:06+01:00</pubDate>
	<wp:post_id>6158</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached an updated competitive landscape for TASQ.<wbr> This slide kit is designed to provide you an global overview of the key events or milestone occurred in the past 12 months that have substantial impact on CRPC treatment landscape.<wbr> The slide deck is now including medical/<wbr>clinical development, marketing, market access aspect (many thanks for franchise &amp; market access team's contribution to this edition).<wbr>As a new feature to this edition, hyperlinks are now added in the table of contents to help you navigate through the slides more easily.<wbr> </div><div>We strongly encourage you to contribute to our knowledge by evaluating some of the "Key Intelligence Questions" included in this document.<wbr> We do always welcome any competitive information or soft intelligence that you may have in your countries.<wbr> </div><!-- Comment details --><a name="oncology10204attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10204_2_TasQ%20TAL%20Final%20Version%202%200.pptx">TasQ TAL Final Version 2 0.pptx</a>&nbsp;&nbsp;(4,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10204">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T17:30:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T17:30:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tokai Inks Agreement to Develop a Companion Diagnostic for Galeterone</title>
	<pubDate>2015-01-12T17:17:18+01:00</pubDate>
	<wp:post_id>6159</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tokai has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with CRPC for use with the company’s galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.<wbr> The companion diagnostic is intented to be used in the 148 patient Ph3 ARMOR-3SV study planned to start 1H:15.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Under the agreement, Tokai has obtained an exclusive, WW license from the Johns Hopkins University to patent applications and know-how covering an assay that has been used to determine the AR-V7 status of prostate cancer patients.<wbr> </div><div>Source: Tokai </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10200">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T17:17:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T17:17:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Tekmira's Update On The Phase I/II Study In Patients With Advanced GI-NET And ACC</title>
	<pubDate>2015-01-12T16:55:05+01:00</pubDate>
	<wp:post_id>6160</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Tekmira's Update On The Phase I/<wbr>II Study In Patients With Advanced GI-NET And ACC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Tekmira, a leading developer of RNAi therapeutics, announced a status update on TKM-PLK1 Phase I/<wbr>II clinical trial currently targeting GI-NET and ACC indications.<wbr> The trial is a multi-center, single arm, open label study to measure TKM-PLK1 efficacy and safety in GI-NET and ACC patients.<wbr> Tekmira has achieved its target enrolment of 55 patients for the Phase I/<wbr>II and final data is expected in mid-2015.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7904">...</a><br></div><div style="margin-bottom: 10px;">Comment: Tekmira has announced on January 11th 2015 the merger with OnCore Biopharma to create a leading Hepatitis B company.<wbr> </div><div>Press release can be found at this <a href="http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=890627" class="defaultlink">link</a>.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7912">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7904">View thread  Endocrinology7904: Tekmira's Update On The Phase I/<wbr>II Study In Patients With Advanced GI-NET And ACC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T16:55:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T16:55:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BioGaia's Biggest Product to be Marketed in Vietnam</title>
	<pubDate>2015-01-12T14:42:54+01:00</pubDate>
	<wp:post_id>6161</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: VietPhap will market BioGaia's ProTectis Baby Drops this year, and later also launch BioGaia ProTectis Baby Drops with vitamin D.<wbr> Both products contain <EM>Lactobacillus reuteri</EM> DSM 17938 (<EM>Lactobacillus reuteri</EM> Protectis).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Today the drops are sold as dietary supplements in 71 countries worldwide.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2191_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">The company is doing licensing, business development, marketing, sales and distribution of a wide range of products, both over-the-counter and prescription drugs, in many different indication areas.<wbr> </div><div style="margin-bottom: 10px;">VietPhap markets its products towards health care professionals.<wbr> </div><div>Source: BioGaia </div><!-- Comment details --><a name="gastroenterology2191attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2191_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2191_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(36,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2191">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T14:42:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T14:42:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biogen Acquires Private UK Company With Chronic Pain Drug For Neuropathic Pain For Up Tor $675m</title>
	<pubDate>2015-01-12T13:19:32+01:00</pubDate>
	<wp:post_id>6162</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Biogen announced on Sunday it would acquire Convergence 
Pharmaceuticals (Cambridge UK) for its experimental drug portfolio to 
treat chronic nerve pain, notably trigeminal neuroalgia and sciatica.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the deal, Biogen Idec will pay Convergence shareholders an 
upfront payment of $200 million.<wbr> Convergence shareholders are eligible to 
receive additional payments up to $475 million contingent on future milestones.<wbr> </div><div style="margin-bottom: 10px;">Convergence will continue to operate out of Cambridge, U.<wbr>K.<wbr>, under the 
leadership of its Chief Scientific Officer, Simon Tate, Ph.<wbr>D.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Purchase</STRONG> </div><div style="margin-bottom: 10px;">The key drug acquired is CVN1014802 a.<wbr>is a novel small molecule 
state-dependent sodium channel blocker.<wbr> It is active against the Nav1.<wbr>7 sodium 
channel which was recently validated as a key pain target by human genetic 
linkage </div><div style="margin-bottom: 10px;">CNV1014802 has reportedly completed three Phase I studies and two Phase 
II studies with single and repeated oral dosing in over 300 patients and 
demonstrated an ideal pharmacokinetic profile together with excellent toleration 
at doses within the expected therapeutic range.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Results To Date</STRONG> </div><div style="margin-bottom: 10px;">Convergence recently reported positive results from a midstage trial with the 
drug in patients with trigeminal neuralgia.<wbr>The study demonstrated a consistent 
reduction of pain severity in 58% of patients and a 66% reduction in the number 
of paroxysms, achieving all primary and secondary endpoints.<wbr> There were no 
serious adverse events related to the drug and the adverse event profile of the 
drug was similar to placebo in the double blind phase of the study.<wbr> </div><div style="margin-bottom: 10px;">The same drug is also being tested to treat sciatica and seen as having the 
potential to treat other nerve pain conditions.<wbr> </div><div style="margin-bottom: 10px;">A phII randomised double-blind placebo-controlled cross-over study in 
patients  Lumbosacral Radiculopathy (Sciatica) trial showed a 
statistically significant difference in the primary endpoint between CNV101802 
and placebo in the Pain Intensity-Numerical Rating Scale (PI-NRS) with a mean 
change at week 3 of -0.<wbr>43 p=0.<wbr>0265.<wbr> Additional exploratory analyses showed that 
for the subset treated by CNV1014802 alone, comprising 60% of patients 
randomised, there was an enhanced statistically significant reduction in pain, 
with a PI-NRS mean change at week 3 of -0.<wbr>72 p=0.<wbr>0039.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commerical Potential As Noted By CEO</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the second set of data Clive Dix CEO 
of Convergence commented "We are delighted to have achieved clinical proof 
of concept with CNV1014802.<wbr> This is the second positive study with this molecule 
and the data confirm our belief that this asset has potenital to be a 
blockbuster treatment for neuropathic pain state.<wbr> The company will 
initially target the commercialisation of CNV1014802 in trigeminal neuralgia and 
other orphan drug conditions, however, these data confirm our belief that this 
molecule will have broad utiliy in neuopathic pain including Sciatica.<wbr> (press 
release 23/<wbr>09/<wbr>14) </div><div style="margin-bottom: 10px;">Convergence's Pipeline </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7878_1_ScreenCapture2.jpg"> </div><div>Source: <A href="http://www.convergencepharma.com/">www.<wbr>convergencepharma.<wbr>com</A><BR> </div><!-- Comment details --><a name="neurology7878attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7878_1_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(88,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7878">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T13:19:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T13:19:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Shire to Acquire NPS Pharmaceuticals for $5.2bn To Expand Its Rare Disease GI Franchise</title>
	<pubDate>2015-01-12T12:48:53+01:00</pubDate>
	<wp:post_id>6163</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Having escaped the clutches of Abbvie, Shire is now pursuing its own 
expansion plans through the acquisition of the specialty biopharmaceutical 
company NPS Pharmaceuticals.<wbr> The purchase will allow Shire to expand its rare 
dissease portfolio particularly in the GI area.<wbr> Shire is expecting to 
accelerate the growth of NPS's Gattex in the US by leveraging Shire's No 2 
ranked GI sales expertise and rare disease specialism.<wbr> The latter is based 
on sales of 5-ASA and enzyme replacement therapies respectively.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_4_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Scope of Shire's Rare Disease Business Prior To The NPS 
Acquisition</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_9_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_10_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Shire will acquire all of the outstanding shares of NPS Pharma at $46 
per share in cash.<wbr> That represents a 51% premium to NPS Pharma's unaffected 
share price of $30.<wbr>47 on December 16, 2014.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Shire is funding the acquisition using its cash on 
hand, its existing $2.<wbr>1 billion committed bank facility, and a 
newly-arranged $850 million short-term bank facility.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">As the transaction is not subject to any financial 
contingency, losing is expected in the first quarter of 2015.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Financial Expectations</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The acquisition is expected to enhance revenue growth by 
2015 and onwards and be accretive to earnings from 2016 and onward.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Expectations in terms of synergies  are 
for approximately 25% to 35% of the Street's consensus forecast of NPS 
Pharma's standalone future operating cost base from 2017 onward.<wbr> These should 
be realized by the beginning of 2016 and then growing 
substantially thereafter.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_3_ScreenCapture4.jpg"></P> </div><div style="margin-bottom: 10px;"><STRONG>NPS Profile &amp; Key Products</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_2_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_5_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_6_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Key Benefits To Be Derived Through The Combination</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_7_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">Two companies have highly complimenatry business models the transaction is 
firmly focused upon growth.<wbr> </div><div>Q/<wbr>A </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld11107c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>After the $5 billion deal for NPS Pharma, Shire has announced today the acquisition of the Californian small biotech Meritage that includes a Phase III ready rare disease drug for $70 million upfront.<wbr> Meritage offers Shire an interesting portfolio on rare disease GI drugs, stressing once more Shire's committement to its GI franchise.<wbr> Shire acquired rights to purchase Meritage in 2014, in connection with its $4.<wbr>2 billion acquisition of rare disease specialist Viropharma.<wbr> </div></div><a name="pharmaworld11064attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(86,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_2_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(101,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(88,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(91,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(150,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(132,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(99,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(101,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(56,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11064_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(238,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11064">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-12T12:48:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-12T12:48:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UK Cancer Drug Fund Poised To De-list Novartis's Afinitor (Everolimus)</title>
	<pubDate>2015-01-09T15:06:04+01:00</pubDate>
	<wp:post_id>6164</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Mentioned as a possibility at the UKINETs meeting before Christmas 
in relation to the drug's use to treat pNET, Novartis is reportedly becoming 
more vocal in its complaint about the de-listing process in which so far six 
breast cancer drugs are poised to be banned.<wbr> Afinitor appears to be one of 
the six having breast cancer amongst kidney and pNET as its approved 
indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>CDF Process Viewed As Unfair &amp; Non Transparent</STRONG> </div><div style="margin-bottom: 10px;">Quoting the company Pharmatimes claims the Swiss major is saying the 
methodology used is unacceptable as it is insufficiently robust and transparent 
and includes a crud cost assessment which doe not reflect the true value of the 
medicine.<wbr> It has apparently urged NHS England to stop the process now and 
enter into constructive dialogue with all stakeholders to find an equitable 
solution.<wbr> </div><div>Novartis seemingly argues that unless the process is stopped, patients will 
face an unacceptable "time of diagnosis" effectively a lottery where they can 
only access drugs posied for de-listing if they are diagnosed before March 12th 
2015.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7983c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Today was announced that NHS England has performed a U-turn on the decision of delisting Everolimus from the CDF, as it was announced in January.<wbr> Novartis has worked with the CDF to reach an agreement for keeping everolimus on the CDF list for advanced breast cancer and kidney cancer as the drug meets the clinical threshold set by the NHS in these indications.<wbr>  Novartis could not find an agreement for well-differentiated pNETs and has accepted delisting everolimus in this indication.<wbr> Novartis will supply Afinitor to pNET patients on 'named patients basis', upon request from oncologists through their local clinical commissioning group (CCG).<wbr> The NHS is due to publish a new list for the revised drugs which will be included in the CDF.<wbr> </div><span style="font-weight: bold; font-style: italic;"></span><a name="Endocrinology7989c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The NHS has published a <a href="http://www.england.nhs.uk/wp-content/uploads/2015/03/ncdf-list-mar-15.pdf" class="defaultlink">new list</a>for the revised drugs which will be included in the CDF - Everolimus is on the CDF list only for advanced breast cancer and metastatic renal cell carcinoma, but has been delisted for well-differentiated pNET.<wbr> </div><span style="font-weight: bold; font-style: italic;"></span><a name="Endocrinology8138c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Afinitor is no longer be available from Cancer Drugs Funds to treat pNET, effectively July 21.<wbr> (Source: Biocentury) </div></div></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7911">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-09T15:06:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-09T15:06:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Synlab to Distribute Genetic Analysis' GA-map Dysbiosis Test in Germany</title>
	<pubDate>2015-01-09T14:13:38+01:00</pubDate>
	<wp:post_id>6165</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The <A href="http://www.pharmaceutical-business-review.com/suppliers/genetic__analysis__molecular__diagnostics__gut__imbalances/products/ga__map__technology">GA-map assay </A>targets dysbiosis, an imbalance of gut microbacteria that can lead to the development of irritable bowel disease and other gastrointestinal aliments.<wbr> While Synlab's 's distribution deal is exclusive for Germany, it retains a non-exclusive option for other markets in Europe and the Middle East.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.genetic-analysis.com/about"><STRONG>Genetic Analysis</STRONG> </A>has developed and launched the first gene-based routine test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the bacteria in the digestive system.<wbr> The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market.<wbr> Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi at Norwegian University of Life Sciences, NMBU and Nofima Mat in Ås.<wbr> </div><div style="margin-bottom: 10px;">With headquarters in Augsburg, Germany, the <A href="http://www.labor-bayer.de/"><STRONG>Synlab</STRONG> group </A>is the leading provider of medical laboratory services in Europe.<wbr> The company offers a full range of laboratory analyses and consultancy services for human and veterinary medicine as well as for the environment.<wbr> In addition to Germany, synlab has branches in 23 European countries as well as in Turkey, Saudi Arabia and Dubai.<wbr> The synlab group has a staff of approx.<wbr> 7,000 across Europe including 4,500 employees in Germany.<wbr> The 175 laboratories of the synlab group perform approx.<wbr> 1 mio.<wbr> tests every day and, in 2013, generated revenues of approx.<wbr> EUR 700 million<EM>.<wbr></EM> </div><div><EM>Source: synlab; Genetic Analysis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2190">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-09T14:13:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-09T14:13:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Dendreon Is In Chapter 11 - Dendreon's Share Fell 75% After Filing For Bankruptcy</title>
	<pubDate>2015-01-09T10:00:33+01:00</pubDate>
	<wp:post_id>6166</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Dendreon Is In Chapter 11 - Dendreon's Share Fell 75% After Filing For Bankruptcy</span>&nbsp;<br><span style="font-size: 12px;">Comment: Dendreon has filed for voluntary federal bankruptcy protection and has reached an agreement with holders of $620 million in convertible debt.<wbr> The company filed for Chapter 11 with $100 million in cash or cash equivalents, and won't need bankruptcy financing.<wbr> As of the period ended 30th Sept 2014, Dendreon had $340 million in assets and $660.<wbr>7 million in liabilities on a book value basis.<wbr> Cost -containment efforts have reduced from 1,500 employees to the workforce of 698 people.<wbr> Dendreon will pursue sale or reorganization in bankruptcy.<wbr> Unless a buyer can be found that is willing to continue producing Provenge, the ownership of Dedreon and Provenge will default back to the lenders.<wbr> Dendreon combined undue optimism in sales projections with excessive risk in its capital structure.<wbr> It is a case of moderate product success and immoderate management failure.<wbr> However, the fall out over Provenge's promise versus performance still lingers - as speculation of leakage information from Medicare/<wbr>Medicaid Insurance Services to hands of investors is being investigated.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10091">...</a><br></div><div>Comment: Dendreon will hold an auction for bidders on 3rd Feb 2015 with a $275 million minimum bid requirement.<wbr> Unless the company sells for enough to repay its $620 million in notes and other creditors, shareholders are unlikely to receive anything from the bankruptcy.<wbr> Dendreon said in court documents that more than 40 parties had signed nondisclosure agreements, indicating interest in bidding on the company's assets.<wbr> If the company does not hold an auction, Dendreon will emerge from bankruptcy under the control of noteholders.<wbr> Those investors include funds associated with Deerfield Management Co, Aristeria Capital, Empyrean Capital Partners, Wolverine Asset Management and Partner Fund Management.<wbr> (Source: Reuters US) </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10199">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10091">View thread  Oncology10091: Dendreon Is In Chapter 11 - Dendreon's Share Fell 75% After Filing For Bankruptcy</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-09T10:00:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-09T10:00:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>IQWiG Decides Dendreon's Provenge Demonstrates No Additional Benefit in New Prostate Cancer Indication</title>
	<pubDate>2015-01-08T18:16:35+01:00</pubDate>
	<wp:post_id>6167</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Germany's Institute for Quality and Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; IQWiG) has published its dossier evaluation for a new approved indication of Provenge, for men with metastatic prostate cancer, with few or no symptoms and for whom chemotherapy is not yet clinically indicated.<wbr> Already, the UK's NICE has issue draft guidance not recommending the drug in this indication.<wbr> </div><div style="margin-bottom: 10px;">The Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA) identified three possible appropriate comparator therapies, including watchful waiting, while maintaining hormone-blocking therapy; this was the treatment which the producer used in its comparison data.<wbr> </div><div style="margin-bottom: 10px;">However, IQWiG had concerns about the study data, particularly with regard to the high number of therapy changers in the control arm, due to which it considered that all endpoints were prone to bias.<wbr> It stated that there was no focus on health-related quality of life in the study data submitted, while in terms of other patient-relevant outcomes, no statistically significant differences could be gleaned.<wbr> In summary, taking into account also higher incidence of certain adverse side effects, IQWiG decided that Provenge showed no additional benefit in this indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to IQWiG, Provenge has been approved in this indication since September 2014.<wbr> Already, the UK's NICE has issue draft guidance not recommending the drug in this indication </div><div style="margin-bottom: 10px;">For two highly influential health technology assessment agencies to give negative assessments of the drug in this new indication will make its chances of progressing to reimbursement in other European countries challenging.<wbr> </div><div style="margin-bottom: 10px;">The G-BA will issue its final resolution on the early benefit assessment of Provenge in this indication within around three months, during which time the producer may be able to improve its prospects with new spoken or written submissions.<wbr> </div><div>Source: IHS </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10197">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-08T18:16:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-08T18:16:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ultragenyx Enters Huntington's Disease Race</title>
	<pubDate>2015-01-08T18:05:46+01:00</pubDate>
	<wp:post_id>6168</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ultragenyx, a clinical-stage botechnology company, has announced a license agreement with Inserm Transfert SA and Institut du Cerveau et de la Moelle Epiniere (ICM) for IP related to triheptanoin (UX007) for the treatment of Huntington's disease (HD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Findings</U>: a potential signal, but larger data sets are needed to confirm.<wbr> </div><div style="margin-bottom: 10px;">The pilot, open-label study examined levels of brain energy metabolism markers - phosphocreatine (PCr) and inorganic phosphate (Pi) - before, during, and after a visual stimulus.<wbr> 10 pts with early HD were treated with UX007 for 1 month then had 31P brain magnetic resonance spectroscopy (MRS).<wbr> After 1 month the MRS profile improved in pts treated with UX007 (vs.<wbr> 13 control pts, p=0.<wbr>005) (see <A href="https://views.thomsonone.com/gateway/PORTALSxDOCUMENTVIEWER.aspx?DocId=68899209&amp;mode=plain&amp;lang=en-US&amp;appName=T1_Web">Neurology paper</A>).<wbr> </div><div style="margin-bottom: 10px;">Given this initial signal, the company will support the development of UX007 in HD in a second investigator sponsored study through an IP agreement covering the treatment of HD with UX007.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7876_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7876_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology7876attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7876_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7876_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7876">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-08T18:05:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-08T18:05:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive Top-Line Results of Elagolix (GnRH antagonist) for Endometriosis</title>
	<pubDate>2015-01-08T15:56:04+01:00</pubDate>
	<wp:post_id>6169</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AbbVie/<wbr>Neurocrine Biosciences have announced positive top-line results from the first of two ongoing Ph3 clinical trials, designed to evaluate the efficacy and safety of elagolix in premenopausal women with endometriosis.<wbr> The top-line results are from a six-month, group-level analysis.<wbr> Patients in the trial will continue on in either post-treatment follow-up or a blinded six-month extension study.<wbr> AbbVie intends to present detailed results from this trial at a future medical conference.<wbr> A second Ph3, randomized, multinational, double-blind, placebo-controlled trial (M12-671) evaluating elagolix in patients with moderate-to-severe endometriosis-related pain is ongoing and results are expected in late 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Results from the trial show that after six months of treatment, both doses of elagolix (150 mg once daily and 200 mg twice daily) met the study's co-primary endpoints (p&lt;0.<wbr>001) of reducing scores of non-menstrual pelvic pain (NMPP) and menstrual pain (or dysmenorrhea), associated with endometriosis, at month three, as well as month six, as measured by the Daily Assessment of Endometriosis Pain scale.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">24-week, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 872 women, age 18 to 49, with moderate-to-severe endometriosis-associated pain.<wbr> </div><div style="margin-bottom: 10px;">It is being conducted at approximately 160 sites in the United States, Puerto Rico and Canada.<wbr> </div><div>Source: AbbVie </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10195">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-08T15:56:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-08T15:56:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Synergy Pharm Updates its Chronic Idiopathic Constipation (CIC) Program</title>
	<pubDate>2015-01-08T14:58:02+01:00</pubDate>
	<wp:post_id>6170</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has completed patient enrollment in the first of two pivotal Ph3 trials evaluating the safety and efficacy of two plecanatide doses (3.<wbr>0 and 6.<wbr>0 mg) in patients with CIC.<wbr> Management expects top-line data results from the first phase 3 CIC trial in 2Q 2015.<wbr> The company plans to file its first NDA with plecanatide in the CIC indication in 4Q 2015.<wbr> Of note, plecanatide 3.<wbr>0 and 6.<wbr>0 mg doses are also being evaluated in the ongoing Ph3 registration program for IBS-C (FDA approval in 2017).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_3_ScreenCapture3.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2211c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Today Synergy  announced that it has successfully completed patient enrollment in the second of two pivotal ph3 trials evaluating the safety and efficacy of two plecanatide doses (3.<wbr>0 and 6.<wbr>0 mg) in patients with chronic idiopathic constipation (CIC).<wbr> Patient enrollment in the first phase 3 CIC trial completed on January 8, 2015.<wbr> </div><div style="margin-bottom: 10px;">Each of the two randomized, 12-week, double-blind, placebo-controlled phase 3 trials are evaluating plecanatide, once-daily oral tablets, in approximately 1350 adult patients with CIC.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint is the proportion of patients who are <EM>Overall Responders</EM> during the 12-week treatment period.<wbr> </div><div style="margin-bottom: 10px;">An <EM>Overall Responder</EM> is a patient who fulfills both &ge; 3 complete spontaneous bowel movements (CSBMs) per week plus an increase of &ge; 1 CSBM from baseline in the same week, for 9 out of the 12 weeks, including &ge; 3 of the last 4 weeks.<wbr> </div><div>Plecanatide has met this endpoint and demonstrated statistical significance at the 3.<wbr>0 mg dose in a phase 2b CIC trial evaluating 951 patients with CIC.<wbr> </div></div><a name="gastroenterology2188attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(75,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2188_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(52,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2188">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-08T14:58:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-08T14:58:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BIND Provides Clinical Update for BIND-014</title>
	<pubDate>2015-01-08T14:00:00+01:00</pubDate>
	<wp:post_id>6171</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In line with the company's expectations, management has announced top line results from Ph2 for mCRPC.<wbr> As of <CHRON>December 15, 2014</CHRON>, BIND-014 demonstrated a median rPFS (PE) of 8.<wbr>1 months with three patients currently on treatment and 60% of the patients enrolled attained a rPFS of 6 months or greater.<wbr> Complete results of the mCPRC trial will be presented at an upcoming medical meeting.<wbr> In parallel, the company has reported the enrollment of the first patient expressing a KRAS mutation in a global, multicenter two-tiered phase 2 trial with BIND-014 in non-small cell lung cancer (NSCLC) patients with KRAS mutant tumors (mutated Kirsten ras oncogene homolog) or squamous histology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Safety and tolerability were also promising, with notable reductions in adverse effects that often limit dosing of conventional docetaxel, including hematologic and non-hematologic toxicities.<wbr> As of <CHRON>December 15, 2014</CHRON>, three patients continue on treatment and 24 patients continue to be followed for overall survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>BIND is initiating global, multicenter, two-stage, Ph2, multi-tumor trial with BIND-014 in patients with cholangiocarinoma, cervical cancer, bladder cancer and head and neck cancers, with anticipated first patient enrollment in 2Q 2015.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10194">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-08T14:00:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-08T14:00:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SOBI Gains Extended Duration Distribution Rights For COMETRIQ for Medullary Thyroid Cancer</title>
	<pubDate>2015-01-08T12:59:24+01:00</pubDate>
	<wp:post_id>6172</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <ORG value="NASDAQ-NMS:EXEL">Exelixis, has 
extended and restructured its agreement with </ORG><ORG>Swedish Orphan Biovitrum 
AB</ORG> to support the distribution and commercialization of 
COMETRIQ<SUP>®</SUP> (cabozantinib) for progressive, unresectable, locally 
advanced or metastatic medullary thyroid cancer (MTC) in the <ORG>EU, <LOCATION value="LC/ch;LB/weur">Switzerland</LOCATION>, <LOCATION value="LC/no;LB/neur">Norway</LOCATION>, <LOCATION value="LC/ru;LB/eeur">Russia</LOCATION>, and <LOCATION value="LC/tr;LB/was">Turkey</LOCATION>.<wbr> </ORG> </div><div style="margin-bottom: 10px;"><STRONG>Original &amp; Extended Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">The agreement, established in <CHRON>February 2013</CHRON> is due to 
expire in <CHRON>December 31, 2015 but</CHRON> will now extend to 
<CHRON>December 31, 2019</CHRON>.<wbr> Moreover, the payment structure of the 
partnership will transition from fixed fees paid by <ORG value="NASDAQ-NMS:EXEL">Exelixis</ORG> to Sobi to support initial build out of 
COMETRIQ European commercial infrastructure to a sales margin-based approach.<wbr> </div><div style="margin-bottom: 10px;">In parts of the territory where COMETRIQ is not approved, Sobi administers a 
Named Patient Use program.<wbr> <ORG value="NASDAQ-NMS:EXEL">Exelixis</ORG> is responsible for regulatory approvals 
in the covered territory, and the company retains the ability to terminate the 
agreement at will at any time upon payment of certain pre-determined fees.<wbr> </div><div style="margin-bottom: 10px;"><ORG value="NASDAQ-NMS:EXEL">Exelixis</ORG> continues to 
maintain commercial rights for all other potential cabozantinib oncology 
indications on a global basis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Expected Milestones For Exelixis in 2015</STRONG> </div><div style="margin-bottom: 10px;"><OL><LI>Receipt of top-line data from the METEOR phase 3 trial of cabozantinib in 
  metastatic renal cell carcinoma in the second quarter; and </LI>
<LI>Regulatory progress with Exelixis's partnered compound cobimetinib 
  for metastatic melanoma in both the <ORG>United States and European 
  Union</ORG>.<wbr> </LI>
</OL> </div><div>Source: <A href="http://www.exelixis.com">www.<wbr>exelixis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7910">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-08T12:59:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-08T12:59:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>'Bipolar Androgen Therapy' Shows Promise for CRPC</title>
	<pubDate>2015-01-08T11:56:21+01:00</pubDate>
	<wp:post_id>6173</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Results from a pilot clinical study show that a certain type of prostate cancer, after months or years of testosterone deprivation, can develop a lethal sensitivity to testosterone in a new treatment approach – “bipolar androgen therapy” BAT – which combines high-dose testosterone with androgen-blocking therapy.<wbr> The researchers have published their findings in <EM>Science Translational Medicine.<wbr> </EM>Denmeade and al.<wbr> are now launching a larger, Ph2 clinical trial of BAT that they hope will open for enrollment by mid 2015.<wbr> Centered at Johns Hopkins, the trial will have multiple recruiting sites, including one at Seattle Cancer Care Alliance led by Schweizer<EM>.<wbr></EM> </div><div style="margin-bottom: 10px;"><EM><A href="http://stm.sciencemag.org/content/7/269/269ra2">Reference</A>: M.<wbr> T.<wbr> Schweizer, E.<wbr> S.<wbr> Antonarakis, H.<wbr> Wang, A.<wbr> S.<wbr> Ajiboye, A.<wbr> Spitz, H.<wbr> Cao, J.<wbr> Luo, M.<wbr> C.<wbr> Haffner, S.<wbr> Yegnasubramanian, M.<wbr> A.<wbr> Carducci, M.<wbr> A.<wbr> Eisenberger, J.<wbr> T.<wbr> Isaacs, S.<wbr> R.<wbr> Denmeade, Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study.<wbr> Sci.<wbr> Transl.<wbr> Med.<wbr> 7, 269ra2 (2015).<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10192">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-08T11:56:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-08T11:56:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bowel Cleansing Effects on the Microbiota</title>
	<pubDate>2015-01-07T18:24:28+01:00</pubDate>
	<wp:post_id>6174</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Published end of last year in <EM>Gut</EM>, the results show that the bowel cleansing using two separate dosages introduces fewer alterations to the intestinal microbiota than a single dose and hence may be preferred in clinical practice.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV>
<P><ABSTRACTTEXT label="OBJECTIVE">An adequate bowel cleansing is essential for a successful colonoscopy.<wbr> Although purgative consumption is safe for the patient, there is little consensus on how the intestinal microbiota is affected by the procedure, especially regarding the potential long-term consequences.<wbr></ABSTRACTTEXT></P>
<H4>DESIGN </H4>
<P><ABSTRACTTEXT label="DESIGN">23 healthy subjects were randomised into two study groups consuming a bowel preparation (Moviprep), either in two separate doses of 1 L or as a single 2-L dose.<wbr> Participants donated faecal samples at the baseline, after bowel cleansing, 14 and 28 days after the treatment.<wbr> The intestinal microbiota composition was determined with phylogenetic microarray as well as quantitative PCR analysis and correlated with the previously quantified faecal serine proteases.<wbr></ABSTRACTTEXT></P>
<H4>RESULTS </H4>
<P><ABSTRACTTEXT label="RESULTS">The lavage introduced an instant and substantial change to the intestinal microbiota.<wbr> The total microbial load was decreased by 31-fold and 22% of the participants lost the subject-specificity of their microbiota.<wbr> While the bacterial levels and community composition were essentially restored within 14 days, the rate of recovery was dose dependent: consumption of the purgative in a single dose had a more severe effect on the microbiota composition than that of a double dose, and notably increased the levels of Proteobacteria, Fusobacteria and bacteria related to Dorea formicigenerans.<wbr> The abundance of the latter also correlated with the amount of faecal serine proteases that were increased after purging.<wbr></ABSTRACTTEXT></P>
<H4>CONCLUSIONS </H4>
<P><ABSTRACTTEXT label="CONCLUSIONS">Our results suggest that the bowel cleansing using two separate dosages introduces fewer alterations to the intestinal microbiota than a single dose and hence may be preferred in clinical practice.<wbr></ABSTRACTTEXT></P></DIV> </div><div><ABBR class="slug-jnl-abbrev" title="Gut"><NLM:ABBREV-JOURNAL-TITLE><EM>Gut</EM></NLM:ABBREV-JOURNAL-TITLE></ABBR> doi:10.<wbr>1136/<wbr>gutjnl-2014-307240 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2201c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The gut flora modifications shown in this small study on healthy subjects are transient (14 days with Moviprep split dose, 1 month with single dose) .<wbr> Another article  in a small number of healthy volunteers has also shown that flora modifications are transient  and that the gut flora reconstitutes after colonic lavage (O'Brien, PLOSPLoS ONE 8(5): e62815.<wbr> doi:10.<wbr>1371/<wbr>journal.<wbr>pone.<wbr>0062815).<wbr> It should be kept in mind that colonoscopies have been routinely performed for over 30 years now and have not been linked to long-term abdominal symptoms or disease.<wbr> .<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2185">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-07T18:24:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-07T18:24:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Biosimilar Gets Closer To FDA Approval: A Milestone For The US Market?</title>
	<pubDate>2015-01-07T15:46:48+01:00</pubDate>
	<wp:post_id>6175</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Briefing documents released by the FDA ahead of the meeting planned for today, January 7th, gave a positive recommendation for Zarzio, a Novartis copy of the Amgen cancer treatment Neupogen, made by its Sandoz generic subsidiary.<wbr> Neupogen (filgastrim) treats neutropenia in patients undergoing chemotherapy.<wbr> The drug generated $1.<wbr>4 billion global sales for Amgen in 2013.<wbr> </div><div style="margin-bottom: 10px;">Biosimilars are amongst the biggest selling medicines in the world and a cheaper version made from biological matter.<wbr> While a number of biosimilars are available in Europe where the products have been allowed since 2005, the US scenario appears very different.<wbr> Regulators have only recently started putting together rules for assessing the safety and efficacy of generics in the US.<wbr> Novartis biosimilars could become the first biologic drug to make it to the US market under a new regulatory pathway that started in 2012.<wbr> </div><div style="margin-bottom: 10px;">Could 2015 become a milestone for biosimilars in the US? If so, the game could dramatically change for America's soaring healthcare costs.<wbr> </div><div>Source: FirstWordPharma, FT, Bloomberg </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11058">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-07T15:46:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-07T15:46:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nestlé Injects Cash in Developer of Drugs Based on Gut Microorganisms</title>
	<pubDate>2015-01-06T18:32:59+01:00</pubDate>
	<wp:post_id>6176</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nestlé Health Science has invested $65M in Seres Health, a US clinical stage biotherapeutic company focused on discovering and developing Ecobiotic® therapeutics.<wbr> The cash injection will help Seres fund final-phase clinical testing of its SER-109, designed to prevent the recurrence of Clostridium difficile infections.<wbr> In connection with the investment, Nestle Health Science's CEO, Greg Behar, joined the Seres Board of Directors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">SER-109, a mixture of bacterial spores.<wbr> </div><div style="margin-bottom: 10px;">SER-109 was developed utilizing the Seres Health Microbiome Therapeutics™ platform.<wbr> </div><div style="margin-bottom: 10px;">The data presented at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) show that in patients with recurrent CDI, SER-109 resulted in clinical cures, with 29 of the trial's 30 patients (97 percent) reaching the 8-week endpoint free of infection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_2182_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Microbiome Therapeutics</U> </div><div style="margin-bottom: 10px;"><A href="http://sereshealth.com/technology/microbiome_therapeutics_platform/">http:/<wbr>/<wbr>sereshealth.<wbr>com/<wbr>technology/<wbr>microbiome_therapeutics_platform/<wbr></A> </div><div>Source: Seres; Nestlé </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2182">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-06T18:32:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-06T18:32:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Commercialization Strategy and Clinical Update of Versartis' LA hGH</title>
	<pubDate>2015-01-06T12:39:47+01:00</pubDate>
	<wp:post_id>6177</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Versartis is aggressively moving ahead with the pediatric GHD global Ph3 registration study expected to start early this year.<wbr> During its conference call entirely dedicated to VRS-317, the company provided a comprehensive update on patients now having completed 12 months of continuous treatment on VRS-317 and the significant positive impact of these data on its plans for advancing the development of VRS-317 for semi-monthly dosing in GHD children and monthly dosing in GHD adults.<wbr> The company also is on track to have an update on its plans for a lifecycle extension to a monthly VRS-317 treatment regimen in GHD children by 2H:15.<wbr> The key differentiating features of VRS-317 as well as the commercialization strategy were reviewed by management.<wbr> Please find below take home messages.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Location:</STRONG> 70 sites (US, Western Europe, and Canada).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG>: Versartis anticipates the ability to provide an interim 6-month height velocity analysis by mid-2016.<wbr> The top-line data on the 12-month height velocity primary endpoint is expected in early 2017 and, if successful, will enable a BLA commission and potential FDA approval by mid-2018.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Partner sought in Japan</STRONG>: Phase 2/<wbr>3 study to start early 2015 as well as an Extension Study that will include GHD children currently receiving daily growth hormone therapies switching to the VRS-317.<wbr> These studies will be conducted in parallel to the pediatric GHD Phase 3 study in the US, Western Europe, and Canada, and if successful, will enable the registration of VRS-317 for the treatment of GHD children, with potential approval in Japan in 2018.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In the U.<wbr>S: </STRONG>With a<STRONG> </STRONG>targeted, specialty Sales Force </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Last month, just before the deal with Pfizer, management reported its LA hGH-CTP being in Ph3 clinical trials in adults was "a little over halfway enrolled at this point".<wbr> The company is shooting "a BLA submission in 2016".<wbr> For children, OPKO is completing a Ph2 trial, with a Ph3 expected to start middle of 2015.<wbr> </div><div style="margin-bottom: 10px;">With Pfizer's committment it is likely possible that </div><div>OPKO will be presenting at the next JPMorgan HC Conference on January 13th.<wbr> </div><!-- Comment details --><a name="endocrinology7906attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(62,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(74,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7906_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(44,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7906">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-06T12:39:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-06T12:39:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NICE Rejects Takeda's Entyvio for Crohn's Disease in Draft Guidance</title>
	<pubDate>2015-01-05T18:27:29+01:00</pubDate>
	<wp:post_id>6178</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The NICE has issued a draft guidance not recommending Takeda Entyvio (vedolizumab), within its marketing authorisation, for the treatment of moderately to severely active Crohn's disease in adults whose disease has responded inadequately to, or has lost response to, either conventional therapy or a tumour necrosis factor-alpha inhibitor, or who cannot tolerate either of these treatment types.<wbr> The draft guidance is available for comments until 27 January 2015, with the final guidance expected in May.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">The company's clinical effectiveness evidence included data from two randomised, double-blind, placebo-controlled trials – GEMINI II and GEMINI III.<wbr> </div><div style="margin-bottom: 10px;">NICE's Appraisal Committee noted in order for it to make a decision it would be appropriate to assess Entyvio in two populations: those who had not had a TNF-alpha inhibitor before and those in whom a TNF-alpha inhibitor has failed.<wbr> </div><div>For the treatment of moderately to severely active Crohn's disease in the first population group, Entyvio was not considered to be cost effective compared with TNF-alpha inhibitors.<wbr> It was noted that the Evidence Review Group's fully incremental analysis yielded an incremental cost-effectiveness ratio (ICER) of GBP758,000 (USD1,178,450) per quality-adjusted life year (QALY) gained for Entyvio versus adalimumab, further adding that the ICER for Entyvio versus adalimumab was higher than that for infliximab in comparison with Entyvio.<wbr> Furthermore, the committee could not recommend Entyvio for treating moderately to severely active Crohn's disease in people for whom the TNF-alpha inhibitor treatment failed, despite being an area of unmet need, as the drug's ICER versus with conventional non-biological therapy was considered to be cost effective.<wbr> The ICER was GBP98,500 per QALY gained.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2181">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T18:27:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T18:27:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights From UKINETs 2014</title>
	<pubDate>2015-01-05T17:49:30+01:00</pubDate>
	<wp:post_id>6179</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: UKINETs 2014 presented a fascinating overview of the characterization and treatment of bronchial neuroendocrine tumours, data from trials with everolimus (RADIANT-4) and pasireotide (LUNA) due to report in 2015 and 2016 respectively.<wbr> Additional information on a new SST-antagonist approach for a diagnostic imaging reinforced the view that this new technology represents the future from an imaging perspective.<wbr> </div><div>A full conference report, including a clinical trials update, is enclosed in a PDF format.<wbr> </div><!-- Comment details --><a name="pharmaworld11054attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_11054_1_UKINETs%255f01Dec14%255freport.pdf">UKINETs_01Dec14_report.pdf</a>&nbsp;&nbsp;(2,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20150331&edate=20150101&rec=11054">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T17:49:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T17:49:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Findings from a RCT of Mesalazine in IBS Published in Gut</title>
	<pubDate>2015-01-05T17:43:08+01:00</pubDate>
	<wp:post_id>6180</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Findings from a RCT of Mesalazine in IBS Published in Gut</span>&nbsp;<br><span style="font-size: 12px;">Comment: This is the first large randomised controlled trial assessing the efficacy and safety of mesalazine in IBS.<wbr> Conclusion of a Ph3, multicenter, tertiary setting, randomized, double-blind, placebo controlled trial in 185 patients with Rome III confirmed IBS shows that mesalazine did not improve the percentage of patients with satisfactory relief of abdominal pain/<wbr>discomfort for at least half of the weeks of the treatment period.<wbr> However mesalazine significantly improved the percentage of patients with satisfactory relief of overall IBS symptoms if sustained responses were required (&gt;75% of treatment period).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2174">...</a><br></div><div style="margin-bottom: 10px;">The rationale of the study is the link between inflammation and IBS, the inflammation increasing mucosal permeability.<wbr> Mesalazine is a very potent anti-inflammatory drug acting specifically on the gut and previous POC on its action in IBS have been previously published.<wbr> </div><div style="margin-bottom: 10px;">The primary end point of the study can be discussed : it has been assessed using a binary scale based on the patient answers to the following weekly question: “Did you have satisfactory relief of your abdominal discomfort or pain during the last week?” The patients were classified as responders if they reported an affirmative answer in at least 50% of weeks over a 3-month treatment period (50% rule).<wbr> With this approach, responders were 69% versus 67 in placebo (NS)… </div><div style="margin-bottom: 10px;">If the response was define as an affirmative answer in at least 75% of weeks over a 3-month treatment period (75% rule, as it was exploratory assessed), then the responders were 43% versus 31% in placebo (NS).<wbr> </div><div style="margin-bottom: 10px;">One of the possible explanations for the lack of effect of mesalazine using the 50% cut-off value could be the high placebo response seen in this trial, which likely masked drug efficacy.<wbr> </div><div style="margin-bottom: 10px;">Another limitation of the study is related to the small sample size (136, adjusted to 178) .<wbr> The sample size calculation may have been limited by lack of data from previous placebo-controlled trials.<wbr> </div><div style="margin-bottom: 10px;">Data with 75% rule, indicating that mesalazine tend to a positive effects but did not reach a statistical significance, suggest a type 2 error.<wbr> The &gt;75% rule is a more restrictive outcome measure and selects a smaller percentage of responders.<wbr> These data indicate that a subgroup of patients with IBS tend to respond better to mesalazine than placebo.<wbr> These more restrictive outcome measures have been previously used in the tegaserod and linaclotide trials and help to distinguish the ‘sustained’ responders to the active treatment from those responding to placebo.<wbr> </div><div>In conclusion, we can highlight <STRONG>the authors’ conclusion : « <EM>the results of the present study indicate that a number of patients show a sustained therapy response and benefits from mesalazine therapy.<wbr> Larger studies assessing the clinical predictors and confirming the beneficial effects of mesalazine are now required</EM></STRONG>.<wbr> » </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2179">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2174">View thread  GastroEnterology2174: New Findings from a RCT of Mesalazine in IBS Published in Gut</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T17:43:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T17:43:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Janssen and Isis Pharm Ink Strategic Deal to Focus on RNA-Targeted Therapeutics for Diseases of the GI Tract</title>
	<pubDate>2015-01-05T17:17:46+01:00</pubDate>
	<wp:post_id>6181</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Under the terms of the agreement, which covers three programs, Isis will receive <MONEY>$35M in upfront payments, including a payment to initiate human lead optimization on the first collaboration target.<wbr> Isis is eligible to receive nearly </MONEY><MONEY>$800M in development, regulatory and sales milestone payments and license fees for these programs.<wbr> Janssen has the option to license a drug from each of the programs once a development candidate is identified and will assume global development, regulatory, and commercialization responsibilities for licensed drugs.<wbr></MONEY> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The collaboration brings together Isis' RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders in the GI tract.<wbr> </div><div>Source: Isis Pharm </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20150331&edate=20150101&rec=2176">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T17:17:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T17:17:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OncoGenex Regains Rights to Custirsen from Teva</title>
	<pubDate>2015-01-05T17:01:46+01:00</pubDate>
	<wp:post_id>6182</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During Q2:15, the companies announced that the Ph3 SYNERGY trial with custirsen in mCRPC failed to demontrate an improvement over strandard chemotherapy in terms of OS.<wbr> Survival results of the Ph3 AFFINITY mCRPC trial are expected late 2015/<wbr>early 2016.<wbr> OncoGenex will now have greater control of custirsen's development, including the modification of the ENSPIRIT statistical analysis plan to involve a more rigorous second interim futility analysis to be completed in Q2:15.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">*Custirsen was evaluated in combination with docetaxel and prednisone vs docetaxel prednisone alone.<wbr><WBR> </WBR> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10191_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Please see @ <A href="http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=842949">http:/<wbr>/<wbr>ir.<wbr>oncogenex.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=842949</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">During the second half of 2014, the AFFINITY trial successfully completed enrollment of 635 men with metastatic CRPC (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=9961" class="defaultlink">Oncology9961: OncoGenex Announced Completion of Patient Enrollment for AFFINITY in mCRPC Post-Docetaxel Setting</a>), and the ENSPIRIT trial completed its first interim futility analysis, which included rigorous criteria in order to continue the trial.<wbr> Based on this analysis, the independent data monitoring committee determined that continued enrollment in the ENSPIRIT trial was warranted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10191_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>AFFINITY</STRONG> is a company-sponsored, randomized Phase 3 trial evaluating whether custirsen, when combined with the second-line chemotherapy, Jevtana® (cabazitaxel), has the potential to improve survival outcomes for metastatic CRPC patients who have progressed following treatment with docetaxel.<wbr> Patients will be randomly selected to receive Jevtana plus prednisone with or without custirsen therapy, and are eligible for the trial regardless of prior therapy with androgen targeting treatments such as Zytiga® (abiraterone acetate) or Xtandi® (enzalutamide).<wbr> The trial will enroll approximately 630 men with metastatic CRPC and is being conducted throughout North America, Europe, Russia and Australia </div><div><STRONG>ENSPIRIT</STRONG> is a company-sponsored Phase 3 trial evaluating the potential of custirsen to improve survival outcomes in patients with advanced or metastatic NSCLC who have progressed after initial chemotherapy treatment has failed.<wbr> Patients will be randomly selected to receive a second-line standard of care, docetaxel treatment, with or without custirsen therapy.<wbr> The trial will enroll approximately 1,100 patients with advanced or metastatic NSCLC and is being conducted internationally.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10218c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Following recent agreement with Teva that OncoGenex has regained rights to custirsen, OncoGenex confirmed on 16th January that their prostate cancer development programme will continue.<wbr> Based upon completion of the interim futility analysis and recommendation of the Independent Data Monitoring Committee (IDMC), OncoGenex is committed to continue Ph3 AFFINITY that is evaluating combination strategy of custirsen and cabazitaxel in post-docetaxel mCRPC setting (Source: PR Newswire, OncoGenex Press Release 16 January) </div></div><a name="oncology10191attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10191_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10191_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(24,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10191_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(130,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_10191_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(125,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20150331&edate=20150101&rec=10191">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T17:01:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T17:01:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Animal Rights Activists Protest Against AstraZeneca's Research Lab in Cambridge</title>
	<pubDate>2015-01-05T16:22:33+01:00</pubDate>
	<wp:post_id>6183</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: About 50 members of CAP (Cambridge against AstraZeneca Planning) and fellow activists waved placards and heard speeches on Saturday afternoon in a 'visual representation' of their opposition to AstraZeneca's plans for a global HQs and animal testing lab in Cambridge as part of the new £330M building on the Biomedical Campus.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to the activists, "AstraZeneca experiments on around 300,000 animals each year .<wbr>.<wbr>.<wbr> another animal lab in Cambridge would not meet the objective of the EU Directive - Directive 2010/<wbr>63/<wbr>EU".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A spokesman for AstraZeneca said: "Our new centre in Cambridge will include a purpose-designed rodent facility.<wbr> The studies carried out there will principally support our early stage cancer research.<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> Wherever possible, we use non-animal methods such as cell culture, computer modelling and high-throughput screening that eliminate the need to use animals early in drug development, or reduce the number needed.<wbr> However, animal studies are still an essential part of the research process and are also required by regulators before they approve a new medicine to be tested in humans".<wbr> </div><div>Source: <A href="http://www.cambridge-news.co.uk/Animal-rights-activists-protest-AstraZeneca/story-25803257-detail/story.html">http:/<wbr>/<wbr>www.<wbr>cambridge-news.<wbr>co.<wbr>uk/<wbr>Animal-rights-activists-protest-AstraZeneca/<wbr>story-25803257-detail/<wbr>story.<wbr>html</A> </div><!-- Comment details --><a name="neurology7873attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7873_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7873_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(73 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20150331&edate=20150101&rec=7873">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T16:22:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T16:22:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tekmira's Update On The Phase I/II Study In Patients With Advanced GI-NET And ACC</title>
	<pubDate>2015-01-05T13:04:35+01:00</pubDate>
	<wp:post_id>6184</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tekmira, a leading developer of RNAi therapeutics, announced a status update on TKM-PLK1 Phase I/<wbr>II clinical trial currently targeting GI-NET and ACC indications.<wbr> The trial is a multi-center, single arm, open label study to measure TKM-PLK1 efficacy and safety in GI-NET and ACC patients.<wbr> Tekmira has achieved its target enrolment of 55 patients for the Phase I/<wbr>II and final data is expected in mid-2015.<wbr> </div><div style="margin-bottom: 10px;">Tekmira reported: </div><div style="margin-bottom: 10px;"><UL><LI>55 patients, including both Phase I and Phase I/<wbr>II studies, have been treated at doses of &ge;0.<wbr>6 mg/<wbr>kg, considered to be in the efficacious dose range based on PC studies;
</LI>
<LI>Of these, 31 patients comprise the GI-NET and ACC population;
</LI>
<LI>9 GI-NET and ACC patients remain actively on treatment and data collection is ongoing;
</LI>
<LI>Tekmira continues to see evidence of anti-tumor activity in some treated patients, including one ACC patient with an almost compete resolution of their disease.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">TKM-PLK1 employs a unique lipid nanoparticle formulation for oncology applications and is administered weekly.<wbr> </div><div>Source: Tekmira Press Release </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7912c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Tekmira has announced on January 11th 2015 the merger with OnCore Biopharma to create a leading Hepatitis B company.<wbr> </div><div>Press release can be found at this <a href="http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=890627" class="defaultlink">link</a>.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7904">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T13:04:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T13:04:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chiasma Raises $33.8 Million To Complete The Oral Octreotide Drug Development For Acromegaly</title>
	<pubDate>2015-01-05T12:48:41+01:00</pubDate>
	<wp:post_id>6185</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Israeli startup Chiasma has raised $33.<wbr>8 million of a planned $56.<wbr>3 million round to fund the oral octreotide project, according to regulatory filings.<wbr> The funds are believed to be for both completing the registration, with file submission to the FDA planned for mid-2015, and for setting up infrastructures for marketing the product.<wbr> Chiasma is clearly preparing to launch the oral octreotide for acromegaly on its own but, according to sources, is still keeping an open mindset to potential partnerships.<wbr> </div><div style="margin-bottom: 10px;">This appears as an investor's vote of confidence for the Chiasma product, especially after Roche cancelled a $595 million commercialization agreement only few months ago for strategic reasons.<wbr> Current investors in the company include MPM Captial, 7-Med Health Ventures LP, ARCH Venture Partners and F2 and F3 Ventures.<wbr> </div><div>Sources: FierceBiotech, Israel Advanced Technology Industries (IATI), MedCity News </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7968c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Chiasma has today announced the appointment of David Stack (CEO and chairman of Pacira Pharmaceuticals) as Chairman of the Board, and John Scarlett (CEO and president of Geron Corporation) as a member of the board.<wbr> Roni Mamluk, CEO, on commenting the news stressed the "benefit from the deep experience and knowledge Dave and John will bring to Chiasma as we move oral octreotide toward a NDA submission by the middle of this year.<wbr>.<wbr>.<wbr>".<wbr> Once again Chiasma is confirming their intention on submitting an NDA to the FDA this year, with possible US approval in 2016.<wbr> <a name="Endocrinology7994c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Further to new board members, Chiasma has now appointed Mark Leuchtenberger as CEO, a proven leader with successful track record in new products commercialization.<wbr> Leuchtenberger has 25 years experience in the pharmaceutical industry and from 1996 to 2002 was at Biogen, responsible for North America and the international commercial operations, including late-stage development, launch and marketing of Avonex, now a $3 billion product.<wbr> Roni Mamluk, previous CEO, will remain in the company as chief development officer.<wbr> Chiasma is also expanding its US operations in the Boston area.<wbr> The company is clearly pushing on a new strategy to ensure the best in-house capabilities and expertise to launch the first formulation of oral octreotide.<wbr> </div></div></div><div>Source: FirstWordPharma </div><span style="font-weight: bold; font-style: italic;"></span><a name="Endocrinology7970c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Chiasma has announced today the closing of a $70 million financing round.<wbr> Participants in the financing included new investors Rock Springs Capital and Sofinnova Ventures, and an undisclosed blue chip public investment fund, as well as existing investors MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners.<wbr> Once again Chiasma has stated it will use the new capital to build its sales and marketing capabilities and prepare for the launch of octreotide capsules in the US.<wbr> The company intends to submit a NDA to the FDA in the second quarter of 2015 and, if the NDA is approved, to launch the product in the US in 2016.<wbr> Chiasma will also conduct additional clinical studies for octreotide capsules to support approval in the European Union and advance new product candidates based on its proprietary TPEA (Transient Permeability Enhancer) technology into preclinical development.<wbr> </div><div>Source: PR Newswire </div></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20150331&edate=20150101&rec=7902">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2015-01-05T12:48:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2015-01-05T12:48:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
